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Abstract 
Obesity-associated adipose tissue (AT) inflammation is characterised by macrophage (ATM) 
infiltration and polarisation from anti-inflammatory (M2) towards pro-inflammatory (M1) 
phenotype. Long chain (LC) n-3 PUFA, eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA), exert various beneficial effects on inflammatory and metabolic parameters in 
relation to obesity. The apolipoprotein Epsilon 4 (APOE4) genotype is associated with a pro-
inflammatory state, lower adiposity yet greater metabolic dysfunction in obesity and an 
altered LC n-3 PUFA status compared to APOE3 genotype. This PhD project aimed to 
investigate the relationships between APOE genotype, adiposity, LC n-3 PUFA status and 
inflammation. 
In an existing data set of 312 participants involved in a fish oil intervention trial [Caslake et 
al., 2008, Kofler et al., 2012] we demonstrated that age, BMI and habitual oily fish intake, but 
not APOE Epsilon genotype, determined plasma LC n-3 PUFA status. APOE Epsilon 
genotype interacted with -219G/T polymorphism (rs405509) to determine plasma apoE and 
select inflammatory marker concentrations. 
In human APOE targeted replacement (TR) mice fed a high-fat diet (HFD) without or with 30 
g EPA+DHA / kg of diet (HFD+FO) for 8 weeks, APOE3, but not APOE4, mice develop 
obesity and impaired glucose tolerance upon HFD feeding that is prevented by dietary fish 
oil. ATM infiltration and phenotype was similar between APOE3 and APOE4 mice. Fish oil 
increased the number of ATM without influencing their phenotype. LC n-3 PUFA enrichment 
of AT was similar, although EPA and DHA levels tended to be 10 – 20% lower in APOE4 
mice compared to APOE3 mice on HFD+FO. In primary murine bone marrow-derived 
macrophages the APOE4 genotype was associated with higher prevalence of the anti-
inflammatory M2 phenotype compared to APOE3 genotype. 
In conclusion, our findings contribute to the current understanding of the potential 
mechanisms through which the APOE Epsilon genotype modulates adiposity and its 
metabolic impact. 
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Chapter 1. Literature review: Obesity, adipose tissue 
inflammation, APOE genotype and fish oil fatty acids 
A literature review of studies in humans and mice 
 
 
Obesity and metabolic health 
Obesity – a world-wide epidemic 
Excess body weight has become a worldwide epidemic with approximately 1 billion 
overweight (BMI 25 – 29.9 kg/m²) and a further 475 million obese (BMI ≥ 30 kg/m
2
) adults 
and is considered one of the most important public health problems in the world today 
[World Obesity Federation, 2014]. Obesity increases the risk of various diseases, including 
cardiovascular disease (CVD), Type 2 Diabetes Mellitus (T2DM), selected cancers and 
premature death [World Obesity Federation, 2014]. The WHO estimates from 2004 indicated 
that overweight and obesity was the fifth leading cause of death in the world accounting for 
2.8 million deaths and 36 million disability-adjusted life years – a measure of the burden of 
disease or lost years of healthy life [WHO, 2009]. Furthermore, the number of overweight or 
obese infants and young children (0 - 5 yr) has increased dramatically over the last two 
decades to 42 million in 2013 and if the current trend continues will increase to 70 million by 
2025 [WHO, 2014]. Without intervention, the obese infants and young children are likely to 
continue to be obese during childhood, adolescence and adulthood, which heightens their 
risk for T2DM, CVD and a variety of other co-morbidities before or during early adulthood 
[Lobstein et al., 2004]. Thus, overweight and obesity is becoming a worldwide problem with 
a major health impact and financial burden. 
Adipose tissue and obesity 
An excess of body weight is associated with adipose tissue (AT) expansion and dysfunction. 
AT was recognised centuries ago as the primary tissue for the storage of lipids and energy, 
but over the past decades it has also been identified to function as an endocrine organ 
producing various bioactive compounds [Frayn et al., 2003, Galic et al., 2010]. It is 
composed of primarily mature adipocytes, though it also contains a stromal vascular fraction 
(SVF) comprising of mesenchymal stem cells, pre-adipocytes, monocytes, macrophages, 
lymphocytes, fibroblasts and endothelial cells that contribute to adipocyte growth, adipocyte 
function and AT homeostasis [Ouchi et al., 2011]. AT produces various bioactive 
compounds, collectively called adipokines, which have an important role in controlling whole-
body metabolism. They include the hormones leptin and adiponectin, growth factors (e.g. 
vascular endothelium growth factor), and chemokines and cytokines, such as monocyte 
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chemoattractant protein (MCP)-1, tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-10 
[Calder et al., 2011A, Frayn et al., 2003, Kalupahana et al., 2011]. Most of these adipokines 
are increased in obesity, with the exception of adiponectin whose levels decrease with 
increasing adiposity (i.e. AT fat mass). There are two different types of AT, brown and white. 
Brown AT contains a large number of mitochondria and uncoupling protein 1 (UCP1) that is 
responsible for the dissipation of energy as heat (thermogenesis). Brown AT is prominent in 
the newborn where it is important for maintaining body temperature, but it descreases with 
increasing age and is only present to small degree in aldult humans. White AT is the most 
abundant type of fat that can account for up to 50 % of body weight in severe obesity.  It is 
dispersed throughout the whole body and classified into subcutaneous and visceral AT. 
White AT is specialised in the storage of lipids and consist of approximately 80 % 
triglycerides (TG). The white AT fat stores reflect the imbalance between energy intake and 
energy expenditure over a long period of time. Excess energy is stored as TG in adipocytes 
predominantly through a pathway involving lipoprotein lipase hydrolysis of circulating 
lipoprotein-TG followed by fatty acid uptake and re-esterification to glycerol 3-phosphate 
[Frayn et al., 2003]. Fat mobilisation involves the action of hormone-sensitive lipase which 
hydrolyses TG releasing non-esterified fatty acids (NEFA). Insulin is an important hormone 
stimulating fat deposition and suppressing fat mobilisation pathways [Frayn et al., 2003]. In 
obesity structural, functional and cellular changes take place in the AT; adipocytes become 
hypertrophic by intracellular TG accumulation, various immune cells start to infiltrate the AT 
resulting in AT inflammation, and plasma concentrations of various adipokines, hormones 
and acute-phase proteins are altered with up to a 10-fold increase in various markers of 
chronic low-grade inflammation [Calder et al., 2011A, Dalmas et al., 2011, Frayn et al., 
2003]. The adipocyte hyperthrophy and AT inflammation in obesity are believed to be an 
underlying cause of the metabolic complications of obesity, which is discussed in more detail 
in the following paragraphs. Adipocyte hyperthophy in obesity could be ameliorated by short 
term strategies aimed at increasing energy expenditure (i.e. physical activity), reducing 
energy intake (i.e. caloric restriction), and/or improving adipocyte function using bioactive 
food or pharmacological compounds. Furthermore, strategies using pharmacological or 
dietary food compounds with anti-inflammatory effects, such as long chain n-3 
polyunsaturated fatty acids, could ameliorate AT inflammation in obesity. The resolution of 
adipocyte hypertrophy and/or AT inflammation will improve AT function and plasma 
adipokine, hormone and acute-phase protein profiles. In summary, AT is an important 
metabolically active and endocrine organ with several dramatic changes occuring in obesity 
which have various health implications that will be discussed in more detail in the following 
paragraphs.  
Obesity and metabolic health 
Obesity is associated with the development of metabolic complications such as metabolic 
syndrome (MetS) and insulin resistance (IR), which increase the risk for T2DM and 
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cardiovascular disease (CVD) [Maury and Brichard, 2010, Van Gaal et al., 2006]. For 
example, obese individuals display dyslipidemia (characterised by high plasma TG and low 
plasma high-density lipoprotein cholesterol (HDL-C)), reduced insulin sensitivity and chronic 
low-grade inflammation. The relation between obesity and metabolic abnormalities has been 
well established, yet a proportion of obese people, termed metabolically healthy obese 
(MHO), do not develop metabolic abnormalities and may not be at an increased risk for 
disease [Karelis et al., 2004, Wildman et al., 2008]. These MHO individuals have a normal 
metabolic profile characterised by a low visceral fat (VAT) content, high plasma HDL-C 
levels, low plasma TG levels and high insulin sensitivity despite their high fat mass and BMI. 
MHO can account for up to one-third of obese people [Karelis et al., 2004, Primeau et al., 
2011]. The prevalence of MHO appears to decrease with age suggesting that it is a 
temporary condition during which the body is still able to ‘cope’ with obesity [Primeau et al., 
2011], with physical activity and cardiovascular fitness being two important determinants of 
the MHO phenotype [Ortega et al., 2012]. 
In addition, AT inflammation appears to be an important determinant of the metabolic 
consequences of obesity. For example, Barbarroja et al. showed that MHO insulin-sensitive 
individuals with a mean BMI of 56 ± 1 (SD) kg/m
2
 lacked the inflammatory response in VAT 
that characterized the metabolically unhealthy obese (MUO) insulin-resistant individuals 
[Barbarroja et al., 2010]. Finally, the expansion capacity of AT has been postulated as a 
potential underlying mechanism connecting obesity to its metabolic complications, which is 
referred to as the adipose tissue expandability hypothesis [Virtue and Vidal-Puig, 2010]. 
According to this hypothesis, each individual has a defined maximum AT expansion 
capacity, which is determined by genetic and environmental factors, and as an individual 
gains weight it eventually reaches its maximum AT expansion capacity. After this point, AT 
cannot expand any further and ectopic lipid deposition occurs in liver, muscle and pancreas 
leading to IR, inflammation and cardiovascular complications. Thus, AT inflammation, 
excess VAT and an impaired AT expansion capacity are important determinants of the 
metabolic consequences of obesity [Barbarroja et al., 2010, Blüher, 2010, Karelis et al., 
2004, Virtue and Vidal-Puig, 2010].  
Obesity and adipose tissue inflammation  
Expansion of AT is characterised by structural, functional and cellular changes that lead to 
local and systemic inflammation in obesity, which has been recognised as an underlying 
cause of the metabolic consequences of obesity [Calder et al., 2011A, Dalmas et al., 2011, 
Osborn and Olefsky, 2012]. In a chronic state of a positive energy balance (i.e. the onset of 
obesity), adipocytes increasingly accumulate intracellular TG and eventually become 
hypertrophic and start to secrete mediators that attract various immune cells that include in 
the early stage predominantly neutrophils, T cells and mast cells [Dalmas et al., 2011, 
Nishimura et al., 2009, Osborn and Olefsky, 2012]. As obesity develops into a chronic state, 
the hypertrophic adipocytes become inflamed and necrotic attracting macrophages which 
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increasingly infiltrate the tissue arranging themselves around the necrotic adipocytes forming 
crown-like structures (CLS) [Slim and Minihane, 2014]. The recruited AT macrophages 
(ATM) will predominantly acquire a pro-inflammatory (M1) phenotype associated with the 
expression of many pro-inflammatory genes (e.g. TNF-α, IL-1β, IL-6, NOS2) and start to 
outnumber the resident ATM that have predominantly an anti-inflammatory (M2) phenotype 
[Lumeng et al., 2007A, Weisberg et al., 2003, Wentworth et al., 2010]. Macrophages can 
adopt a range of phenotypes between M1 and M2, but the simplified M1/M2 model of 
macrophage polarisation is most frequently used [Morris et al., 2011]. The cellular alterations 
in obese AT are associated with an increased production of pro-inflammatory mediators and 
a decreased production of anti-inflammatory mediators by SVF cells (which includes 
macrophages) and hypertrophic adipocytes, which results in local and systemic inflammation 
[Fain et al., 2004, Maury and Brichard, 2010, Slim and Minihane, 2014]. It has been well 
established that specifically ATM infiltration is associated with systemic chronic low-grade 
inflammation, which in turn contributes to increased risk for systemic IR, metabolic disease 
and CVD [Barbarroja et al., 2010, Hotamisligil, 2006, Osborn and Olefsky, 2012, Shoelson et 
al., 2006, Van Gaal et al., 2006]. For example, Cancello et al. showed that weight loss was 
associated with a reduction in ATM and reduction in systemic low-grade inflammation in 
obese subjects [Cancello et al., 2005]. ATM infiltration in VAT is likely to be most detrimental 
to metabolic health, as excess VAT and the inflammatory response in VAT have not only 
been linked to the MUO phenotype, but VAT depots also have a greater ATM content than 
subcutaneous AT (SAT) [Barbarroja et al., 2010, Bruun et al., 2005, Cancello et al., 2006, 
Karelis et al., 2004]. Finally, AT from lean and metabolically healthy humans and mice also 
contains immune cells, including a considerable number of ATM with an anti-inflammatory 
M2 phenotype, which are involved in maintaining homeostasis [Lumeng et al., 2007A, 
Osborn and Olefsky, 2012]. These findings support that not all ATM have a detrimental 
effect on metabolic function and M2 ATM appear to be important for AT function [Dalmas et 
al., 2011, Morris et al., 2011].  
 
In summary, excess AT in obesity is associated with AT inflammation and various metabolic 
complications resulting in an increased risk for T2DM and CVD. However, not all obese 
individuals show AT inflammation and a metabolically unhealthy phenotype, suggesting 
genetic, nutritional and other environmental factors may be involved in determining AT 
inflammation and metabolic complications in obesity. 
Apolipoprotein E (APOE) genotype, adiposity and inflammation 
Apolipoprotein E – protein function  
There is accumulating evidence supporting the involvement of apolipoprotein E (apoE) in the 
development of AT, obesity and obesity-related metabolic complications [Huang et al., 2015, 
Kypreos et al., 2009, Slim and Minihane, 2014]. ApoE is a 34.2 kDa arginine-rich protein 
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consisting of 299 amino acids with lipoprotein-binding elements located in the C-terminal 
domain and receptor-binding elements in the N-terminal domain that is encoded by the 
APOE gene. ApoE is expressed in various tissues, including liver (≥ 80 %), brain and AT, 
and macrophages which can account for up to 20 % of its production in tissues [Kockx et al., 
2007, Mahley, 1988]. ApoE is known to play an important role in lipoprotein metabolism, 
where it serves as a cofactor in hepatic very-low-density lipoprotein (VLDL) synthesis, a 
cofactor in the hydrolysis of VLDL remnants into low-density lipoprotein (LDL) particles in 
circulation, and a high-affinity ligand for receptor-mediated cellular uptake of remnants of 
chylomicron (CM) and VLDL particles [Mahley, 1988]. But besides its well-known role in 
lipoprotein metabolism, apoE has immunomodulatory, anti-inflammatory and anti-oxidative 
properties [Jofre-Monseny et al., 2008A, Minihane et al., 2007]. These immunomodulatory 
and anti-inflammatory effects have predominantly been shown in vitro using models of an 
induced-inflammatory response, where apoE modulated the immunological function of 
lymphocytes [Curtiss, 2000, Kelly et al., 1994, Pepe and Curtiss, 1986] and the phenotype of 
macrophages [Baitsch et al., 2011], reduced the lipopolysaccharide (LPS)-induced 
inflammatory response in microglia [Jofre-Monseny et al., 2008A, Lynch et al., 2003] and 
inhibited the gene expression of cell adhesion molecules in endothelial cells [Stannard et al., 
2001]. Some examples of the anti-oxidative properties reported for apoE are, inhibition of 
lipid oxidation [Miyata and Smith, 1996, Ramassamy et al., 1999], inhibition of membrane 
oxidation [Jofre-Monseny et al., 2007A] and modulation of nitric oxide production [Colton et 
al., 2004, Jofre-Monseny et al., 2007A]. 
Apolipoprotein E and adipose tissue function  
Early studies revealed that the expression of apoE increased linearly with time upon 
differentiation in adipocytes with apoE being essential for lipid accumulation [Huang et al., 
2006, Zechner et al., 1991]. ApoE deficiency has been associated with an impaired fatty acid 
uptake, decreased TG synthesis and increased TG hydrolysis in primary adipocytes and 
with an impaired plasma TG clearance, reduced body fat mass and smaller adipocytes in 
apoE
-/-
 mice [Hofmann et al., 2008, Huang et al., 2006]. Furthermore, apoE is a component 
of VLDL-derived TG-rich lipoproteins, which are the main source of fatty acids for AT in both 
the fasting and fed state and play an important role in AT development [Voshol et al., 2009]. 
A link between apoE, lipoprotein metabolism and the development of obesity was 
demonstrated by Chiba et al. who reported that VLDL-induced adipogenesis was apoE-
dependent and that apoE-deficient ob/ob mice were protected from diet-induced obesity 
despite their higher plasma VLDL levels [Chiba et al., 2003]. In summary, these findings 
clearly indicate a role for apoE in AT development and the development of obesity. 
Apolipoprotein E – genetic variants 
Two common single nucleotide polymorphisms (SNPs) in the APOE gene 388T/C (ε4 
variant, rs429358) and 526C/T (ε2 variant, rs7412) give rise to the three common allelic 
variants ε2, ε3 and ε4 which are associated with amino acid changes in the apoE protein 
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and referred to as Epsilon gene variants (Table 1.1). The most common variant and often 
referred to as wild type is apoE3 that contains a cysteine (Cys) and an arginine (Arg) at 
position 112 and 158. The apoE2 isoform is characterized by an amino acid change at 
position 158 (Arg -> Cys), which causes a 50 – 100 fold weaker binding affinity for the LDL 
receptor compared to the apoE3 isoform. The apoE4 isoform is distinguished by an amino 
acid change at position 112 (Cys -> Arg), which results in an interaction between the N- and 
C-terminal domain that is associated with a change in lipoprotein binding preference from 
HDL towards VLDL and CM and a lower chemical and thermal protein stability compared to 
the apoE3 isoform [Hatters et al., 2006]. The three common allelic variants of the APOE 
gene (ε2, ε3 and ε4) give rise to six possible APOE Epsilon genotypes, which are in order of 
prevalence from most common to least common E3/E3, E3/E4, E2/E3, E4/E4, E2/E4 and 
E2/E2 [Singh et al., 2006]. The APOE3 (E3/E3) genotype is often referred to as the wild 
type. The distribution of the APOE genotypes differs between ethnicities, but in a Caucasian 
population most people have the APOE3 genotype (E3/E3; 65 %), 25 % are APOE4 carriers 
(E2/E4, E3/E4, E4/E4) and 10 % are APOE2 carriers (E2/E3, E2/E2) [Eichner et al., 2002, 
Singh et al., 2006]. 
 
Table 1.1. Human apoE isoforms and their key differences. 
ApoE 
isoform 
Amino 
acid at 
112/158 
Domain 
interaction 
Stability, 
folding 
behaviour 
LDLR 
binding 
affinity 
Lipo-
protein 
preference 
Associated 
blood lipid 
changes  
apoE2 Cys/Cys No 
Most stable, 
no folding 
intermediates 
Low HDL 
Type II hyper-
lipoproteinaemia  
apoE3 Cys/Arg No 
Mediate stable, 
folding 
intermediates 
High HDL  
apoE4 Arg/Arg Yes 
Least stable, 
folding 
intermediates 
High VLDL, CM 
Moderately 
(~8%) increased 
LDL cholesterol  
Table describing key differences between the three common apoE isoforms, i.e. amino acid at position 
112 and 158 of the protein; protein domain interaction between the N- and C-terminus; protein 
conformational stability and folding behaviour; LDL receptor binding affinity; lipoprotein preference; and 
associated blood lipid changes [Hatters et al., 2006, Minihane et al., 2007, Jofre-Monseny et al., 
2008A]. ApoE, apolipoprotein E; Arg, arginine; Cys, cysteine; CM, chylomicron; HDL, high-density 
lipoprotein; LDLR, low-density lipoprotein receptor; Type II hyper-lipoproteinaemia, high triglyceride 
with normal cholesterol levels; VLDL, very low-density lipoprotein.  
 
APOE Epsilon genotype and disease risk 
Almost two decades ago, the APOE4 allele was first discovered as a major risk factor for 
Alzheimer’s Disease (AD) [Corder et al., 1993, Strittmatter et al., 1993, Takeda et al., 2010], 
with E3/E4 and E4/E4 at relative risk of AD of 3-fold and 15-fold relative to the E3/E3 
genotype [Bertram et al., 2007]. Subsequent studies revealed the APOE4 allele was also 
associated with the risk of coronary heart disease (CHD), with APOE4 carriers having 6 – 42 
% increased CHD risk compared to those with APOE3 genotype (Table 1.2) [Bennet et al., 
2007, Song et al., 2004, Wilson et al., 1996].  
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Table 1.2. Meta-analyses on APOE Epsilon genotype and CHD risk. 
Study details APOE Epsilon 
genotype* 
CHD risk compared to 
subjects with APOE3 
genotype 
Reference 
Meta-analysis 
including 9 studies 
published between 
1987 and 1996 
APOE2 carriers† 
 
APOE4 carriers† 
OR = 0.98, 95% CI 0.85 – 1.14 
 
OR = 1.26, 95% CI 1.13 – 1.41 
[Bennet et 
al., 2007] 
Meta-analysis 
including 48 studies 
published between 
1966 and 2004 
APOE2 carriers 
 
APOE4 carriers 
OR = 0.98, 95% CI 0.66 – 1.46 
 
OR = 1.42, 95% CI 1.26 – 1.61 
[Song et al., 
2004] 
Meta-analysis 
including 112 studies 
between 1970 and 
2007 with each study 
including at least 500 
cases 
APOE2 carriers 
 
APOE4 carriers 
 
OR = 0.80, 95% CI 0.70 – 0.90 
 
OR = 1.06, 95% CI 0.99 – 1.13 
[Wilson et 
al., 1996] 
APOE Epsilon genotypes were defined as APOE3 genotype (E3/E3); APOE2 carriers (E2/E2, E2/E3); 
and APOE4 carriers (E3/E4, E4/E4), unless stated otherwise. † APOE2 carriers (E2/E2, E2/E3, E2/E4) 
and APOE4 carriers (E2/E4, E3/E4, E4/E4). 95% CI, 95% confidence interval; APOE, apolipoprotein E; 
CHD, coronary heart disease; OR, odds ratio. 
 
Plasma apoE concentrations exist in an APOE Epsilon genotype-dependent manner with the 
highest plasma levels in APOE2 carriers and lowest plasma levels in APOE4 carriers 
[Moreno et al., 2009]. The increased CHD risk has traditionally been attributed to the 
approximately 8 % higher plasma LDL-cholesterol (LDL-C) levels in APOE4 carriers relative 
to those with APOE3 genotype, however this cannot solely explain the increased risk and 
suggests other lipoprotein-independent mechanisms, such as inflammation and oxidative 
stress, are involved in the APOE4 – CHD association [Law et al., 1994, Minihane et al., 
2007].  
APOE Epsilon genotype and obesity 
Limited human cross-sectional studies provide accumulating evidence supporting a link 
between APOE Epsilon genotype, adiposity and the metabolic consequences of obesity 
[Elosua et al., 2003, Kolovou et al., 2009, Sima et al., 2007, Slim and Minihane, 2014] (Table 
1.3). Various studies indicated that the APOE4 allele was more prevalent in obese people 
though there was some inconsistency [Elosua et al., 2003, Kolovou et al., 2009, Oh and 
Barrett-Connor, 2001, Sima et al., 2007, Volcik et al., 2006] and APOE Epsilon genotype 
interacted with BMI to determine metabolic and/or inflammatory parameters [Kofler et al., 
2012, Marques-Vidal et al., 2003, Pouliot et al., 1990]. For example, the APOE4 allele was 
more prevalent in obese people compared to people with a normal weight (30 % vs. 15 %, p 
< 0.05) and in people with MetS compared to normal weight healthy controls (13.5 % vs. 8.2 
%, p < 0.05) in 279 subjects from Romanian population [Sima et al., 2007]. Besides, 
Marques-Vidal et al. showed that APOE Epsilon genotype interacted with BMI to determine 
plasma total cholesterol (TC), LDL-C, total insulin and bioactive insulin in 266 healthy men 
Slim (2015), Chapter 1. Literature review 
27 
without hypolipidemic or antidiabetic drug treatment, with APOE4 carriers having higher 
levels compared to other APOE Epsilon genotypes and the difference enlarging with 
increasing BMI [Marques-Vidal et al., 2003]. These findings suggest that the APOE Epsilon 
genotype may influence adiposity and interact with adiposity (BMI) to determine the 
metabolic consequences of increased adiposity, something that may already manifest itself 
in childhood [Ellis et al., 2011]. In summary, literature suggests an interplay between APOE 
Epsilon genotype and AT to determine risk factors for disease (e.g. IR and MetS), which has 
recently been corroborated in a mouse model humanised for the different apoE isoforms 
[Arbones-Mainar et al., 2008 and 2010]. Arbones-Mainar et al. showed that the APOE4 
allele was associated with an impaired expandability of VAT, an impaired adipocyte 
differentiation and a greater predisposition to develop impaired glucose tolerance upon high-
fat diet feeding compared to APOE3 allele in human APOE targeted replacement mice. 
Thus, APOE Epsilon genotype is a potential determinant of AT expansion, adiposity and 
predisposition to develop metabolic complication in obesity. 
APOE Epsilon genotype and oxidative stress 
The potential involvement of oxidative stress in the APOE4 – disease association is 
supported by a greater penetrance of the APOE4 allele on CHD risk in smokers, who have a 
habitual pro-oxidative and low-grade pro-inflammatory status, relative to non-smokers after 
correction for plasma LDL-C [Humphries et al., 2001, Talmud et al., 2005]. For example, 
CHD hazard ratios corrected for classical CHD risk factors were 3.81 and 1.68 for male 
APOE4 and APOE3 smokers compared to non-smoking APOE3 in the Framingham cohort 
[Talmud et al., 2005] and 2.79 and 1.47 for male APOE4 and APOE3 smokers compared to 
combined group of non-smokers in the Northwick Park Heart Study II [Humphries et al., 
2001]. This implies that oxidative and inflammatory mechanisms could be involved in the 
APOE4 – CHD association. In fact, the presence of a pro-oxidative status in APOE4 carriers 
was supported by Dietrich et al. who reported 29 % higher F2-isoprostanes levels (a 
biomarker of lipid oxidation) in mildly-hypercholesterolaemic APOE4 carriers compared to 
non-carriers [Dietrich et al., 2005]. These observations have been confirmed in vitro using 
stable transfected cell lines expressing apoE3 and apoE4 revealing the apoE4 isoform was 
associated with approximately 40 % higher membrane lipid oxidation and 30 – 60 % higher 
superoxide levels [Jofre-Monseny et al., 2008B]. Using APOE3 and APOE4 targeted 
replacement (TR) mice the APOE4 allele was associated with lower alpha tocopherol tissue 
levels in liver, lung, muscle and heart (reaching only significance for lung) and 50 % higher 
plasma α-TOH uptake [Jofre-Monseny et al., 2008B, Huebbe et al., 2010]. Thus, current 
evidence suggests that the APOE4 genotype is associated with higher levels of oxidative 
stress. The differential antioxidant capacity of the apoE isoforms (E2 > E3 > E4) has been 
suggested to be underlying the poorer oxidative status associated with APOE4 genotype 
[Jofre-Monseny et al., 2007B, Miyata and Smith, 1996]. These differential antioxidant 
capacities of the apoE isoforms have been related to the differential folding and stability of 
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the proteins affecting the radical scavenging activity of the positively charged amino acids 
located in the receptor binding domain of the apoE protein [Jofre-Monseny et al., 2007B, 
Pham et al., 2005]. 
APOE Epsilon genotype and inflammation in humans 
A pro-inflammatory status in APOE4 carriers could also be involved in the APOE4 – disease 
association, especially since inflammation is a well-recognised component of CHD and AD 
pathology [Hansson and Hermansson, 2011, Latta et al., in press]. Although previous in vitro 
studies and in vivo studies in mice have demonstrated the APOE4 allele is associated with a 
pro-inflammatory state in predominantly microglia and brain tissue [Jofre-Monseny et al., 
2008A], these findings are of relevance since microglia (considered to be the macrophages 
of the brain) share many functional characteristics with macrophages that play a key role in 
AT inflammation in obesity. However, the impact of APOE Epsilon genotype on the 
inflammatory status in humans is still unknown. The scarce human studies available have 
primarily investigated the impact of APOE Epsilon genotype on plasma levels of C-reactive 
protein (CRP), an acute phase protein released by the liver upon stimulation with 
inflammatory cytokines and a widely-used but not exclusive marker of CHD risk [Pearson et 
al., 2003]. These studies have demonstrates that in contrary to their 6 – 42 % increased 
CHD risk APOE4 carriers have lower plasma CRP levels and APOE2 carriers have higher 
CRP levels despite their 0 – 20 % lower CHD risk compared to the APOE3 genotype (Table 
1.4). For example, in the Ludwigshafen Risk and Cardiovascular Health Study involving 
patients with and without coronary artery disease, the APOE4 genotype (E3/E4, E4/E4) was 
associated with 19 % lower and the APOE2 genotype (E2/E3, E2/E2) was associated with 
21 % higher circulating CRP levels compared to APOE3 genotype (E3/E3) [März et al., 
2004]. Besides, Tziakas et al. reported in patients with acute coronary syndrome and chronic 
stable angina lower circulating IL-10 levels in APOE4 carriers compared to non-carriers 
[Tziakas et al., 2006], which is in line with in vitro data indicating a reduced production of IL-
10 upon LPS-stimulation in APOE4 macrophages compared to APOE3 macrophages [Jofre-
Monseny et al., 2007B]. Finally, plasma VCAM-1 levels have been reported to be 
significantly higher in APOE2 and APOE4 carriers compared to the APOE3 genotype, with 
the opposite effect for plasma P-selectin levels, in 312 healthy subjects enrolled in a fish oil 
intervention trial [Kofler et al., 2012]. In this study, they also reported an interaction between 
APOE Epsilon genotype and BMI to determine plasma inflammatory marker concentrations. 
APOE Epsilon genotype had the strongest effect in the normal weight subjects (BMI ≤ 24.9 
kg/m
2
) and APOE2 carriers were most sensitive to the detrimental effects of an increased 
BMI [Kofler et al., 2012]. These findings suggest that APOE Epsilon genotype could interact 
with adiposity to determine inflammatory status in humans, something that warrants further 
investigation in particular in relation to AT inflammation in obesity. 
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Table 1.3. Summary of key human studies investigating the association between APOE Epsilon genotype, adiposity and metabolic consequences of obesity. 
Study design and study population Main findings Reference 
Prospective birth cohort study 
investigating the associations between 
APOE Epsilon genotype, plasma lipids, 
PA, CRF, and adiposity (n = 292 
children, age 8 yr) 
APOE4 genotype was associated with lower BMI (WMD 0.87 kg/m
2
, 95%CI 0.26 – 1.47), truncal 
fat mass and waist circumference compared to non-APOE4 carriers.  
APOE Epsilon genotype interacted with CRF for child BMI: 
Children with low CRF:  E4 had lower BMI vs. E3 (WMD -1.78 kg/m
2
, 95%CI -2.74 – -0.83) 
Children with high CRF: E4 had similar BMI to E3 (WMD 0.07 kg/m
2
, 95%CI -0.59 – 0.73) 
[Ellis et al., 
2011] 
Cross sectional study investigating the 
associations between APOE Epsilon 
genotype, adiposity and fasting plasma 
insulin and glucose levels (n = 2,929) 
Fasting glucose and insulin in obese men:   E4 > E3 
Fasting glucose and insulin in normal weight men:  E4 = E3 
[Elosua et 
al., 2003]  
Study investigating association between 
APOE Epsilon genotype and MetS (n = 
147 subjects with severe obesity (BMI 
48.7 kg/m
2
), of which 116 MetS 
patients). 
APOE Epsilon genotype frequencies in MetS patients:  E2 > E3 = E4 
E4 was higher in obese without MetS vs. MetS patients (23 % vs. 9 %) 
Prevalence of MetS:  
Overall,  79 % 
In E2,   84 % 
In E4,   56 %  
[Ferreira et 
al., 2011] 
Study investigating the association 
between APOE Epsilon genotypes and 
obesity in CHD patients (n = 359 CHD 
patients and 248 controls).  
APOE Epsilon genotype frequencies: 
E2 was higher in normal weight CHD patients vs. controls (3 % vs. 23 %) 
E3 was higher in normal weight CHD patients vs. controls (83 % vs. 57 %) 
E4 was similar in normal weight CHD patients and controls (11 % vs. 20 %) 
E3 was lower in obese vs. normal weight CHD patients (69 % vs. 83 %) 
E4 was higher in obese vs. normal weight CHD patients (13 % vs. 6 %) 
[Kolovou et 
al., 2009] 
Study investigating the associations 
between APOE Epsilon genotype, 
alcohol intake, BMI, smoking and plasma 
lipid levels (n = 266 healthy men) 
Plasma TC and LDL-C,  E2 < E3 < E4, enlarged with increasing BMI 
Plasma apoE and apoB:apoE, E2 > E3 > E4 
Plasma bioactive insulin, E2 = E3 < E4, enlarged with increasing BMI 
[Marques-
Vidal et al., 
2003] 
Cross sectional study investigating the 
association between APOE Epsilon 
genotype and plasma lipids (n = 191 
subjects with and 1,062 without family 
history of diabetes) 
Non-diabetic men with/without family history: 
BMI, waist circumference, waist-to-hip ratio  E2 = E3 = E4 
Non-diabetic women with family history: 
BMI, waist-to-hip ratio     E2 = E3 = E4 
Waist circumference,     E2 = E3 < E4 
Non-diabetic women without family history: 
BMI, waist circumference, waist-to-hip ratio,  E2 = E3 = E4 
[Oh and 
Barrett-
Connor, 
2001] 
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Table 1.3. continued. 
Study design and study population Main findings Reference 
Cross-sectional study investigating the 
association between APOE Epsilon 
genotypes, dietary intake, and BMI with 
serum lipid levels (n = 996) 
BMI: E2 = E3 = E4 
 
[Petkeviciene 
et al., 2012] 
Cross sectional study investigating the 
associations between APOE Epsilon 
genotype, body fatness and plasma 
lipoproteins (n = 63 healthy sedentary 
premenopausal women)  
APOE3 genotype: body fatness ↑ → plasma VLDL-C, LDL-C, TG, apoB ↑, HDL-C ↓ 
APOE2 genotype: body fatness ↑ → plasma VLDL-C ↑, apoB, LDL-C, HDL-C ↓ 
APOE4 genotype: no association  
[Pouliot et 
al., 1990] 
Population-based cohort study 
investigating the association between 
SNPs in transcriptional pathways of 
glucose and lipid metabolism and 
features of MetS (n = 3,575) 
APOE4 was associated with abdominal obesity  (PR = 1.12, 95% CI 1.03 – 1.23)  
APOE4 was associated with low plasma HDL-C (PR = 1.21, 95% CI 1.07 – 1.37). 
APOE2 was not associated with MetS features. 
[Povel et al., 
2011] 
Study investigating the association 
between APOE Epsilon genotype and 
the risk of MetS or/and CHD (n = 91 
control subjects, 117 MetS patients, 71 
obese CHD patients). 
APOE Epsilon allele frequencies: 
E4 was higher in very obese vs. normal weight subjects (35 % vs. 15 %) 
E4 was higher in MetS patients vs. controls (13.5 % vs. 8.2 %) 
E2 was higher in controls vs. MetS patients (14.5 % vs. 7.3 %) 
E2 was higher in controls vs. CHD patients (14.5 % vs. 6.4 %) 
[Sima et al., 
2007] 
Prospective study investigating the 
impact of APOE Epsilon genotype on 
LDL-C, IMT and CHD risk (n = 3,187 
African Americans, 9,304 Whites) 
African Americans: 
BMI, E2 > E3 > E4  
Whites: 
BMI, E2 = E3 = E4 
[Volcik et al., 
2006] 
Cross-sectional study investigating the 
association between abdominal obesity 
and APOE Epsilon genotype (n = 853) 
APOE Epsilon allele frequencies were similar in subjects with and without abdominal obesity. 
Subjects with abdominal obesity: E3 was associated with higher plasma TG (E3 > E2 > E4) 
Subjects without abdominal obesity: E4 was associated with lower plasma HDL-C (E2 > E3 > E4)  
[Zarkesh et 
al., 2012] 
This table is a summary of the main findings from studies investigating the association between APOE Epsilon genotype, obesity and its complications. APOE 
Epsilon genotypes were defined as APOE3 genotype (E3/E3); APOE2 carriers (E2/E2, E2/E3); and APOE4 carriers (E3/E4, E4/E4), unless stated otherwise. 
95% CI, 95% confidence interval; APOE, apolipoprotein E; BMI, body mass index; CHD, coronary heart disease; CRF, cardiorespiratory fitness; HDL-C, high- 
density lipoprotein cholesterol; IMT, carotid artery intima-media thickness; LDL-C, low- density lipoprotein cholesterol; MetS, metabolic syndrome; PA, 
physical activity; PR, prevalence ratio; SNP, single nucleotide polymorphism; VLDL-C, very-low density lipoprotein cholesterol; WMD, weighted mean 
difference.   
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Table 1.4. Human studies investigating the association between APOE Epsilon genotype and circulating CRP levels.  
Study design and study population Results Reference 
Cross-sectional study (n = 562 Japanese 
Americans from 68 extended kindreds) 
CRP,  E2 > E3 = E4 (1.20 mg/L vs. 0.72 mg/L vs. 0.74 mg/L) [Austin et al., 
2004] 
Study involving six-month aerobic exercise (n = 
117 healthy sedentary subjects)  
CRP,  E2 = E3 > E4 (2.84 mg/L (E2/E3) vs. 2.59 mg/L (E3/E3) vs. 1.90 ± 2.13 (E3/E4)) 
Exercise did not change CRP levels. 
[Angelopoulo
s et al., 2008] 
Three prospective cohort studies (n = 2,010 
subjects without CVD history) 
PRINCE study:  
CRP,  E2 = E3 > E4 (1.6 mg/L (E2/E3) vs. 1.6 mg/L (E3/E3) vs. 1.2 mg/L (E3/E4)) 
Physicians’ Health Study:  
CRP,  E2 = E3 > E4 (1.1 mg/L (E2/E3) vs. 1.6 mg/L (E3/E3) vs. 0.9 mg/L (E3/E4)) 
[Chasman et 
al., 2006] 
Cross-sectional study (n = 211 subjects with low 
HDL-C† and 157 normolipidemic subjects) 
Subjects with low HDL-C: 
CRP,  E3 > E4 (1.72 mg/L (E2/E3, E3/E3) vs. 1.14 mg/L (E2/E4, E3/E4, E4/E4)) 
VCAM-1, ICAM-1 and E-sel, E2 = E3 = E4 
Normolipidemic subjects: 
CRP,  E3 > E4 (1.29 mg/L (E2/E3, E3/E3) vs. 0.63 mg/L (E2/E4, E3/E4, E4/E4)) 
VCAM-1, ICAM-1 and E-sel, E2 = E3 = E4 
[Kahri et al., 
2006] 
Placebo-controlled crossover fish oil intervention 
trail (n = 312 healthy subjects) 
CRP, E2 > E3 > E4 (82.8. ng/mL vs. 59.5 ng/mL vs. 56.1 ng/mL) 
TNF-α, IL-6, IL-10, E-sel, P-sel, ICAM-1 and VCAM-1 (E2 = E3 = E4) 
APOE Epsilon genotype interacted with BMI for CRP. 
Normal weight subjects (25 – 30 kg/m
2
): CRP, E2 > E3 = E4  
[Kofler et al., 
2012] 
Cross sectional study (n = 739 CAD patients and 
570 controls) 
CRP,  E2 > E3 > E4 (E2 had 21% higher and E4 had 19% lower levels than E3) [März et al., 
2004] 
Cross sectional study (n = 166 ACS and 70 CSA 
patients) 
ACS patients:  
CRP,  E2 = E3 > E4 (8.7 mg/L vs. 9.1 mg/L vs. 4.5 mg/L)  
IL-10,  E2 = E3 = E4 (6.9 pg/mL vs. 6.7 pg/mL vs. 5.6 pg/mL) 
CSA patients:  
CRP,  E3 > E2 > E4 (7.1 mg/L vs. 6.3 mg/L vs. 2.0 mg/L)  
IL-10,  E2 = E3 = E4 (28.6 pg/mL vs. 17.8 pg/mL vs. 14.3 pg/mL)  
[Tziakas et 
al., 2006] 
This table is not an exhaustive list of studies investigating the association between APOE Epsilon genotype and circulating CRP levels. Unless stated otherwise, results are 
summarised for APOE2 carriers (E2/E3, E2/E2), APOE3 genotype (E3/E3) and APOE4 carriers (E3/E4, E4/E4). †Low HDL was defined as HDL-C levels below the 10th 
percentile cut-off level. 95% CI, 95% confidence interval; ACS, acute coronary syndrome; APOE, apolipoprotein E; BMI, body mass index; CAD, coronary artery disease; CSA, 
chronic stable angina; CVD, cardiovascular disease; E-sel, E-selectin; HDL-C, high-density lipoprotein-cholesterol; CRP, C-reactive protein; ICAM-1, intercellular cell adhesion 
molecule-1; IL, interleukin; LDL-C, low-density lipoprotein-cholesterol; P-sel, P-selectin; TNF-α, tumor necrosis factor-α; VCAM-1, vascular cell adhesion molecule-1. 
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Apolipoprotein E and SNPs in APOE promoter region 
Like the majority of other human genes APOE is highly polymorphic with 333 SNPs to date 
described (www.ncbi.nlm.nih.gov/snp/?term=apoE). In addition to the APOE Epsilon 
genotypes, SNPs in the APOE promoter region can alter the transcriptional activity of APOE 
thereby potentially impacting on disease risk. In fact, SNPs in the APOE promoter region 
have been shown to influence AD risk [Bizzarro et al., 2009, Lambert et al., 2002, Lescai et 
al., 2011, Wang et al., 2000]. Almost a decade ago five common genetic variations in the 
APOE promoter region were identified; -491A/T (rs449647), -427T/C (rs769446), -219G/T 
(rs405509), –186G/T and +113G/C (rs440446) [Artiga et al., 1998, Lambert et al., 1998]. 
The -491A/T (rs449647) and -219C/T (rs405509) SNPs, but not -427T/C (rs769446), have 
been shown to modulate the APOE transcriptional activity in vitro, where the -491T and -
219G allelic variants were associated with respectively decreased and increased 
transcriptional activity of APOE compared to -491A and -219T variants [Artiga et al., 1998, 
Geng et al., 2011]. For example, Artiga et al. showed that the 491T variant was associated 
with 37 % decreased and the -219G variant with 69 % increased transcriptional activity of 
APOE compared to wild type haplotypes (-491A and -219T) in a human hepatoma cell line 
(HepG2) [Artiga et al., 1998]. In line with this, human studies demonstrated that the -219G/T 
polymorphism and APOE Epsilon genotype determine plasma apoE concentrations 
[Lambert et al., 2000, Moreno et al., 2003, Moreno et al., 2009]. The plasma apoE 
concentrations exist in a APOE genotype-dependent manner (E2 > E3 > E4) [Moreno et al., 
2009]. The -219T allele was associated with decreased plasma apoE concentrations in 
dose-dependent manner (p < 0.01) in the ECTIM study adjusting for APOE Epsilon 
genotype (plasma apoE concentrations, 4.9 ± 1.8 (SD) for -219GG; 4.7 ± 1.7 for -219GT; 
and 4.1 ± 1.5 mmol/L for -219TT) [Lambert et al., 2000]. The -219T allele was also 
associated with an increased AD risk (OR = 1.30, 95% CI 1.06 – 1.60, for -219TT) in 2390 
AD patients and controls, but this effect disappeared after correcting for presence of the 
APOE4 allele with further investigation in APOE4 carriers revealing no effect of the -219T 
allele on AD risk (OR = 4.77, 95% CI 3.18 – 7.17, for -219T * APOE4 vs. OR = 5.31, 95% CI 
2.93 – 9.63, for -219G * APOE4) [Lescai et al., 2011]. However, a potential involvement of 
SNPs in APOE promoter region in other disease pathologies associated with APOE Epsilon 
genotype, such as CHD, still needs to be investigated though there have been some reports 
concerning atherosclerosis, IR and T2DM [Banares et al., 2012, Geng et al., 2011, 
Komurcu-Bayrak et al., 2011]. In summary, the -219G/T (rs405509) and -491A/T (rs449647) 
polymorphism in the APOE promoter region have been shown to affect APOE gene 
expression levels and impact on AD risk, however the impact on other risk factors for 
disease including IR and inflammation remain to be elucidated. 
APOE Epsilon genotype – adiposity, inflammation and disease risk 
In summary, the pro-inflammatory effects of the APOE4 allele compared to APOE3 allele 
that have been well-established in vitro and in vivo in animal models, suggest that a 
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differential inflammatory status associated with APOE Epsilon genotype may be involved in 
the APOE Epsilon genotype – disease association, especially given the fact that both CHD 
and AD (on which APOE Epsilon genotype impacts) have a well-established inflammatory 
component. However, the impact of the APOE4 genotype on inflammatory status in humans 
is still unknown and remains to be established. Furthermore, recent reports in humans and 
human APOE TR mice suggest that AT may be involved in mediating the effect of APOE 
Epsilon genotype on metabolic diseases associated with obesity [Kofler et al., 2012, 
Arbones-Mainar et al., 2008 and 2010]. For example, Arbones-Mainar et al. showed that 
APOE Epsilon genotype impacted on diet-induced obesity, VAT expansion and AT 
dysfunction in human APOE TR mice. In humans, obesity is associated with local and 
systemic low-grade inflammation and AT dysfunction [Hotamisligil, 2006, Calder et al., 
2011A] that in turn leads to conditions such as MetS, IR and CVD [Maury and Brichard, 
2010, Van Gaal et al., 2006]. Therefore, we hypothesize that APOE Epsilon genotype and 
SNPs in the APOE promoter region may impact on disease risk through modulating AT 
inflammation and function in particular in obesity, which in turn determines systemic 
inflammatory and metabolic parameters and subsequent disease risk. Finally, APOE Epsilon 
genotype has been shown to impact on long chain (LC) n-3 polyunsaturated fatty acid 
(PUFA) status [Chouinard-Watkins et al., 2013, Conway et al., 2014, Plourde et al., 2009, 
Vandal et al., 2014], with LC n-3 PUFA having important beneficial effects on inflammatory 
and metabolic processes which will be discussed in more detail in the next paragraphs. 
These findings suggest a potential involvement of LC n-3 PUFA status in the relationship 
between APOE Epsilon genotype, adiposity and inflammation. 
Omega 3 (n-3) polyunsaturated fatty acids 
Long chain n-3 PUFA – structure  
Fatty acids are hydrocarbon chains consisting of 4 to 28 carbons (usually unbranched and 
even-numbered) that contain a methyl group (-CH3) at one end at a carboxylic acid (-COOH) 
at the other end. Fatty acids can be saturated, i.e. without a double bond (C-C), or contain 
one (monounsaturated) or more (polyunsaturated) double bonds (C=C). Most unsaturated 
fatty acids have a cis configuration, i.e. the hydrogen atoms on either side of the double 
bond are oriented in the same direction, resulting in a bend in the molecular structure of the 
molecule. The omega (n-x) nomenclature classifies fatty acids based on the number of 
carbon atoms, the number of double bonds and the location of their first double bond from 
the methyl end. Fatty acids are not only an important source of energy providing 37 kJ per 
gram, but they are also important constituents of cell membrane and serve as signalling 
molecules regulating gene expression [Calder 2011B, Ruston and Drevon, 2005]. Fatty 
acids can be present as free NEFA or as part of more complex lipids TG and phospholipids 
(PL).  
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Figure 1.1. Structures of various common dietary fatty acids, illustrating palmitic acid (C16:0), 
oleic acid (C18:1 n-9), linoleic acid (C18:2 n-6), arachidonic acid (C20:4 n-6), α-linolenic acid 
(C18:3 n-3), eicosapentaenoic acid (C20:5 n-3) and docosahexaenoic acid (C22:6 n-3). 
 
Long chain n-3 PUFA – recommended intakes and dietary resources 
PUFA can only be produced by plants and phytoplankton, and since mammals cannot 
interconvert n-6 and n-3 PUFA they have to acquire through their diet both linoleic acid (LA, 
C18:2 n-6) and α-linolenic acid (ALA, C18:3 n-3), which they can further metabolise through 
series of desaturation and elongation steps. The most important dietary n-3 PUFAs are ALA 
and LC n-3 PUFA eicosapentaenoic acid (EPA, C20:5 n-3) and docosahexaenoic acid 
(DHA, C22:6 n-3) (Figure 1.1). Only ALA is considered to be an essential fatty acid, since 
EPA and DHA can be synthesised from ALA, although the bioconversion is very low in 
humans (0.2 – 6% for EPA, 0 – 0.5% for DHA) [Arterburn et al., 2006, Minihane et al., 2000]. 
EPA and DHA are also referred to as marine n-3 PUFA, since they are present in 
considerable amounts in oily fish (± 2 g EPA+DHA / 100g [SACN, 2004]) such as mackerel 
and salmon. Many organizations and expert committees have acknowledged the important 
role of LC n-3 PUFA in human health, but so far no dietary reference intakes (DRI) have 
been set for EPA and DHA [Aranceta and Perez-Rodrigo, 2012, Flock et al., 2013, Harris et 
al., 2009, Kris-Etherton et al., 2009]. Various national and international organisations provide 
guidance on desirable intakes of EPA and DHA from fish. The recommendations in adults 
C16:0
C18:1 n-9
C18:2 n-6
C20:4 n-6
C18:3 n-3
C20:5 n-3
C22:6 n-3
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are based mainly on the primary and secondary prevention of CVD and range from one to 
two portions of oily fish per week or 250 – 500 mg EPA and DHA per day [Aranceta and 
Perez-Rodrigo, 2012, Mozaffarian and Rimm, 2006]. For the maintenance of normal plasma 
TG and blood pressure in adult men and women intakes of 2 – 4 g/d and 3 g/d have been 
recommended [Aranceta and Perez-Rodrigo, 2012, Flock et al., 2013, Lorente-Cebrian et 
al., 2013]. Flock et al. reviewed the extensive data on the effect of LC n-3 PUFA on CVD 
outcomes and recommended an intake of 566 mg/d for EPA and DHA, which is associated 
with the greatest risk reduction (37 %) in CHD mortality [Flock et al., 2013, Harris et al., 
2008]. In the UK the current recommendation for optimal health is 450 mg/d, which would be 
available if people would consume at least two portions of fish a week of which one is oily 
[SACN, 2004]. This consumption would confer into significant public health benefits to the 
UK population in terms of reducing the risk of CVD, as the UK population has low fish intake 
and is considerd a high risk population for CVD. The tolerable upper intake level for EPA 
and DHA is still unknown, but long term intakes up to 5 g/d are considered safe for adults 
[EFSA, 2012]. Intakes of 2 – 6 g/d induce an increase in LDL-C concentration of about 3 %, 
however since it is associated with a decrease in TG and no change in total cholesterol it 
may not have an adverse effect on the risk of CVD [EFSA, 2012]. In summary, more studies 
are needed to determine the optimal DRI for different populations based on age, gender, 
body weight, race, health status and genotype [Flock et al., 2013]. 
Long chain n-3 PUFA – function 
LC n-3 PUFA have various physiological roles in many different processes including the 
regulation of platelet function, vascular function, cognitive and visual development, bone 
turnover, immune function, insulin sensitivity and plasma TG concentrations [For full list see 
Calder, 2012], of which many processes are linked to cardiovascular and inflammatory 
diseases [Calder, 2012]. In fact, LC n-3 PUFA intake has been associated with a reduced 
risk of CVD events that is primarily attributed to the prevention of cardiovascular mortality, 
though findings are somewhat inconsistent [Calder, 2004, Flock et al., 2013, Harris et al., 
2008, Mozaffarian and Wu, 2011, Von Schacky, 2015]. For example, a meta-analysis of six 
epidemiologic studies conducted in the United States showed that an intake of about 500 
mg/d of EPA and DHA achievable by the consumption of two portions of oily fish per week 
was associated with a 37 % reduced risk of CHD mortality [Harris et al., 2008]. Meta-
analyses of randomized, double-blind, placebo controlled trials (RCTs) demonstrated that 
LC n-3 PUFA reduce sudden death and fatal myocardial infarction, with no effect on all-
cause mortality, in patients with existing or previous CVD (Table 1.5) [Bucher et al., 2002, 
Casula et al., 2013, Kwak et al., 2012]. A meta-analysis of 16 prospective cohort studies 
indicated that a moderate dietary EPA and DHA intake of 250 mg/d was sufficient to reduce 
the risk for cardiac death by about 30% in generally healthy individuals without known heart 
disease [Harris et al., 2009]. The cardioprotective effects of LC n-3 PUFA have been 
ascribed to their anti-arrhythmic actions [Von Schacky, 2008, Harris et al., 2009] and 
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beneficial effect on various cardiovascular risk factors, including blood pressure [Gelijnse et 
al., 2002], platelet reactivity and thrombosis [Hornstra, 2001], plasma TG concentrations 
[Harris, 1996], vascular function [Nestel et al., 2002] and inflammation [Adkins and Kelly 
2010, Calder, 2006, Calder, 2012]. Low doses of EPA and DHA (0.5 – 1 g EPA+DHA / d) 
are unlikely to reduce CVD risk and incidence, but they may reduce mortality by their anti-
arrhythmic effects improving post-myocardial infarct survival [Von Schacky, 2008]. Besides, 
there is evidence indicating LC n-3 PUFA could elevate the disease burden of conditions 
with an inflammatory component, which have been best-established for rheumatoid arthritis 
and inflammatory bowel disease [Calder, 2006, Calder et al., 2011A, Rangel-Huerta et al., 
2012]. For example, recent meta-analyses showed that LC n-3 PUFA reduce nonsteroidal 
anti-inflammatory drug use and tend to improve tender and swollen joint count, morning 
stiffness and physical function in patients with rheumatoid arthritis [Lee et al., 2012] and 
reduce the risk of relapse in patients with Crohn’s Disease [Lev-Tzion et al., 2014]. These 
findings indicate that LC n-3 PUFA can reduce the burden of inflammatory diseases. Finally, 
a comprehensive review on diet and low-grade inflammation with special focus on 
inflammation in overweight and obesity showed there is overwhelming evidence indicating 
LC n-3 PUFA have anti-inflammatory effects in humans when consumed at sufficient doses 
(≥ 2 g/d) [Calder et al., 2011A]. Whether there may be effects at lower doses remains to be 
elucidated. Most studies have investigated the effects of LC n-3 PUFA on plasma 
inflammatory marker concentrations which may not fully reflect tissue inflammatory status 
and may be rather an insensitive biomarker of inflammatory status in humans. Gene 
expression profiling of peripheral blood mononuclear cells, which can be obtained from 
whole blood, may provide a more sensititve biomarker of the effects of LC n-3 PUFA on 
inflammation. Finally, LC n-3 PUFA appear to have anti-obesogenic effects that could be 
important in the prevention of obesity [Buckley and Howe, 2010, Flachs et al., 2014, Mori et 
al., 1999]. The anti-obesogenic and anti-inflammatory effects of LC n-3 PUFA will be 
discussed in more detail in the next paragraphs. 
Long chain n-3 PUFA in obesity and metabolic disease  
LC n-3 PUFA have been shown to exert potent anti-obesogenic effects in a considerable 
number of animal studies and disease models, but their effects in humans are inconsistent 
and human studies with appropriate design, size and duration are lacking [Buckley and 
Howe, 2010, Flachs et al., 2006, Lorente-Cebrián et al., 2013, Puglisi et al., 2011]. 
Prospective cohort studies found conflicting associations between fish intake and body 
weight in humans. For example, in the prospective Nurse’s Health Study a high fish intake (≥ 
5 portions / wk) was associated with a higher prevalence of obesity compared to low intake 
(< 1 portion / month) in women [Iso et al., 2001], whereas in the Health Professional Follow-
Up Study a high fish intake (≥ 5 portions / wk) was associated with lower prevalence of 
overweight compared to low intake (< 1 portion / month) in men [He et al., 2002]. Most RCTs 
have investigated the effect of LC n-3 PUFA either from fish or fish oil supplements on body 
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weight and body composition in combination with caloric restriction or exercise in overweight 
and obese individuals and reported either a beneficial or neutral effect of LC n-3 PUFA (0.3 
to 3.0 g/day) on body weight and/or body fat in combination with caloric restriction or 
exercise [Buckley and Howe, 2010, Lorente-Cebrián et al., 2013]. The first meta-analysis 
investigating the association between LC n-3 PUFA intake either from fish or fish oil 
supplements and body composition indicated that LC n-3 PUFA might influence body 
composition (Table 1.6) [Bender et al., 2014]. In more detail, individuals consuming fish or 
fish oil supplements showed a greater reduction in body weight (weighted mean difference 
(WMD) -0.59 kg, 95% CI -0.96 – -0.21), BMI (WMD 0.24 kg/m
2
, 95% CI -0.40 – -0.08), body 
fat (WMD -0.49%, 95% CI -0.97 – -0.01) and waist circumference (WMD -0.81 cm, 95% CI -
1.34 – -0.28) compared to control [Bender et al., 2014]. Only few studies (n = 3 RCT) 
investigated the association between LC n-3 PUFA intake either from fish or fish oil 
supplements and lean body mass, which likely explains why Bender et al. observed no 
difference in fat mass (WMD -0.36 kg, 95% CI -0.96 – 0.24) or lean body mass (WMD -0.19 
kg, 95% CI -0.72 – 0.33) [Bender et al., 2014]. In line with the above mentioned gender-
difference in the association between fish intake and body weight in the prospective cohort 
studies they also observed a trend for a stronger effect on waist circumference in men. The 
effect of LC n-3 PUFA either from fish consumption or fish oil supplements have shown 
inconsistent effects on body composition in RCTs and prospective cohort studies. One 
potential explanantion is that LC n-3 PUFA intake achieved by fish consumption may have a 
differential effect on body composition than LC n-3 PUFA intake achieved by fish oil 
supplements even if they provide a similar dose of LC n-3 PUFA. Fish namely contains 
several important nutrients, such as vitamin D, iodine, selenium, and antioxidants, which are 
missing from supplements. Moreover, a portion of fish often replaces meat whereas 
supplements are generally taken on top of the normal diet not accounting for the additional 
calories available in these supplements. Thus, LC n-3 PUFA intake achieved by fish 
consumption likely has addititional benificial effects on the overall dietary pattern and the 
dietary intake of other nutrients such as vitamin D. In summary, the effect of LC n-3 PUFA 
on body weight and body composition in healthy individuals remains nevertheless 
controversial and more RCTs are needed [Lorente-Cebrián et al., 2013].  
The potential mechanisms through which LC n-3 PUFA may reduce body weight and 
improve body composition in overweight and obese individuals include an enhanced post-
prandial satiety and regulation of genes involved in β-oxidation and adipogenesis [Buckley 
and Howe, 2010]. For example, a small cross-over study by Couet et al. showed that dietary 
fat replacement with fish oil (6 g/day containing 1.1 g EPA and 0.7 g DHA) resulted in a 
reduction in fat mass (-0.88 ± 0.16 (SD) vs. -0.30 ± 0.34 kg, p < 0.05) but no change in body 
weight (-0.70 ± 0.62 vs. -0.54 ± 0.52 kg) that was associated with an increased β-oxidation 
(1.06 ± 0.17 vs 0.87 ± 0.13 mg kg
-1
 min
-1
, p<0.05) in six healthy young adults (n = 5 men; 
mean age 23 ± 2 (SD) year; BMI 21.9 ± 1.6 kg/m
2
) [Couet et al., 1998]. More studies are 
needed to confirm the effects of LC n-3 PUFA on body weight, fat mass and β-oxidation in 
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healthy individuals. The effect of LC n-3 PUFA in animal studies are more convincing and 
include reduced AT expansion, reduced adipocyte proliferation and improved fatty acid 
oxidation that contribute to the prevention of diet-induced obesity in mice [Flachs et al., 
2009, Puglisi et al., 2011]. 
Regarding metabolic parameters, LC n-3 PUFA have been shown to improve insulin 
sensitivity and glucose homeostasis in various animal models of obesity and metabolic 
disease, but their effects in humans remain controversial [Akinkuolie et al., 2011, Flachs et 
al., 2014, Jafari et al., 2013]. In mice, LC n-3 PUFA decrease AT mass and improve various 
associated metabolic parameters including systemic IR, dyslipidemia, hepatic steatosis and 
AT inflammation, with the changes in metabolic parameters being independent of changes in 
AT mass [Puglisi et al., 2011]. Epidemiological studies in humans revealed a lower 
prevalence of impaired glucose tolerance (IGT) and T2DM in populations with a high fish 
intake, but prospective cohort studies have found contradictive effects of fish intake on risk 
of T2DM [Jafari et al., 2013]. Various meta-analyses reported no effect of LC n-3 PUFA 
intake on risk of T2DM in humans, but there is accumulating evidence that the effects are 
dependent on ethnicity or geographical location (Table 1.7). For example, a recent meta-
analysis of 24 prospective cohort studies showed that LC n-3 PUFA only exert beneficial on 
T2DM risk in Asian populations but not in Western populations, with a relative risk ratio for 
T2DM of 0.87 (95% CI 0.79 – 0.96) in Asian countries and 1.16 (95% CI 1.04 – 1.28) in 
Western countries comparing the highest with lowest LC n-3 PUFA intake [Zheng et al., 
2012]. These findings implicate the potential involvement of gene-diet interactions, although 
other factors such as type of fish (oily, lean, shellfish), other nutrients in fish (e.g. selenium, 
vitamin D) and preparation method (e.g. deep frying, steamed, raw), or other non-fish related 
differences in habitual diet or overall lifestyle may also be involved in the ethnic and 
geographical differences in the association between fish intake and risk of T2DM [Wallin et 
al., 2012, Zheng et al., 2012]. There is no effect of LC n-3 PUFA on glycemic control and 
insulin sensitivity - a measure of both insulin responsiveness and insulin resistance - in 
T2DM patients and people without T2DM (Table 1.8). These finding are in line with a recent 
review on the effects of LC n-3 PUFA on glucose homeostasis and insulin sensitivity in 
various categories of human subjects (healthy individuals, subject with MetS, T2DM 
patients, and CVD patients) reporting no change or a marginal improvement in IGT and IR in 
T2DM patients, a potential marginal improvement in IGT and IR in MetS patients, and no 
change or an impairment in glycemic control in healthy individuals [Flachs et al., 2014].  
The fatty acid composition of plasma or serum lipids (cholesterol esters (CE) and 
phospholipids (PL)) is known to mirror dietary intake over the last 6 – 8 weeks and also 
reflects endogenous fatty acid metabolism [Warensjo et al. 2006], whereas the fatty acid 
composition of AT reflects long-term intake [Hodson et al. 2008]. Thus serum and AT fatty 
acid composition can be used as a biomarker of short and long term fat quality [Warensjo et 
al., 2006]. An altered fatty acid profile has been shown to predict the development of IR 
[Iggman et al., 2010, Warensjo et al, 2009], T2DM [Vessby et al., 1994], MetS [Warensjo et 
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al, 2005, Warensjo et al, 2006], CVD [Ohrvall et al., 1996, Sundstrom et al., 2001] and 
mortality [Warensjo et al, 2008] in healthy 50-year-old men over period of 10 – 20 years of 
follow-up. The unfavourable fatty acid profile is characterised by high levels of palmitic acid 
(16:0) and low levels of linoleic acid (18:2 n-6) in plasma lipid esters and a proportionally 
higher level of palmitoleic acid (16:1 n-7) and and dihomo-gamma-linolenic (20:3 n-6), and is 
induced by diets rich in saturated fat and probably lower in polyunsaturated fatty acids 
[Vessby 2003, Warensjo et al, 2006]. The concentrations of EPA and DHA in serum lipids 
and AT did not relate to IR [Iggman et al., 2010] or predict the development of MetS 
Warensjo et al., 2006]. Moreover, a moderate LC n-3 PUFA supplementation (3.6 g/d for 12 
weeks) failed to modulate insulin sensititvity and secretion in healthy individuals on either a 
high saturated or high monounsaturated fat diet [Giacco et al., 2007]. These findings 
suggest dietary LC n-3 PUFA have no direct effect on insulin sensitivity and do not predict 
development of IR and MetS in healthy individuals. However, the fatty acid profile of 
saturated fatty acids and its desaturation products, i.e. palmitic acid (16:0) and palmitoleic 
acid (16:1 n-7), in serum lipids and AT predict the development of IR and MetS.  
The beneficial effects of LC n-3 PUFA on features of MetS observed in mice are likely 
mediated through AT, as LC n-3 PUFA not only reduce AT inflammation and IR but also 
improve the storage and secretory functions of AT [Puglisi et al., 2011, Slim and Minihane, 
2014]. For example, LC n-3 PUFA increase mitochondrial biosynthesis and β-oxidation in AT 
that at least partially account for their anti-obesogenic effects [Flachs et al., 2009]. In 
summary, there is a neutral or modest beneficial effect of LC n-3 PUFA on body weight and 
adiposity in humans and rodents. The effect of LC n-3 PUFA on features of MetS in mice is 
established and include improvement of dyslipidemia, glucose tolerance and insulin 
sensitivity, but their effects in humans remain controversial. There appears to be no 
beneficial effect of LC n-3 PUFA on plasma insulin or glucose homeostasis in healthy 
individuals, however its 20 – 30 % plasma TG lowering effect is well-established [Flachs et 
al., 2014]. 
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Table 1.5. Overview of meta-analyses investigating the relationship between fish and long chain n-3 PUFA intake and risk of cardiovascular disease events. 
Study details Outcome Effect of n-3 PUFA on CVD risk compared to control (unless specified otherwise) Reference 
Meta-analysis 
including 11 RCT 
(n = 15,806) 
All-cause mortality 
and MI in MI and 
CHD patients 
LC n-3 PUFA supplementation (0.5 to 9.7 g/day, ≥ 6 months): 
All-cause mortality   RR = 0.8, 95% CI 0.7 – 0.9 (9 studies, n = 15,495) 
Sudden cardiac death   RR = 0.7, 95% CI 0.6 – 0.9 (5 studies, n = 13,060) 
Fatal MI    RR = 0.7, 95% CI 0.6 – 0.8 (8 studies, n = 15,375) 
Non-fatal MI    RR = 0.8, 95% CI 0.5 – 1.2 (9 studies, n = 15,015) 
[Bucher et 
al., 2002] 
Meta-analysis 
including 11 RCT 
(n = 15,348) 
Secondary 
prevention in CVD 
patients 
LC n-3 PUFA supplementation (≥ 1 g/day, ≥ 1 yr): 
All-cause mortality   RR = 0.89; 95% CI 0.78 – 1.02 
Sudden death    RR = 0.67; 95% CI 0.52 – 0.87 
Cardiac death    RR = 0.68; 95% CI 0.56 – 0.83 
MI     RR = 0.75; 95% CI 0.63 – 0.88 
Stroke     RR = 1.31; 95% CI 0.90 – 1.90 
[Casula et 
al., 2013] 
Meta-analysis 
including 29 RCT 
(n = 35,144) 
Mortality and 
restenosis in high 
risk CV patients 
n-3 PUFA supplementation (0.9 to 6.9 g/d): 
All-cause mortality   RR = 0.88, 95% CI 0.64 – 1.03 (25 studies, n = 34,501) 
Restenosis    RR = 0.89, 95% CI 0.72 – 1.06 (14 studies, n = 3,553) 
[Fillion et 
al., 2010] 
Meta-analysis 
including 48 RCT 
(n = 36,913) and 
41 prospective 
cohort studies 
All-cause mortality, 
cardiovascular 
events, cancer 
High vs. low LC n-3 PUFA intake, prospective cohort studies (≥ 6 months): 
All-cause mortality   RR = 0.65, 95% CI 0.48 – 0.88 (3 studies, n = 3,801) 
Combined CV events   RR = 0.91, 95% CI 0.73 – 1.13 (7 studies, n = 69,702) 
Cancer    RR = 1.02, 95% CI 0.87 – 1.19 (10 studies, n = 112,460) 
Sudden death    RR = 0.44, 95% CI 0.21 – 0.91 (1 study, n = 5,734) 
Cardiovascular death   RR = 0.79, 95% CI 0.63 – 0.99 (11 studies, n = 107,303) 
Fatal MI    RR = 0.42, 95% CI 0.21 – 0.82 (2 studies, n = 6,534) 
Non-fatal MI    RR = 0.93, 95% CI 0.69 – 1.26 (4 studies, n = 59,475) 
Angina     N/A 
Stroke     RR = 0.87, 95% CI 0.72 – 1.04 (4 studies, n = 52,026) 
Heart failure    N/A 
Peripheral vascular event  RR = 0.94, 95% CI 0.84 – 1.04 (1 study, n = 12,512) 
Revascularisation intervention  RR = 1.07, 95% CI 0.76 – 1.50 (2 studies, n = 18,075) 
Diagnosis of diabetes   RR = 1.20, 95% CI 1.05 – 1.37 (2 studies, n = 14,398) 
[Hooper et 
al., 2004] 
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Table 1.5. continued. 
Study details Outcome Effect of n-3 PUFA on CVD risk compared to control (unless specified otherwise) Reference 
Meta-analysis 
including 48 RCT 
(n = 36,913) and 
41 prospective 
cohort studies 
All-cause mortality, 
cardiovascular 
events, cancer 
High vs. low LC n-3 PUFA supplementation, RCTs (0.4 to 7.0 g/d , ≥ 11 months): 
All-cause mortality   RR = 0.87, 95% CI 0.73 – 1.03 (44 studies, n = 36,195) 
Combined CV events   RR = 0.95, 95% CI 0.82 – 1.12 (31 studies, n = 35,140) 
Cancer    RR = 1.07, 95% CI 0.88 – 1.30 (10 studies, n = 17,433) 
Sudden death    RR = 0.85, 95% CI 0.49 – 1.48 (37 studies, n = 19,387) 
Cardiovascular death   RR = 0.85, 95% CI 0.68 – 1.06 (44 studies, n = 36,195) 
Fatal MI    RR = 0.86, 95% CI 0.60 – 1.25 (38 studies, n = 9,849) 
Non-fatal MI    RR = 1.03, 95% CI 0.70 – 1.50 (25 studies, n = 14,145) 
Angina     RR = 0.77, 95% CI 0.59 – 1.02 (25 studies, n = 17,198) 
Stroke     RR = 1.17, 95% CI 0.91 – 1.51 (26 studies, n = 33,305) 
Heart failure    RR = 0.51, 95% CI 0.31 – 0.85 (20 studies, n = 7,684) 
Peripheral vascular event  RR = 0.26, 95% CI 0.07 – 1.06 (17 studies, n = 20,430) 
Revascularisation intervention  RR = 1.05, 95% CI 0.97 – 1.12 (23 studies, n = 14,887) 
Diagnosis of diabetes   RR = 0.87, 95% CI 0.15 – 5.08 (2 studies, n = 16,520) 
Body weight    WMD = -0.59 kg, 95% CI -1.91 – 0.73 (7 studies, n = 1,970) 
Serum TC    WMD =  0.03 mmol/L, 95% CI -0.06 –  0.12 (17 studies, n = 3,918) 
Serum LDL-C    WMD =  0.13 mmol/L, 95% CI  0.03 –  0.22 (12 studies, n = 1,673) 
Serum HDL-C    WMD =  0.01 mmol/L, 95% CI -0.03 –  0.05 (17 studies, n = 3,912) 
Serum TG    WMD = -0.40 mmol/L, 95% CI -0.56 – -0.23 (14 studies, n = 2,096) 
Blood pressure  
 systolic   WMD = -1.03 mmHg, 95% CI -3.30 – 1.25 (7 studies, n = 2,743) 
 diastolic   WMD = -0.23 mmHg, 95% CI -1.10 – 0.64 (7 studies, n = 2,743) 
[Hooper et 
al., 2004] 
Meta-analysis 
including 14 RCT 
(n = 20,485) 
Secondary 
prevention in CVD 
patients 
LC n-3 PUFA supplementation (0.4 to 4.8 g/d , ≥ 1 yr): 
All-cause mortality   RR = 0.96, 95% CI 0.90 – 1.02 (13 studies, n = 20,292) 
Sudden cardiac death   RR = 0.93, 95% CI 0.66 – 1.30 (5 studies, n = 11,668) 
Cardiovascular death   RR = 0.91, 95% CI 0.84 – 0.99 (11 studies, n = 13,974) 
All CV events    RR = 0.99, 95% CI 0.89 – 1.09 (14 studies, n = 20,485) 
MI     RR = 0.81, 95% CI 0.65 – 1.01 (11 studies, n = 16,207) 
Angina    RR = 0.77, 95% CI 0.50 – 1.18 (7 studies, n = 1,671) 
Congestive heart failure RR = 0.92, 95% CI 0.73 – 1.17 (6 studies, n = 8,422) 
TIA and stroke    RR = 1.13, 95% CI 0.77 – 1.66 (7 studies, n = 10,284) 
[Kwak et 
al., 2012] 
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Table 1.5. continued. 
Study details Outcome Effect of n-3 PUFA on CVD risk compared to control (unless specified otherwise) Reference 
Meta-analysis 
including 12 RCT 
(n = 32,779) 
Arrhythmias, 
sudden cardiac 
death, cardio-
vascular death, all-
cause mortality 
LC n-3 PUFA supplementation (0.5 to 2.8 g/day, ≥ 1 months): 
All-cause mortality   OR = 0.92, 95% CI 0.82 – 1.03 (11 studies, n = 32,439) 
Sudden cardiac death   OR = 0.81, 95% CI 0.52 – 1.25 (6 studies, n = 31,111)  
Cardiac death   OR = 0.80, 95% CI 0.69 – 0.92 (11 studies, n = 32,519)  
Risk of appropriate implantable  
cardiac defibrillator intervention  OR = 0.90, 95% CI 0.55 – 1.46 ( 3 studies, n = 1148) 
[Leon et 
al., 2008] 
Meta-analysis 
including 11 
prospective RCT  
(n = 39,044) 
Cardiovascular 
death 
LC n-3 PUFA supplementation (0.27 to 4.8 g/d, ≥ 1 yr): 
All-cause mortality   OR = 0.92, 95% CI 0.85 – 0.99 (11 studies, n = 39,044) 
Sudden cardiac death   OR = 0.87, 95% CI 0.76 – 0.99 (6 studies, n = 37,796) 
Cardiovascular death   OR = 0.87, 95% CI 0.79 – 0.95 (11 studies, n = 39,044) 
Nonfatal cardiovascular event  OR = 0.92, 95% CI 0.85 – 0.99 (9 studies, n = 38,096) 
[Marik and 
Varon et 
al., 2009] 
Meta-analysis 
including 20 RCT 
(n = 68,680) 
All-cause mortality, 
sudden death, 
cardiac death, MI, 
stroke. 
LC n-3 PUFA supplementation (mean 1.5 g/d, ≥ 1 yr): 
All-cause mortality  RR = 0.96; 95% CI 0.91 – 1.02 (17 studies, n = 63,279) 
Sudden death    RR = 0.87; 95% CI 0.75 – 1.01 (7 studies, n = 41,751) 
Cardiac death   RR = 0.91; 95% CI 0.85 – 0.98 (13 studies, n = 56,407) 
MI     RR = 0.89; 95% CI 0.76 – 1.04 (13 studies, n = 53,875) 
Stroke     RR = 1.05; 95% CI 0.93 – 1.18 (9 studies, n = 52,589) 
[Rizos et 
al., 2012] 
Meta-analysis 
including 18 RCT 
and 11 
prospective 
studies (n = 
51,264)  
Cardiac, 
cardiovascular, all-
cause mortality. 
LC n-3 PUFA supplementation, RCTs (0.27 to 6 g/d, ≥ 1 month): 
All-cause mortality   RR = 0.95, 95% CI 0.89 – 1.01 (17 studies, n = 51,264)  
Cardiac mortality   RR = 0.89, 95% CI 0.83 – 0.96 (14 studies, n = 48,500) 
 
Dose-response relationships increasing intake from < 0.20 to 0.20 g/d LC n-3 PUFA intake, 
prospective cohort studies (n ≥ 1000, ≥ 3 yr follow-up): 
All-cause mortality   RR = 0.98, 95% CI 0.89 – 1.08 (8 studies, n = 194,037) 
Cardiac, cardiovascular, or  
sudden cardiac death   OR = 0.64, 95% CI 0.46 – 0.89 (7 studies, n = 123,122) 
[Trikalinos 
et al., 
2012] 
This table is a non-exhaustive list of recent meta-analyses investigating the association between LC n-3 PUFA and risk of CVD. 95% CI, 95% confidence 
interval; CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; LC n-3 PUFA, long chain n-3 polyunsaturated fatty acid; MI, 
myocardial infarction; N/A, not applicable; OR, odds ratio; RCT, randomized controlled trial; RR, relative risk; T2DM, Type 2 Diabetes Mellitus; TIA, transient 
ischemic attack.  
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Table 1.6. Review and meta-analyses investigating the effect of long chain n-3 PUFA on body weight and body composition. 
Study details Outcome Effect of LC n-3 PUFA on body weight and body composition compared to control Reference 
Meta-analysis 
including 15 
RCTs (n = 934) 
Body composition 
measures 
Total fish or fish oil intake (0.2 to 3.4 g/d for 3 wks up to 3 yr): 
BW WMD -0.59 kg, 95% CI -0.96 – -0.21 (12 studies) 
BMI WMD -0.24 kg/m
2
, 95% CI -0.40 – -0.08 (13 studies) 
WC WMD -0.81 cm, 95% CI -1.34 – -0.28 (7 studies) 
BF WMD -0.49%, 95% CI -0.97 – -0.01 (7 studies) 
FM WMD -0.36 kg, 95% CI -0.96 – 0.24 (3 studies) 
FFM WMD -0.19 kg, 95% CI -0.72 – 0.33 (3 studies) 
[Bender et 
al., 2014] 
Meta-analysis 
including 7 RCTs 
(n = 1,970)  
All-cause mortality, 
cardiovascular 
events, cancer 
BW  WMD = -0.59 kg, 95% CI -1.91 – 0.73  [Hooper et 
al., 2004] 
Review of 10 
studies  
Body weight, fat 
mass 
Prospective studies: 
Potential inverse relation between LC n-3 PUFA and body weight and fat mass, but lacking 
consistency. 
 
RCTs: 
Conflicting results of the effect of LC n-3 PUFA in combination with CR and/or exercise on body 
weight and fat mass in overweight and obese subjects. 
[Lorente-
Cebrián et 
al., 2013] 
LC n-3 PUFA, long chain n-3 polyunsaturated fatty acid; BF, body fat; BMI, body mass index; BW, body weight; CR, caloric restriction; FM, fat mass, FFM, 
lean body mass (fat free mass); RCT, randomized controlled trial; WC, waist circumference; WMD, weighted mean difference, i.e. difference in means. 
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Table 1.7. Recent meta-analyses investigating the relationship between fish and long chain n-3 
PUFA intake and risk of Type 2 Diabetes Mellitus. 
Study details T2DM risk compared to control Reference 
Meta-analysis 
including 16 
prospective studies 
(n = 24,082 T2DM 
patients and 527,441 
participants)  
For each 1 serving / week increase in total fish intake:  
Asia/Australia        RR = 0.98, 95% CI 0.97 – 1.00 
Europe        RR = 1.03, 95% CI 0.96 – 1.11 
U.S.         RR = 1.05, 95% CI 1.02 – 1.09 
 
For each 0.3 g/day increase in LC n-3 PUFA intake:  
Asia/Australia        RR = 0.90, 95% CI 0.82 – 0.98 
Europe        RR = 0.98, 95% CI 0.70 – 1.37  
U.S.         RR = 1.17, 95% CI 1.09 – 1.26 
[Wallin et 
al., 2012] 
Meta-analysis 
including 16 
prospective studies 
(n = 25,670 T2DM 
patients and 540,184 
participants) 
For each 100 g/day increase in fish/seafood intake 
(13 studies, n = 481,489): 
Overall         RR = 1.12, 95% CI 0.94 – 1.34 
Asia         RR = 0.89, 95% CI 0·81 – 0.98 
North America/ 
Europe        RR = 1.38, 95% CI 1.13 – 1.70 
 
For each 250 mg/day increase in LC n-3 PUFA intake 
(16 studies, n = 440,873): 
Overall         RR = 1.04, 95% CI 0.97 – 1.10 
Asia         RR = 0.95, 95% CI 0.91 – 0.99 
North America/ 
Europe        RR = 1.12, 95% CI 1.05 – 1.20 
 
For each 3% of total fatty acids increase in circulating 
LC n-3 PUFA (5 studies, n = 10,382): 
Overall         RR = 0.94, 95% CI 0.75 – 1.17  
[Wu et al., 
2012] 
Meta-analysis 
including 24 
prospective cohort 
studies (n = 24,509 
T2DM patients and 
545,275 participants) 
Total fish intake (highest vs. lowest): 
Overall         RR = 1.07, 95% CI 0.91 – 1.25 
Asian countries       RR = 0.89, 95% CI 0.81 – 0.98 
Western countries   RR = 1.20, 95% CI 1.01 – 1.44 
 
LC n-3 PUFA intake (highest vs. lowest): 
Overall         RR = 1.07, 95% CI 0.95 – 1.20 
Asian countries       RR = 0.87, 95% CI 0.79 – 0.96 
Western countries   RR = 1.16, 95% CI 1.04 – 1.28 
[Zheng et 
al., 2012] 
This table is a non-exhaustive list of recent meta-analyses investigating the association between LC n-
3 PUFA intake and risk of T2DM. LC n-3 PUFA, long chain n-3 polyunsaturated fatty acid; RR, relative 
risk; T2DM, Type 2 Diabetes Mellitus. 
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Table 1.8. Recent meta-analyses investigating the effect of long chain n-3 PUFA on glycemic 
control and insulin sensitivity. 
Study 
details 
Outcome Effect of LC n-3 PUFA compared to control Reference 
Meta-
analysis 
including 11 
RCTs  
(n = 618) 
IS By study population: 
Overall             SMD = 0.08, 95% CI -0.11 – 0.28 
T2DM            SMD = -0.02, 95% CI -0.81 – 0.77 
Without T2DM SMD = 0.09, 95% CI -0.09 – 0.28 
 
By measure of IS: 
HOMA            SMD = 0.30, 95% CI 0.03 – 0.58 
QUICKI            SMD = 0.08, 95% CI -0.51 – 0.68 
Other test        SMD = -0.02, 95% CI -0.33 – 0.29 
[Akinkuolie 
et al., 
2011] 
Meta-
analysis 
including 16 
studies in 
T1DM and 
T2DM 
patients  
(n = 425) 
Fasting 
glucose, 
HbA1c 
Fasting glucose (mmol/L): 
Overall       WMD = -0.06, 95% CI -0.71 – 0.59 
T1DM       WMD = -1.86, 95% CI -3.1 – -0.61 
T2DM       WMD = 0.43, 95% CI 0.00 – 0.87 
 
HbA1c (%): 
Overall         WMD = 0.16, 95% CI -0.10 – 0.41 
T1DM         WMD = 0.17, 95% CI -0.09 – 0.43 
T2DM         WMD = 0.14, 95% CI -0.41 – 0.68 
[Friedberg 
et al., 
1998] 
Meta-
analysis 
including 23 
RCTs in 
T2DM 
patients  
(n = 1,075) 
Fasting 
glucose, 
fasting 
insulin, 
HbA1c 
Fasting glucose (mmol/L) (16 studies, n = 930): 
WMD = 0.16, 95% CI -0.13 – 0.46  
 
Fasting insulin (pmol/L) (8 studies, n = 529): 
WMD = -4.19, 95% CI -13.09 – 4.71  
 
HbA1c (%) (15 studies, n = 848): 
WMD = 0.01, 95% CI -0.03 – 0.01 
[Hartweg 
et al., 
2008] 
Meta-
analysis 
including 18 
RCTs in 
T2DM 
patients 
(n = 823) 
Fasting 
glucose, 
HbA1c 
Fasting glucose (mmol/L) (12 studies, n = 649): 
WMD = 0.26, 95% CI -0.08 – 0.60  
 
HbA1c (%) (15 studies, n = 660): 
WMD = 0.15, 95% CI -0.08 – 0.37  
[Montori et 
al., 2000] 
This table is a non-exhaustive list of recent meta-analyses investigating the association between LC n-
3 PUFA intake and insulin sensitivity and glycemic control. HbA1c, glycated haemoglobin; HOMA, 
homeostasis model assessment; IR, insulin resistance; IS, insulin sensitivity; LC n-3 PUFA, long chain 
n-3 polyunsaturated fatty acid; QUICKI, quantitative insulin sensitivity check index; RCT, randomized 
controlled trial; RR, relative risk; SMD, standard mean difference; T1DM, Type 1 Diabetes Mellitus; 
T2DM, Type 2 Diabetes Mellitus; WMD, weighted mean difference, i.e. difference in means. 
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Long chain n-3 PUFA in inflammatory disease 
LC n-3 PUFA are anti-inflammatory and have been associated with a decreased 
inflammatory response in in vitro models and in humans, which is of relevance to the low-
grade inflammation in obesity [Calder, 2006, Calder et al., 2011A, Puglisi et al., 2011, 
Rangel-Huerta et al., 2012]. For example, a meta-analysis of sixty-eight RCTs showed that 
LC n-3 PUFA lower circulating CRP (weighted mean difference (WMD) -0.20, 95% CI -0.28 
– -0.12, p < 0.001) and IL-6 (WMD -0.22, 95% CI -0.38 – -0.06, p < 0.01), but not TNF-α 
(WMD -0.11, 95% CI -0.24 – 0.03, ns.) in subjects with chronic non-autoimmune disease [Li 
et al., 2014]. In addition, LC n-3 PUFA lower circulating CRP (WMD -0.18, 95% CI -0.28 – -
0.08, p < 0.01), TNF-α (WMD -0.12, 95% CI -0.16 – -0.07, p < 0.001) and possibly IL-6 
(WMD -0.09, 95% CI - 0.18 – 0.01, p = 0.07) in healthy subjects. In another study LC n-3 
PUFA supplementation (1.8 g/d of EPA and DHA for 2 months) decreased the plasma 
plasminogen activator inhibitor-1 levels and inflammatory gene expression in AT (i.e. 
chemoattractant plasminogen activator urokinase receptor, macrophage surface markers 
CD11b and CD18 and macrophage phagocytic activity marker CD68) which was associated 
with a lower fat mass and adipocyte diameter, in overweight women (BMI 30 kg/m
2
) with 
T2DM [Kabir et al., 2007]. However in this study there was no effect of LC n-3 
supplementation on plasma TNF-α and IL-6 levels. The dose of LC n-3 PUFA, EPA and 
DHA seems to be important for the effects on inflammatory outcomes [Calder et al., 2011A, 
Li et al., 2014]. For example, in the meta-analysis described above a higher dose of EPA (≥ 
median) has been associated with a greater CRP-lowering effect whereas a lower dose of 
DHA (< median) was associated with a greater IL-6 lowering effect in healthy subjects [Li et 
al., 2014]. 
In vitro studies have confirmed the anti-inflammatory effects of EPA and DHA in 
macrophages, which are known to play an important role in AT inflammation in obesity 
[Mullen et al., 2010, Oliver et al., 2012]. For example, EPA and DHA (25 mM) decreased the 
LPS-induced cytokine production of IL-1β, IL-6 and TNF-α and nuclear factor-kappa B (NF-
κB) transcription activity in human THP-1-derived macrophages [Mullen et al., 2010]. In line 
with this, DHA (50 μM) significantly attenuated the LPS-induced inflammatory response 
(lower NF-κB activation, lower TNF-α production and greater IL-10 production) in J774.2 
macrophages, which in turn decreased adipocyte inflammation (lower IL-6 and TNF-α 
production, and greater IL-10 production) and maintained adipocyte insulin-sensitivity in an 
in vitro co-culture model with 3T3-L1 adipocytes [Oliver et al., 2012]. Besides LC n-3 PUFA 
reduced ATM infiltration and/or AT inflammation markers in various mouse models of diet-
induced obesity [Muurling et al., 2003, Oh et al., 2010, Saraswathi et al., 2007, Todoric et 
al., 2006]. A recent fish oil intervention trial investigating the effect of LC n-3 PUFA (3.36 g 
EPA+DHA / d) on AT inflammation in 55 severely obese non-diabetic patients undergoing 
elective bariatric surgery, showed LC n-3 PUFA decreased inflammatory gene expression in 
subcutaneous, but not visceral, AT [Itariu et al., 2012]. In summary, LC n-3 PUFA are anti-
inflammatory molecules with the potential to reduce inflammation in obesity. 
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Long chain n-3 PUFA and mechanism of action 
The effects of LC n-3 PUFA on cell and tissue function have been suggested to be mediated 
through three general mechanisms; 1) transcription factor function and cell signalling; 2) cell 
membrane and lipid raft fatty acid composition influencing membrane fluidity, protein 
composition and receptor function; 3) cell membrane fatty acid composition influencing 
production of fatty acid-derived bioactive mediators [Calder, 2012, Kalupahana et al., 2011].  
Effect on receptors and sensors 
The first mechanism through which LC n-3 PUFA exert their anti-inflammatory effect is via 
surface and/or intracellular receptors and sensors, including transcription factors NF-κB, 
peroxisome proliferator-activated receptors (PPARs) and nuclear factor erythroid 2 related 
factor 2 (Nrf2), which are discussed separately in more detail in the following paragraphs. 
Recently it has also been suggested that LC n-3 PUFA can exert beneficial effects though 
G-protein coupled receptor (GPR)120 and GPR40 which are able to bind LC n-3 PUFA and 
are involved in signal transduction [Calder 2011B, Kalupahana et al., 2011, Tomita et al., 
2014]. Interestingly, it was shown that an agonist of the GPR120 receptor that is highly 
expressed in inflammatory macrophages was able to diminish the LPS-induced inflammatory 
response (TNF-α and IL-6 production, IκB phosphorylation) in macrophages, whereas the 
anti-inflammatory effect of DHA on macrophage response to LPS was abolished in GPR120 
knock-down cells [Calder, 2011B, Oh et al., 2010]. On the other hand, activation of GPR40 
that is highly expressed in intestinal and pancreatic cells by LC n-3 PUFA is involved in the 
regulation of glucose metabolism through the augmentation of glucose-dependent insulin 
secretion [Tomita et al., 2014]. 
Effect on nuclear factor kappa-B (NF-κB) target genes 
NF-κB is the key transcription factor involved in the upregulation of inflammatory cytokine, 
adhesion molecule and COX-2 genes [May and Ghosh, 1998] and has been linked to 
inflammation-associated metabolic diseases [Baker et al., 2011]. Some examples of 
extracellular stimuli resulting in NF-κB activation are binding of TNF-α to its receptor and 
binding of LPS (also known as endotoxin) to the Toll-like receptor 4 receptor. LC n-3 PUFA 
have been shown to reduce the expression of inflammatory cytokines (TNF-α, IL-1, IL-6, IL-
8, IL-12) and proteins (COX-2, iNOS) upon LPS stimulation in various cell types [Calder, 
2011B]. For example, Lee et al. showed that DHA (5 - 50 μM) decreased the LPS-induced 
protein expression of COX-2, iNOS, and IL-1α in RAW 264.7 macrophages which involved 
the inhibition of NF-κB activation and decreased IκB degradation [Lee et al., 2004]. In 
addition, they showed that lauric acid (C12:0), which is a potential ligand for Toll-like 
receptors, augmented the NF-κB activation in macrophages, but this could be reversed by 
EPA and DHA. Furthermore, recent data indicate that LC n-3 PUFA, in particular DHA, can 
also influence NF-κB activation far more upstream at cell membrane level via modulation of 
lipid raft formation [Calder, 2011B], with two recent studies showing DHA exerts its inhibitory 
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effects on NF-κB activation at the Toll-like receptor 4 receptor level [Lee et al., 2004, Wong 
et al., 2009].  
Effect on peroxisome proliferator-activated receptors (PPARs) 
The PPAR family includes PPAR-α, PPAR-γ and PPAR-δ, which are regulators of fatty acid 
metabolism, glucose homeostasis, cellular proliferation, differentiation and apoptosis and 
inflammation [Chinetti et al., 2000, Delerive et al., 2001]. PPAR-α and PPAR-γ have been 
well described and, besides their function in metabolic control, are also involved in the 
control of the inflammatory response. They have anti-inflammatory effects which encompass 
the direct regulation of anti-inflammatory gene expression and interference with NF-κB 
activation [Calder, 2011B, Chinetti et al., 2000, Delerive et al., 2001]. PPAR-α is 
predominantly expressed in the liver and an important regulator of fatty acid β-oxidation and 
energy homeostasis, with its target genes being involved in peroxisome proliferation, fatty 
acid oxidation and uptake of fatty acid from circulation (hypolidemia) [Chinetti et al., 2000, 
Delerive et al., 2001]. PPAR-γ is mainly expressed in adipocytes where it is essential for 
adipocyte differentiation and stimulates lipid storage and insulin sensitivity [Chinetti et al., 
2000, Delerive et al., 2001]. However, macrophages also express PPAR-α and PPAR-γ, in 
particular upon differentiation, where they are important in controlling the inflammatory 
mediator production [Chinetti et al., 2000]. LC n-3 PUFA and their metabolites are 
endogenous ligands for PPARs [Calder, 2011B, Chinetti et al., 2000]. The activation of 
PPAR by LC n-3 PUFA involves binding to PPAR followed by translocation from the cytosol 
to the nucleus where it either forms heterodimer with retinoic acid receptor or binds to 
transcription factor NF-κB. The dimerisation with retinoic acid receptor results in binding to 
peroxisome proliferator response element and induction of the expression of its target genes 
(including anti-inflammatory mediators). The binding to NF-κB prevents binding of NF-κB to 
its response element inhibiting the expression of NF-κB target genes. Thus, PPAR activation 
by LC n-3 PUFA has both metabolic and anti-inflammatory down-stream effects.  
Effect on nuclear factor erythroid 2 related factor 2 (Nrf2) 
Nrf2 is a key transcription factor involved in the oxidative stress response, which plays an 
important role in health resilience (i.e. the ability to cope with stress, produce a protective 
response and return to homeostasis after a stress challenge) [De Roos and Duthie, 2015, 
Stefanson and Backovic, 2014]. Nrf2 regulates the transcription of many important 
antioxidant and detoxification genes, including glutathione peroxidise (GPx), superoxide 
dismutase (SOD), heme oxygenase-1 (HO-1), catalase, glutathione-S-transferases (GST) 
and NAD(P)H:quinone oxidoreductase-1 (NQO1), and activates proteasomal and chaperone 
proteins that are involved in repairing and degradating damaged proteins. Reactive oxygen 
species (ROS) are produced by normal energy metabolism and function as signalling 
molecules. At low and moderate concentrations ROS activate Nrf2 resulting in an antioxidant 
response, whereas high levels of ROS activate NF-κB resulting in a proinflammatory 
response [Stefanson and Backovic, 2014]. Dietary fatty acids, in particular EPA and DHA, 
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are prone to oxidation and are believed to increase ROS levels just enough to activate Nrf2 
[De Roos and Duthie, 2015]. For example, oxidized EPA and DHA have been shown to 
activate Nrf2 and induce Nrf2 target gene expression in endothelial cells [Ishikado et al., 
2013, Majkova et al., 2011]. Furthermore, the induction of the Nrf2 target gene HO-1 has 
been shown to modulate polarisation towards the anti-inflammatory M2 phenotype and 
increase the production of IL-10 in macrophages [Naito et al., 2014], which provides a 
potential link between the Nrf2 pathway and the pro- and anti-inflammatory macrophage 
phenotype. Thus dietary LC n-3 PUFA are able to prime the Nrf2 pathway resulting in 
upregulation of the above described enzymes prior to oxidative stress, which increases the 
cellular fitness to respond more robustly to an oxidative assault without activating the more 
intense inflammatory NF-κB pathway (i.e. improved resilience) [Stefanson and Backovic, 
2014].  
Effect on bioactive mediator production 
The second and third mechanism through which LC n-3 PUFA exert anti-inflammatory 
effects is via incorporation into cell membrane phospholipids where they are involved in 
membrane protein function [Murphy, 1990], membrane fluidity [Stubbs and Smith, 1984], 
lipid raft formulation [Yaqoob et al., 2009], and serve as substrates for enzymes to produce 
bioactive lipid mediators including eicosanoids, resolvins, protectins and maresins [Buckley 
et al., 2014, Calder, 2011B, Spite et al., 2014]. Eicosanoids are a family of active mediators 
consisting of prostaglandins, prostacyclins, thromboxanes and leukotrienes, that serve as 
regulators of inflammation and are produced from arachidonic acid (AA, C20:4 n-6) and 20-
carbon PUFA EPA (C20:5, n-3). Phospholipid membranes of immune cells are in general 
rich in AA, which serves as major substrate for enzymes cyclooxygenase (COX) and 
lipoxygenase (LOX) to produce the predominantly pro-inflammatory eicosanoids 2-series 
prostaglandins (PG) and 4-series leukotrienes (LT) [Bagga et al., 2003, Ratnayake and Galli, 
2009]. On the other hand, EPA serves as a substrate for the same enzymes to produce less 
inflammatory 4-series PG and 5-series LT [Bagga et al., 2003, Ratnayake and Galli, 2009]. 
Besides, EPA and DHA are incorporated into phospholipid membranes in a dose-response 
manner partly at the expense of AA, resulting in less substrate available for production of its 
more pro-inflammatory eicosanoids [Calder, 2006]. Thus, LC n-3 PUFA cause a shift in 
eicosanoid production towards more anti-inflammatory mediators. Finally, EPA and DHA 
give rise to lipid mediators with potent pro-resolving properties, including resolvins, 
protectins and maresins [Buckley et al., 2014, Spite et al., 2014]. The E-series (EPA-
derived) and D-series (DHA-derived) resolvins and DHA-derived protectins have potent anti-
inflammatory effects in macrophages and microglia [Calder, 2009]. The lipid mediators 
appear to be potent mediators involved in the resolution of inflammation and metabolic 
diseases [Buckley et al., 2014, Spite et al., 2014]. 
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Research gaps 
Obesity has become a worldwide problem with major health, social and financial implications 
by increasing the risk for metabolic complications, various diseases and premature death 
[World Obesity Federation, 2014]. However, a proportion of obese people are not at an 
increased risk for these obesity-related comorbidities and display a MHO phenotype [Karelis 
et al., 2004, Wildman et al., 2008]. Investigations into the determinants of MHO phenotype is 
of great importance to increase our understanding of what factors determine metabolic 
health in obesity, which can be possibly used to reduce the disease burden associated with 
obesity. So far, a low cardiorespiratory fitness, low AT expansion capacity, excess VAT and 
AT inflammation have been shown to be determinants of MHO phenotype [Barbarroja et al., 
2010, Karelis et al., 2004, Virtue and Vidal-Puig, 2010]. However, our knowledge of how 
common genetic variants interact with nutrition and other environmental factors to cause 
metabolic disease in obesity is still very poor, and the identification of protective and 
susceptibility genes is essential to help us understand why not all people with obesity 
develop metabolic disease [Osborn and Olefsky, 2012]. The immune system and 
metabolism are highly integrated and obesity-associated inflammation is an important 
contributing factor to T2DM and CVD, therefore unravelling what genetic variants interact 
with nutrition and other environmental factors to determine AT inflammation is of great 
importance [Osborn and Olefsky, 2012].  
In the past decades, the APOE Epsilon genotype has been identified as an important 
determinant of AD and CHD risk [Bennet et al., 2007, Corder et al., 1993, Song et al., 2004, 
Strittmatter et al., 1993, Takeda et al., 2010, Wilson et al., 1996], with recent studies 
suggesting involvement in obesity and its associated metabolic complication as well [Elosua 
et al., 2003, Kolovou et al., 2009, Marques-Vidal et al., 2003, Pouliot et al., 1990, Sima et al., 
2007]. Research from our group and other research groups has demonstrated that the 
APOE4 genotype is associated with a pro-inflammatory state [Jofre-Monseny et al., 2008], 
an impaired AT expandability and greater predisposition to the metabolic complications of 
obesity [Arbones-Mainar et al., 2008 and 2010], an altered LC n-3 PUFA status [Chouinard-
Watkins et al., 2013, Conway et al., 2014, Plourde et al., 2009, Vandal et al., 2014] and 
APOE Epsilon genotype interacts with adiposity to determine plasma inflammatory marker 
concentrations [Kofler et al., 2012]. Furthermore, LC n-3 PUFAs exert various beneficial 
effects on inflammatory and metabolic parameters altered in obesity [Flachs et al., 2009, 
Puglisi et al., 2011, Kalupahana et al., 2011], and these effects may be influenced by factors 
determining their plasma and tissue concentrations [Walker et al., 2013]. The impact of 
APOE Epsilon genotype on obesity and inflammation in humans is still relatively unknown 
and its impact on AT inflammation and ATM phenotype (polarisation) has never been 
investigated. Moreover, the potential involvement of LC n-3 PUFA status in the relationships 
between APOE Epsilon genotype, adiposity and inflammation has not been established. 
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Research question and objectives 
The overall aim of this PhD project is to investigate the relationships between APOE Epsilon 
genotype, adiposity, LC n-3 PUFA status and inflammation in order to advance the 
knowledge in the area, with the following specific objectives;  
1.) To investigate the relationships between APOE Epsilon genotype, adiposity, LC n-3 
PUFA status and inflammation, and the potential involvement of SNPs in APOE 
promoter region, in participants involved in a fish oil intervention trial (FINGEN) 
[Caslake et al., 2008, Kofler et al., 2012]. 
2.) To investigate the independent and interactive impact of APOE Epsilon genotype 
and fish oil on the development of diet-induced obesity (DIO) and whole-body 
glucose tolerance in human APOE3 and APOE4 TR mice.  
3.) To investigate the independent and interactive impact of APOE Epsilon genotype 
and fish oil on LC n-3 PUFA status and AT inflammation (ATM infiltration rate and 
phenotype) in human APOE3 and APOE4 TR mice.  
4.) To conduct a pilot study investigating the impact of APOE Epsilon genotype on the 
‘basal’ phenotype of macrophages in primary murine bone marrow-derived 
macrophages (BMM) to corroborate our findings from in vivo studies in human 
APOE TR mice. 
Hypotheses 
We hypothesise that the APOE Epsilon genotype is a determinant of inflammatory status, 
adiposity (i.e. AT expansion), and metabolic consequences of obesity, as well as a 
determinant of LC n-3 PUFA metabolism and the responsiveness to LC n-3 PUFA 
supplementation. In more detail, we hypothesize that compared to APOE3 allele the APOE4 
allele will be associated with;  
1.) a pro-inflammatory status,  
2.) a reduced AT expandability,  
3.) a greater predisposition to metabolic consequences of obesity,  
4.) an altered LC n-3 PUFA metabolism,  
5.) an impaired responsiveness to LC n-3 PUFA supplementation. 
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Chapter 2. APOE genotype, adiposity, long chain n-3 
polyunsaturated fatty acids and inflammation: 
Relationships between -219G/T and E2/E3/E4 APOE 
genotypes, adiposity, long chain n-3 polyunsaturated 
fatty acids and plasma inflammatory markers in the 
FINGEN cohort.  
Retrospective analysis of baseline and response to intervention data from a double-blind 
placebo controlled cross-over fish oil intervention trial 
 
 
Introduction 
Overview of obesity, inflammation and long chain n-3 PUFA status 
Worldwide approximately 1 billion people are overweight (BMI 25 – 29.9 kg/m²) and a further 
475 million people are obese (BMI ≥ 30 kg/m
2
) [World Obesity Federation, 2014]. Obesity is 
associated with a state of systemic chronic low-grade inflammation and metabolic 
complications, such as metabolic syndrome (MetS) and insulin resistance (IR), which in turn 
increase the risk of developing Type 2 Diabetes Mellitus (T2DM) and cardiovascular disease 
(CVD) [Maury and Brichard, 2010, Van Gaal et al., 2006]. However, not all obese individuals 
develop the metabolic complications which lead to the increased risk of T2DM or CVD. 
Approximately one-third of obese people, termed metabolically healthy obese (MHO), have 
a normal metabolic profile characterised by a low visceral fat (VAT) content, high-density 
lipoprotein-cholesterol (HDL-C) levels, low triglyceride (TG) levels, high insulin sensitivity 
and low inflammation, despite their high fat mass [Barbarroja et al., 2010, Karelis et al., 
2004, Perrault et al., 2014, Wildman et al., 2008]. The MHO individuals have a lower risk of 
T2DM and CVD compared to metabolically unhealthy obese (MUO) and a similar risk of 
CVD compared to normal weight and metabolically healthy individuals [Primeau et al., 2011]. 
Tissue inflammatory status has emerged as an important determinant of the metabolic 
consequences of obesity, as the immune system and metabolic pathways involved in 
macronutrient metabolism and utilisation, including ATP production, are highly integrated 
[Osborn and Olefsky, 2012]. For example, a nutrient surplus and saturated fatty acids (SFA) 
can trigger intracellular stress signals potentiating pro-inflammatory signalling, whereas long 
chain (LC) n-3 polyunsaturated fatty acids (PUFA), eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) exert anti-inflammatory effects [Osborn and Olefsky, 2012]. 
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Furthermore, lower plasma EPA and DHA levels have been reported in MUO, but not MHO, 
compared to healthy lean individuals suggesting a lower whole-body availability of these LC 
n-3 PUFA that might also persist at tissue levels in MUO [Fernandez-Real et al., 2003, 
Perrault et al., 2014]. In summary, metabolic disease in obesity is associated with low-grade 
chronic inflammation and a poor LC n-3 PUFA status. 
Long chain n-3 PUFA and inflammation 
LC n-3 PUFA intake and status have been shown to be associated with a decreased 
inflammatory response in in vitro and animal models and in humans [Calder, 2006, Calder et 
al., 2011A, Puglisi et al., 2011]. For example, LC n-3 PUFA reduced ATM infiltration and AT 
inflammatory marker expression in various mouse models of diet-induced obesity [Muurling 
et al., 2003, Oh et al., 2010, Saraswathi et al., 2007, Todoric et al., 2006]. Besides, EPA and 
DHA supplementation (3.36 g/d) for 8 weeks decreased inflammatory gene expression in 
subcutaneous AT in 55 severely obese non-diabetic patients undergoing elective bariatric 
surgery [Itariu et al., 2012]. In healthy elderly subjects, EPA and DHA supplementation (1.8 
g/d) for 26 weeks decreased the expression of genes involved in inflammatory and 
atherogenic-related pathways, such as nuclear factor kappa-B (NF-κB) pathway, in 
peripheral blood mononuclear cells compared to a high-oleic acid sunflower control oil (4.0 
g/d) [Bouwens et al., 2009]. Therefore, LC n-3 PUFA may provide a potential strategy to 
resolve the chronic low-grade inflammation associated with obesity.  
APOE Epsilon genotype, inflammation and long chain n-3 PUFA status 
In addition to dietary fatty acids and associated tissue fatty acid status, common gene 
variants in inflammatory genes are likely to be independently or interactively important 
determinants of inflammatory status [Slim and Minihane, 2014]. Genetic variants in the 
apolipoprotein E (APOE) gene have emerged as an important determinant of inflammation, 
with the APOE Epsilon 4 (APOE4) genotype being associated with a pro-inflammatory state 
[Jofre-Monseny et al., 2008A, Lynch et al., 2003, Maezawa et al., 2006, Ophir et al., 2005, 
Tsoi et al., 2007]. ApoE is produced by hepatocytes, astrocytes in the brain and by 
adipocytes and macrophages in adipose tissue (AT). There is increasing evidence that apoE 
plays a role in AT development, the development of obesity and its related metabolic 
complications [Kypreos et al., 2009]. In the FINGEN study we demonstrated that APOE 
Epsilon genotype interacts with adiposity to determine plasma inflammatory marker 
concentrations [Kofler et al., 2012] suggesting that APOE Epsilon genotype may exert it 
effects on inflammation in part through modulation of AT metabolism. Limited studies 
investigating the association between APOE Epsilon genotype and adiposity in humans 
have provided accumulating evidence supporting a link between APOE Epsilon genotype, 
adiposity and the metabolic consequences of obesity [Elosua et al., 2003, Kolovou et al., 
2009, Sima et al., 2007]. Although there is some inconsistency, the APOE4 allele appears to 
be more prevalent in obese people [Elosua et al., 2003, Kolovou et al., 2009, Oh and 
Barrett-Connor, 2001, Sima et al., 2007, Volcik et al., 2006]. A few studies have reported an 
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interaction between APOE Epsilon genotype and BMI to determine metabolic and/or 
inflammatory parameters [Kofler et al., 2012, Marques-Vidal et al., 2003, Pouliot et al., 
1990]. These findings suggest that the APOE Epsilon genotype may influence adiposity and 
inflammatory status and interact with adiposity to determine the metabolic consequences of 
increased adiposity.  
Besides, APOE Epsilon genotype has been shown to impact on LC n-3 PUFA status, with 
APOE4 carriers having an altered DHA metabolism and suboptimal LC n-3 PUFA 
bioavailability [Plourde et al., 2009, Chouinard-Watkins et al., 2013, Vandal et al., 2014]. For 
instance, DHA concentrations in plasma triglycerides (TG) were increased by only 75 % in 
APOE4 carriers after a 6 week supplementation with 3 g/d EPA and DHA compared to a 240 
% increase in non-carriers [Plourde et al., 2009]. A kinetics study using isotopically labelled 
DHA revealed 31 % lower DHA levels in plasma total lipids and a more rapid β-oxidation of 
DHA 1 – 28 days post-dose (40 mg [
13
C]DHA) in APOE4 carriers compared to non-carriers 
[Chouinard-Watkins et al., 2013]. These findings suggest that APOE Epsilon genotype 
modulates the incorporation of EPA and DHA into plasma lipids, which in turn may affect 
their bioavailability and ability to exert beneficial effects [Carvalho-Wells et al., 2012, 
Minihane et al., 2000, Olano-Martin et al., 2010]. Currently little is known regarding the 
impact of APOE Epsilon genotype on tissue fatty acid status, which will be investigated in 
this thesis. 
In addition, the impact of APOE Epsilon genotype on inflammatory status and the 
responsiveness to EPA and DHA supplementation may be modulated by single nucleotide 
polymorphisms (SNPs) in the APOE promoter region, which are known to affect gene 
expression. As discussed in Chapter 1, the -219G/T (rs405509) and -491A/T (rs449647) 
polymorphisms in the APOE promoter region affect APOE expression levels and impact on 
Alzheimer’s Disease (AD) risk, which is independent of APOE Epsilon genotype for -491A/T 
polymorphism but not for -219G/T polymorphism [Lambert et al., 2002, Wang et al., 2000, 
Lescai et al., 2011, Artiga et al., 1998]. In more detail, the -491T allele and -219G allele were 
associated with respectively a 63 % decreased and 169 % increased transcriptional activity 
of APOE in a human hepatic cell line compared to wild type haplotypes (-491A and -219T) 
[Artiga et al., 1998]. In line with this, the -219T allele was associated with decreased plasma 
apoE concentrations in dose-dependent manner in the ECTIM study, adjusting for APOE 
Epsilon genotype (plasma apoE concentrations, 4.9 ± 1.8 (SD) for -219GG; 4.7 ± 1.7 for -
219GT; and 4.1 ± 1.5 mmol/L for -219TT, p < 0.01) [Lambert et al., 2000]. Besides, the -
219T allele was associated with an increased AD risk (OR = 1.30, 95 % CI 1.06 – 1.60 for -
219TT) in 2,390 AD patients and controls, but this effect disappeared after correcting for 
presence of the APOE4 allele and further investigation in APOE4 carriers revealed no 
significant effect of -219T allele on AD risk (OR = 4.77, 95% CI 3.18 – 7.17 for -219T/APOE4 
vs. OR = 5.31, 95% CI 2.93 – 9.63 for -219G/APOE4) [Lescai et al., 2011]. These findings 
suggest that APOE Epsilon genotype interacts with SNP in the APOE promoter region to 
determine its expression levels and likely its impact on disease risk. However, the 
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independent and interactive (with APOE Epsilon E2 / E3 / E4 genotypes) impact of SNPs in 
the APOE promoter region on inflammatory status and the responsiveness to EPA and DHA 
supplementation remains to be elucidated.  
 
In conclusion, inflammation is likely to be an important modulator of the phenotype 
associated with obesity which may be influenced by APOE Epsilon genotype and LC n-3 
PUFA status. However our understanding of how these factors interact (Figure 2.1) is 
incomplete.  
 
 
Figure 2.1. Schematic overview of the associations and interactions between APOE Epsilon 
genotype, SNPs in APOE promoter region, LC n-3 PUFA status, inflammation and disease. 
Black solid arrows indicate a direct effect of one factor on another factor. Grey dotted arrows 
indicate how one factor can modulate the relationship between two other factors. APOE, 
apolipoprotein E; CVD, cardiovascular disease; LC n-3 PUFA, long chain n-3 polyunsaturated 
fatty acids; T2DM, type 2 Diabetes Mellitus. 
 
Research gaps 
Our understanding of how common genetic variants interact with dietary and other 
environmental factors to cause metabolic disease is still very poor [Osborn and Olefsky 
2012]. The identification of protective and susceptibility genes is crucial to help us, among 
others, explain why not all people with obesity develop metabolic diseases. In addition, more 
studies are needed to obtain a full understanding of the determinants of LC n-3 PUFA 
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status
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status, which is particularly important for predicting the likely health benefits associated with 
dietary intakes [Walker 2013]. We previously discussed how APOE Epsilon genotype and 
LC n-3 PUFA status may influence inflammation, which is an important modulator of the 
phenotype associated with obesity. The interactive impact of APOE Epsilon genotype and 
SNP in the APOE promoter region to determine LC n-3 PUFA status and inflammatory 
marker concentrations is currently unknown.  
Research question 
The overall aim of this study was to further investigate the relationships between APOE 
genotype, adiposity, fatty acid status and inflammation by using the existing data set from 
the FINGEN study [Caslake 2008, Kofler 2012] and perform novel genotyping for the -
219G/T polymorphism (rs405509) in APOE promoter region. The data was used to, 1.) 
perform an analysis of the determinants of LC n-3 PUFA status; 2.) investigate the impact of 
APOE Epsilon genotype, -219G/T genotype and -219G/T * APOE Epsilon haplotype on the 
plasma inflammatory marker concentrations; and 3.) to investigate the impact of the APOE 
genotypes on the plasma inflammatory marker responsiveness to LC n-3 PUFA 
supplementation. 
Hypotheses 
1) Age, gender, adiposity, APOE Epsilon genotype and the -219G/T polymorphism 
(rs405509) in APOE promoter region influence plasma LC n-3 PUFA status, with a 
poorer LC n-3 PUFA status in young versus old; men versus women; obese versus lean 
individuals; and APOE4 carriers versus those with APOE3 genotype, which may interact 
with the -219G/T genotype.  
2) APOE Epsilon genotype will interact with -219G/T polymorphism to determine plasma 
apoE and possibly plasma inflammatory marker concentrations. The highest plasma 
apoE concentrations are expected in those with APOE2 and -219GG genotype. The 
highest plasma inflammatory marker concentrations are expected in those with -219GG 
* APOE4 haplotype. 
3) APOE Epsilon genotype interacts with the -219G/T polymorphism to determine the 
plasma inflammatory marker responsiveness to LC n-3 PUFA supplementation. A poorer 
response is expected in APOE4 carriers compared to APOE3 genotype, which may 
interact with the -219G/T allele.  
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Materials & Methods 
This study used an existing data set from the FINGEN study [Caslake et al., 2008, Kofler et 
al., 2012, Rudkowska et al., 2014]. The primary aim of the original FINGEN study was to 
investigate the independent and interactive impact of APOE Epsilon genotype, age and 
gender on the responsiveness of over 40 biochemical markers of CHD to a modest dose fish 
oil intervention [Caslake et al., 2008, Miles et al., 2010, Kofler et al., 2012, Rudkowska et al., 
2014]. All data regarding APOE Epsilon genotype, habitual diet, plasma biochemistry, 
plasma fatty acid status in the phosphatidylcholine (PC) fraction, and plasma inflammatory 
marker concentrations was available from the existing FINGEN study data set. Only 
genotyping for the -219 G/T polymorphism (rs405509) in the APOE promoter region had to 
be performed as part of my PhD analysis. For completeness the current largely original 
analysis includes a small amount of published FINGEN data; where this occurs it is clearly 
indicated and referenced. 
 
FINGEN Study Timeline 
    V1               V2                           V3                V4                         V5                 V6 
      
 
 
    t=0               t=8                         t=20              t=28                       t=30             t=38 wk 
 
Figure 2.2. Timeline of the FINGEN study; a double-blind placebo controlled cross-over trial 
with three dietary intervention arms; 0.7 g EPA+DHA / day (LFO), 1.8 g EPA+DHA / day (MFO) 
and control oil (CO). The volunteers received each dietary intervention (CO / LFO / MFO) in 
random order separated by a 12 week washout period. At each visit (V1 – V6) a 12-h fasting 
blood sample was collected. A food frequency questionnaire (FFQ) was completed twice during 
the study period. t, time point; V, visit; wk, week. 
 
FINGEN study design and volunteers 
The FINGEN study was a double-blind placebo controlled cross-over trial with three 
intervention arms (0.7 g EPA+DHA / d and 1.8 g EPA+DHA / d and control oil) conducted at 
the Universities of Glasgow, Newcastle, Reading and Southampton between 2003 and 2006 
(Figure 2.2). Volunteers in the FINGEN study were generally fit and healthy and were 
prospectively recruited according to APOE Epsilon genotype (E2/E4 carriers were 
excluded), age (20 – 70 years) and gender, creating a study population with fairly equal 
distribution of males and females, all ages and all APOE genotypes. The dietary intervention 
consisted of modest doses of EPA and DHA (0.7 g/d and 1.8 g/d), which can be achieved 
through increased consumption of 2 – 4 portions of oily fish per week. The study design, fish 
oil capsule composition and volunteer exclusion criteria have been described in detail before 
[Caslake et al., 2008]. Briefly, randomization of the subjects to treatment order was achieved 
Arm 3 
CO/LFO/
MFO 
Washout Arm 2 
CO/LFO/
MFO 
 
Washout Arm 1  
CO/LFO/
MFO 
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by using a computer-generated random number table. APOE Epsilon genotypes were 
evenly randomised over the six treatment arm options. -219 G/T genotypes were not 
randomised over the treatment arm options, as the genotyping for the -219G/T alleles was 
performed retrospectively. An 8 week intervention period is long enough to observe an effect 
on plasma lipid profile, but is unlikely long enough to establish a new homeostasis in AT fatty 
acid composition or establish an effect on AT biology since the adipocyte turnover in 
humans is approximately 10 % per year independently of age or BMI [Spalding et al., 2008]. 
The FINGEN study was approved by the local research ethics committees (LRES) and all 
individuals provided informed written consent prior to participation. 
Study data description 
The APOE Epsilon genotyping, biochemical analysis of CHD risk markers and analysis of 
the fatty acid composition in the plasma PC lipid fraction has been described elsewhere 
[Caslake et al., 2008, Kofler et al., 2012]. The measures of interest regarding plasma LC n-3 
PUFA status were EPA, docosapentaenoic acid (DPA), DHA and total LC n-3 PUFA 
(EPA+DPA+DHA) measured as a percentage (%) of total fatty acids, and the ratio of EPA to 
arachidonic acid (AA) and SFA to PUFA in the plasma PC lipid fraction. The plasma 
inflammatory markers investigated were C-reactive protein (CRP), tumor necrosis factor 
(TNF)-α, interleukin (IL)-6, IL-10, intercellular adhesion molecule (ICAM)-1, vascular cellular 
adhesion molecule (VCAM)-1, E-selectin (E-sel) and P-selectin (P-sel). A food frequency 
questionnaire (FFQ) was completed twice during the study period to characterise habitual 
diet. The FFQ was modified from the European Prospective Investigation into Cancer and 
Nutrition FFQ that contained 154 items. An additional eight questions regarding fish 
consumption were included and fish groups were classified according to Welch et al. [Welch 
et al., 2002]. The data from the FFQ was used to calculate intakes of energy and nutrients 
using portion size information and nutrient composition values from the 6th edition of 
McCance and Widdowson food tables and Windiets2005 (developed by Dr. Alan Wise, 
Robert Gordon University, UK). Data was available for total energy intake, percentage of 
total energy derived from fat, percentage of total energy derived from alcohol, fatty acid 
intake split into SFA, monounsaturated fatty acids (MUFA) and PUFA, ratio of PUFA:SFA, 
portions of oily fish per week, fruit and vegetable intake (number of portions per week, 
absolute daily intake (g/d) and percentage of total energy).  
Analysis of single nucleotide polymorphisms 
The selection of the additional SNP in the APOE promoter region rs405509 was based on 
the literature review summarised in the introduction of this chapter and in the main 
introduction. Briefly, the selected non-synonymous SNPs in the APOE promoter region have 
been shown to impact on 1.) APOE gene expression, 2.) apoE protein levels, and 3.) interact 
with APOE Epsilon genotype to determine disease risk. The -219G/T (rs405509) and -
491A/T polymorphism (rs449647) in the APOE promoter region were selected for further 
analysis. We added novel data to the existing data set from the FINGEN study by 
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conducting additional genotyping for the -219G/T (rs405509) polymorphism using existing 
DNA samples. Unfortunately, we were unable to genotype the FINGEN participants for the -
491A/T polymorphism (rs449647) due to a lack of validity of the Custom TaqMan SNP 
Genotyping Assay (Assay ID: AHFAYSD; Life Technologies, Paisly, UK). Briefly, genotyping 
of the FINGEN participants using this SNP Genotyping Assay identified a single population 
homozygous for -491A allele suggesting all FINGEN participants (n = 312) are homozygous 
for the -491A allele. We think this is very unlikely a true result given a minor allele frequency 
(MAF) of T = 0.18 in Caucasian populations (www.ncbi.nlm.nih.gov/SNP) that predicts 
approximate 50 carriers of the -491T allele in the FINGEN study. Therefore the data was not 
used and this SNP is not further discussed in this piece of work. The genotyping of -219G/T 
(rs405509) was performed using real-time polymerase chain reaction (RT-PCR) and Pre-
designed TaqMan SNP Genotyping Assay (Assay ID: C____905013_10; Life Technologies) 
on the Applied Biosystems 7500 Real-Time PCR system (Life Technologies). Each reaction 
(10 μl) contained 5 μl TaqMan Genotyping Master Mix (Life Technologies), 0.5 μl 
primer/probe mix and 4.5 μl DNA sample (containing 1 to 20 ng purified genomic DNA). The 
following reaction cycles were performed: pre-PCR read (1x 1 min 60 °C), holding stage (1x 
10 min 95 °C), 40 apmplification cycles (40x 15 sec 95 °C, 1 min 60°C), followed by a post-
PCR read (1 min 60 °C). A negative control without genomic DNA template (NTC) was taken 
along with every assay. The -219G/T alleles were automatically assigned by the Applied 
Biosystems software and presented in the Allelic Discrimination Plot. The amplification data 
and Allelic Discrimination Plot were visually inspected to verify the allocation of the -219G/T 
alleles. The DNA had been previously isolated from the buffy coat layer of 10 mL of blood 
drawn into tubes containing EDTA with the use of Qiagen DNA Blood Mini Kit (Qiagen Ltd, 
Crawley, United Kingdom).  
Statistical analysis 
Data is shown for the participants who completed the study (n = 312) excluding participants 
with significant outlying values. Outliers were identified prior to analysis by visual inspection 
of the frequency distribution plot with the fitted normal distribution for the individual outcome 
measures. Values outside of the fitted normal distribution and outside of the physiological 
range were considered outliers and excluded from further analysis. Age, gender, BMI, 
smoking and habitual oily fish intake were chosen as covariates because of their potential 
impact on plasma fatty acid status and/or plasma inflammatory marker concentrations. Study 
centre (Glasgow, Newcastle, Reading and Southampton) was also added as covariate. 
 
Analysis of Variance (ANOVA) was performed on baseline data (visit 1 values) to determine 
the effect of APOE Espilon genotype, -219G/T genotype, age, gender and BMI on fatty acid 
composition in the plasma PC lipid fraction and plasma inflammatory marker concentrations 
adding the factors as single explanatory variable, followed by adjusted ANOVA analysis 
(ANCOVA) including additional covariates age, gender, BMI, centre, smoking and habitual 
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oily fish intake in the model (Figure 2.3). Subsequently, interaction terms were added to the 
ANCOVA model to determine the interactive effect of APOE Espilon genotype, -219G/T 
genotype, age, gender and BMI on the outcome measures. The effects (main and interaction 
effect) were considered statistically significant when p < 0.05. 
 
Figure 2.3. Primary analysis model using mixed effect model.  
 
 
ANCOVA analysis on outcome data (end of treatment values) with baseline (value at 
beginning of respective treatment period) and sequence (order of treatments) as covariates 
was performed to determine the effect of treatment, followed by adjusted ANCOVA analysis 
including additional covariates age, gender, BMI, centre, smoking and habitual oily fish 
intake in the model. Subsequently, interaction terms were added to the adjusted ANCOVA 
model to determine potential interaction effects between treatment and BMI, APOE 
genotype, -219G/T genotype or -219G/T * APOE haplotype. The effects (main and 
interaction effect) were considered statistically significant when p < 0.05. Upon finding a 
significant main effect of the factors, differences between groups were investigated using the 
student’s t-test with Bonferroni correction.  
 
A repeated–measures ANOVA analysis on visit (V)1, V3 and V5 baseline data (beginning of 
respective treatment period) had been undertaken to test for period, sequence and carry-
over effects. The V1, V3 and V5 baseline values (value at beginning of intervention) for all 
outcome measures did not change over time (p > 0.05). In addition, there was no effect of 
sequence (treatment order) on response to treatment for plasma fatty acid composition 
outcome measures and for most of the plasma inflammatory markers (p > 0.05), with the 
exception of TNF-α and ICAM-1 for which the effect of treatment was investigated per 
treatment arm. Although subsequent investigation of treatment effect according to treatment 
arm for TNF-α and ICAM-1 revealed a significant effect of treatment in arm 1 for plasma 
TNF-α and ICAM-1 concentrations (p < 0.05), comparison of plasma TNF-α and ICAM-1 
concentrations according to treatment revealed no difference between end-of-treatment and 
baseline (beginning-of-treatment) values for the different treatments in intervention arm 1 (p 
> 0.05).  
 
yij  = µ + τσij + πj + ξi + εij 
 
yij is trait value for subject i at end of time period j 
τσij is effect of treatment on subject i during time period j 
πj  is effect of time period j 
ξi is person specific effect (modelled as random effect) 
εij is normally distributed random error  
 Slim (2015), Chapter 2. APOE genotype, adiposity, long chain n-3 polyunsaturated fatty acids and inflammation 
61 
S
lim
 (2
0
1
5
), C
h
a
p
te
r 1
. L
ite
ra
tu
re
 re
v
ie
w
 
Select multiple linear regression analysis had been undertaken to determine 1.) what 
factors, i.e. APOE Epsilon genotype, -219G/T genotype, age, gender, BMI and habitual oily 
fish intake, were the strongest determinants of baseline plasma LC n-3 PUFA, EPA and 
DHA status and plasma inflammatory marker concentrations and 2.) how much of the 
variation in these outcomes was explained by our model. Smoking was added as a covariate 
to the regression model because of its potential impact on plasma fatty acid status and 
plasma inflammatory marker concentrations. The regression model was based on the 
univariate ANOVA analysis and contained for plasma LC n-3 PUFA, EPA and DHA status,  
APOE Epsilon genotype (reference is APOE3), age (continuous), gender (reference is 
male), BMI (continuous), smoking (reference is not-smoker) and habitual oily fish intake 
(continuous) as explanatory variables. The regression model for plasma inflammatory 
marker concentrations contained APOE Epsilon genotype (reference is APOE3), -219G/T 
genotype (reference is -219GG), age (continuous), gender (reference is male), BMI 
(continuous), smoking (reference is not-smoker) and habitual oily fish intake (continuous) as 
explanatory variables. 
 
All statistical analysis was performed using STATA 11.0 software.  
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Results 
Key findings from previous publications 
The primary aim of the FINGEN study was to investigate the independent and interactive 
impact of APOE Epsilon genotype, age and gender on the responsiveness of over 40 
biochemical markers of CHD to a modest dose of fish oil intervention, with its primary 
findings published [Caslake et al., 2008, Miles et al., 2010, Kofler et al., 2012] and 
summarised in Table 2.2.  
 
Table 2.1. Baseline characteristics according to gender. 
 Women Men All 
Characteristics    
APOE Epsilon genotype (n) 
E2 
E3 
E4 
 
49 
55 
59 
 
38 
56 
55 
 
87 
111 
114 
Age (yr) 45 ± 1.0 45 ± 1.0 45 ± 0.7 
BMI (kg/m
2
) 24.3 ± 0.3 26.1 ± 0.2* 25.1 ± 0.2 
Weight (kg) 64.8 ± 0.8 81.9 ± 0.9* 73.0 ± 0.8 
Waist (cm) 61.6 ± 0.7 66.7 ± 0.6* 64.1 ± 0.5 
MetS (%, n) 11% (18) 26% (39)* 18% (57) 
Habitual diet    
Energy intake (kJ/d) 9.7 ± 0.3 10.6 ± 0.3* 10.1 ± 0.2 
Fat intake (% of total energy) 30.0 ± 0.5 29.7 ± 0.3 29.9 ± 0.3 
SFA intake (% of total energy) 11.6 ± 0.3 11.6 ± 0.2 11.6 ± 0.2 
MUFA intake (% of total energy) 8.5 ± 0.2 8.9 ± 0.1 8.7 ± 0.1 
PUFA intake (% of total energy) 4.5 ± 0.1 4.5 ± 0.1 4.5 ± 0.1 
Oily fish intake (portions / week) 1.1 ± 0.1 0.9 ± 0.1 1.0 ± 0.1 
Plasma biochemistry    
TG (mmol/L) 1.04 ± 0.03 1.34 ± 0.05* 1.18 ± 0.03 
TC (mmol/L) 5.15 ± 0.08 5.15 ± 0.08 5.15 ± 0.06 
LDL-C (mmol/L) 3.17 ± 0.07 3.33 ± 0.90 3.25 ± 0.05 
HDL-C (mmol/L) 1.60 ± 0.03 1.25 ± 0.02* 1.44 ± 0.02 
glucose (mmol/L) 4.96 ± 0.04 5.33 ± 0.04* 5.14 ± 0.03 
All values are mean ± SEM. Women (n = 163), men (n = 149) and all participants (n = 312). Metabolic 
syndrome was defined as having at least three of the following criteria: increased waist circumference 
(≥ 102 cm in men and ≥ 88 cm in women; ≥ 90 cm in Asian men and ≥ 80 cm in Asian women); 
elevated triglycerides (≥ 1.7 mmol/L); decreased high-density lipoprotein cholesterol (< 1.03 mmol/L for 
men, < 1.29 mmol/L for women); blood pressure > 130/85 mmHg or active treatment for hypertension; 
fasting plasma glucose level > 5.6 mmol/L or active treatment for hyperglycaemia. Student’s t-test was 
used to test for differences in baseline characteristics for women and men, *p < 0.05. Pearson’s chi-
square test was used to test for differences in frequency distribution of APOE Epsilon genotype and 
MetS (%) in women and men, *p < 0.05. APOE, apolipoprotein E; BMI, body mass index; HDL-C, high 
density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; MetS, metabolic syndrome; 
MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids; 
TG, triglycerides; TC, total cholesterol. 
 
The study population description, plasma PC fatty acid composition, plasma lipid, 
apolipoprotein and oxidative stress marker response to treatment have been previously 
described by Caslake et al. [Caslake et al., 2008]. Briefly, the study population consisted of 
312 individuals with roughly equal number of men and women, APOE2 carriers (E2/E2 and 
E2/E3), wild-type APOE3 (E3/E3) and APOE4 carriers (E3/E4 and E4/E4), and roughly 
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equal numbers across the decades of life 20 – 70 years (Table 2.1). The men were 
somewhat overweight (BMI 26.1 ± 0.2 kg/m
2
) and pre-hypertensive (systolic blood pressure 
129 ± 1.3 and diastolic blood pressure 76 ± 0.09 mmHg). The blood lipids and plasma 
glucose and insulin levels were within the normal ranges as recommended by the British 
Cardiac Society and others [British Cardiac Society, 1998]. The habitual energy intake was 
higher in men than women (10.6 ± 0.26 vs. 9.69 ± 0.24 kJ/d, p < 0.05) with similar habitual 
fat intake (total fat, SFA, MUFA and PUFA) (Table 2.1) [Caslake et al., 2008], which were 
comparable to averages in the United Kingdom (UK) [Swan, 2004]. The consumption of oily 
fish in both men (0.9 portions / day) and women (1.1 portions / day) was far above the UK 
average of 0.33 portions / wk [Swan, 2004]. Fish oil supplementation increased the plasma 
LC n-3 PUFA concentration in the PC lipid fraction by 3 – 4 absolute percentage from 7.3 % 
to 10.3 % in response to 0.7 g EPA+DHA / day and from 7.1 % to 11.9 % in response to 1.8 
g EPA+DHA / day, with a greater response in women than men (p < 0.05) [Caslake et al., 
2008]. There was no impact of APOE Epsilon genotype or age on the fatty acid response to 
treatment.  
Caslake et al. showed that APOE Epsilon genotype interacted with gender to determine 
plasma TG response to treatment (Table 2.2). The findings in Kofler et al. suggested that 
APOE Epsilon genotype influences the inflammatory status in human subjects, but its impact 
on cardiovascular and neurodegenerative disease risk is likely to be modulated a by number 
of factors, such as gender and BMI (Table 2.2). 
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Table 2.2. Key FINGEN findings from previous publications. 
Study Key findings  
Caslake et al. (2008) Plasma LC n-3 PUFA concentration in response to treatment 
Plasma LC n-3 PUFA concentration in PC lipid fraction 
increased from 7.3 % to 10.3 % in response to 0.7 g EPA+DHA 
/ day and from 7.1 % to 11.9 % in response to 1.8 g EPA+DHA / 
day. The response was greater in women than men. There was 
no impact of APOE Epsilon genotype or age on the response to 
treatment. 
  
 Plasma lipid response to treatment 
 The plasma TG-lowering effect of EPA and DHA was 8 % in 
response to 0.7 g EPA+DHA / day and 11 % in response to 1.8 
g EPA+DHA / day. The greatest plasma TG-lowering response 
was observed in APOE4 men (15 – 23 %). 
 
The plasma LDL-C-raising effect of EPA and DHA was 2 – 3 % 
in response to 0.7 g and 1.8 g EPA+DHA / day. There was no 
effect of APOE Epsilon genotype on the plasma LDL-C 
response. 
 
Kofler et al. (2012) Plasma lipids and CVD risk score 
There was a significant impact of the APOE Epsilon genotype 
on the plasma TC:HDL-C ratio, TG, %HDL3 and the 
Framingham 10-year CVD risk score, with an overall trend for a 
lower and higher risk in APOE2 and APOE4 carriers compared 
to the APOE3 genotype. 
 
The impact of APOE Epsilon genotype interacted with gender 
for TG and %HDL3, with APOE Epsilon genotype explaining 
respectively 7 % and 4 % of the variation in these outcomes. 
The impact of APOE Epsilon genotype on TC:HDL-C was 
greater in females compared to males, which explained 16 % 
and 6 % of the variability in this outcome in females and males. 
  
 Plasma inflammatory marker concentrations 
There was an effect of APOE Epsilon genotype on plasma 
CRP, VCAM-1 and P-sel, of which the effect interacted with BMI 
for CRP and P-sel. The effect of genotype was most 
pronounced in the normal weight BMI group (≤ 24.9 kg/m
2
). In 
this subgroup, APOE2 carriers had lower concentrations 
compared to the other APOE Epsilon genotypes, but these 
benefits were entirely negated at a higher BMI. 
 
Plasma CRP levels were in the order of E2 > E3 > E4, with 23% 
higher levels in APOE2 carriers and 21% lower levels in APOE4 
carriers compared to APOE3 genotype. 
 
Plasma VCAM-1 levels were higher in APOE2 and APOE4 
carriers compared to APOE3 genotype. 
 
Plasma P-sel were lower in APOE2 and APOE4 carriers 
compared to APOE3 genotype  
 
APOE, apolipoprotein E; CRP, C-reactive protein; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid; HDL3, the most dense HDL subfraction; HDL-C, high-density lipoprotein 
cholesterol; LC n-3 PUFA, long chain n-3 polyunsaturated fatty acids; LDL-C, low-density lipoprotein 
cholesterol; P-sel, P-selectin; PC, phosphatidylcholine; TC, total cholesterol; TG, triglycerides; VCAM-
1, vascular cell adhesion molecule-1.   
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Findings from newly analysed outcomes 
The following paragraphs describe the results of the newly analysed outcomes that were 
part of the original analysis conducted as part of this PhD project. The -219G/T genotyping 
data will be described first, followed by the determinants of plasma long chain n-3 PUFA 
status and the determinant of plasma inflammatory marker concentrations. 
Single nucleotide polymorphism in the APOE gene region  
The FINGEN participants were genotyped for the -219G/T (rs405509) polymorphism in the 
APOE promoter region to investigate its independent impact and its interaction with the 
APOE Epsilon genotype on plasma inflammatory marker concentrations and their 
responsiveness to treatment.  
-219G/T alleles across APOE Epsilon genotypes  
Overall, half of the participants were heterozygous carrying one copy of the -219G and -
219T allele, a quarter carried two copies of the -219G allele and a quarter carried two copies 
of the -219T allele. The MAF for -219G/T (rs405509) was T = 0.50, which is in line with the 
reported MAF of T = 0.49 in European populations [Ensemble Genome Browser]. The -219G 
allele was associated with the APOE2 genotype (Pearson χ
2
(4) = 52.2, p < 0.001), whereas 
the -219T allele was more frequent in those with APOE3 and APOE4 genotype (Table 2.3).  
 
Table 2.3. Frequency distribution of the -219G/T alleles across APOE Epsilon genotypes.  
APOE Epsilon 
genotype 
-219G/T allele frequency (%) 
GG GT TT 
APOE2 40 (46%) 45 (52%) 2 (2%) 
APOE3 24 (22%) 49 (44%) 37 (34%) 
APOE4 12 (11%) 63 (55%) 39 (34%) 
All 76 (24%) 157 (51%) 78 (25%) 
-219G/T alleles were associated with APOE Epsilon genotype, Pearson χ
2
(4) = 52.2, p < 0.001. APOE2 
(E2/E2, E2/E3, n = 87), APOE3 (E3/E3, n = 111), APOE4 (E3/E4, E3/E4, n = 114). APOE, 
apolipoprotein E. 
 
Plasma apoE concentrations according to -219G/T * APOE Epsilon 
haplotype 
Baseline characteristics of the -219G/T genotype subgroups are presented in Table 2.4. The 
-219G/T polymorphism in the APOE promoter region has been shown to affect APOE 
expression levels [Artiga et al., 1998, Geng et al., 2011] and potentially modulate disease 
risk [Lambert et al., 2002, Wang et al., 2000, Lescai et al., 2011]. Therefore, the impact of -
219G/T genotype on the baseline plasma apoE concentrations was investigated 
independently and according to APOE Epsilon genotype. The average plasma apoE 
concentration at baseline was 35.8 ± 0.5 (SEM) μg/ml. Plasma apoE concentrations were 
determined by APOE Epsilon genotype (p < 0.001), but not -219G/T genotype (p = 0.87), 
adjusting for age, gender, BMI, centre, smoking and habitual oily fish intake (Table 2.5). 
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APOE2 carriers had approximately 28 % higher plasma concentrations compared to those 
with APOE3 and APOE4 genotype (p < 0.05). However, the impact of APOE Epsilon 
genotype on plasma apoE concentrations interacted with -219G/T genotype (p < 0.05) with 
the greatest effect in the -219GG group. In this subgroup, APOE2 carriers and APOE4 
carriers had respectively 18 % higher and 25 % lower plasma apoE concentrations 
compared to those with APOE3 genotype (p < 0.05). In addition, we observed a trend for 
lower plasma apoE concentrations with an increasing number of -219T alleles in those with 
the APOE2 and APOE3 genotype, but not in those with APOE4 genotype for which the 
opposite was evident. In APOE4 carriers the presence of the minor -219T allele restored 
plasma apoE concentrations to levels comparable to the APOE3 genotype. 
 
Table 2.4. Baseline characteristics according to -219G/T genotypes. 
 -219GG -219GT -219TT All  
Characteristics     
Women (%, n) 61% (46) 48% (76) 51% (40) 53% (163) 
Age (yr) 46 ± 2 44 ± 1 45 ± 1 45 ± 1 
Weight (kg) 72.5 ± 1.5 73.1 ± 1.1 73.2 ± 1.5 73.0 ± 0.8 
BMI (kg/m
2
) 25.5 ± 0.4 25.0 ± 0.3 25.2 ± 0.4 25.2 ± 0.2 
Waist (cm) 64.7 ± 1.0 63.6 ± 0.7 64.1 ± 0.9 64.0 ± 0.5 
MetS (%, n) 20% (15) 18% (29) 17% (13) 18% (57) 
Smokers (%, n) 5% (4) 17% (26) 10% (8)* 12% (38) 
Plasma inflammatory 
markers 
    
CRP (mg/l) 1.75 ± 0.24 1.38 ± 0.12 1.33 ± 0.13 1.45 ± 0.09 
TNF-α (pg/ml) 1.61 ± 0.11 1.48 ± 0.06 1.63 ± 0.09 1.55 ± 0.05 
IL-6 (pg/ml) 1.20 ± 0.15 1.28 ± 0.11 1.38 ± 0.14 1.28 ± 0.07 
IL-10 (pg/ml) 0.92 ± 0.11 1.08 ± 0.08 1.02 ± 0.13 1.03 ± 0.06 
ICAM-1 (ng/ml) 319 ± 16 287 ± 9 317 ± 15 302 ± 7 
VCAM-1 (ng/ml) 1974 ± 107 1804 ± 72 1997 ± 98 1892 ± 51 
E-sel (ng/ml) 70.9 ± 4.3 76.1 ± 3.0 70.0 ± 3.6 73.2 ± 2.1 
P-sel (ng/ml) 68.6 ± 7.3 63.7 ± 4.9 60.8 ± 6.5 64.1 ± 3.4 
All values are mean ± SEM. -219G/T genotype groups, -219GG (n = 76), -219GT (n = 157), -219TT (n 
= 78). One participant had missing -219G/T data. Metabolic syndrome was defined as having at least 
three of the following criteria: increased waist circumference (≥ 102 cm in men and ≥ 88 cm in women; 
≥ 90 cm in Asian men and ≥ 80 cm in Asian women); elevated triglycerides (≥ 1.7 mmol/L); decreased 
high-density lipoprotein cholesterol (< 1.03 mmol/L for men, < 1.29 mmol/L for women); blood pressure 
> 130/85 mmHg or active treatment for hypertension; fasting plasma glucose level > 5.6 mmol/L or 
active treatment for hyperglycaemia. Student’s t-test using Bonferroni correction was used to test for 
differences in baseline characteristics for the -219G/T genotype groups, there were no significant 
differences. Pearson’s chi-square test was used to test for differences in frequency distribution of 
women (%), MetS (%) and Smokers (%) in the -219G/T genotype groups, *p < 0.05. APOE, 
apolipoprotein E; BMI, body mass index; CRP, C-reactive protein; E-sel, E-selectin; ICAM, intercellular 
adhesion molecule; IL, interleukin; MetS, metabolic syndrome; P-sel, P-selectin; TNF, tumor necrosis 
factor; VCAM, vascular cellular adhesion molecule. 
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Table 2.5. Baseline plasma apoE concentrations (μg/mL) according to -219G/T * APOE Epsilon haplotype. 
 -219GG -219GT -219TT All ANOVA Model 1 Model 2 
APOE2 43.9 ± 1.3
a
 41.7 ± 1.2
a 
41.5 ± 1.6
a 
42.7 ± 0.9
a 
APOE Epsilon p<0.001 p<0.001 
APOE3 37.3 ± 1.9
b
 33.1 ± 1.0
b 
31.7 ± 0.9
a 
33.5 ± 0.7
b 
-219G/T p=0.89 p=0.87 
APOE4 28.1 ± 1.7
c
 32.8 ± 0.8
b 
34.6 ± 1.5
a 
32.9 ± 0.7
b 
-219G/T*APOE Epsilon p<0.01 p<0.05 
All 39.3 ± 1.1
a 
35.4 ± 0.6
b 
33.4 ± 0.9
b 
    
All values are mean ± SEM. -219G/T * APOE Epsilon haplotypes, -219GG * E2 (n = 40), -219GT * E2 (n = 45), -219TT * E2 (n = 2), -
219GG * E3 (n = 24), -219GT * E3 (n = 49), -219TT * E3 (n = 37), -219GG * E4 (n = 12), -219GT * E4 (n = 63), -219TT * E4. (n = 39). 
Model 1, ANOVA main-effects model (unadjusted) including APOE Epsilon genotype, -219G/T genotype and -219G/T * APOE Epsilon as 
explanatory variables. Model 2, ANOVA mixed-effects model (adjusted) including covariates age, gender, BMI, centre, smoking, habitual 
oily fish intake. Group differences were determined with Student’s t-test with Bonferroni correction, different letters in the columns indicate 
different means p < 0.05 and different letters in the row ‘all by -219G/T genotype’ indicate different means p < 0.05. There were no mean 
differences between the -219G/T genotypes in APOE2 and APOE3 carriers. In APOE4 carriers, the plasma apoE concentrations were 
significantly lower in those with -219GG genotype compared to -219TT genotype, p < 0.05. APOE, apolipoprotein E. 
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Determinants of plasma long chain n-3 PUFA status 
Plasma LC n-3 PUFA status has been linked to metabolic health in obesity and low-grade 
inflammation [Fernandez-Real et al., 2003, Perrault et al., 2014, van Bussel et al., 2011]. 
Therefore, we investigated potential determinants of LC n-3 PUFA concentrations in the 
plasma PC lipid fraction. In the phospholipid membrane, n-3 PUFA EPA and n-6 PUFA AA 
serve as ligands for enzymes to produce respectively more anti-inflammatory and 
proinflammatory lipid mediators which play an important role in the inflammatory response 
[Buckley et al., 2014]. Hence, we investigated the ratio of EPA to AA in the plasma PC lipid 
fraction. Overall, there was a significant effect of habitual oily fish intake, age and BMI on 
baseline plasma LC n-3 PUFA concentrations (p < 0.05), whereas APOE Epsilon genotype, 
-219G/T genotype, -219G/T * APOE Epsilon haplotype, gender, smoking, alcohol intake and 
habitual diet other than oily fish intake had no significant impact on the plasma LC n-3 PUFA 
concentrations at baseline (Appendix 2-1). The factors with a significant effect and a 
considerable effect size are discussed in more detail below. 
Habitual oily fish intake impacts on plasma long chain n-3 PUFA status 
As expected, habitual oily fish intake (portions / wk) had a significant effect on the LC n-3 
PUFA, EPA and DHA concentrations (% of total fatty acids) and the EPA to AA ratio (p < 
0.001), but not on DPA concentrations and SFA to PUFA ratio in plasma PC lipid fraction at 
baseline (Table 2.6). The LC n-3 PUFA, EPA and DHA concentrations and the EPA to AA 
ratio increased across quintiles of oily fish intake, with higher values in the highest three 
quintiles (≥ 0.7 portions / wk) compared to lowest two quintiles (< 0.5 portions / wk) of oily 
fish intake (p < 0.05). 
Age influences plasma long chain n-3 PUFA status 
A significant effect of age on the baseline LC n-3 PUFA, EPA, DPA and DHA concentrations 
(% of total fatty acids) and EPA to AA ratio (p < 0.01), but not SFA to PUFA ratio (p = 0.36) 
in plasma PC lipid fraction was evident in the study population adjusted for gender, BMI, 
centre, smoking and habitual oily fish intake. Since gender has been shown to affect LC n-3 
PUFA status in blood lipid fractions [Caslake et al., 2008, Crowe et al., 2008], the impact of 
age on plasma fatty acid concentrations was further investigated in men and women 
separately. This revealed a similar effect of age in both men and women with an overall 
trend of increasing levels and ratios with increasing age (Table 2.7), which reached only 
statistical significance in women (p < 0.01). Plasma EPA concentrations were higher in 
women aged 50 – 70 yr compared to those aged < 50 yrs (p < 0.05) and plasma LC n-3 
PUFA and DHA concentrations were higher in women aged 60 – 70 yr compared to women 
aged 20 – 29 yr and 40 – 49 yr (p < 0.05). Moreover, a trend was observed for increasing 
plasma DPA concentrations with age from 0.9 % to 1.2 % in women, but not men. The EPA 
to AA ratio in the plasma PC lipid fraction was higher in women aged 50 – 70 yr compared to 
those aged 40 – 49 yr (p < 0.05).  
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Table 2.6. Baseline plasma LC n-3 PUFA status across quintiles of oily fish intake. 
 Q1 Q2 Q3 Q4 Q5 
  
Oily fish intake (portions / wk)  0 0.2 – 0.5 0.7 – 0.9 1.0 – 1.6 1.7 – 7.7 Model 1 Model 2 
EPA 1.35 ± 0.08
a
 1.43 ± 0.06
a
 1.68 ± 0.10
ab
 1.68 ± 0.10
ab
 2.02 ± 0.14
b
 p<0.001 p<0.001 
DPA 1.11 ± 0.04 1.08 ± 0.03 1.13 ± 0.04 1.10 ± 0.01 1.13 ± 0.03 p=0.85 p=0.69 
DHA 3.66 ± 0.14
a
 3.78 ± 0.12
a
 4.47 ± 0.14
ab
 4.47 ± 0.15
b
 4.89 ± 0.16
b
 p<0.001 p<0.001 
LC n-3 PUFA 5.93 ± 0.19
a 
6.35 ± 0.16
a 
7.35 ± 0.23
b 
7.43 ± 0.24
bc 
8.44 ± 0.29
c 
p<0.001 p<0.001 
EPA:AA ratio 0.14 ± 0.01
a 
0.15 ± 0.01
ab 
0.19 ± 0.01
c 
0.18 ± 0.01
bc 
0.22 ± 0.01
c 
p<0.001 p<0.001 
SFA:PUFA ratio 1.02 ± 0.01 1.04 ± 0.01 1.03 ± 0.01 1.04 ± 0.01 1.01 ± 0.01 p=0.83 p=0.71 
All values are mean ± SEM. Model 1,
 
ANOVA main-effects model (unadjusted) including only habitual oily fish intake (portions / wk) as explanatory variable. Model 2, 
ANOVA mixed-effects model (adjusted) including covariates age, gender, BMI, centre, smoking. Quintile differences were determined with Student’s t-test using 
Bonferroni correction, different letters indicate different means p < 0.05. EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid; LC n-
3 PUFA, long chain n-3 polyunsaturated fatty acid; EPA:AA ratio, ratio of EPA to arachidonic acid; SFA:PUFA ratio, ratio of saturated fatty acids to PUFA. 
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Table 2.7. Baseline plasma LC n-3 PUFA status across age in men and women. 
Men 20 - 29 yr 30 - 39 yr 40 - 49 yr 50 - 59 yr 60 - 70 yr Model 1 Model 2
 
EPA 1.56 ± 0.15 1.50 ± 0.09 1.55 ± 0.09 1.63 ± 0.10 1.78 ± 0.15 p=0.50 p=0.52 
DPA 1.14 ± 0.04 1.11 ± 0.04 1.18 ± 0.04 1.16 ± 0.04 1.21 ± 0.03 p=0.48 p=0.62 
DHA 3.87 ± 0.24 3.88 ± 0.20 4.14 ± 0.18 4.15 ± 0.18 4.58 ± 0.23 p=0.14 p=0.61 
LC n-3 PUFA 6.44 ± 0.34 6.55 ± 0.28 6.80 ± 0.25 7.09 ± 0.25 7.71 ± 0.33 p<0.05 p=0.18 
EPA:AA ratio 0.16 ± 0.02 0.16 ± 0.01 0.15 ± 0.01 0.17 ± 0.01 0.20 ± 0.02 p=0.09 p<0.05 
SFA:PUFA ratio 1.00 ± 0.02 1.02 ± 0.01 1.03 ± 0.02 1.05 ± 0.01 1.04 ± 0.02 p=0.31 p=0.40 
        
Women 20 - 29 yr 30 - 39 yr 40 - 49 yr 50 - 59 yr 60 - 70 yr Model 1 Model 2
 
EPA 1.35 ± 0.17
ab
 1.55 ± 0.14
ab
 1.33 ± 0.08
a
 1.96 ± 0.18
b
 2.00 ± 0.19
b
 p<0.01 p<0.01 
DPA 0.84 ± 0.06
a
 1.03 ± 0.05
ab
 1.05 ± 0.04
b
 1.16 ± 0.04
b
 1.02 ± 0.05
b
 p<0.001 p<0.001 
DHA 3.86 ± 0.22
a
 4.26 ± 0.21
ab
 4.05 ± 0.19
a
 4.50 ± 0.21
ab
 5.04 ± 0.24
b
 p<0.01 p<0.01 
LC n-3 PUFA 6.38 ± 0.43
a 
7.07 ± 0.37
a b 
6.54 ± 0.28
a
 7.61 ± 0.37
ab
 8.40 ± 0.41
b 
p<0.01 p<0.01 
EPA:AA ratio 0.15 ± 0.02
ab 
0.17 ± 0.02
ab 
0.14 ± 0.01
a 
0.21 ± 0.02
b
 0.22 ± 0.02
b 
p<0.01 p<0.01 
SFA:PUFA ratio 1.03 ± 0.01 1.02 ± 0.02 1.01 ± 0.01 1.02 ± 0.01 1.05 ± 0.02 p=0.46 p=0.52 
All values are mean ± SEM. Age groups 20 – 29 yr (n = 21 men, n = 29 women), 30 – 39 yr (n = 34 men, n = 31 women), 40 – 49 yr (n = 34 men, n = 34 
women), 50 – 59 yr (n = 36 men, n = 41 women), 60 – 70 yr (n = 24 men, n = 28 women). Model 1, ANOVA main-effects model (unadjusted) including only age 
as explanatory variable. Model 2, ANOVA mixed-effects model (adjusted) including covariates gender, BMI, centre, smoking, habitual oily fish intake. Group 
differences were determined with Student’s t-test using Bonferroni correction, different letters indicate different means p < 0.05. EPA, eicosapentaenoic acid ; 
DPA, docosapentaenoic acid; DHA, docosahexaenoic acid; LC n-3 PUFA, long chain n-3 polyunsaturated fatty acid; EPA:AA ratio, ratio of EPA to arachidonic 
acid; SFA:PUFA ratio, ratio of saturated fatty acids to PUFA. 
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BMI is associated with plasma long chain n-3 PUFA and DHA 
There was a significant effect of BMI on plasma LC n-3 PUFA and DHA concentrations in 
the PC lipid fraction at baseline (p < 0.05) adjusting for age, gender, centre, smoking, 
habitual oily fish intake (Table 2.8). To get a clearer picture of the impact of BMI on the 
plasma LC n-3 PUFA concentrations adjusted predicted plasma concentrations are 
presented in Figure 2.4. These predictions reveal that plasma LC n-3 PUFA and DHA 
concentrations decrease with increasing BMI, with LC n-3 PUFA concentrations being 
significantly lower in obese subjects (BMI ≥ 30 kg/m
2
) compared to normal weight subjects 
(BMI < 25 kg/m
2
) (p < 0.05). 
 
Table 2.8. Baseline plasma LC n-3 PUFA status according to body mass index (BMI). 
 < 25 kg/m
2 
25 - 29.9 kg/m
2 
≥ 30 kg/m
2 
Model 1 Model 2
 
EPA 1.65 ± 0.08 1.58 ± 0.06 1.64 ± 0.10 p=0.76 p=0.23 
DPA 1.08 ± 0.02 1.15 ± 0.02 1.08 ± 0.05 p<0.05 p=0.45 
DHA 4.37 ± 0.10 4.03 ± 0.10 4.40 ± 0.21 p<0.05 p<0.01 
LC n-3 PUFA 7.20 ± 0.18 6.87 ± 0.15 7.16 ± 0.29 p=0.36 p<0.05 
EPA:AA ratio 0.18 ± 0.01 0.17 ± 0.01 0.18 ± 0.01 p=0.47 p=0.09 
SFA:PUFA ratio 1.02 ± 0.01
a
 1.04 ± 0.01
b 
1.01 ± 0.01
ab 
p=0.09 p<0.05 
All values are mean ± SEM. BMI groups < 25 kg/m
2
 (n = 155), 25 – 29.9 kg/m
2
 (n = 128) and ≥ 30 
kg/m
2
 (n = 29). Model 1, ANOVA main-effects model (unadjusted) including only BMI as explanatory 
variable. Model 2, ANOVA mixed-effects model (adjusted) including covariates gender, centre, 
smoking, habitual oily fish intake. Group differences were determined with Student’s t-test using 
Bonferroni correction, different letters indicate different means p < 0.05. EPA, eicosapentaenoic acid; 
DPA, docosapentaenoic acid; DHA, docosahexaenoic acid; LC n-3 PUFA, long chain n-3 
polyunsaturated fatty acid; EPA:AA ratio, ratio of EPA to arachidonic acid; SFA:PUFA ratio, ratio of 
saturated fatty acids to PUFA. 
 
Figure 2.4. Predicted baseline eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA),  
docosahexaenoic acid (DHA) and long chain (LC) n-3 polyunsaturated fatty acid (PUFA) 
concentrations (% of total fatty acids) in plasma phosphatidylcholine lipid fraction tended to 
decrease with increasing body mass index (BMI). Data are predicted concentrations adjusted 
for age, gender, centre, smoking and habitual oily fish intake and are presented as mean ± 
SEM. BMI groups < 25 kg/m
2
 (n = 155), 25 – 29.9 kg/m
2
 (n = 128) and ≥ 30 kg/m
2
 (n = 29). Group 
differences were determined with Student’s t-test using Bonferroni correction, different letters 
indicate different means p < 0.05.  
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To investigate if the decreased LC n-3 PUFA concentration in obese subjects could be 
attributed to an increased oxidation of these fatty acids, the ratio of plasma oxidized LDL-C 
(oxLDL-C) to plasma apolipoprotein B (apoB) concentrations was investigated as a marker 
of oxidative status. The oxLDL-C to apoB ratio reflects the proportion of oxidatively modified 
LDL-C relative to the total LDL particles and is a measure of lipid oxidation. There was no 
effect of BMI on the plasma oxLDL-C to apoB ratio at baseline adjusting for age, gender, 
centre, smoking and habitual oily fish intake (p = 0.80) (Appendix 2-2).  
Plasma long chain n-3 PUFA status in response to treatment 
Caslake et al. have reported that gender, but not APOE Epsilon genotype or age, influenced 
the LC n-3 PUFA response to treatment in the FINGEN study [Caslake et al., 2008]. A 
potential impact of BMI on the plasma fatty acid response to treatment was not investigated. 
Here, we report no effect of BMI (p ≥ 0.41), -219G/T genotype (p ≥ 0.57) or -219G/T * APOE 
Epsilon haplotype (p ≥ 0.57) on the plasma LC n-3 PUFA response to treatment (Table 2.9). 
 
  
S
lim
 (2
0
1
5
), C
h
a
p
te
r 2
. A
P
O
E
 g
e
n
o
ty
p
e
, a
d
ip
o
s
ity
, lo
n
g
 c
h
a
in
 n
-3
 p
o
ly
u
n
s
a
tu
ra
te
d
 fa
tty
 a
c
id
s
 a
n
d
 in
fla
m
m
a
tio
n 
7
3
   
Table 2.9. The impact of APOE genotype and BMI on the plasma long chain n-3 PUFA response to treatment.  
 CO 0.7FO 1.8FO Model 1 Model 2     
 0 wk 8 wk 0 wk 8 wk 0 wk 8 wk T T T*BMI T*G T*E T*G*E 
EPA 1.60 ± 0.04 1.60 ± 0.04
a
 1.66 ± 0.05 2.88 ± 0.06
b
 1.63 ± 0.05 3.78 ± 0.07
c
 p<0.001 p<0.001 p=0.42 p=0.31 p=0.71 p=0.49 
DPA 1.09 ± 0.01 1.08 ± 0.01
a 
1.10 ± 0.01 1.21 ± 0.01
b 
1.08 ± 0.01 1.29 ± 0.02
c 
p<0.001 p<0.01 p=0.18 p=0.48 p=0.49 p=0.69 
DHA 4.41 ± 0.07 4.33 ± 0.07
a 
4.38 ± 0.07
 
6.22 ± 0.07
b 
4.29 ± 0.07
 
6.78 ± 0.08
c 
p<0.001 p<0.001 p=0.88 p=0.63 p=0.71 p=0.90 
LC n-3 PUFA 
 
7.17 ± 0.11 7.06 ± 0.11
a 
7.21 ± 0.12
 
10.3 ± 0.12
b 
7.06 ± 0.11
 
11.9 ± 0.14
c 
p<0.001 p<0.001 p=0.35 p=0.50 p=0.85 p=0.57 
EPA:AA ratio 0.18 ± 0.01 0.18 ± 0.01
a 
0.18 ± 0.01
 
0.34 ± 0.01
b 
0.18 ± 0.01
 
0.47 ± 0.01
c 
p<0.001 p<0.001 p=0.36 p=0.60 p=0.76 p=0.80 
SFA:PUFA ratio 1.03 ± 0.01 1.03 ± 0.01 1.03 ± 0.01 1.03 ± 0.01 1.03 ± 0.01 1.03 ± 0.01 p=0.62 p=0.79 p=0.88 p=0.37 p=0.73 p=0.71 
All values are percentage (%) of total fatty acids in the plasma phosphatidylcholine lipid fraction, mean ± SEM. Model 1, ANCOVA main-effects model containing treatment (T) 
with sequence and baseline value as covariates. Model 2, ANCOVA mixed-effects model containing treatment (T), treatment * BMI (T*BMI), treatment * -219G/T genotype 
(T*G), treatment * APOE Epsilon genotype (T*E), and treatment * -219G/T * APOE Epsilon haplotype (T*G*E) and covariates sequence, baseline value, age, gender, BMI, 
centre, smoking, habitual oily fish intake. Student’s t-test using Bonferroni correction revealed no difference in the before treatment (0 wk) values between treatment groups, p 
> 0.05. Student’s t-test using Bonferroni correction was used to determine differences in the after treatment (8 wk) values between treatment groups, different letters indicate 
different means p < 0.05. 0.7FO, 0.7 g EPA+DHA / day; 1.8FO, 1.8 g EPA+DHA / day; CO, control oil; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, 
docosahexaenoic acid; LC n-3 PUFA, long chain n-3 polyunsaturated fatty acid; EPA:AA ratio, ratio of EPA to arachidonic acid; SFA:PUFA ratio, ratio of saturated fatty acids to 
PUFA. 
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Determinants of plasma inflammatory marker concentrations 
Kofler et al. reported the effect of APOE Epsilon genotype and its interaction with age, 
gender and BMI on plasma inflammatory marker concentrations [Kofler et al., 2012], as 
summarised in Table 2.2 and detailed in Table 2.10 below with APOE Epsilon genotype 
influencing select inflammatory markers. Besides, we demonstrated that APOE Epsilon 
genotype interacted with -219G/T genotype to determine plasma apoE concentrations. 
Therefore, we investigated the impact of -219G/T genotype and -219G/T * APOE Epsilon 
haplotype on baseline plasma inflammatory marker concentrations. Furthermore, we 
investigated the impact of other potential determinants of plasma inflammatory marker 
concentrations, including age, gender, BMI and habitual oily fish intake. In line with the 
literature, we observed a significant effect of gender (p < 0.05), BMI (p < 0.05), but not of 
age (p ≥ 0.07), on plasma inflammatory marker concentrations at baseline (Appendix 2-3). 
Men had higher baseline plasma TNF-α and E-sel concentrations than women (p < 0.05). 
Obese individuals (≥ 30 kg/m
2
) had higher baseline plasma CRP and E-sel compared to lean 
individuals (< 25 kg/m
2
) (p < 0.05). 
 
Table 2.10. Impact of APOE Epsilon genotype on plasma inflammatory marker concentrations 
as published by Kofler et al. (2012). 
 APOE2 APOE3 APOE4 G G*BMI 
CRP (mg/l) 1.69 ± 0.13
a
 1.38 ± 0.10
b
 1.09 ± 0.06
c
 p<0.01 p<0.05 
TNF-α (pg/ml) 1.53 ± 0.07 1.61 ± 0.12 1.76 ± 0.08 ns ns 
IL-6 (pg/ml) 1.54 ± 0.29 1.34 ± 0.16 1.63 ± 0.15 ns ns 
IL-10 (pg/ml) 1.09 ± 0.15 1.24 ± 0.16 1.20 ± 0.18 ns ns 
ICAM-1 (ng/ml) 298 ± 13 307 ± 13 304 ± 7 ns ns 
VCAM-1(ng/ml) 1975 ± 89
a
 1721 ± 91
ab
 2043 ± 55
bc
 p<0.05 ns 
E-sel (ng/ml) 70.6 ± 4.1 79.5 ± 3.7 68.5 ± 1.8 p=0.05 p<0.001 
P-sel (ng/ml) 59.5 ± 8.2
a
 82.8 ± 6.7
b
 56.1 ± 2.8
a
 p<0.01 p<0.05 
These results have been published by Kofler et al. (2012) and are not part of our original data analysis. 
All values are mean ± SEM. APOE Epsilon genotypes, APOE2 (n = 87), APOE3 (n = 111), APOE4 (n 
= 114). General linear modelling was used to determine the independent and interactive impact of 
APOE Epsilon genotype (G), gender, age and BMI on the plasma inflammatory marker concentrations. 
There was no significant interaction between age and genotype and gender and genotype. Group 
differences were determined using post hoc analysis with Bonferroni correction, different letter indicate 
different means p < 0.05. APOE, apolipoprotein E; CRP, C-reactive protein; E-sel, E-selectin; ICAM, 
intercellular adhesion molecule; IL, interleukin; ns, non-significant; P-sel, P-selectin; TNF, tumor 
necrosis factor; VCAM, vascular cellular adhesion molecule. 
 
Habitual oily fish intake determined plasma IL-10 
There was a significant effect of habitual oily fish intake (portions / week) on plasma IL-10 
concentrations adjusting for age, gender, BMI, centre and smoking (p < 0.01), but not on any 
of the other inflammatory markers (Appendix 2-4). Individuals in the highest quintile of oily 
fish intake (1.7 – 7.7 portions / week) had borderline significant higher plasma IL-10 
concentrations compared to those who consume no oily fish (lowest quintile of oily fish 
intake) (1.35 ± 0.16 (SEM) vs. 0.84 ± 0.09 pg/ml, p = 0.05). The predicted plasma IL-10 
concentrations adjusted for age, gender, BMI, centre and smoking illustrate how predicted 
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plasma IL-10 concentrations increase across quintiles of oily fish intake after accounting for 
covariates (Figure 2.5). Oily fish is rich in LC n-3 PUFA and to explore if the beneficial effect 
of oily fish intake on plasma IL-10 was mediated through plasma LC n-3 PUFA status, the 
association between quintiles of plasma LC n-3 PUFA and plasma IL-10 concentrations was 
investigated. There was no association between the quintiles of plasma LC n-3 PUFA and 
plasma IL-10 concentrations (p = 0.17; Appendix 2-5).  
 
Figure 2.5. Predicted plasma interleukin (IL)-10 concentrations increase across quintiles (Q) of 
oily fish intake, with individuals in the highest quintile of oily fish intake (Q5, 1.7 – 7.7 portions / 
week) having significantly higher predicted IL-10 levels compared to individuals in the lowest 
quintile of oily fish intake (Q1, 0 portions / week) (p < 0.05). Habitual oily fish intake quintiles (Q) 
ranges were Q1, 0; Q2, 0.2 – 0.5; 0.7 – 0.9; Q4, 1.0 – 1.6; Q5, 1.7 – 7.7 portions / week. Data are 
predicted concentrations adjusted for age, gender, BMI, centre and smoking, mean ± SEM. 
Group differences were determined with Student’s t-test using Bonferroni correction, *p < 0.05. 
 
-219G/T * APOE Epsilon haplotype determined plasma P-sel and VCAM-1  
Baseline characteristics of the -219G/T genotype subgroups are presented in Table 2.8. We 
found no effect of the -219G/T genotype on baseline plasma inflammatory marker 
concentrations (p ≥ 0.10). However, there was an effect of the -219G/T * APOE Epsilon 
haplotype on baseline plasma P-sel and VCAM-1 concentrations adjusting for age, gender, 
BMI, centre, smoking and habitual oily fish intake (p < 0.01) (Table 2.11). Individuals with -
219GG * APOE3 haplotype had higher plasma P-sel concentrations compared to those with 
-219TT * APOE4 haplotype (p < 0.05). 
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Table 2.11. Baseline plasma inflammatory marker concentrations according to -219G/T * APOE 
Epsilon haplotype. 
  -219GG -219GT -219TT Model 1 Model 2 
CRP  APOE2 1.67 ± 0.29 1.46 ± 0.17 2.09 ± 1.22 p=0.40 p=0.34 
(mg/l) APOE3 1.41 ± 0.19 1.55 ± 0.23 1.23 ± 0.16   
 
APOE4 2.45 ± 1.03 1.20 ± 0.22 1.39 ± 0.20   
TNF-α  APOE2 1.51 ± 0.08 1.53 ± 0.12 2.16 ± 1.20 p=0.60 p=0.24 
(pg/ml) APOE3 1.62 ± 0.25 1.42 ± 0.11 1.58 ± 0.13   
 
APOE4 1.92 ± 0.36 1.50 ± 0.09 1.66 ± 0.11   
IL-6  APOE2 1.24 ± 0.23 1.36 ± 0.23 0.46 ± 0.22 p=0.73 p=0.81 
(pg/ml) APOE3 1.36 ± 0.25 1.11 ± 0.15 1.33 ± 0.22   
 
APOE4 0.74 ± 0.16 1.36 ± 0.18 1.49 ± 0.20   
IL-10  APOE2 0.99 ± 0.12 0.97 ± 0.14 0.62 ± 0.11 p=0.86 p=0.90 
(pg/ml) APOE3 0.97 ± 0.27 1.19 ± 0.15 1.10 ± 0.22   
 
APOE4 0.61 ± 0.15 1.08 ± 0.15 0.97 ± 0.163   
ICAM-1  APOE2 319 ± 23 286 ± 15 345 ± 93 p=0.54 p=0.57 
(ng/ml) APOE3 314 ± 27 271 ± 18 330 ± 22   
 
APOE4 327 ± 42 300 ± 14 303 ± 22   
VCAM-1 APOE2 2135 ± 145 1806 ± 108 2450 ± 507 p<0.01 p<0.01 
(ng/ml) APOE3 1607 ± 184 1487 ± 136 2042 ± 117   
 
APOE4 2172 ± 264 2052 ± 115 1933 ± 159   
E-sel  APOE2 73.6 ± 6.4 69.7 ± 5.4 52.8 ± 3.23 p=0.12 p=0.08 
(ng/ml) APOE3 71.1 ± 7.5 88.6 ± 6.2 74.3 ± 5.0   
 
APOE4 61.4 ± 8.1 71.0 ± 3.9 66.9 ± 5.3   
P-sel  APOE2 56.7 ± 11
ab
 45.7 ± 6.4
ab
 68.8 ± 21
ab
 p<0.01 p<0.01 
(ng/ml) APOE3 97.9 ± 12
a 
83.1 ± 11
ab
 72.5 ± 11
ab
   
 
APOE4 48.5 ± 6.8
ab
 61.0 ± 6.9
ab
 49.4 ± 7.4
b 
  
All values are mean ± SEM. -219G/T * APOE Epsilon haplotypes, -219GG * APOE2 (n = 40), -219GT * 
APOE2 (n = 45), -219TT * APOE2 (n = 2), -219GG * APOE3 (n = 24), -219GT * APOE3 (n = 49), -
219TT * APOE3 (n = 37), -219GG * APOE4 (n = 12), -219GT * APOE4 (n = 63), -219TT * APOE4 (n = 
39). Model 1, ANOVA main-effects model (unadjusted) including only -219G/T * APOE Epsilon 
haplotype as explanatory variable. Model 2, ANOVA mixed-effects model (adjusted) including 
covariates age, gender, BMI, centre, smoking, habitual oily fish intake. Group differences were 
determined with Student’s t-test with Bonferroni correction, different letters indicate different means p < 
0.05. APOE, apolipoprotein E; CRP, C-reactive protein; E-sel, E-selectin; ICAM, intercellular adhesion 
molecule; IL, interleukin; P-sel, P-selectin; TNF, tumor necrosis factor; VCAM, vascular cellular 
adhesion molecule. 
 
Plasma inflammatory markers response to treatment 
Overall, there was no effect of treatment on any of the plasma inflammatory markers CRP, 
TNF-α, IL-6, IL-10, ICAM-1, VCAM-1, E-sel and P-sel evident in crude analysis and after 
adjusting for age, gender, BMI, centre, smoking and habitual oily fish intake (p ≥ 0.24) (Table 
2.12). Although a main effect of treatment was absent a significant interaction between 
treatment and APOE Epsilon genotype was evident for plasma VCAM-1 (p = 0.02), where 
stratification according to APOE Epsilon genotype did not reveal an effect of treatment (p ≥ 
0.22) indicating that APOE Epsilon genotype largely explains the variation in plasma VCAM-
1 concentrations (Figure 2.6). No significant interactions between treatment and APOE 
Epsilon genotype were evident for the other inflammatory markers, although a borderline 
non-significant treatment * APOE Epsilon genotype interaction was observed for IL-6 (p = 
0.11). There were no significant interactions between treatment and -219G/T genotype (p ≥ 
0.19), -219G/T * APOE Epsilon haplotype (p ≥ 0.06) or BMI (p ≥ 0.30).  
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Figure 2.6. Change (%) in plasma vascular cell adhesion molecule 1 (VCAM-1) concentration 
according to APOE Epsilon genotype after treatment with control oil (CO) or fish oil (0.7g 
EPA+DHA / d (0.7FO) and 1.8g EPA+DHA / d (1.8FO)) for 8 weeks. EPA, eicosapentaenoic acid; 
DHA, docosahexaenoic acid. APOE2 (E2/E2, E2/E3, n = 87), APOE3 (E3/E3, n = 111), APOE4 
(E3/E4, E3/E4, n = 114). Groups did not differ, Student’s t-test with Bonferroni correction p > 
0.05. APOE, apolipoprotein E. 
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Table 2.12. Plasma inflammatory marker response to treatment.  
 CO 0.7FO 1.8FO   
 0 wk 8 wk 0 wk 8 wk 0 wk 8 wk Model 1 Model 2 
CRP (mg/l) 1.68 ± 0.12 1.69 ± 0.11 1.53 ± 0.11 1.57 ± 0.11 1.46 ± 0.09 1.56 ± 0.10 p=0.60 p=0.56 
TNF-α (pg/ml) 1.56 ± 0.04 1.51 ± 0.04 1.55 ± 0.04 1.47 ± 0.04 1.58 ± 0.05 1.50 ± 0.04 p=0.64 p=0.64 
IL-6 (pg/ml) 1.25 ± 0.06 1.17 ± 0.06 1.23 ± 0.07 1.12 ± 0.06 1.25 ± 0.07 1.05 ± 0.06 p=0.31 p=0.30 
IL-10 (pg/ml) 1.14 ± 0.07 1.06 ± 0.07 1.00 ± 0.05 1.03 ± 0.07 1.02 ± 0.07 0.96 ± 0.06 p=0.47 p=0.47 
ICAM-1 (ng/ml) 299 ± 7 320 ± 7 301 ± 7 311 ± 7 311 ± 8 315 ± 7 p=0.32 p=0.32 
VCAM-1(ng/ml) 1881 ± 51 1891 ± 51 1833 ± 52 1832 ± 52 1868 ± 49 1831 ± 50 p=0.72 p=0.71 
E-sel (ng/ml) 74 ± 2 76 ± 2 73 ± 2 77 ± 2 75 ± 2 76 ± 2 p=0.41 p=0.42 
P-sel (ng/ml) 64 ± 4 67 ± 4 59 ± 3 63 ± 3 62 ± 3 68 ± 4 p=0.82 p=0.83 
All values are mean ± SEM. Model 1, ANOVA main-effects model (unadjusted) including treatment as explanatory variable with sequence and baseline value as 
covariates. Model 2, ANOVA mixed-effects model (adjusted) including covariates sequence, baseline value, age, gender, BMI, centre, smoking, habitual oily fish 
intake. 0.7FO, 0.7 g eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) / day; 1.8FO, 1.8 g EPA+DHA / day; CO, control oil; CRP, C-reactive protein; 
E-sel, E-selectin; ICAM, intercellular adhesion molecule; IL, interleukin; P-sel, P-selectin; TNF, tumor necrosis factor; VCAM, vascular cellular adhesion 
molecule. 
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Summary results 
Table 2.13. Main findings from this study of the FINGEN trial. 
Determinants of plasma LC n-3 PUFA, EPA and DHA concentrations  
 
1. Habitual plasma LC n-3 PUFA, EPA and DHA concentrations 
Oily fish intake 
moderate intake (≥ 0.7 portions / wk) > low intake (< 0.5 portions / wk)  
 
Age and gender 
50 years and older > younger than 50 years (trend) 
age effect was stronger in women than men 
 
BMI 
obese (BMI ≥ 30 kg/m
2
) < normal weight subjects (BMI < 25 kg/m
2
) 
 
APOE genotype 
no effect of APOE Epsilon genotype, -219G/T genotype or -219G/T * APOE Epsilon 
haplotype  
 
2. Response to supplementation 
no effect of -219G/T genotype or -219G/T * APOE Epsilon haplotype 
 
APOE Epsilon genotype interacts with -219G/T to determine plasma apoE 
-219G/T genotype 
-219G allele is associated with the APOE2 genotype  
 
plasma apoE concentrations 
APOE2 > APOE3 and APOE4 
 
APOE Epsilon genotype interacted with -219G/T genotype.  
In -219GG subgroup: APOE2 > APOE3 > APOE4  
 
Plasma apoE increased with increasing number of -219T alleles in those with APOE2 and 
APOE3 genotype. The opposite was evident for APOE4 genotype.  
 
Plasma inflammatory marker concentrations 
 
1. Habital plasma inflammatory marker concentrations 
Habitual oily fish intake and plasma IL-10  
highest quintile (1.7 – 7.7 portions / week) > lowest quintile (0 portions / week).  
 
-219G/T * APOE Epsilon haplotype and plasma P-sel and VCAM-1 
P-sel:   -219GG * APOE3 > -219TT * APOE4 haplotype  
VCAM-1: no difference between haplotypes 
 
2. Response to supplementation 
no effect of supplementation on plasma inflammatory markers  
 
Plasma LC n-3 PUFA, EPA and DHA concentrations in the plasma PC lipid fraction. APOE, 
apolipoprotein E; BMI, body mass index; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; 
LC n-3 PUFA, long chain n-3 polyunsaturated fatty acids; P-sel, P-selectin; PC, phosphatidylcholine; 
VCAM-1, vascular cell adhesion molecule-1. 
 
The main findings from this study are summarised in Table 2.13. To determine what factors, 
i.e. APOE Epsilon genotype, age, gender, BMI and habitual oily fish intake, were the 
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strongest determinant of the baseline plasma LC n-3 PUFA concentrations, we performed 
multiple linear regression analysis (Appendix 2-6). Briefly, this analysis revealed that age 
and habitual oily fish intake were significant determinants of plasma LC n-3 PUFA (age β = 
0.035, p < 0.001 and oily fish intake β = 0.632, p < 0.001), EPA (age β = 0.011, p < 0.01 and 
oily fish intake β = 0.151, p < 0.001) and DHA concentrations (age β = 0.019, p < 0.001 and 
oily fish intake β = 0.291, p < 0.001). BMI was only a significant determinant of the plasma 
LC n-3 PUFA (β = -0.093, p < 0.01) and DHA concentrations (β = -0.057, p < 0.01). APOE 
Epsilon genotype and gender did not determine plasma LC n-3 PUFA, EPA and DHA 
concentrations. Our regression model explained only 26 %, 11 % and 17 % of the variation 
in the plasma LC n-3 PUFA, EPA and DHA concentrations respectively, indicating that 
additional factors not included in our model are important in determining plasma LC n-3 
PUFA concentrations. 
To determine what factors, i.e. -219G/T genotype, APOE Epsilon genotype, age, gender, 
BMI and habitual oily fish intake, were the strongest determinant of the baseline plasma 
inflammatory marker concentrations, we performed similar multiple linear regression 
analysis (Appendix 2-6). In brief, APOE Epsilon genotype was a significant determinant of 
the plasma VCAM-1 (APOE2 β = 307.609, p < 0.05 and APOE4 β = 344.072, p < 0.01), E-
sel (APOE2 β = -9.609, ns. and APOE4 β = -12.030, p < 0.05) and P-sel concentrations 
(APOE2 β = -36.536, p < 0.001 and APOE4 β = -26.772, p < 0.01). In contrast, -219G/T 
genotype was not a determinant of plasma inflammatory marker concentrations. BMI was a 
determinant of plasma CRP (β = 0.090, p < 0.01) and VCAM-1 concentrations (β = -35.856, 
p < 0.05). Gender was a determinant of plasma IL-6 (β = -0.257, p < 0.01) and E-sel 
concentrations (β = -8.645, p < 0.01) and habitual oily fish intake (portions / week) was 
determinant of plasma IL-10 concentrations (β = 0.181, p < 0.001). Age and smoking did not 
determine plasma inflammatory marker concentrations. Our regression model explained only 
between 3 % and 10 % of the variation indicating that our model was a poor predictor of 
plasma inflammatory marker concentrations and other additional factors are important in 
determining plasma inflammatory marker concentrations. 
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Discussion 
This study used an existing data set from the FINGEN study [Caslake et al., 2008, Kofler et 
al., 2012] to further investigate the APOE Epsilon genotype * adiposity * LC n-3 PUFA * 
inflammation relationships and included novel genotyping for the -219G/T polymorphism 
(rs405509) in the APOE promoter region. The aim of the study was to 1.) perform an 
analysis of the determinants of LC n-3 PUFA status; 2.) investigate the impact of APOE 
Epsilon genotype, -219G/T genotype and -219G/T * APOE Epsilon haplotype on plasma 
inflammatory marker concentrations; and 3.) to investigate the impact of the APOE 
genotypes on the plasma inflammatory marker concentrations response to LC n-3 PUFA 
supplementation. Our main findings were that habitual oily fish intake, age and BMI 
determined plasma LC n-3 PUFA status; APOE Epsilon genotype interacted with -219G/T 
polymorphism to determine plasma apoE concentrations; -219G/T * APOE Epsilon 
haplotype determined plasma P-sel and VCAM-1 concentrations but not their response to 
treatment; and APOE Epsilon genotype determined plasma VCAM-1 response to treatment. 
Furthermore, there was no effect of treatment (i.e. fish oil supplementation) on plasma 
inflammatory marker concentrations, although habitual oily fish intake was a determinant of 
plasma IL-10 concentrations at baseline.  
Determinants of plasma fatty acid status 
In summary, we showed that habitual oily fish intake, age and BMI are determinants of 
plasma LC n-3 PUFA status. As expected habitual oily fish intake increased plasma LC n-3 
PUFA concentrations. Plasma LC n-3 PUFA concentrations also increased with age but only 
in women and not in men following full adjustment, with individuals aged ≥ 50 years having a 
higher plasma LC n-3 PUFA status compared to individuals aged < 50 years. Obese 
subjects (BMI ≥ 30 kg/m
2
) had lower plasma LC n-3 PUFA status compared to subjects with 
a normal weight (BMI < 25 kg/m
2
).  
In published FINGEN findings, Caslake et al. reported a greater increase in LC n-3 PUFA 
concentrations in the plasma PC lipid fraction upon fish oil supplementation in women 
compared to men, but observed no effect of age on the LC n-3 PUFA responsiveness to 
supplementation [Caslake et al., 2008]. Our findings are supported by other studies reporting 
an effect of age and gender on the EPA and DHA concentration in plasma lipid fractions 
[Childs et al., 2008, Crowe et al., 2008, Tavendale et al., 1992, Dewailly et al., 2001A and 
2001B, Babin et al., 1999, Vandal et al., 2008, Walker et al., 2013], red blood cells [Sands et 
al., 2011, Ogura et al., 2010, Walker et al., 2013] and AT [Bolton-Smith et al., 1997, Childs 
et al., 2008, Ogura et al., 2010, Walker et al., 2013]. The strength of the current FINGEN 
analysis is the prospective recruitment by gender and age approach, allowing a meaningful 
comparison across the decades of life (20 – 70 yr) in groups matched for gender. This 
provides considerable power to examine the impact of gender and age independently and 
interactively. Several studies have shown that women have higher DHA levels compared to 
men [Crowe et al., 2008, Bakewell et al., 2006, Garneau et al., 2012]. The impact of age on 
 Slim (2015), Chapter 2. APOE genotype, adiposity, long chain n-3 polyunsaturated fatty acids and inflammation 
82 
S
lim
 (2
0
1
5
), C
h
a
p
te
r 1
. L
ite
ra
tu
re
 re
v
ie
w
 
the LC n-3 PUFA response to supplementation appears to be dependent on the plasma lipid 
fraction, cells or tissues studied. A recent comprehensive study investigating the impact of 
age and gender on the incorporation of EPA and DHA in plasma PC, cholesterol esters 
(CE), NEFA, TG, mononuclear cells, red blood cells, platelets, buccal cells and 
subcutaneous AT in a double-blind randomised, controlled intervention trial providing fish oil 
supplements corresponding to 0, 1, 2, or 4 portions of oily fish per week showed that the 
effect of age and gender is dependent on the plasma lipid fraction, cell type or tissue studied 
[Walker et al., 2013]. For example, they reported increasing EPA and DHA concentrations in 
plasma TG and AT with increasing age, with significantly higher DHA levels in AT of old (60 
– 79 yr) compared to middle aged (40 – 59 yr) and young (30 – 39 yr) individuals. Moreover, 
women had higher baseline DHA concentrations in AT compared to men, with no difference 
in EPA concentrations. Regarding the response to supplementation, the increase in EPA 
levels in plasma TG was higher with increasing age, whereas the opposite was true for the 
increase in DHA levels in AT. However, no age or gender differences were observed in the 
plasma PC fraction, although the increase in EPA concentrations in response to 
supplementation in the plasma PC fraction tended to be larger in old compared to young 
individuals. In conclusion, these and other results clearly indicate a role for age and gender 
in determining EPA and DHA concentrations and their response to supplementation in 
plasma lipids, cells and AT.  
The gender related effects on LC n-3 PUFA, in particular EPA and DHA, concentrations and 
their incorporation into plasma lipids, cells and AT have been suggested to be attributed to 
the sex hormones [Walker et al., 2013, Crowe et al., 2008]. Studies using stable isotopes 
have shown that women are more efficient than men in converting α-linolenic acid (ALA) into 
EPA and DHA [Pawlowsky et al., 2001, Burdge et al., 2002A and B] and the female sex 
hormones are responsible for this [Childs et al., 2008]. The increased conversion may 
account for the higher habitual LC n-3 PUFA status in women. However, it should be 
mentioned that any difference in fatty acid metabolism, including their synthesis, 
interconversion and degradation may be responsible for differences in LC n-3 PUFA status 
[Arterburn et al., 2006].  
There was a large jump in plasma EPA concentrations in women between the age of 40 – 
49 yr and 50 – 59 year in our study. This finding is the opposite of what one would expect 
given that the female sex hormones play an important role in the biosynthesis of EPA from 
ALA and postmenopausal women suffer from lower oestrogen levels. It suggests a 
difference in partitioning of fatty acids in postmenopausal women with less stored for 
potential pregnancy and more found in plasma lipid pools. The higher plasma LC n-3 PUFA 
concentrations with increasing age in women in our study may be reflective of, as previously 
reported, a higher LC n-3 PUFA concentration in AT with age, especially in women. This is 
reasonable given that the total body fat mass increases with age and ALA and EPA are 
preferably mobilised from AT relative to the other n-3 PUFA [Puglisi et al., 2011, Childs et 
al., 2008]. ALA is the most abundant n-3 PUFA in AT with a concentration of approximately 
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1 % of total fatty acids, whereas EPA and DHA are present in only very small amounts (< 
0.3 % of total fatty acids) which increase upon dietary fish oil supplementation [Arterburn et 
al., 2006, Puglisi et al., 2011, Clifton et al., 2004, Andersen et al., 1999]. The age-related 
increase in plasma and tissue LC n-3 PUFA status is relevant based on the current opinion 
that low-grade inflammation is underlying various age-related diseases, including MetS, 
T2DM and CVD [Osborn and Olefsky, 2012, Maury and Brichard, 2010, Van Gaal et al., 
2006]. In addition, the lower plasma EPA and DHA levels in overweight subjects and MUO, 
but not MHO, compared to lean healthy subjects suggests a lower whole-body availability of 
these LC n-3 PUFA that might also persist at tissue levels in overweight and MUO 
individuals [Fernandez-Real et al., 2003, Perrault et al., 2014]. In line with this we also 
observed a lower LC n-3 PUFA concentration in the plasma PC lipid fraction in obese 
subjects (BMI ≥ 30 kg/m
2
) compared to subjects with normal weight (BMI < 25 kg/m
2
), 
suggesting depletion of circulating LC n-3 PUFA in obesity. These findings suggest a 
potential clinical relevance of LC n-3 PUFA in maintaining AT function and metabolic health 
[Puglisi et al., 2011]. Thus the increased plasma LC n-3 PUFA concentration in older 
individuals could be a natural response to hold down the age-related inflammatory disease 
progression. 
Plasma  phospholipid (PL) fatty acid profile reflects dietary intake and endogenous fatty acid 
metabolism. Thus, the increasing levels of LC n-3 PUFA in older subjects and decreased LC 
n-3 PUFA levels in obese subjects could reflect a differential fat intake and/or altered fatty 
acid metabolism. A low fat diet has been shown to alter fatty acid pattern in plasma 
phospholipid fatty acids and cholesteryl esters in a manner similar to that observed with 
feeding of LC n-3 PUFA [Raatz et al., 2001]. Besides, when the relative supply of n-3 fatty 
acids is more abundant, n-3 fatty acid are preferentially desaturated and elongated relative 
to n-6 fatty acids [Holman, 1998]. Hence, the increased LC n-3 PUFA levels in older subjects 
may reflect increased endogenous synthesis which may result from an relative abundance of 
n-3 fatty acids and/or low fat intake. On the other hand, the lower LC n-3 PUFA levels in 
obese subject may relate to a high absolute fat and/or n-6 fatty acid intake.  
We found no significant effect of APOE Epsilon genotype on the fatty acid composition of the 
PC lipid fraction - the most abundant plasma PL fraction - compared to scarce other human 
studies which determined the fatty acid composition of plasma TG [Plourde et al., 2009] and 
plasma total lipids [Chouinard-Watkins et al., 2013]. Thus, it is possible that the plasma lipid 
fraction, i.e. TG, PL, CE and total lipids, will influence the impact of APOE Epsilon genotype 
on circulating fatty acid status in humans.  
In this study we corrected for habitual oily fish intake hence our reported age-dependent 
effects on plasma EPA and DHA concentrations were independent of dietary intake. In line 
with this, several studies have reported higher EPA and DHA levels in older individuals 
independent of a differential dietary intake [Bolton-Smith et al., 1997, Crowe et al., 2008]. 
These findings all together clearly indicate a role for age and gender in determining EPA and 
DHA concentrations and their response to supplementation in plasma lipids, cells and 
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adipose tissue, which appears to be independent of dietary intake [Walker et al., 2013, 
Bolton-Smith et al., 1997, Crowe et al., 2008]. 
Determinants of plasma inflammatory marker concentrations 
To our knowledge, this study was the first to investigate the impact of the -219G/T * APOE 
Epsilon haplotype on plasma inflammatory marker concentrations. We showed that the -
219G/T * APOE Epsilon haplotype determined baseline plasma P-sel and VCAM-1 
concentrations, with APOE Epsilon genotype generally being a stronger determinant than 
the -219G/T genotype. The plasma P-sel concentrations tended to be consistently higher in 
those with APOE3 genotype compared to APOE2 and APOE4 genotype across the -219G/T 
genotypes, with a trend for decreasing plasma P-sel concentrations with an increasing 
number of -219T alleles in those with APOE3 genotype. Plasma VCAM-1 levels tended to be 
higher in APOE2 and APOE4 carriers compared to those with APOE3 genotype, with no 
differences across the -219G/T genotypes. 
-219G/T * APOE Epsilon haplotype 
In line with previous reports, we also observed an association between the -219G allele and 
the APOE2 genotype in the FINGEN study [Lambert et al., 2002, Lescai et al., 2011, Wang 
et al., 2000]. The MAF for -219G/T (rs405509) in the FINGEN study was T = 0.50 and 
corresponded to the reported MAF of T = 0.494 [Ensemble Genome Browser, NCBI dbSNP 
database]. The -219G/T polymorphism in the APOE promoter region has been shown to 
modulate the APOE expression levels both in vitro and in vivo, where the -219T allele 
decreases APOE transcriptional activity and plasma apoE levels compared to the other 
allelic variant [Artiga et al., 1998, Lambert et al., 2000, Moreno et al., 2003]. In agreement 
with previous findings [Moreno et al., 2003, Lambert et al., 2000], we also observed a dose-
dependent decrease in plasma apoE concentrations with increasing number of -219T alleles 
in APOE2 carriers and those with the APOE3 genotype, but not in APOE4 carriers for which 
the opposite effect was evident. This APOE Epsilon genotype-dependent effect contradicts 
with a previous report from the ECTIM-study, in which there was a similar effect of -219G to 
T substitution on plasma apoE concentrations after stratification for APOE Epsilon genotype 
[Lambert et al., 2000]. At this moment, we do not have a mechanistic explanation for the 
APOE Epsilon genotype-dependent effect of the -219T allele on plasma apoE 
concentrations. A SNP located very close to the promoter of a gene can change the 
expression of that gene or a more distant gene. The most common mechanism through 
which the SNP modulates gene expression is by altering the binding of proteins in the 
regulatory gene region, although it could also alter CpG sites affecting methylation of the 
region or alter binding of non-coding RNA (ncRNA). The altered binding of proteins in the 
regulatory gene region can lead to a loss or gain of enhancer or repressor transcription 
factor binding, nucleosome repositioning and/or altered long-range chromatin interactions 
which will affect gene expression. The -219G/T polymorphism may affect the binding of 
proteins in the regulatory gene region of APOE which subsequently alters APOE gene 
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expression levels and potentially plasma apoE concentrations. The apoE isoforms differ in 
their stability, apoE2 is most stable, apoE3 intermediate stable and apoE4 least stable 
[Hatters et al., 2006], and in their protein turnover and recycling [Heeren et al., 2004, Huang 
et al., 2011, Rellin et al., 2008]. Hence the -219G/T polymorphism may interact with the 
apoE isoforms to determine its effects on plasma apoE concentrations.  
Although findings are somewhat inconsistent, studies suggest an impact of the -219G/T 
polymorphism and a potential interaction with APOE Epsilon genotype to determine disease 
risk [Bizzaro et al., 2009, Lambert et al., 2000, Lambert et al., 2002 Lescai et al., 2011, 
Heijmans et al., 2002], something that warrants further investigation especially given that 
most studies have not specifically looked at -219G/T * APOE Epsilon haplotypes. For 
example, Lambert et al. showed that -419A/T (rs449647) and -219G/T (rs405509) 
polymorphisms in the APOE promoter region interact with APOE Epsilon genotype to 
determine risk of dementia in elderly, the 491A/−219T/APOE4 haplotype was associated 
with increased risk of dementia (OR = 3.5, 95 % CI 2.5 – 5.0) whereas the −491A/−
219G/APOE3 haplotype was associated with a decreased risk (OR = 0.6, 95 % CI 0.5 – 0.9) 
[Lambert et al., 2004]. To our knowledge, we are the first to report an effect of -219G/T * 
APOE Epsilon haplotype on plasma inflammatory marker concentrations in a study 
population comprising of healthy individuals without disease, with a normal weight (BMI < 25 
kg/m
2
, 50 %) and mainly non-smokers (88 %). The -219G/T * APOE Epsilon haplotype 
determined plasma P-sel concentrations, which tended to be consistently higher in those 
with APOE3 genotype compared to APOE2 and APOE4 carriers across the -219G/T 
genotypes. In addition, there was a trend for decreasing plasma P-sel concentrations with an 
increasing number of -219T alleles in those with APOE3 genotype. P-sel is expressed by 
endothelium and platelets upon activation by inflammatory mediators (such as thrombin and 
TNF-α) [Hartwell et al., 1998] where it mediates leukocyte rolling and recruitment, and its 
plasma concentrations are increased in people with thrombotic disorders, ischemic heart 
disease, and obesity [Blann and Lip, 1997, Ferri et al., 1999]. Therefore, -219G/T * APOE 
Epsilon haplotype may impact on plasma P-sel levels through modulation of the 
inflammatory response and/or platelet activation. 
Here, we also report a significant effect of -219G/T * APOE Epsilon haplotype on plasma 
VCAM-1 concentrations. However, only non-significant differences in the order of higher 
levels in APOE2 and APOE4 carriers compared to those with APOE3 genotype and no 
differences across the -219G/T genotypes were observed. The differences between the 
APOE Epsilon genotypes were published by Kofler et al. [Kofler et al., 2012] and are in line 
with previous reports that apoE protein suppresses VCAM-1 expression in a genotype-
dependent manner (E2 > E3 > E4) in endothelial cells [Stannard et al., 2001]. VCAM-1 is an 
important protein involved leukocyte rolling and transmigration that is upregulated during 
endothelial activation, although its soluble levels may not necessary represent cell-surface 
levels [Videm and Albrigtsen, 2008]. Thus, our findings suggests a potential differential 
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endothelial activation according to -219G/T * APOE Epsilon haplotypes, something that 
warrants further investigation. 
 
In summary, we demonstrated for the first time that the APOE Epsilon genotype and -
219G/T * APOE Epsilon haplotype, but not the -219G/T genotype, were a determinant of the 
plasma P-sel and VCAM-1 concentrations, indicating that APOE Epsilon genotype rather 
than -219G/T genotype is a strong determinant of plasma P-sel and VCAM-1 concentrations. 
These findings were unlikely to be mediated through plasma LC n-3 PUFA status as there 
was no independent or interactive effect of the -219G/T and APOE Epsilon genotype on 
plasma LC n-3 PUFA concentrations. However, plasma apoE concentrations were affected 
by the -219G/T * APOE Epsilon haplotype suggesting that APOE transcriptional activity may 
interact with APOE Epsilon genotype to determine its effects disease risk. All together, the 
current data suggests that the impact of APOE Epsilon genotype may depend on other 
factors, such as SNPs in APOE gene region, BMI and gender, and illustrates the complex 
interplay of factors in the development of physiological conditions, such as a pro-
inflammatory state. Furthermore, this data highlights the importance of research in specific 
homogenous populations in order to be able to determine genotype-phenotype associations. 
Plasma inflammatory marker responsiveness to treatment 
A low and modest dose fish oil intervention (0.7 and 1.8 g EPA+DHA / d) had no effect on 
any of the plasma inflammatory marker concentrations in the FINGEN study. These findings 
are in line with the inconsistent and often neutral effects of LC n-3 PUFA on plasma 
inflammatory markers in healthy individuals in marine n-3 PUFA intervention trials [Calder, 
2006, Calder et al., 2011A, Myhrstad et al., 2011A, Yang et al., 2012]. On the contrary, a 
large review on the dietary factors and low-grade inflammation in relation to overweight and 
obesity reviewing marine n-3 PUFA intervention studies showed that LC n-3 PUFA can 
lower circulating levels of CRP, IL-6, TNF-α, IL-18, ICAM-1, VCAM-1 and E-sel in various 
study populations [Calder et al., 2011A]. In addition, a meta-analysis analysing sixty-eight 
RCTs showed that LC n-3 PUFA lower circulating CRP, IL-6 and TNF-α levels in subjects 
with chronic non-autoimmune disease and healthy subjects [Li et al., 2014]. There was a 
negative linear relationship between the daily dose of EPA and the effect size on circulating 
CRP levels in healthy subjects, suggesting that a higher dose of EPA results in a greater 
CRP lowering effect. The null-findings in this study are most likely resulting from the 
relatively low physiological doses of EPA and DHA used, since most studies reporting anti-
inflammatory effect of EPA and DHA have used a high dose (≥ 3.0 g EPA+DHA / d) [Calder 
2006, Myhrstad et al., 2011A, Yang et al., 2012, Calder et al., 2011A] which could only 
realistically be achieved through fish oil supplementation rather than diet. A meta-analysis 
analysing seven studies reported that EPA and DHA decrease plasma ICAM-1 levels (5 
ng/ml, 95 % CI -10.07 – -0.27) regardless of dose in young (≤ 55 yr), but not older (> 55 yr) 
subjects [Yang et al., 2012]. The failure to observe an effect on plasma ICAM-1 
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concentrations in our study could therefore be in part due to the wide age of our study 
population. However, we did report a positive effect of habitual oily fish intake on plasma IL-
10 concentrations, suggesting that there may be other compounds in oily fish that exert 
beneficial effects on certain plasma inflammatory marker concentrations. 
 
A strength of the current FINGEN data analysis is the prospective recruitment according to 
APOE Epsilon genotype (E2, E3 and E4) (E2/E4 carriers were excluded), age and gender. 
This provided us significant power to evaluate the effects of APOE Epsilon genotype, age 
and gender on plasma LC n-3 PUFA status and plasma inflammatory marker concentrations 
independently and interactively. The equal distribution of the -219G/T alleles (50 % / 50 %) 
in the FINGEN study population also allowed a meaningful comparison across the -219G/T 
genotypes. The FINGEN study was not specifically designed to evaluate the effect of APOE 
Epsilon genotype and its interaction with adiposity (BMI) to determine plasma LC n-3 PUFA 
status and plasma inflammatory marker concentrations and their response to LC n-3 PUFA 
supplementation. However, the study protocol had a broad BMI inclusion range of 18.5 to 
32.0 kg/m
2
, which resulted in a study population with a large range of BMI and fairly equal 
number of normal weight (< 25 kg/m
2
, n = 155) and overweight individuals (25 – 29.9 kg/m
2
, 
n = 128) with some obese individuals (≥ 30 kg/m
2
, n = 29) also included. This provided us 
significant power to evaluate a potential interaction of APOE Epsilon genotype and body 
weight. We also investigated the plasma LC n-3 PUFA status and plasma inflammatory 
marker concentrations response to LC n-3 PUFA supplementation. The FINGEN study was 
a double-blind placebo controlled cross-over trial, which is considered the gold standard to 
investigate the effect of nutritional compounds on health outcomes in humans. There is no 
potential bias from not-blinded volunteers and/or researchers or the placebo-effect. 
Moreover, in cross-over trials subjects receive a sequence of different treatments in a 
random order and subjects serve as their own controls. This increased our power to detect a 
true effect with a similar number of volunteers, as the response in nutritional studies is often 
considerable different from individual to individual (inter-individual variation). 
 
A limitation of this study is that we assessed circulating fatty acid status and inflammatory 
markers as biomarkers of whole body fatty acid and inflammatory status, which is routinely 
conducted. The plasma PL fraction is the only valid marker of short term availability for EPA 
and one of the valid markers for DHA [Schuchardt and Hahn, 2013]. Thus, we used the 
correct plasma lipid fraction to study circulating EPA and DHA availability. Although there is 
generally a good correlation between circulating levels and whole-body status, circulating 
levels may not fully reflect tissue levels in all instances [Minihane et al., under review]. A 
strength of our study is that we used a range of soluble markers of inflammation, including 
acute phase proteins, cytokines and adhesion molecules, which are associated with 
inflammation in metabolic diseases [Calder et al., 2013]. This provided a more complete 
measure of inflammation than a single biomarker. There is a considerable between-
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individual variation and a number of modifiers influence the concentrations of the soluble 
inflammatory markers, including age, gender, adiposity, genetics, diet, smoking, physical 
(in)activity, gut microbiota and use of certain medication [Calder et al., 2013]. In our study, 
we corrected for many of these modifiers including age, gender, adiposity (BMI) and 
smoking, which makes our analysis investigating the effect of -219G/T and APOE Epsilon 
genotype on plasma inflammatory markers concentrations more robust. It is uncertain what 
contribution is made by various organs and tissues to the circulating inflammatory profile. 
Hence the circulating profile, in addition to being non-tissue specific, may over- or under-
represent the inflammatory state of individual organs. This is therefore recognised as a 
limitation of this study. 
 
An exclusion criteria for the FINGEN was a habitual oily fish intake of > 1 portion per week 
as determined by the FFQ. Our analysis showed that the average intake was 0.9 and 1.1 
portions per week in men and women. Therefore either volunteers were not completely 
honest at screening or when completing the FFQ, where they likely exaggerated their fish 
intake given the average fish intake in the UK is 0.33 portions per week. The latter can also 
explain the high upper level of oily fish intake in the highest quintile of habitual oily fish 
intake, which was 7.7 portions per week. The high habitual oily fish intake at baseline might 
have influenced the outcomes on various levels. First habitual oily fish intake could have 
influenced EPA and DHA status in the plasma PC fraction, as plasma phospholipids and red 
blood cell EPA and DHA concentrations reflect respectively short-term and long-term dietary 
intake [Risé et al., 2007]. The plasma phospholipid EPA concentrations increase in a linear 
dose-dependent manner in response to supplementation reaching a new steady state within 
one month of supplementation [Arterburn et al., 2006]. The plasma phospholipid DHA 
concentrations increase in a dose-dependent saturable manner in response to 
supplementation, with DHA concentration approaching saturation at dose of approximately 2 
mg/d. The kinetics of red blood cell EPA and DHA concentrations follow a similar pattern to 
plasma phospholipids, but reach a steady state after 4 to 6 months of supplementation 
[Arterburn et al., 2006]. Thus, individuals with a high habitual oily fish intake would have 
higher plasma phosphatidylcholine and red blood cell EPA and DHA concentrations. 
Besides, fish oil supplementation in combination with a high oily fish intake could have 
resulted in saturation of plasma phospholipid DHA concentrations. Several in vitro studies 
suggested DHA has more potent anti-inflammatory effects than EPA in macrophages 
[Mullen et al., 2010, Oliver et al., 2012, Weldon et al., 2007]. Therefore saturation of plasma 
phospholipid DHA concentrations may explain the limited changes in plasma inflammatory 
marker concentrations from baseline. 
The proportion of smokers was not similar for the -219G/T genotypes. Smoking induces 
oxidative stress and inflammation [van der Vaart et al., 2004] and this might have possibly 
confounded our results. 
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We have used the ratio of plasma oxidized LDL-C to plasma apolipoprotein B (apoB) 
concentrations as a biomarker of oxidative status to investigate if the decreased LC n-3 
PUFA concentrations in obese subjects could be attributed to an increased non-enzymatic 
oxidation of these fatty acids. However, this measure gives us no information about whether 
there is an effect of BMI on the sequestering of these fatty acid into mitochondrial and/or 
peroxisomal (enzymatic) fatty acid oxidation. 
 
In conclusion, we demonstrated that the -219G/T * APOE Epsilon haplotype is a determinant 
of plasma apoE concentrations and select plasma inflammatory marker concentrations, 
without affecting plasma LC n-3 PUFA concentrations in the PC lipid fraction or plasma 
inflammatory marker response to LC n-3 PUFA supplementation. In line with previous 
findings, our data support an interaction between SNPs in the APOE promoter region and 
APOE Epsilon genotype to determine plasma apoE concentrations and potentially disease 
risk markers. 
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Chapter 3. In vivo studies – diet-induced obesity and 
metabolic function: The interactive impact of APOE 
Epsilon genotype and fish oil on diet-induced obesity 
and whole-body glucose handling. 
Studies in human APOE3 and APOE4 targeted replacement mice 
 
 
Introduction 
Adipose tissue and metabolic disease 
Obesity is associated with metabolic complications, such as metabolic syndrome (MetS) and 
insulin resistance (IR), which in turn increase the risk of developing Type 2 Diabetes (T2DM) 
and cardiovascular disease (CVD) [Maury and Brichard, 2010, Van Gaal et al., 2006]. 
Although the link between obesity and metabolic abnormalities has been well established, 
approximately one-third of obese people, termed metabolically healthy obese (MHO), have a 
normal metabolic profile characterised by a low visceral fat (VAT) content, high high-density 
lipoprotein-cholesterol (HDL-C) levels, low triglyceride (TG) levels and high insulin 
sensitivity, despite their high fat mass [Wildman et al., 2008, Karelis et al., 2004]. In addition, 
adipose tissue (AT) inflammation, in which macrophages play a pivotal role, is an important 
determinant of the metabolic consequences of obesity. For example, Barbarroja et al. 
showed that MHO insulin sensitive individuals (mean BMI 56 ± 1 (SD) kg/m
2
) lacked the 
inflammatory response in VAT that characterised the metabolically unhealthy obese (MUO) 
insulin resistant individuals [Barbarroja et al., 2010]. Finally, the expansion capacity of the 
AT has been postulated as the underlying mechanism connecting obesity to IR, which is 
referred to as the adipose tissue expandability hypothesis [Virtue and Vidal-Puig, 2010]. 
According to this hypothesis, each individual has a defined maximum AT expansion capacity 
which is determined by genetic and environmental factors, and as an individual gains weight 
it eventually reaches its maximum AT expansion capacity. After this point, the AT cannot 
store TG anymore and excess lipids start to accumulate in other tissues such as liver, 
muscle and pancreas. This ectopic lipid deposition causes toxic effects in these tissues 
leading to IR, inflammation and cardiovascular complications. Thus, an impaired AT 
expansion capacity, excess VAT and macrophage-mediated inflammation in VAT are 
important determinants of the metabolic consequences of obesity [Virtue and Vidal-Puig, 
2010, Karelis et al., 2004, Barbarroja et al., 2010]. 
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Apolipoprotein E and adipose tissue metabolism 
There is accumulating evidence indicating that apolipoprotein E (apoE) plays a role in AT 
development, the development of obesity and its related metabolic complications [Kypreos 
et al., 2009, Slim & Minihane, 2014]. Zechner et al. were the first to show that apoE 
expression increases linearly with time upon differentiation and correlated with lipid content 
and free intracellular cholesterol content in 3T3-L1 adipocytes [Zechner et al., 1991]. In line 
with this, Huang et al. showed that endogenous apoE expression is required for lipid 
accumulation and apoE deficiency decreased the expression of genes involved in adipocyte 
differentiation in primary adipocytes [Huang et al., 2006]. In addition, freshly isolated 
adipocytes from apoE
-/-
 mice exhibit an impaired fatty acid uptake, decreased TG synthesis 
and increased TG lipolysis and apoE
-/-
 mice have an impaired plasma TG clearance, less 
body fat and smaller adipocytes, yet an improved glucose tolerance compared to wild type 
mice [Huang et al., 2006, Hofmann et al., 2008]. These studies clearly indicate a role for 
apoE in AT development, including adipocyte differentiation and adipocyte lipid metabolism.  
Secondly, the very low-density lipoprotein (VLDL)-derived TG-rich lipoproteins, which 
contain apoE, play an important role in AT development by being the main source of fatty 
acids for AT in both the fasting and fed state [Voshol et al., 2009]. Although VLDL plays an 
important role in AT development, it could also be argued that AT development plays a 
crucial role in VLDL metabolism and the clearance of TG-rich VLDL particles from the blood 
stream. Lastly, the apoE-recognising receptors low-density lipoprotein receptor (LDLR), 
VLDL receptor (VLDLR) and LDL-related protein 1 (LRP1) have been implicated in AT 
development [Karagiannides et al., 2008, Goudriaan et al., 2001, Hofmann et al., 2007]. 
These observations suggest a potential link between apoE, lipoprotein metabolism and the 
development of obesity, which was first demonstrated by Chiba et al. who showed that the 
VLDL-induced adipogenesis was apoE-dependent [Chiba et al., 2003]. In more detail, apoE-
deficient VLDL failed to induce differentiation of apoE
-/-
 bone marrow stromal cells into 
adipocytes, which could be restored by incubation of apoE-deficient VLDL with apoE. In 
addition, apoE-deficient ob/ob mice were protected from high fat diet (HFD)-induced obesity 
despite their higher plasma VLDL levels [Chiba et al., 2003]. These findings clearly indicate 
an interactive role of apoE and lipoprotein metabolism in AT development and diet-induced 
obesity (DIO). 
Finally, limited studies investigating the association between APOE Epsilon genotype and 
adiposity in humans have provided accumulating evidence supporting a link between APOE 
Epsilon genotype, adiposity and the metabolic consequences of obesity [Sima et al., 2007, 
Kolovou et al., 2009, Elosua et al., 2003]. To start, various studies reported a higher 
prevalence of the APOE4 allele in obese people, although there is some inconsistency 
[Sima et al., 2007, Kolovou et al., 2009, Elosua et al., 2003, Volcik et al., 2006, Oh and 
Barrett-Connor, 2001]. In addition, few studies reported an interaction between APOE 
Epsilon genotype and BMI to determine metabolic and/or inflammatory parameters [Kofler et 
al., 2012, Marques-Vidal et al., 2003, Pouliot et al., 1990]. For example, Marques-Vidal et al. 
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showed that APOE Epsilon genotype interacted with BMI to determine plasma total 
cholesterol, LDL-cholesterol (LDL-C), total insulin and bioactive insulin in 266 healthy men 
without hypolipidemic or antidiabetic drug treatment, with APOE4 carriers having higher 
levels compared to other APOE Epsilon genotypes and the difference enlarging with 
increasing BMI [Marques-Vidal et al., 2003]. These findings suggest that APOE Epsilon 
genotype may influence adiposity and APOE Epsilon genotype may interact with adiposity 
(BMI) to determine the metabolic consequences of increased adiposity. 
APOE Epsilon genotype and metabolic function in obesity 
The capacity of AT to buffer excess nutrients and macrophage-mediated AT inflammation 
are important determinants for maintaining adipocyte function and a metabolic healthy profile 
in obesity [Virtue and Vidal-Puig, 2010, Barbarroja et al., 2010, Osborn and Olefsky, 2012]. 
Recent studies in human APOE3 and APOE4 targeted replacement (TR) mice have shown 
that the APOE4 allele is associated with an impaired AT expandability and a greater 
predisposition to the metabolic complications of obesity [Arbones-Mainar et al., 2008 and 
2010]. In more detail, APOE4 TR mice had an impaired expandability of the epididymal VAT 
depot and a greater epididymal adipocyte size, an impaired insulin sensitivity, and an 
impaired ex vivo adipocyte differentiation and lipid storage capacity. APOE4 TR mice also 
showed a greater predisposition to develop glucose intolerance upon HFD feeding 
compared to APOE3 TR mice. Besides, the APOE4 genotype has been associated with pro-
inflammatory state [Jofre-Monseny et al., 2008A], with AT inflammation being an important 
determinant of AT dysfunction [Osborn and Olefsky, 2012]. In conclusion, these findings 
indicate that APOE Epsilon genotype impacts on AT function and the metabolic 
complications of obesity.  
Long chain n-3 PUFA and adipose tissue function 
Long chain (LC) n-3 polyunstaurated fatty acids (PUFA) exert various beneficial effects on 
AT function that include reducing AT expansion, AT inflammation and improving fatty acid 
oxidation (Table 3.1) [Flachs et al., 2009]. The ability of LC n-3 PUFA to reduce the HFD-
induced increase in AT mass is dependent on the genetic background of mice [Puglisi 2011]. 
However, the beneficial effects on systemic IR, dyslipidemia, hepatic steatosis, AT 
inflammation and IR are independent of changes in AT mass [Puglisi et al., 2011]. The 
effects of LC n-3 PUFA in humans are less convincing with a modest beneficial or neutral 
effect on body weight and body composition in combination with caloric restriction or 
exercise (Table 1.5, Chapter 1) [Bender et al., 2014, Lorente-Cebrián et al., 2013] and no 
effect on glycemic control and insulin sensitivity (Table 1.7, Chapter 1) [Akinkuolie et al., 
2011, Jafar et al., 2013]. Besides, LC n-3 PUFA have anti-inflammatory effects and reduced 
AT inflammation in various strains of mice [Todoric et al., 2006, Saraswathi et al., 2007, 
Muurling et al., 2003, Oh et al., 2010]. Therefore, LC n-3 PUFA may provide a potential 
therapeutic molecule to reverse the unfavourable adipocyte phenotype and hypothesized AT 
inflammation associated with the APOE4 allele.  
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Table 3.1. The effects of long chain n-3 PUFA on adipose tissue function [Flachs et al., 2009, 
Puglisi et al., 2011, Moreno-Aliaga et al., 2010]. 
Adipocyte function Effect 
Adipogenesis Inhibit adipocyte proliferation and differentiation 
Induce apoptosis post-confluent pre-adipocytes 
Reduce adipocyte hypertrophy and hyperplasia 
Lipid metabolism Increase mitochondrial biosynthesis and oxidative capacity 
Increase β-oxidation 
Improve triglyceride storage and reduce lipolysis 
Adipokine secretion  Increase adiponectin expression 
Inflammation and 
oxidative stress 
Decrease inflammatory cytokine production 
Decrease oxidative stress 
 
Research gaps 
Our understanding of how genetic determinants interact with nutrition and other 
environmental factors to cause metabolic disease is still poor, and the identification of 
protective and susceptibility genes is crucial to help us, among others, explain why not all 
people with obesity become insulin resistant [Osborn and Olefsky, 2012]. The AT 
expandability hypothesis proposes that an inadequate AT expansion capacity, rather than 
obesity itself, is the key feature linking a positive energy balance to development of T2DM 
[Virtue and Vidal-Puig, 2010]. In addition, macrophage-mediated AT inflammation causing 
AT dysfunction is recognised as the underlying pathology causing systemic IR and systemic 
inflammation in obesity [Osborn and Olefsky, 2012]. Although the AT expansion capacity 
and AT inflammation can be linked, more knowledge is needed about the factors that 
determine both AT expansion capacity and macrophage-mediated AT inflammation.  
Previous research from our group and others have demonstrated that the APOE4 allele is 
associated with an impaired AT expandability and greater predisposition to the metabolic 
complications of obesity in vivo [Arbones-Mainar et al., 2008 and 2010] and a pro-
inflammatory macrophage phenotype in vitro [Jofre-Monseny et al., 2007A]. LC n-3 PUFA 
reduce DIO, improve AT function, decrease AT inflammation and improve insulin sensitivity 
[Flachs et al., 2009, Puglisi et al., 2011, Lottenberg et al., 2012], providing a potential 
strategy to reverse the adipocyte dysfunction and metabolic complications associated with 
the APOE4 allele. However, the interactive impact of APOE Epsilon genotype and fish oil 
fatty acids on DIO and metabolic function, and the ability of fish oil to reverse the AT 
dysfunction associated with the APOE4 allele has never been investigated. 
Research question 
The aim of this study was to investigate the independent and interactive impact of APOE 
Epsilon genotype and fish oil on the development of obesity and whole-body glucose 
tolerance in human APOE3 and APOE4 TR mice. 
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Hypotheses 
Previous research has demonstrated that the APOE4 allele is associated with an impaired 
AT expandability and greater predisposition to the metabolic complications of obesity (i.e. IR 
and ectopic lipid deposition in the liver). In addition, the APOE4 allele has been associated 
with pro-inflammatory state and AT inflammation is an important determinant of AT 
dysfunction. AT dysfunction is in turn thought to be the driving force behind the systemic IR 
and low-grade inflammation in obesity. Therefore, we hypothesise that APOE4 TR mice will 
gain less weight yet have a greater AT dysfunction and poorer whole-body glucose tolerance 
upon HFD feeding compared to APOE3 TR mice. LC n-3 PUFA eisopentaenoic acid (EPA) 
and docosahexaenoic (DHA) have beneficial effects on adipocyte function besides their anti-
inflammatory effects. Therefore, we hypothesise that dietary fish oil will reduce the AT 
inflammation and resolve the adipocyte dysfunction associated with the APOE4 allele in 
mice upon HFD feeding, thereby improving whole-body glucose tolerance. 
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Materials & Methods 
A mouse model humanised for the human APOE3 and APOE4 gene was used to investigate 
the independent and interactive impact of APOE Epsilon genotype and fish oil on the 
development of obesity and its metabolic complications. Studies in human APOE3 and 
APOE4 TR mice allowed us, to use an experimental design tailored specifically to answer 
our research question; control for many confounding intrinsic and environmental factors 
difficult to control for in human studies, such as genetic background and diet; and collect AT 
biopsies and perform a thorough investigation into the role of apoE in AT development. The 
specific outcome measures of interest concerning the development of obesity were body 
weight gain, food intake and food efficiency. Metabolic function was investigated by 
performing detailed analysis of plasma biochemistry; estimating whole-body IR using the 
homeostatic model assessment-insulin resistance (HOMA-IR) index; and performing an 
intra-peritoneal glucose tolerance test (IPGTT) to measure whole-body glucose tolerance. 
The expression levels of key genes involved in AT development and insulin sensitivity were 
analysed to obtain further insight into potential underlying mechanisms. 
Animals & treatment 
This animal experiment was conducted in accordance with the United Kingdom Animals 
(Scientific Procedures) Act of 1986 under license from the Home Office. All efforts were 
made to reduce the number of animals and severity of the experiment by following the 3R’s. 
A power calculation was employed to minimise the number of animals without losing 
statistical power, with 10 mice per genotype * diet group enabling us to detect a 
standardised mean difference (SMD) of 1.45 with power of 90 % at significance level of α = 
0.05. The statistical power was calculated using the SMD for a two sample comparison of 
means with null hypothesis μ1 = μ2 (Figure 3.1), as no data was available from previous 
studies in human APOE3 and APOE4 TR mice regarding our main outcome of interest, i.e. 
AT macrophage infiltration and phenotype. Our experimental methods, in particular 
procedures on living animals, were designed and performed to minimise pain, suffering and 
distress - that may be suffered by the mice - without losing out on the quality of the data, for 
example by using appropriate anaesthetics. 
 
Figure 3.1. Statistical power and sample size calculation. 
The formula for calculation of the statistical power and sample size  
SMD = (μ1 - μ2) / δ = √ ((2 * (Zα/2 + Zβ)
2
) / n) 
Zα/2 = Z0.025 = 1.960; Zβ = Z0.10 = 1.282 
The standardised mean difference (SMD) for a two sample comparison of means (μ) with a given 
standard deviation (δ = δ1= δ2) and balanced design (n = n1 = n2) can be calculated by dividing the 
mean difference (μ1 - μ2) by standard deviation of the means (δ), or by taking the square root of the 
square of the sum of the Z-value corresponding to the 2-sided significance level α = 0.05 (Zα/2) and Z-
value for a given power of 90%, β = 1 – 0.90 = 0.10 (Zβ) multiplied by two and divided by sample size 
(n). 
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Mice 
Twenty 5 – 6 week old male human APOE3 (HomozygousB6.129P2-Apoe
tm2(APOE*3)Mae 
N8, 
Model #1548-M) and twenty 6 – 8 week old male human APOE4 (HomozygousB6.129P2-
Apoe
tm2(APOE*4)Mae 
N8, Model #1549-M) TR mice were purchased from Taconic (Germantown, 
NY, USA). The APOE3 and APOE4 TR mice are homozygous for the human APOE3 or 
APOE4 gene by targeted replacement of the endogenous mouse Apoe gene. The 
expression of the human apoE3 or apoE4 isoform is under the control of the murine Apoe 
regulatory sequence and thus apoE3 and apoE4 are produced at physiological levels 
[Sullivan et al., 1997]. The human APOE3 TR mice show a similar plasma lipid profile to wild 
type mice on a standard low fat diet despite their 2-fold lower VLDL remnant clearance rate, 
but are more susceptible to HFD-induced hypercholesterolemia and atherosclerosis 
compared to wild type mice [Sullivan et al., 1997]. Compared to the human APOE3 TR mice, 
human APOE4 TR mice in turn have a 2-fold lower VLDL remnant clearance rate but similar 
VLDL secretion rate, and a greater susceptibility to HFD-induced atherosclerosis [Knouff et 
al., 1999]. Male mice were used to reduce potential variation arising from the female 
oestrous cycle. 
 
 
Figure 3.2. Time line of studies in human APOE3 and APOE4 targeted replacement (TR) mice. 
Forty male human APOE3 and APOE4 TR mice were purchased and allowed to acclimatise for 4 
weeks prior to dietary intervention (Run-in period). At age of 13 – 14 week, APOE3 and APOE4 
mice were randomly allocated to a high-fat diet (HFD; 45 kcal% from fat) without or with long 
chain omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (30 g 
EPA+DHA / kg of diet with a ratio of 2:3; HFD+FO) for 8 weeks (n = 10 mice per APOE Epsilon 
genotype * diet group). Food and water was provided ad libitum. Body weight (BW) and food 
intake (FI) were monitored every second day. At 8 weeks, whole-body glucose tolerance was 
assessed using an intra-peritoneal glucose tolerance test (IPGTT). APOE, apolipoprotein E.  
-4 wk 0 wk 4 wk 8 wk
APOE4-HFD
(n=10)
APOE4-HFD+FO
(n=10)
20 male APOE3
and
20 male APOE4
TR mice 
(9-10 wk old)
Maintenance-diet
APOE3-HFD
(n=10)
APOE3-HFD+FO
(n=10)
Run-in Dietary intervention
IPGTT
BW & FI 
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Mice were allowed to acclimatise for 4 weeks before the commencement of the dietary 
intervention (Figure 3.2). During the run-in period mice were fed a palletised maintenance 
diet (Rat and Mouse No.3 Breeding Expanded diet (RM3); SDS Diets, Essex, UK). The mice 
were housed in groups of five per cage with two cages per APOE Epsilon genotype * diet 
group, allowed free access to food and water unless stated otherwise, and maintained under 
a 12 h light – 12 h dark cycle (7 am – 7 pm; lights on 7:00) in a temperature-controlled 
environment (21 °C, humidity 55 %) in a pathogen-free facility at the University of East 
Anglia. Mice were identified by ear tagging with miniature lightweight ear tags (Kent 
Scientific Corporation, Torrington, USA).  
Dietary intervention 
At the age of 13 – 14 weeks, the APOE3 and APOE4 TR mice were randomly allocated to a 
palletised high-fat diet (45 % calories (kcal%) from fat, 0.02 g / 100 g cholesterol; 
D07011903, Research Diets, New Brunswick, NJ, USA) without (HFD) or with long chain 
omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (30 g 
EPA+DHA / kg of diet; D12111601, Research Diets) (HFD+FO) for 8 weeks (n = 10 mice per 
APOE Epsilon genotype * diet group). Older mice (13 – 14 weeks) were used rather than 
younger mice (6 – 8 weeks), because obesity is a stronger trigger of metabolic complications 
at an older age. The diet compositions are given in Table 3.2. Briefly, D07011903 (HFD) was 
modified from standard D12451 (Research Diets) to contain no sucrose and D12111601 
(HFD+FO) was modified from D07011903 to contain 12 g EPA and 18 g DHA per kg of diet 
in a ratio of 2:3, by replacing fat from lard with a blend of Menhaden fish oil (In-house 
Research diets) and DHASCO oil (a generous gift from DSM Nutritional Products, Colombia, 
USA). The HFD+FO diet would provide an obese mouse (40 g) with a food intake of 5 g/d 
daily with 60 mg EPA + 90 mg DHA, which corresponds to a dose of 3750 mg EPA+DHA / 
kg of body weight / d.  
 
The composition of the HFD was designed to specifically induce obesity (‘fattening’) without 
triggering diabetes or IR. In particular, sucrose levels of the diets were kept low, because 
they are not only known to induce IR in mice, but also counteract the anti-inflammatory effect 
of fish oil in AT [Ma et al., 2011]. The standard D12451 containing 45 kcal% from fat has 
been shown to induce DIO in wild type C57BL/6 mice [Duffaut et al., 2009] and HFD feeding 
for 8 to 10 weeks was sufficient to induce considerable macrophage influx into AT (average 
AT macrophage turnover is 8 weeks) in mice [Lumeng et al., 2007A]. Furthermore, 
replacement of dietary fat with 27 % Menhaden fish oil (wt/wt; Menhaden oil: 16 % EPA and 
9 % DHA) resulting in a daily dosage of 3750 mg EPA + DHA / kg of body weight per mouse 
has been shown to reduce AT inflammation - an important determinant of metabolic 
complications in obesity [Osborn and Olefsky, 2012] - in wild type C57BL/6 mice on HFD (60 
kcal% from fat) [Oh et al., 2010]. The interactive impact of APOE Epsilon genotype and fish 
oil on AT inflammation is discussed in Chapter 4.   
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Table 3.2. Dietary components and fatty acid composition of the experimental diets. 
 High-fat control diet 
(HFD) 
High-fat fish oil diet 
(HFD+FO) 
Macronutrients g / 100 g kcal% g / 100 g kcal% 
Protein 24 20 24 20 
Carbohydrate 41 35 41 35 
Fat 24 45 24 45 
Total  100  100 
kcal/g 4.73  4.73  
Ingredient g/kg g/kg 
Casein 200 200 
L-cysteine 3 3 
Corn starch 246 246 
Maltodextrin 100 100 
Sucrose 0 0 
Cellulose 50 50 
Soybean oil 25 25 
Lard 178 85 
Menhaden oil 0 72 
DHASCO oil 0 20  
Mineral mix  10 10 
Dicalcium phosphate 13 13 
Calcium Carbonate 6 6 
Potassium Citrate 17 17 
Vitamin mix 10 10 
Choline bitartrate 2 2 
LC n-3 PUFA   
EPA (g / kg of diet) 0 18 
DHA (g / kg of diet) 0 12 
EPA:DHA ratio 0 0.67 
Fatty acid composition 
% of total fatty acids 
  
14:0 1.1 5.0* 
16:0 21.0 19.2* 
16:1 n-7 1.5 5.9* 
17:0 0.4 1.1* 
18:0 11.4 8.2* 
18:1 n-9 34.7 23.7* 
18:2 n-6 14.2 16.7* 
18:3 n-6 ND 0.1 
18:3 n-3 1.6 2.0* 
18:4 n-3 ND 0.9* 
20:0 0.2 1.0 
20:1 0.6 0.6  
20:2 0.7 0.4* 
20:4 n-6 0.2 0.6* 
20:5 n-3 (EPA) ND 4.0* 
22:5 n-3 ND 0.1* 
22:6 n-3 (DHA) ND 6.0* 
24:1 ND 0.8* 
*Fatty acid content (% of total fatty acids) of HFD+FO is different from HFD, Student’s t-test p < 0.05 (n 
= 3). 14:0, myristic acid; 16:0, palmitic acid; 16:1 n-7, palmitoleic acid; 17:0, margaric acid; 18:0, 
stearic acid; 18:1 n-9, oleic acid; 18:2 n-6, linoleic acid; 18:3 n-6, gamma-linolenic acid; 18:3 n-3, 
alpha-linolenic acid; 18:4 n-3, stearidonic acid; 20:0, icosanoioc acid; 20:1, gondoic acid; 20:4 n-6, 
arachidonic acid; 20:5 n-3, eicosapentaenoic acid (EPA); 22:5 n-3, docosapentaenoic acid; 22:6 n-3, 
docosahexaenoic acid (DHA); 24:1, nervonic acid; HFD, high-fat diet; HFD+FO, high fat diet containing 
30 g EPA+DHA per kg of diet; LC n-3 PUFA, long chain n-3 polyunsaturated fatty acids; ND, not 
detected. 
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Diet composition 
The HFD contained 45 kcal% from fat which resembles the current average UK diet that 
contains approximately 35 kcal% from fat [Great Britain NDNS Report, 2011]. The major 
source of fat was lard which is rich in saturated fat (SFA, 44 %) and the SFA:MUFA:PUFA 
ratio (40:40:10 g / 100 g food) [McCance & Widdowson’s The Composition of Foods 
Integrated Dataset, 2002] corresponds to the average dietary SFA:MUFA:PUFA ratio of the 
UK population (30:30:15 g/d), i.e. 40 % SFA [Great Britain NDNS Report, 2011]. The 
EPA:DHA ratio of the HFD+FO diet resembled the EPA:DHA ratio of oily fish, which is the 
major dietary source of EPA and DHA, and thereby corresponds to the EPA:DHA ratio of the 
average UK diet [Welch et al., 2010]. The EPA and DHA content of the HFD+FO resulted in 
an animal dosage of 3750 mg EPA+DHA / kg of body weigt / day which corresponds – 
based on allometric scaling and body surface (BSA)-based calculation – to a human 
equivalent dose of 36 g EPA+DHA / d in a normal weight adult (70 kg) (Figure 3.3) [U.S. 
Department of Health and Human Services, 2005]. This is a supra-physiological dose 
corresponding to 12 portions of oily fish per day and 12-fold the physiological daily intake 
achievable with fish oil supplements (3 g EPA+DHA / d). Also, it is beyond physiological 
tolerable levels previously approached in human intervention trials (≤ 5.6 – 8.4 g EPA+DHA / 
d) (for review see Calder et al. [Calder et al., 2006 and 2011A]). However, this is the first 
study investigating the impact of fish oil on AT inflammation according to APOE Epsilon 
genotype and a wide array of previous mouse studies investigating the impact of LC n-3 
PUFA on a range of health outcomes and specifically on AT inflammation in a DIO model 
have used comparable animal dosages in the range of 1763 mg / kg of body weight to 3750 
mg / kg of body weight [Oh et al., 2010, Todoric et al., 2006, Saraswathi et al., 2007]. Thus, 
to prevent null findings resulting from too low dosages, a higher dosage was chosen based 
on previous studies reporting beneficial effects of fish oil on AT inflammation. 
 
Figure 3.3. Conversion of the Animal Dose (AD) to the Human Equivalent Dose (HED) [U.S. 
Department of Health and Human Services, 2005]. 
The formula for conversion of the Animal Dose (AD) to the Human Equivalent 
Dose (HED), as proposed by the FDA 
HED (mg / kg) = AD (mg/kg) * ([Wanimal (kg) / Whuman (kg)]
0.33
) 
The AD is translated to the HED using a conversion factor. This conversion factor is calculated by 
raising the division product of the species body weights (W) to the power of 0.33. The 0.33 value is 
result of 1 – b value, where b is the allometric exponent of 0.67 that scales the bodyweight well with the 
body surface area [U.S. Department of Health and Human Services, 2005]. 
 
The fatty acid composition of the experimental diets is presented in Table 3.2. Diets 
contained sufficient levels of tert-Butylhydroquinone (tBHQ) and vitamin E to protect the fatty 
acids from oxidation. The feed pellets were colour marked, packaged per 1 kg, and stored at 
-80 °C in the dark. Every week a new package was used and stored at 4 °C in the dark. 
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Feed and water were provided ad libitum, unless stated otherwise, and fresh food was 
provided every 2
nd
 / 3
rd
 day. The fatty acid composition of the experimental diets did not 
significantly change over three days at room temperature (Appendix 3-1). Body weight and 
food intake were monitored every 2
nd
 / 3
rd
 day. The dietary intervention started and finished 
two weeks earlier for the APOE4 TR mice compared to the APOE3 TR mice, because the 
APOE4 mice were two weeks older upon arrival. 
Sample and tissue collection 
Following eight weeks of dietary intervention, an IPGTT was performed over two subsequent 
mornings, testing in a random order ten mice (two cages housing each five mice) per day. 
Forty-eight hours after the IPGTT, mice were randomly (per cage of five mice) sacrificed by 
exsanguination during three subsequent mornings. Blood was collected by cardiac puncture 
under isoflurane anaesthesia in Lithium-Heparin coated microtubes (Sarstedt, Leicester, 
UK), coagulated for 30 minutes at room temperature, centrifuged for 10 min at 2,000 g at 20 
°C, after which plasma was collected, frozen on dry-ice and stored at -80 °C. Mice were 
perfused with 30 – 40 ml ice-cold PBS containing heparin (10 units/ml; Sigma-Aldrich, 
Dorset, UK) before removing the other tissues and organs. One epididymal AT was collected 
in DMEM (4500 mg/L glucose; Sigma-Aldrich, Dorset, UK) and placed in an incubator (37 
°C, 5% CO2 - 95% O2) for isolation of the stromal vascular fraction (see Chapter 4). The 
second epididymal AT was snap frozen on dry-ice, and stored at -80 °C for RNA isolation 
and analysis of the fatty acid composition (see Chapter 4). The epididymal gonadal fat depot 
was chosen for analysis, because it is the largest and anatomically easiest to collect VAT 
depot, although VAT comprises also of mesenteric and retroperitoneal AT. Throughout this 
chapter, epididymal AT will be referred to as VAT. 
Whole body insulin-resistance  
The whole-body IR was estimated using the HOMA-IR index, using the fasting plasma 
glucose and insulin concentrations and formula “glucose (mmol/L) x fasting insulin (mU/L) / 
22.5” [Matthews et al., 1985]. 
Intra-peritoneal glucose tolerance test 
Prior to testing, mice were fasted 10 – 16 hr overnight that is suitable for studies focussing 
on glucose utilisation [Ayala et al., 2010]. An IPGTT was performed with intra-peritoneal (IP) 
injection of a fixed glucose load based on a glucose dose of 2 g/kg of body weight [Ayala et 
al., 2010] and the average body weight of 40 g that provided 8 mg D-glucose in saline 
solution. A fixed glucose load was preferred above the more commonly used glucose dose 
based on the individual weight of the mice to prevent that the glucose load would be biased 
by the increased fat mass in obese mice as lean mass is the principal site for glucose 
disposal [Ayala et al., 2010]. Animals were denied food during the course of the test. Water 
was provided ad libitum. A drop of blood was collected using tail snip blood sampling, which 
is considered an appropriate method for blood sampling during GTT [Ayala et al., 2010], for 
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determination of glucose using the AlphaTRAK 2 glucometer calibrated for mice (Abbott 
Laboratories Ltd., Maidenhead, UK) at time points 0, 10, 20, 30, 60 and 120 min. Whole-
blood glucose levels obtained with the AlphaTRAK 2 glucometer correlate relatively well with 
plasma glucose levels determined with enzymatic assays that are considered the medium of 
choice for glucose assessment [Ayala et al., 2010]. An additional 30 μl blood sample was 
collected at time points 0, 15 and 120 min into EDTA-coated microvette tubes (Sarstedt), 
centrifuged for 10 min at 2,000 g at 20 °C to collect plasma, which was stored at -80 °C for 
determination of insulin levels.  
Biochemical analysis 
Plasma total cholesterol (TC), HDL-C, TG and glucose concentrations were measured using 
commercial IL Test
TM
 assays (Instrumentation Laboratory UK Ltd., Warrington, UK). Plasma 
non-esterified fatty acids (NEFA) levels were measured using the commercial colorimetric 
assay (Randox Laboratories Ltd., Crumlin, UK). Liver function was investigated by analysing 
the plasma concentrations of enzymes commonly included in a liver function test which give 
an indication of liver inflammation and damage [British Liver Trust, 2007], namely alanine 
aminotransferase (ALT), alkaline phosphatase (ALP) and aspartate aminotransferase (AST) 
using commercial IL Test
TM
 assays (Instrumentation Laboratory UK Ltd.). The plasma levels 
of ALT and AST, two aminotransferases enzymes present in hepatocytes which leak into the 
bloodstream when hepatocytes are damaged, can be increased up to 20 – 50 times in liver 
inflammation (hepatitis). ALT is more specific to the liver, whereas increased AST levels can 
also be an indication of muscle damage. ALP is an enzyme found in liver bile duct and 
increased plasma levels can indicate obstructive or cholestatic liver disease. All analyses 
were performed according to manufacturers’ instructions using the ILab-650 analyser 
(Instrumentation Laboratory UK Ltd.). The ILab-650 analyser was calibrated against specific 
calibrators with a Coefficient of Variation (CV) < 5 %. Quality control samples (QCs) were 
included to validate each assay. Plasma non-HDL-C levels, consisting of LDL-C plus VLDL-
C, were calculated by subtracting HDL-C from TC. The plasma LDL-C levels cannot be 
estimated from TC, HDL-C and TG using the Friedewald formula [Friedewald et al., 1972], 
because the use of this formula is not valid in mice [Emeson et al., 1995]. 
Plasma samples (5 μl) were analysed in duplicate for insulin using a commercial ELISA kit 
(Millipore Ltd., Livingston, UK) and BMG Omega plate reader (BMG Labtech, Aylesbury, UK) 
according to manufacturers’ instructions (intra and inter assay CV%; 11.3 and 21.0 %).  
Plasma interleukin-10 (IL-10) was analysed in singlet (5-fold dilution) using commercial 
Mouse IL-10 ELISA Ready-Set-Go (2nd Generation) kit (eBiosciences, Hatfield, UK) and 
BMG Omega plate reader (BMG Labtech) according to manufacturers’ instructions. Thirty-
eight out of the 40 samples had values below the sensitivity of the assay (32 pg/ml), 
indicating that the 5-fold dilution factor was too high. There was not enough sample to rerun 
the analysis for IL-10. Therefore, the data of 38 samples was extrapolated using the 2
nd
 
polynomial regression fit standard curve obtained from the serial dilution of the top standard 
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(4000 pg/ml) on each plate. Future experiments are recommended to use a 2-fold dilution 
factor for the samples to fall within the detection range (32 – 4000 pg/ml) of the assay. Four 
samples (one from each APOE Epsilon genotype*diet group) were analysed in duplicate to 
determine the within assay CV of 28.4 %.  
Plasma adiponectin and leptin levels were analysed in singlet (2000-fold and no dilution 
factor) using commercial ProcartaPlex
TM
 Simplex Immunoassays (eBiosciences) according 
to manufacturers’ instructions using Luminex 200 System (Luminex, Austin, United States). 
Six samples were analysed in duplicate to determine the within assay CV of < 10 %. The 
STartStation 3.0 software (Applied Cytometry, Dinnington, UK) was used to analyse the 
data. 
RNA isolation 
Total RNA was isolated from epididymal AT using Ambion® TRIzol reagents (Life 
Technologies, Paisley, UK) followed by Chloroform extraction according to the 
manufacturers’ instructions. Briefly, 150 – 400 mg of tissue was homogenised in 1 ml TRIzol 
with one pre-cooled stainless steel bead in a pre-cooled tube for 5 min at 50 Hz using the 
TissueLyser LT (Qiagen, Manchester, UK). After centrifugation at 12,000 g for 10 min at 4 
°C, the fat layer was removed and the supernatant was collected, mixed with 0.2 ml Phenol-
Chloroform-Isoamyl alcohol 25:24:1 (Life Technologies) and incubated for 2 – 3 min at room 
temperature. The RNA-containing aqueous phase was collected after centrifugation at 
12,000 g for 15 min at 4 °C. Total RNA was precipitated with 0.5 ml 100 % isopropanol 
(Fisher Scientific, Loughborough, UK), washed with 1 ml 75 % ethanol, and resuspended in 
nuclease free water (Promega UK Ltd, Southampton, UK) and incubated at 60 °C for 10 min. 
RNA was cleaned-up using an overnight ethanol precipitation with 0.1 volumes 3 M sodium 
acetate (pH 5.2) (Fisher Scientific) and 2.2 volumes 100 % ethanol (Sigma-Aldrich) at -20 
°C, centrifugation at 12,000 g for 10 min at 4 °C, 70 % ethanol wash and centrifugation for 5 
min, and air-dried before resuspension in RNase-free water. The RNA concentration and 
purity were measured using the NanoDrop Spectrophotometer ND-1000 (Thermo Fisher 
Scientific Inc., Waltham, MA USA).  
mRNA expression analysis by real-time quantitative PCR 
Real-time quantitative PCR (RT-QPCR) was performed on individual samples (n = 10 per 
group). One μg of total RNA was treated with DNase I (Thermo Scientific Fermantas) and 
used for cDNA synthesis using Invitrogen™ Oligo (dT) primers and SuperScript® II Reverse 
Transcriptase (Life Technologies) according to manufacturers’ instructions. RT-QPCR 
reactions were performed with Precission qPCR Mastermix (PrimerDesign Ltd., 
Southampton, UK) using SYBR green detection technology and the Applied Biosystems 
7500 Real-Time PCR system (Life Technologies). Each reaction (20 μl) contained 10 μl 
Precission qPCR Mastermix, 1 μl forward primer (6 μM), 1 μl reverse primer (6 μM), 3 μl 
RNase-free water and 5 μl cDNA (10-fold dilution). The following cycles were performed: 1x 
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10 min 95 °C, 40 amplification cycles (40x 15 sec 95 °C, 1 min 60 °C), followed by a 
continuous melting curve (15 sec 95 °C, 1 min 60 °C, 30 sec +∆ 1 % up to 95 °C, 15 sec 60 
°C). A negative control without cDNA template (NTC) and a negative control without reverse 
transcriptase (-RT) were taken along with every assay. Data was normalized against the 
reference genes actin, beta (Actb), ATP synthase, H+ transporting mitochondrial F1 
complex, beta subunit (Atp5b) and glyceraldehyde-3-phosphate dehydrogenase (Gapdh) 
which were chosen for their most stable gene expression levels between mice (Appendix 3-
2). The reference gene expression stability and the optimal reference genes were 
established by screening 3 – 4 samples per group for the expression levels of Actb, Gapdh, 
Rpl13a, 18S, Eif4a2, and Atp5B using the 6-gene geNorm SYBR green detection kit 
(PrimerDesign Ltd.) with the above described reaction conditions. The primers for 
apolipoprotein E (Apoe) were designed using primer-BLAST 
(www.blast.ncbi.nlm.nih.gov/Blast). Primers for solute carrier family 2 (facilitated glucose 
transporter) member 4 (Slc2a4, Glut4) were designed by PrimerDesign (PrimerDesign Ltd.). 
Primer sequences are presented in Table 3.3. A standard curve was generated using serial 
dilutions of a pooled sample (pooled cDNA from all experimental samples) to determine 
reactions’ amplification efficiency and sensitivity. Samples with a non-exponential 
amplification, indicating poor reaction efficiency, were omitted from analysis. Samples with 
cycle threshold (CT) values below the sensitivity limit of the assay but 5 or more CT’s greater 
than the NTC for that assay (indication of target-specific amplification), were assigned the CT 
value corresponding to the detection limit of that assay, in order to minimise the bias 
resulting from the exclusion of these samples on the end results (Appendix 3-2, Table A3-
2.1). The mRNA expression levels were calculated using the ∆∆CT method and gene-
specific amplification efficiencies [Hellemans et al., 2007] with the qbase+ software 
(Biogazelle, Zwijnaarde, Belgium). All mRNA expression levels are presented as relative 
quantity scaled to the average across all samples per target gene and normalised to the 
geometric mean of the reference genes Actb, Atp5b and Gapdh.  
 
Table 3.3. Primers used for mRNA expression analysis using RT-QPCR. 
Gene Primer Sequence Product size 
Apoe 
F: 5’- TGCGTTGCTGGTCACATTCC -3’  
R: 5’- CAGGTAATCCCAAAAGCGACC -3’ 
146 
Glut4 (Slc2a4) 
F: 5’- CCAGTATGTTGCGGATGCTAT -3’  
R: 5’- TTTTAGGAAGGTGAAGATGAAGAAG -3’ 
88 
Apoe, apolipoprotein E; Glut4, solute carrier family 2 (facilitated glucose transporter), member 4 
(Slc2a4). 
 
Statistical analysis 
The independent and interactive impact of APOE Epsilon genotype and diet on body weight 
and food intake was determined using repeated-measures Analysis of Variance (ANOVA) 
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with body weight or food intake at time point 0 – 8 weeks as dependent variables, time 
(Week (9 levels)) as a within-subject variable, genotype (G) and diet (D) (main and 
interaction effect) as independent between-subject variables, and was considered 
statistically significant when p < 0.05. The independent and interactive impact of APOE 
Epsilon genotype and diet on other outcome measures was analysed using 2 x 2 factorial 
univariate ANOVA with G, D and G*D as independent variables and considered statistically 
significant when p < 0.05. In the presence of a significant APOE Epsilon genotype * diet 
(G*D) interaction effect, post-hoc analysis was performed using the two-tailed Student’s t-
test with Bonferroni correction to analyse differences between the APOE Epsilon genotype * 
diet groups. Differences were considered significant at p < 0.008 (= 0.05 / 6). Statistical 
analysis of the mRNA expression levels in AT was done using log transformed values. Data 
with a non-normal distribution and/or unequal variances was analysed using a non-
parametric Kruskal-Wallis test and was considered statistically significant when p < 0.05. 
Post-hoc Mann-Whitney U test with Bonferroni correction was employed to test for 
differences between the APOE Epsilon genotype * diet groups and was considered 
significant at p < 0.008 (= 0.05 / 6). Various outcome measures had not-normally distributed 
data and/or unequal variances which was not improved and often worsened by log (
10
log or 
e
log), square root (√x) or inverse (1/x) transformation, and as a consequence for many 
outcome measures non-parametric testing had to be employed. In the results section, the 
statistical test employed will be clearly indicated in the tables and figures. All statistical 
analysis was performed using SPSS 18.0. 
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Results 
Development of diet-induced obesity 
 
Figure 3.4. The effect of APOE Epsilon genotype and diet on the development of diet-induced 
obesity in human APOE3 and APOE4 targeted replacement mice fed a high-fat diet (HFD) or 
HFD containing 30 g EPA+DHA / kg of diet (HFD+FO). Data is presented as mean ± SEM, n = 10 
mice per group. Statistical analysis was done by ANCOVA to test for genotype (G), diet (D) and 
G*D interaction effect; between-animal analysis revealed a significant effect of diet (F1,36 = 
7.805, p<0.01) on body weight, with no effect of APOE Epsilon genotype (F1,36 = 1.781, p = 0.19) 
or APOE Epsilon genotype * diet interaction (F1,36 = 2.819, p = 0.10). Group comparisons at each 
time point were done by Student’s t-test with Bonferroni correction; *APOE3-HFD is different 
from APOE3-HFD+FO and APOE4-HFD+FO, p < 0.05. APOE, apolipoprotein E; HFD, high-fat 
diet; HFD+FO, HFD containing 30 g EPA+DHA / kg of diet. 
 
At the start of the dietary intervention, the mice (age 13 – 14 weeks) had a similar body 
weight of 29.0 gram (range 25.0 – 32.1 g). Between-animal analysis revealed there was a 
significant effect of diet (F1,36 = 7.805, p < 0.01), but not of APOE Epsilon genotype (F1,36 = 
1.781, p = 0.19), on bodyweight at the end of the dietary intervention (week 8), which did not 
interact with genotype (F1,36 = 2.819, p = 0.10). Group comparison revealed that from 3 
weeks onwards, APOE3 mice on HFD had a significantly higher body weight than APOE3 
and APOE4 mice on HFD+FO (36.6 ± 0.5 (SEM) vs. average of 32.8 ± 0.4 g, p<0.05; Figure 
3.4). This difference in body weight persisted over the course of the dietary intervention, with 
APOE3 mice on HFD reaching a final body weight of 43.9 ± 1.1 g compared to APOE4 mice 
on HFD+FO (the leanest group) reaching only 38.3 ± 0.8 g. There was an overall trend for a 
difference in final body weight between APOE3 and APOE4 mice fed the HFD (43.9 ± 1.1 
vs. 40.4 ± 1.9 g, p = 0.36) though this did not reach significance. In summary, HFD feeding 
resulted in the development of DIO that was prevented by dietary fish oil in APOE3 mice. 
Moreover, there was a strong trend for diet to interact with APOE Epsilon genotype to 
determine the development of DIO, with APOE4 mice being more resistant to DIO. 
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The accumulation of especially VAT is associated with an increased risk for metabolic 
complications and disease in obesity. In line with the findings on body weight, there was an 
effect of diet on VAT weight (F1,35 = 410.5, p < 0.05), but surprisingly in the opposite 
direction (Figure 3.5A). Mice on HFD+FO had a consistent higher VAT weight compared to 
the control HFD. In addition, there was an effect of APOE Epsilon genotype (F1,35 = 1517, p 
< 0.05) with APOE3 mice having a consistently higher VAT weight compared to APOE4 
mice. However, the effect of diet and APOE Epsilon genotype on VAT weight disappeared 
after correcting for body weight (diet F1,35 = 21.709, p = 0.14 and APOE Epsilon genotype 
F1,35 = 7.457, p = 0.22), which provides a more robust estimate of adiposity (Figure 3.5B). In 
summary, the APOE3 genotype and dietary fish oil were associated with a greater VAT 
weight. 
 
A      B 
     
Figure 3.5. The effect of APOE Epsilon genotype and diet on epididymal visceral adipose tissue 
(VAT) in human APOE3 and APOE4 targeted replacement mice fed a high-fat diet (HFD) or HFD 
containing 30 g EPA+DHA / kg of diet (HFD+FO). Epididymal VAT weight in g [A] and % of body 
weight [B]. Data is presented as mean ± SEM, n = 10 mice per group. Statistical analysis was 
done by two-way ANOVA to test for genotype (G), diet (D) and G*D interaction effect. Group 
comparisons by Student’s t-test with Bonferroni correction revealed no difference between 
groups. APOE, apolipoprotein E; HFD, high-fat diet; HFD+FO, HFD containing 30 g EPA+DHA / 
kg of diet. 
 
Given the important role apoE plays in AT development, including adipocyte differentiation 
and adipocyte lipid accumulation, the Apoe mRNA expression levels in VAT were 
investigated. The Apoe mRNA expression levels were significantly lower in VAT of APOE3 
mice on HFD compared to all other three groups (p < 0.001) (Figure 3.6). 
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Figure 3.6. The relative mRNA expression 
of apolipoprotein E (Apoe) in the 
epididymal visceral adipose tissue (VAT) of 
human APOE3 and APOE4 targeted 
replacement mice fed a high-fat diet (HFD) 
(black bar) or a HFD containing 30 g 
EPA+DHA / kg of diet (HFD+FO) (white 
bars). APOE Epsilon genotype interacted 
with diet to determine Apoe expression 
levels (p < 0.001), with APOE3 mice on HFD 
having significantly lower expression 
levels than the three other groups (p < 
0.001). Data is presented as relative 
quantity normalised to the reference genes 
Actb, Atp5B and Gapdh, mean ± SEM, n = 9 
– 10 mice per group. Statistical differences 
were tested using ANOVA for the effects of 
APOE Epsilon genotype (G), diet (D) and 
G*D interaction and considered statistically 
significant when p < 0.05. Only significant 
effects are displayed on top of the figure. 
Differences in the mRNA expression 
between the groups were tested using 
Student’s t-test with Bonferonni correction, 
***p < 0.001.  
 
Food intake and food efficiency 
To investigate if the difference in body weight could be related to a differential food intake, 
we calculated the average food intake and food efficiency (Figure 3.7). APOE Epsilon 
genotype interacted with diet to determine food intake (p < 0.001). In more detail, APOE3 
mice on HFD had a consistently higher average food intake compared to the other three 
groups (APOE3-HFD 3.2 ± 0.1 g / mouse / day vs. APOE3-HFD+FO 2.8 ± 0.0, APOE4-HFD 
2.6 ± 0.1, APOE4-HFD+FO, 2.6 ± 0.1 g / mouse / day, p < 0.05) (Figure 3.7A), which was 
most pronounced in the first three weeks of HFD feeding (Figure A3-3.1, Appendix 3-3). In 
addition, the average food intake of APOE3 mice on HFD+FO was higher compared to 
APOE4 mice on a similar diet (2.8 ± 0.0 vs. 2.6 ± 0.1 g / mouse / day, p < 0.01). The overall 
food efficiency, calculated by dividing the body weight gain (g) by food intake (g), of the mice 
did not significantly differ between the groups, and on average mice gained 0.7 g of body 
weight for each gram of food consumed (Figure 3.7B), with no difference in the weekly food 
efficiencies either (Figure A3-3.2, Appendix 3-3). The higher average food intake, yet similar 
food efficiencies, of APOE3 mice on HFD compared to APOE3 mice on HFD+FO is in line 
with the greater body weight gain observed in these mice. Noteworthy, we observed 
anecdotally over the course of the dietary intervention that APOE3 mice were generally 
more active than APOE4 mice and hypothesize that perhaps APOE3 mice had a higher daily 
energy expenditure compared to APOE4 mice. This could explain the observed similar food 
efficiency and similar body weight of APOE3 and APOE4 mice on HFD+FO, despite the 
higher food intake of APOE3 mice.  
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A      B 
      
Figure 3.7. The average food intake [A] and food efficiency [B] of human APOE3 and APOE4 
targeted replacement mice fed a high-fat diet (HFD) without or with 30 g EPA+DHA / kg of diet 
(HFD+FO). Data is presented as mean ± SEM, n = 10 mice per group. The average food intake 
(g/day) per mouse was calculated by dividing the joint food intake (g) of 5 mice in a single cage 
by 5 (accounting for the 5 mice) and then by 56 days. The average food efficiency was 
calculated by dividing the total body weight gain (g) by the total food intake (g). Statistical 
analysis was done by ANOVA for APOE Epsilon genotype (G), diet (D) and G*D interaction 
effect or by Kruskal-Wallis test for G*D effect and considered statistically significant when p < 
0.05. Significant effects are displayed on top of the figure. Differences between the groups were 
tested using Mann-Whitney U test with Bonferroni correction, *p < 0.008 (= 0.05 / 6). APOE, 
apolipoprotein E; HFD, high-fat diet; HFD+FO, HFD containing 30g EPA+DHA/kg of diet; ns, not 
significant. 
 
Plasma lipid profile 
APOE Epsilon genotype interacted with diet to determine plasma TG (F1,35 = 14.115, p < 
0.01), total cholesterol (TC) (F1,35 = 10.566, p < 0.01), non-HDL-C (F1,34 = 17.422, p < 
0.001), and non-esterified fatty acids (NEFA) (F1,31 = 8.284, p < 0.01), but not plasma HDL-C 
(Table 3.4). Furthermore, there was a significant effect of diet on plasma glucose levels 
(F1,35 = 260.041, p < 0.05), with a borderline non-significant effect of APOE Epsilon genotype 
(F1,35 = 146.277, p = 0.05). In line with the differences in body weight, plasma TG levels 
were significantly higher in APOE3 mice on HFD compared to the other three groups (p < 
0.05). The plasma TG levels (71 – 128 mg/dL) were in general higher than previous reported 
values in APOE3 and APOE4 TR mice on a HFD (48 ± 4 (SD) and 66 ± 31 mg/dL 
respectively) [Knouff et al., 1999]. Plasma TC levels were higher in mice on HFD compared 
to those on HFD+FO (119 to 137 mg/dL vs. 91 to 100 mg/dL, p < 0.05), with APOE3 mice on 
HFD having the highest levels also compared to APOE4 mice on HFD (137 ± 3 vs. 119 ± 5 
mg/dL, p < 0.05). The plasma TC levels in the mice on HFD (119 to 137 mg/dL) were in line 
with previous reports in APOE3 and APOE4 mice on a HFD (122 ± 43 (SD) and 130 ± 27 
mg/dL respectively), whereas the plasma TC levels in the mice on HFD+FO (91 – 100 
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mg/dL) were more in the direction of plasma levels of APOE3 and APOE4 mice on a chow 
diet (75 ± 26 (SD) and 72 ± 27 mg/dL) [Knouff et al., 1999].  
 
Table 3.4. The effect of APOE Epsilon genotype and diet on the plasma biochemistry in human 
APOE3 and APOE4 TR mice fed a high-fat diet (HFD) or HFD containing 30 g EPA+DHA / kg of 
diet (HFD+FO).  
Plasma lipids  
APOE3-
HFD 
APOE3-
HFD+FO 
APOE4-
HFD 
APOE4-
HFD+FO 
 
TG (mg/dL) 128 ± 10
a 
71 ± 6
b 
81 ± 9
b 
84 ± 5
b ANOVA 
p<0.01; G*D 
TC (mg/dL) 137 ± 3
a 
91 ± 4
bd 
119 ± 5
c 
100 ± 5
bd ANOVA 
p<0.01; G*D 
HDL-C (mg/dL) 116 ± 3
 
99 ± 7
 
107 ± 6
 
82 ± 4
 ANOVA 
ns. 
non-HDL-C (mg/dL) 20 ± 2
a
 10 ± 1
b
 12 ± 1
ab
 17 ± 2
ab
 
ANOVA 
p<0.001; G*D 
NEFA (mmol/L) 1.7 ± 0.1
ac 
0.7 ± 0.1
b 
1.3 ± 0.2
ac 
0.9 ± 0.1
bc ANOVA 
p<0.01; G*D 
Glucose (mg/dL) 327±16
a 
276 ± 6
ab 
290 ± 13
a 
241 ± 9
b ANOVA 
p<0.05; D 
Liver enzymes      
ALT (IU/L) 49 ± 8
a 
21 ± 1
b 
31 ± 8
ab
 17 ± 1
b
 
Kruskal-Wallis 
p<0.001; G*D 
AST (IU/L) 106 ± 12
 
123 ± 21
 
105 ± 14
 
79 ± 7
 ANOVA 
ns. 
ALP (IU/L) 63 ± 4
 
49 ± 3
 
62 ± 5
 
62 ± 5
 ANOVA 
ns. 
Adipokines/ 
cytokines 
    
 
IL-10 (pg/ml) 301 ± 55 378 ± 43 278 ± 35 536 ± 138 
ANOVA 
ns. 
Adiponectin (μg/ml) 194 ± 22 183 ± 29 207 ± 22 214 ± 18 
ANOVA 
ns. 
Leptin (ng/ml) 6.7 ± 0.5 5.1 ± 0.5 5.5 ± 0.8 4.4 ± 0.4 
ANOVA 
ns. 
Values are mean ± SEM in non-fasted plasma samples of 7 – 10 animals per group. Statistical 
analysis was done by ANOVA for APOE Epsilon genotype (G), diet (D) and G*D interaction effect 
using un- or 
10
log-transformed data, or by Kruskal-Wallis test for G*D effect and considered statistically 
significant when p < 0.05. Significant effects are indicated in the last column of the table. Differences 
between the groups were tested using Student’s t-test or Mann-Whitney U test with Bonferroni 
correction; different letters indicate differences between the APOE Epsilon genotype*diet groups, p < 
0.008 (= 0.05 / 6). ALP, alkaline phosphatase; ALT, alanine aminotransferase; APOE, apolipoprotein 
E; ASP, aspartate aminotransferase; HDL-C, high-density lipoprotein cholesterol; HFD, high-fat diet; 
HFD+FO, HFD containing 30 g EPA+DHA / kg of diet; IL-10, interleukin 10; IU, international units; 
NEFA, non-esterified fatty acids; non-HDL-C, non-HDL-C consisting of low-density lipoprotein and very 
low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.  
 
Plasma HDL-C levels showed a similar trend as plasma TC levels, with higher circulating 
levels in APOE3 and APOE4 mice on HFD (116 ± 3 and 107 ± 6 mg/dL) and lower levels in 
APOE3 on HFD+FO (99 ± 7 mg/dL) and lowest levels in APOE4 mice on HFD+FO (82 ± 4 
mg/dL). Plasma HDL-C levels were similar to previous reports of 74 to 107 mg/dL in APOE3 
and APOE4 mice on a HFD [Knouff et al., 1999]. APOE Epsilon genotype interacted with 
diet to determine plasma non-HDL-C levels, which is the sum of LDL-C and VLDL-C. Briefly, 
HFD+FO feeding tended to decrease plasma non-HDL-C levels in APOE3 mice but 
 Slim (2015), Chapter 3. In vivo studies – obesity and metabolic function 
110 
S
lim
 (2
0
1
5
), C
h
a
p
te
r 1
. L
ite
ra
tu
re
 re
v
ie
w
 
increased plasma non-HDL-C levels in APOE4 mice (Table 3.4). The plasma non-HDL-C 
levels were increased in APOE3 mice on HFD compared to APOE3 mice on HFD+FO (20 ± 
2 vs. 10 ± 1 mg/dL, p < 0.05). The plasma NEFA levels tended to be lower in mice on 
HFD+FO compared to those on HFD, with APOE3 mice on HFD having significantly higher 
NEFA levels than APOE3 and APOE4 mice on HFD+FO (1.7 ± 0.1 mmol/L vs. 0.7 ± 0.1 and 
0.9 ± 0.1 mmol/L, p < 0.05) (Table 3.4). The non-fasted plasma glucose levels were 241 – 
327 mg/dL and much higher than previous reported non-fasted glucose levels (160 – 175 
mg/dL) in APOE3 and APOE4 TR mice fed a HFD [Arbones-Mainar et al., 2008]. APOE3 
and APOE4 mice on HFD+FO had significantly lower plasma glucose levels compared to 
their counterparts on HFD (327 ± 16 vs. 276 ± 6 mg/dL and 290 ± 13 vs. 241 ± 9 mg/dL, p < 
0.05). In addition, there was a non-significant trend for lower non-fasted glucose levels in 
APOE4 mice compared to APOE3 mice (p = 0.05). 
Plasma liver enzymes  
APOE Epsilon genotype interacted with diet to determine plasma ALT levels (Kruskal-Wallis 
p < 0.001), but not plasma AST and ALP (Table 3.5). Briefly, APOE3 mice on HFD had 
increased plasma ALT levels compared to APOE3 and APOE4 mice on HFD+FO (49 ± 8 
IU/L vs. 21 ± 1 and 17 ± 1 IU/L, p < 0.05). The plasma ALT levels in APOE3 mice on HFD 
(49 IU/L) were modestly lower than reference values for C57BL/6 mice (50 – 89 IU/L), 
whereas the other groups had plasma levels (≤ 31 IU/L) far below this reference range. 
These results suggest that APOE3 mice on HFD had a slightly higher degree of liver 
inflammation compared to the mice on HFD+FO, although values were still within the 
physiological range. Furthermore, the findings were not confirmed by plasma AST and ALP 
levels, which revealed no significant differences between the APOE Epsilon genotype * diet 
groups. Plasma AST levels were within normal range for C57BL/6 mice (46 – 392 IU/L) and 
plasma ALP levels were below reference values for C57BL/6 mice (111 – 275 IU/L).  
Plasma adipokines and cytokines  
Plasma adiponectin levels were on average 200 μg/ml and there was no significant effect of 
APOE Epsilon genotype (F1,31 = 5.737, p = 0.25) or diet (F1,31 = 0.034, p = 0.88) (Table 3.5). 
Plasma leptin levels ranged from 4.4 to 6.7 ng/ml. Although there was no significant main 
effect of APOE Epsilon genotype (F1,35 = 0.176, p = 0.18) or diet (F1,35 = 0.125, p = 0.13), 
APOE4 mice on HFD+FO tended to have lower levels compared to APOE3 mice on HFD 
(4.4 ± 0.4 ng/ml vs. 6.7 ± 0.5 ng/ml). These differences in plasma leptin levels corresponded 
to the difference in body weight (Table 3.4), with lower leptin levels in mice with a lower body 
weight. The plasma IL-10 levels were approximately 300 – 500 pg/ml. Overall there were no 
differences in plasma IL-10 levels between APOE Epsilon genotypes (F1,36 = 12.295, p = 
0.18), although there was a trend for higher plasma IL-10 levels in APOE3 and APOE4 mice 
on HFD+FO diet (F1,36 = 127.461, p = 0.06). 
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Insulin resistance 
To investigate the impact of APOE Epsilon genotype and diet on insulin sensitivity whole-
body IR was estimated at the end of the 8 week dietary intervention using the HOMA-IR 
index. This revealed that APOE3 mice on HFD developed IR compared to the APOE3 and 
APOE4 mice on HFD+FO (HOMA-IR 23.3 ± 4.5 vs. 4.6 ± 0.7 and 5.1 ± 0.8, p < 0.001) 
(Figure 3.8C) associated with higher fasting plasma insulin levels (1.17 ± 0.20 ng/ml vs. 0.30 
± 0.05 and 0.33 ± 0.04 ng/ml, p < 0.01) (Figure 3.8B). Fasting plasma glucose levels tended 
to be higher in APOE3 mice on HFD, but this did not reach statistical significance (Figure 
3.8A). 
Given the important role insulin-regulated glucose transporter Glut4 plays in insulin-
stimulated glucose uptake, the Glut4 mRNA expression levels in epididymal VAT were 
investigated. APOE Epsilon genotype interacted with diet to determine Glut4 expression 
levels (F1,35 = 7.033, p < 0.05) (Figure 3.8D). APOE3 mice on HFD had the lowest Glut4 
expression levels in VAT, but HFD+FO feeding resulted in a 5-fold increase in Glut4 
expression in APOE3 mice. The beneficial effect of fish oil on Glut4 expression in VAT was 
however completely absent in APOE4 mice. 
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A      B 
  
C      D 
  
Figure 3.8. Fasting plasma glucose [A] and insulin [B], the homeostatic model assessment – 
insulin resistance (HOMA-IR) index [C] and mRNA expression of insulin-regulated glucose 
transporter Glut4 in epididymal adipose tissue [D] in human APOE3 and APOE4 targeted 
replacement mice after 8 weeks of high-fat diet (HFD) without or with 30 g EPA+DHA / kg of diet 
(HFD+FO) feeding. Data is presented as mean ± SEM, n = 9 – 10 mice per group. The HOMA-IR 
was calculated using formula ‘glucose (mmol/L) x fasting insulin (mU/L) / 22.5’ from Matthews 
et al. Diabetologia (1985). mRNA expression levels are relative quantities normalised to the 
reference genes Actb, Atp5B and Gapdh. Statistical analysis was done by ANOVA for APOE 
Epsilon genotype (G), diet (D) and G*D interaction effect using un- or 
10
log-transformed data 
and considered statistically significant when p < 0.05. Significant effects are displayed on top 
of the figure. Differences between the groups were tested using Student’s t-test with Bonferroni 
correction, *p < 0.05, **p < 0.01. APOE, apolipoprotein E; Glut4, solute carrier family 2 
(facilitated glucose transporter) member 4 (Slc2a4); HFD, high-fat diet; HFD+FO, HFD 
containing 30 g EPA+DHA / kg of diet. 
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Glucose tolerance test 
The glucose tolerance after 8 weeks of HFD feeding was investigated using an intra-
peritoneal glucose tolerance test (IPGTT). After a 10 – 16 hour fast, mice received a fixed 
glucose load of 8 mg, corresponding to an average dosage of 2 g glucose / kg of body 
weight, and plasma glucose and insulin levels were monitored for 120 minutes (Figure 3.9). 
There was a significant effect of diet on plasma glucose during the IPGTT (F1,25 = 6.488, p < 
0.05), with a trend for lower plasma glucose levels in mice on HFD+FO (Figure 3.9A) 
although plasma glucose area under the curve (AUC) values were similar (Figure 3.9C). 
There were large differences in the plasma insulin levels during the IPGTT with a significant 
effect of diet (F1,35 = 23.184, p < 0.001) that interacted with APOE Epsilon genotype (F1,35 = 
4.398, p < 0.05). Overall, APOE3 mice on HFD had significantly higher plasma insulin levels 
and AUC compared to APOE3 and APOE4 mice on HFD+FO (p < 0.05) (Figure 3.9B and 
3.9D). This dramatically increased insulin production to clear plasma glucose in the APOE3 
mice on HFD indicate an impaired insulin sensitivity in these mice, which is in line with the 
estimated HOMA-IR index. Furthermore, these results reveal that supplementation with 
dietary fish oil on a HFD background significantly improved glucose clearance and 
decreased insulin production during a glucose challenge (IPGTT) indicating improved insulin 
sensitivity, which could be mediated through increased mRNA expression of the insulin-
regulated glucose transporter Glut4 (Figure 3.8D). 
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Figure 3.9. continues on next page… 
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…continued from previous page 
      
Figure 3.9. Glucose tolerance in human APOE3 and APOE4 targeted replacement mice after 8 
weeks of high-fat diet (HFD) feeding without or with 30 g EPA+DHA / kg of diet (HFD+FO). After 
a 10 – 16 hour fast, animals received intra-peritoneal injection providing 8 mg glucose (based 
on average dose of 2 g / kg of body weight). Plasma glucose [A] and plasma insulin [B] were 
recorded at the indicated time points and the area under curve (AUC) was calculated [C,D]. 
Values are mean ± SEM, n = 9 – 10 mice per group. Statistical analysis of plasma glucose and 
insulin levels during glucose tolerance test [A,B] was done by repeated measures ANOVA with 
Greenhouse-Geisser correction to test for genotype (G), diet (D) and G*D interaction effect 
using un- or 
10
log-transformed data; within-subjects analysis revealed a significant effect of 
time on plasma glucose levels (F5,125 = 145.498, p < 0.001) that did not interact with genotype 
(F5,125 = 1.735, p = 0.16), diet (F5,125 = 2.203, p = 0.08) or genotype*diet (F5,125 = 0.585, p = 0.66) 
and a significant effect of time on plasma insulin levels (F2,70 = 57.365, p < 0.001) that interacted 
with diet (F2,70 = 5.075, p < 0.01) and genotype*diet interaction (F2,70 = 3.657, p < 0.05), but not 
with genotype (F2,70 = 0.145, p = 0.86). Between-subject analysis revealed a significant effect of 
diet on plasma glucose and insulin levels (F1,25 = 6.488, p < 0.05 and F1,35 = 23.184 , p < 0.001) 
that interacted with genotype for plasma insulin (F1,35 = 4.398, p < 0.05) but not for plasma 
glucose (F1,25 = 0.242, p = 0.63). There was no effect of genotype on plasma glucose and insulin 
(F1,25 = 0.015, p = 0.90 and F1,35 = 3.283, p = 0.08). Differences between the groups were tested 
using Student’s t-test with Bonferroni correction; #APOE3-HFD is different from APOE3-
HFD+FO and APOE4-HFD+FO at t = 0 min (p < 0.01), APOE3-HFD is different from APOE4-HFD, 
APOE3-HFD+FO and APOE4-HFD+FO at t = 20 min (p < 0.05) and APOE3-HFD is different from 
APOE4-HFD+FO at t = 120 min (p < 0.01). Statistical analysis of plasma glucose and insulin area 
under the curve (AUC) [C,D] was done by ANOVA for APOE Epsilon genotype (G), diet (D) and 
G*D interaction effect using un- or 
10
log-transformed data and considered statistically 
significant when p < 0.05. APOE, apolipoprotein E; HFD, high-fat diet; HFD+FO, HFD containing 
30 g EPA+DHA / kg of diet.  
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Discussion 
In summary, we showed that APOE3 mice developed DIO and IR upon HFD feeding 
associated with an increased food intake and body weight gain, an increased HOMA-IR 
index and increased plasma insulin levels during the glucose tolerance test, and this was 
prevented by dietary fish oil. However, APOE4 mice were resistant to the development of 
DIO and IR upon HFD feeding. Plasma lipid and adipokine levels reflected the differential 
body weight, the plasma levels of TG, TC, non-HDL-C, HDL-C and NEFA and leptin tended 
to increase with increasing body weight with no change in plasma adiponectin levels. The 
highest circulating levels were in general observed in the obese APOE3 mice on HFD that 
also showed a trend towards liver inflammation indicated by increased plasma ALT levels.  
APOE Epsilon genotype and fish oil determine the development of obesity  
In line with a limited number of previous studies in human APOE3 and APOE4 TR mice we 
demonstrated that APOE3 mice develop DIO and IR upon HFD feeding, with APOE4 mice 
being resistant to both DIO and IR [Arbones-Mainar et al., 2008 and 2010]. However, we are 
the first to show that dietary fish oil can prevent the development of obesity and IR in APOE3 
mice on a HFD background. Our findings from the IPGTT contradict previous reports on 
glucose tolerance and IR in APOE3 and APOE4 mice [Arbones-Mainar et al., 2008 and 
2010]. Briefly, body weight of the APOE3 and APOE4 mice upon HFD feeding in our study 
were roughly similar to those reported by Arbones-Mainar et al., after taking into account the 
approximate 7 wk age difference of the animals in our study compared to their study (age at 
start intervention 13 – 14 wks vs. 7 wks) [Arbones-Mainar et al., 2008 and 2010]. On the 
contrary, our findings from the IPGTT indicating APOE3, but not APOE4, mice develop IR 
after 8 weeks of HFD feeding, were the opposite of Arbones-Mainar et al. their findings from 
an oral GTT (OGTT) showing APOE4, but not APOE3, mice develop IR upon HFD feeding 
[Arbones-Mainar et al., 2008]. However, their reported effects of PPAR activation through 
rosiglitazone treatment on glucose handling during OGTT in APOE3 and APOE4 mice were 
similar to the beneficial effects of dietary fish oil on glucose handling during IPGTT in 
APOE3, but not in APOE4, mice in our study [Arbones-Mainar et al., 2010]. These important 
differences most likely relate to difference in the composition of the diets; our diet contained 
24 % fat, 0.02 % cholesterol but no sucrose, whereas their HFD contained 21.1 % fat, 0.2 % 
cholesterol and 34.1 % sucrose [Arbones-Mainar et al., 2008 and 2010], with sucrose known 
to promote the development of IR in mice [Neuhofer et al., 2013]. Thus, human APOE3 TR 
mice develop DIO along with IR, whereas human APOE4 TR mice are resistant to DIO and 
concurrent IR on a high-fat non-diabetogenic diet. Finally, dietary fish oil prevented DIO and 
IR in APOE3 TR mice on a high-fat non-diabetogenic background.  
To investigate if the differential body weight gain was the result of a differential food intake 
and food efficiency, we monitored food intake every second day and estimated the average 
food efficiency over the course of the dietary intervention. Briefly, APOE3 mice on HFD had 
a consistent higher average food intake, yet a similar overall food efficiency, compared to 
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the other three groups, which was in line with their greater body weight gain. However, 
APOE3 mice on HFD+FO had a higher food intake, yet similar food efficiency and body 
weight, compared to APOE4 mice. This indicates that APOE3 mice have a higher energy 
expenditure compared to APOE4 mice on HFD+FO, which we speculated to be explained by 
a greater activity resulting in a higher energy expenditure in these mice. However, mice were 
housed below their thermoneutrality of 30 °C at 21 °C and studies have indicated that at 
temperature below thermoneutrality (20 °C and 24 °C) energy expenditure from activity, 
although still contributing to daily energy expenditure, has no effect on total daily energy 
expenditure in mice [Virtue et al., 2012]. Thus, the observed differences in activity between 
the APOE Epsilon strains are unlikely to lead to differences in total daily energy expenditure 
or explain our results, although future studies using comprehensive laboratory animal 
monitoring systems need to confirm this. A potential difference in the metabolic response to 
fish oil between the APOE3 and APOE4 genotype cannot be excluded, as we did not 
investigate metabolic function using respiratory chambers and fish oil increase β-oxidation 
[Flachs et al., 2005]. Although a differential responsiveness to fish oil remains to be 
investigated, the limited studies have found supporting evidence for an increased β-oxidation 
in APOE4 compared to APOE3 mice on either a low or high fat diet [Conway et al., 2014, 
Huebbe et al., 2014]. Future studies using metabolic chamber systems should elucidate 
potential differences between the APOE3 and APOE4 mice in basal metabolic rate and total 
daily energy expenditure and their responsiveness to dietary fish oil. Huebbe et al. recently 
investigated energy metabolism, food conversion and fat deposition in human APOE TR 
mice and showed that APOE4 mice tended to have a higher basal energy expenditure than 
APOE3 mice that was associated with increased uncoupling protein (Ucp) and fatty acid 
binding protein 4 (Fabp4) protein expression in skeletal muscle suggesting an increased 
uncoupling of mitochondrial respiration through Ucp and increased fatty acid oxidation 
[Huebbe et al., 2014]. However, the impact of dietary fish oil on energy expenditure was not 
investigated in this study and thus remains a potential interaction between APOE Epsilon 
genotype and dietary fish oil to determine energy expenditure in human APOE TR mice to 
be elucidated. In addition, they showed that APOE3 mice had an increased food intake 
associated with lower plasma leptin levels and a more efficient food conversion and fat 
storage associated with increased expression of genes involved in TG synthesis in AT (fatty 
acid syntase (Fasn), diacylglycerol acyltransferase 1 (Dgat1)) compared to APOE4 mice. 
Furthermore, they confirmed a greater physical activity in APOE3 mice compared to APOE4 
mice indicated by a longer running time and longer running distance in voluntary running 
wheel experiments. Altogether, these findings indicate that APOE4 mice are less efficient in 
conversion of food into body fat, they exhibit a lower physical activity level, yet a similar 
energy expenditure, which cannot be fully accounted for by their lower food intake 
suggesting a dissipation of energy in APOE4 mice compared to APOE3 mice that would 
explain their differential predisposition to develop obesity. Future studies should investigate 
the dissipation of energy in APOE4 mice by looking into mitochondrial density and Ucp 
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expression in liver, brown AT and epididiymal AT that contains more mitochondria than other 
white AT [Bjørndal et al., 2011]. 
Besides, we showed that dietary fish oil prevented DIO and IR in APOE3 mice on a high-fat 
non-diabetogenic background, which is in line with various animal studies reporting anti-
obesogenic effects of fish oil in mice, though it is becoming clear that this is dependent on 
the genetic background [Puglisi et al., 2011]. The anti-obesity effects of EPA and DHA are in 
part attributed to the induction of a metabolic switch resulting in increased β-oxidation and 
reduced lipogenesis in the metabolically active organs, such as AT, liver and muscle 
[Kalupahana et al., 2011]. For example, replacement of 15 % of the constitute lipids in a 
HFD with EPA and DHA reduced the development of obesity and was associated with an 
increased expression of genes regulating mitochondrial biosynthesis (PPARg1a and Nrf1), 
an upregulation of genes involved in the oxidative phosphorylation system and an increase 
in mitochondrial protein levels accounting for the increased β-oxidation and decreased 
lipogenesis in white AT of mice [Flachs et al., 2005]. Thus, an increased β-oxidation in AT, 
liver and muscle likely contributes to the observed anti-obesogenic effects of EPA and DHA 
in APOE3 mice. Though dietary fish oil could also have improved satiety in APOE3 mice 
resulting in a lower food intake contributing to the prevention of DIO [Buckley and Howe, 
2010]. In summary, findings from our study and others suggest that APOE3 is an ‘energy-
thrifty’ allele and APOE4 is an ‘energy-dissipative’ allele [Huebbe et al., 2014]. Future 
studies using metabolic chamber systems and whole-body imaging techniques should shed 
light on potential differences in body composition, basal metabolic rate (BMR) and total daily 
energy expenditure between the APOE3 and APOE4 mice and between the HFD and 
HFD+FO group.  
APOE Epsilon genotype and adipose tissue development 
There is accumulating evidence that apoE plays a role in AT development and the 
development of pathologies associated with obesity, such as IR [Kypreos et al., 2009, Slim 
and Minihane, 2014], paving the way for APOE Epsilon genotype to have potential impact on 
AT development. The development of AT, or adipogenesis, occurs in circumstances of a 
positive energy balance and involves both an increase in adipocyte number (hyperplasia) 
and an increase in adipocyte size due to increased fat storage (hypertrophy) [Fruebeck, 
2008]. In order for AT to expand and adipocytes to increase in size and number, 
extracellular matrix remodelling also has to occur [Virtue and Vidal-Puig, 2010, Divoux and 
Clement, 2011]. An adequate formation of new adipocytes is required for AT expansion, with 
a limited pre-adipocyte formation from stem cells expecting to contribute to a limited AT 
expansion capacity [Virtue and Vidal-Puig, 2010]. Arbones-Mainar et al. demonstrated that 
APOE4 mice have fewer but larger adipocytes after 8 weeks of HFD feeding compared to 
APOE3 mice [Arbones-Mainar et al., 2008] suggesting that formation of new adipocytes 
rather than adipocyte expansion is contributing to the reduced AT expansion in APOE4 
mice. Hence, it would have been very interesting to have measured adipocyte number and 
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size in this study. Future studies are recommended to investigate adipocyte number and 
morphology using immunohistochemistry. The formation of new adipocytes or adipogenesis 
is a complex process involving many transcription factors, cofactors and signalling 
intermediates from various pathways (Figure 3.10) [Rosen and MacDougald, 2006]. It is split 
into two phases; ‘determination’ involving commitment of pluripotent stem cells to the 
adipocyte lineage (i.e. pre-adipocyte), and ‘terminal differentiation’ involving differentiation of 
the pre-adipocyte into mature adipocyte [Rosen and MacDougald, 2006]. PPAR-γ is both 
sufficient and essential for adipogenesis, and is required for both the initiation and 
maintenance of the differentiated state in adipocytes [Rosen and MacDougald, 2006]. 
Besides, several members of the CCAAT-enhancer-binding protein (C/EBP) family are 
involved in adipogenesis, with C/EBPα being an important inducer of many adipocyte genes 
and crucial for the attainment of insulin sensitivity [Rosen and MacDougald, 2006].  
 
 
Figure 3.10. A simplified overview of the complex transcriptional cascade regulating 
adipogenesis. Peroxisome proliferator-activated receptor γ (PPARγ) is the core transcription 
factor regulating adipogenesis, with its expression being regulated by variety of pro-adipogenic 
(white) and anti-adipogenic (dark grey) factors. In addition, a yet-unidentified ligand is able to 
activate PPARγ, with the expression of this ligand proposed to to be induced by the 
transcription factor sterol response element-binding protein-1c (SREBP1c). A second important 
transcription factor regulating adipogenesis is CCAAT-enhancer binding protein α (C/EBPα), 
which is regulated through various inhibitory protein-interactions. Other members of the C/EBP 
family also either stimulate (C/EBPβ, C/EBPδ) or suppress (C/EBPγ, CHOP) adipogenesis. 
Black lines indicate effects on gene expression and grey lines indicate effects on protein 
activity. Figure has been modified from Rosen and MacDougald (2002). C/EBP, CCAAT-
enhancer binding protein; CHOP, transcription factor homologous to CCAAT-enhancer binding 
protein; GATA2/3, GATA transcription factors 2 and 3; KLF, Krüppel-like factor; PPARγ, 
peroxisome proliferator-activated receptor γ; SREBP1c, sterol response element-binding 
protein-1c.  
 
A potential mechanism linking APOE Epsilon genotype to adipogenesis signalling pathways 
is endoplasmic reticulum (ER)-stress that is increasingly recognised as one of the underlying 
causes of metabolic dysfunction in obesity [Hotamisligil, 2010]. Nutritional excess and an 
accumulation of unfolded and misfolded proteins within the ER are two known causes of ER-
stress triggering the unfolded protein response (UPR) which activates metabolic and 
inflammatory signalling pathways [Hotamisligil, 2010]. The apoE4 protein is known to have a 
greater tendency to form a molten globule state (a destabilization of the protein 
Genes of terminal 
adipocyte 
differentiation
PPARγ
C/EBPα
Ligand
GATA2/3
KLF15KLF5 KLF2
SREBP1c
C/EBPδ
C/EBPβ
C/EBPγ
CHOP
KROX20
 Slim (2015), Chapter 3. In vivo studies – obesity and metabolic function 
120 
S
lim
 (2
0
1
5
), C
h
a
p
te
r 1
. L
ite
ra
tu
re
 re
v
ie
w
 
conformation), show a lower protein stability and is increasingly subjected to intracellular 
degradation compared to the apoE3 protein [Hatters et al., 2006, Heeren et al., 2004, Rellin 
et al., 2008]. These protein characteristics could predispose the apoE4 protein to be 
increasingly recognised as misfolded protein leading to the UPR response and ER-stress. 
Indeed, Zhong et al. showed that murine astrocytes expressing murine apoE with similar 
biophysical properties as human apoE4 (Arg-61 apoE) showed an increased expression of 
UPR markers (including CHOP) indicative of increased ER-stress that was associated with 
astrocyte dysfunction [Zhong et al., 2009]. Moreover, they concluded that the Arg-61 apoE, 
having similar characteristics to apoE4 isoform, is recognized as an abnormally folded 
protein in the ER, eliciting an ER-stress response [Zhong et al., 2009]. In line with this, Cash 
et al. showed an increased ER-stress response in APOE4 compared to APOE3 
macrophages with increased expression of CHOP (a marker of UPR response) after 
incubation with oxidized-LDL and concluded that apoE4 provides a second hit to exacerbate 
oxidized-LDL-induced ER stress in macrophages [Cash et al., 2012]. Although never 
investigated, this makes it tempting to speculate that also in adipocytes the apoE4 protein is 
recognised as an abnormally folded protein triggering UPR response and increasing ER 
stress and CHOP expression that in turn would negatively impact on adipogenesis. As 
shown in Figure 3.10, CHOP is a negative regulator of adipogenesis by inhibiting C/EBPβ, 
an important pro-adipogenic transcription factor that induces PPARγ and C/EBPα. Moreover, 
C/EBPβ and sterol response element-binding protein-1c (SREBP-1c) increase the 
production of a to-be-indentified ligand of PPARγ, which has been shown to be essential for 
initiation of adipogenesis, but not for maintaining PPARγ-dependent gene expression in 
mature adipocytes [Rosen and MacDougald, 2006]. Thus, increased ER-stress resulting in 
an increased CHOP expression inhibits the PPARγ ligand production through C/EBPβ, 
thereby inhibiting the initiation of adipogenesis. Although obesity is known to be associated 
with increased ER-stress in liver and AT, the mechanism as to how ER-stress and related 
signalling pathways impact on the regulation of adipogenesis and adipocyte function in vivo 
remains an important unanswered question [Hotamisligil, 2010]. Future studies should 
investigate the potential impact of the APOE4 genotype on the determination and terminal 
differentiation phases of adipogenesis process and the potential involvement of ER-stress.  
Adipose tissue Apoe mRNA expression is decreased in obese APOE3 mice  
As mentioned earlier, the expression of apoE increases upon differentiation and correlates 
with lipid content in adipocytes [Zechner et al., 1991]. Thus, Apoe mRNA expression levels 
in AT could provide a hint towards the level of adipocyte differentiation. In addition, Apoe 
expression in AT also appear to be modulated by the state of feeding in mice. In more detail, 
Apoe expression in AT of mice was reduced in DIO and hyperphagia, but was increased by 
fasting [Huang et al., 2007]. These findings were interpreted by Kypreos et al. as an intrinsic 
defence mechanism existing in AT which limits adipogenesis by reducing the expression of 
apoE in the fed state [Kypreos et al., 2009]. In fact, we showed that the expression of Apoe 
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in AT was significantly lower in APOE3 mice on HFD compared to APOE3 mice on 
HFD+FO, as well as to the APOE4 mice on either of the two diets. Thus, this proposed 
mechanism could explain the lower Apoe expression in the AT of APOE3 mice on a HFD, as 
these mice gained more weight compared to the other mice and developed DIO. Our 
findings are similar to those reported by Arbones-Mainar et al., who showed that HFD 
feeding decreased the Apoe expression in the epididymal AT by almost 40 % in APOE3, but 
not in APOE4, mice compared to 8 weeks chow feeding and this was associated with a 30 
% greater weight gain in APOE3 mice upon HFD feeding compared to APOE4 mice 
[Arbones-Mainar et al., 2008]. Furthermore, another study by Arbones-Mainar et al. showed 
that treatment with ROSI, a PPAR-γ agonist, in the last 4 weeks of a 16-week HFD feeding 
intervention increased the Apoe expression in the epididymal AT of APOE3 mice, but this 
was completely blunted in APOE4 mice. Similarly APOE3 mice showed an 80 % greater 
weight gain upon HFD feeding compared to APOE4 mice, with no effect of ROSI treatment 
on body weight in both APOE3 and APOE4 mice [Arbones-Mainar et al., 2010]. However, 
only the fold difference in mRNA expression levels were given making it difficult to make a 
direct comparison to relative expression levels reported in our study. Nevertheless, these 
results indicate a role for apoE in the process of adipogenesis and suggest that obesity is a 
negative regulator of AT Apoe expression.  
Fish oil prevents the development of insulin resistance in APOE3 mice 
In this study, we measured fasting glucose and insulin levels and performed an IPGTT in 
APOE3 and APOE4 mice after 8 weeks of dietary intervention with HFD or HFD+FO as 
initial screening test of glucose metabolism. Briefly, there was no significant effect of diet or 
genotype on glucose levels both in the fasting state and during the IPGTT. However, APOE3 
mice on HFD had in both the fasting state and during the IPGTT significantly higher insulin 
levels compared to all other three groups, indicating an impaired insulin action and reduced 
insulin sensitivity in these mice. The reduced insulin sensitivity was accompanied by an 
increase in plasma free fatty acid (NEFA) and TG levels. These results are in line with 
previous findings showing that diet-induced obesity leads to the development of IR in human 
APOE3 targeted replacement mice [Kleemann et al., 2010, Arbones-Mainar et al., 2010].  
The LC n-3 PUFA EPA and DHA have been shown to exert various beneficial effects on 
obesity and its complications. They have anti-obesogenic effects in both humans [Bender et 
al., 2014, Mori et al., 1999] and rodents [Puglisi et al., 2011], lower plasma TG levels [Harris, 
1997, Minihane et al., 2000], have anti-inflammatory effects [Itariu et al., 2012] and 
potentially improve insulin sensitivity [Akinkuolie et al., 2011, Kalupahana et al., 2011]. 
However, many of these effects, including the anti-obesogenic, anti-inflammatory and insulin 
sensitising effects, have not been investigated according to APOE Epsilon genotype. As 
discussed above, we are the first to report anti-obesogenic effects of fish oil in APOE3 mice, 
but not APOE4 mice. In addition, this is the first study investigating the insulin sensitising 
effects of fish oil in human APOE TR mice. We observed a strong trend that dietary fish oil 
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improves insulin sensitivity, indicated by the lower plasma insulin levels, in APOE3 and 
APOE4 TR mice, despite causing a slight increase in VAT mass. These insulin sensitising 
effects are in line with a recent report that the effects of dietary fish oil on metabolic 
parameters, including systemic IR, are independent of changes in AT mass in other strains 
of mice [Puglisi et al., 2011]. However, LC n-3 PUFA failed to consistently improve insulin 
sensitivity in humans (standard mean difference (SMD) = 0.08, 95% CI -0.11 – 0.28) 
although improvements are seen in HOMA-IR (SMD = 0.30, 95% CI 0.03 – 0.58) [Akinkuolie 
et al., 2011] possibly due to a modest decrease in fasting insulin levels [Hartweg et al., 
2008]. Fish oil fatty acids EPA and DHA exert various beneficial effects in liver, muscle and 
AT that together account for their insulin sensitising effects in mice [Kalupahana et al., 
2011]. Briefly, EPA and DHA promote hepatic fatty acid oxidation (β-oxidation) and suppress 
lipogenesis through inhibition of the enzymes involved in TG synthesis, thereby reducing 
hepatic TG accumulation [Kalupahana et al., 2011]. Besides, EPA and DHA increase β-
oxidation in AT and muscle preventing fatty acid intermediate accumulation in these tissues 
[Kalupahana et al., 2011]. Finally, EPA and DHA alleviate AT inflammation through the 
production of special proresolving mediators (e.g. resolvins and protectins) and activation of 
G-coupled receptors, whilst increasing the secretion of adiponectin, leptin and visfatin, which 
all contribute to a better AT function improving systemic insulin sensitivity [Kalupahana et al., 
2011].  
Given the important role insulin-regulated glucose transporter Glut4 plays in insulin-
stimulated glucose uptake, the Glut4 mRNA expression levels in the epididymal VAT were 
investigated. We demonstrated that EPA and DHA increased the Glut4 mRNA expression 
levels in VAT of APOE3 mice that could account for the observed beneficial effects on 
insulin sensitivity and glucose tolerance. However surprisingly, the beneficial effects of EPA 
and DHA on Glut4 expression in VAT were not observed in APOE4 mice. Glut4 is an insulin-
regulated glucose transporter mainly expressed in muscle and AT that is responsible for 
insulin-stimulated glucose uptake into these tissues [Bell et al., 1990]. The binding of insulin 
to its receptor leads to phosphorylation of the insulin receptor substrate (IRS) proteins, 
subsequent activation of the type I phosphatidylinositol 3-kinase (PI3K) and protein kinase B 
(PKB), also known as Akt, which results in Glut4 translocation from intracellular vesicles to 
the cell membrane increasing glucose uptake [Elmendorf, 2004].  
EPA and DHA exert their beneficial effect through various signalling pathways. For instance, 
in the liver the effects on oxidative processes are mediated through activation of PPAR-α 
and 5' AMP-activated protein kinase (AMPK) and inhibition of the carbohydrate-responsive 
element-binding protein (ChREBP) and sterol regulatory element-binding proteins (SREBP), 
such as SREBP-1a and SREBP-1c, resulting in the suppression of lipogenesis [Lottenberg 
et al., 2012, Kalupahana et al., 2011]. In AT, activation of PPAR-γ and AMPK are 
responsible for the increased β-oxidation, with PPAR-γ also being responsible for mediating 
the beneficial effects on adipocyte function and insulin sensitivity [Lottenberg et al., 2012, 
Kalupahana et al., 2011]. Finally, EPA and DHA exert their anti-inflammatory and insulin 
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sensitising effects through G-coupled receptors, such as GPR40 and GPR120, which are 
receptors that can be activated by long chain fatty acids [Oh et al., 2010]. For example, 
GPR120 is highly expressed in mature adipocytes and has been shown to be essential in 
mediating the anti-inflammatory and insulin sensitising effects of EPA and DHA [Oh et al., 
2010]. In adipocytes, EPA and DHA have been shown to improve glucose uptake via 
activation of Gq/11-coupled protein receptors (e.g. GPR120) and PI3K, which inhibit down-
stream signalling to IKKβ / NF-κB (inhibitor of nuclear factor kappa-B kinase / nuclear factor 
kappa-B) and JNK / AP1 (c-Jun N-terminal kinase / activator protein-1) pathways (that 
otherwise impair insulin receptor signalling by disrupting serine phosphorylation of IRS-1) 
and increase Glut4 translocation to the cell surface resulting in increased glucose uptake 
[Oh et al., 2010, Kalupahana et al., 2012]. This poses a mechanism via which EPA and DHA 
can improve insulin signalling in adipocytes, although EPA and DHA can also influence the 
plasma membrane Glut4 concentration by improving membrane fluidity [Lottenberg et al., 
2012]. 
 
A strength of this study is the use of a mouse model humanised for the human APOE3 and 
APOE4 gene variant. Human APOE TR mice express human APOE under control of the 
murine regulatory sequence and produce apoE at physiological levels. This gives us a 
complete in vivo model for direct comparison of APOE Epsilon isoform-specific effects. In 
addition, this mouse model allowed us to use an experimental design tailored specifically to 
answer our research question while controlling for many confounding intrinsic and 
environmental factors difficult to control for in human studies, such as genetic background 
and diet. This provided us significant power to evaluate the effects of APOE Epsilon 
genotype and fish oil on the development of obesity and its metabolic complications. 
Furthermore, in human studies it is difficult to study internal organs, such as the liver and 
visceral AT, whereas a mouse model provides free access to our tissue of interest (i.e. AT). 
This enabled us to perform a thorough investigation into the role of apoE in AT development, 
which is a strength of this study. 
Achieving obesity in mice is not easy as they are resistant to obesity on a low fat diet, and 
require a HFD containing usually at least 40 – 45 kcal% from fat. Diets with 60 kcal% from 
fat have also been used to induce DIO in mice, but we think this is rather unrepresentative of 
the human diet that on average contains 35 kcal% from fat. The EPA to DHA ratio of the 
HFD+FO diet was 2:3 and similar to that of oily fish - the main dietary source of EPA and 
DHA - and corresponded to the ratio observed for the average UK diet.  
 
Our study was designed to compare the APOE3 with the APOE4 genotype and the HFD+FO 
with HFD, i.e. compare the effect of APOE Epsilon genotype and fish oil on a HFD 
background. We did not have the financial resources to include a low-fat diet group for both 
APOE3 and APOE4 TR mice, which would have been another appropriate control. Similarly 
the inclusion of wild type C57BL/6 mice carrying murine apoe would have provided a control 
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condition allowing to discriminate between the effect of human APOE and murine apoe. 
However, the latter would be less relevant than the low-fat diet control.  
The dose of EPA and DHA used in this study was supra-physiological, but typical of a dose 
used in comparable published studies. The HFD+FO diet provided each mouse with a food 
intake of 3 g/d daily 36 mg EPA + 54 mg DHA, which corresponds to a dose of 2250 mg 
EPA+DHA per kg of body weight per day in an obese mouse (40 g). This corresponds to 
human equivalent dose of 21.6 g EPA+DHA per day in a normal weight adult (70 kg) [U.S. 
Department of Health and Human Services, 2005], which corresponds to 7.2 portions of oily 
fish per day and is beyond physiological tolerable levels previously approached in human 
intervention trials (≤ 5.6 – 8.4 g EPA+DHA / d) (for review see Calder et al. [Calder et al., 
2006 and 2011A]). The energy density of the diets was 3.75 kcal per gram and mice ate 3 
grams per day, hence their energy intake was 14.2 kcal. The HFD+FO provided the mice 
with 90 mg EPA+DHA per day and thus the dose of EPA and DHA per unit of energy was 
6.3 mg/kcal. The daily energy intake in the UK is approximately 2,300 kcal [HSCIC, 2012] 
which would adequate to 14.5 grams of EPA+DHA per day. Thus the dose of EPA and DHA, 
either expressed per unit of body weight or per unit of energy intake, in this study was 
beyond physiological tolerable levels approached in humans. The dose-response curve of 
EPA and DHA may not been linear. It could be saturable or U-shaped with adverse effects at 
either ends of the spectrum. Hence, it would have been helpful to include a group with a 
more physiological dose in this study to aid the dose-response comparisons.  
 
An oral or IPGTT are widely used in the published literature to assess glucose tolerance in 
mice and are recognised as a robust method to evaluate glucose handling, however the gold 
standard to assess IR in mice is the euglycemic clamp method [Ayala et al., 2010]. We 
showed that APOE3 mice on HFD had impaired insulin action and reduced insulin sensitivity 
using IPGTT, these findings should be corroborated with an insulin tolerance test (ITT) or 
hyperinsulinemic-euglycemic clamp [Ayala et al., 2010]. A strength of this study is the use of 
a fixed glucose load in the IPGTT. This reduced the chance of misdiagnosing obese mice as 
being glucose intolerant due to giving them more glucose for the same amount of lean mass, 
which would have occured when the glucose load was based on body weight [Ayala et al., 
2010]. However, using a glucose load based on lean body mass is most correct when body 
composition data is available [Ayala et al., 2010]. An oral GTT is a more physiological test 
than an IPGTT, but the first is also influenced by other factors, such as gastric emptying and 
incretin secretion, which are bypassed by the IPGTT [Ayala et al., 2010]. 
 
A limitation of this study was that we did not measure adipocyte number and size, which 
would have provided important information on adipocyte morphology and important clues 
towards the potential impact of APOE4 genotype on formation of new adipocytes. Future 
studies in human APOE3 and APOE4 TR mice are recommended to investigate adipocyte 
number and morphology using immunohistochemistry. 
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Future studies should also investigate liver TG levels in human APOE3 and APOE4 TR 
mice, which would provide a measure of fatty liver. This would give us a greater insight into 
any potential disturbance in metabolism in the liver of APOE3 mice on a HFD that could 
explain the severe IR observed in these mice. Furthermore, LC n-3 PUFA promote fatty acid 
oxidation and suppress lipogenesis in liver thereby reducing hepatic TG accumulation 
[Kalupahana et al., 2011], which could contribute to their insulin sensitising effects in APOE3 
and APOE4 mice indicated by the improved HOMA-IR and improved glucose tolerance 
during the IPGTT. 
 
In conclusion, we showed that the APOE3, but not the APOE4 genotype, is associated with 
the development of DIO, dylipidemia and IR in human APOE TR mice upon HFD feeding 
and this can be prevented by dietary fish oil. The potential involvement of AT inflammation in 
the development of IR in APOE3 and APOE4 mice will be explored in the next chapter. 
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Chapter 4. In vivo studies – inflammation: The 
interactive impact of APOE Epsilon genotype and fish oil 
on adipose tissue inflammation. 
Studies in human APOE3 and APOE4 targeted replacement mice 
 
 
Introduction 
Adipose tissue inflammation 
In obesity, the expansion of adipose tissue (AT) is associated with structural and functional 
changes together with changes in cellular composition and cell phenotype [Dalmas et al., 
2011, Ouchi et al., 2011]. The adipocytes increasingly take up triglycerides becoming 
hypertrophic and start to secrete mediators that attract macrophages, which increasingly 
infiltrate the AT. These recruited AT macrophages (ATM) will predominantly acquire a pro-
inflammatory (M1) phenotype and start to outnumber the resident ATM that have an anti-
inflammatory (M2) phenotype [Weisberg et al., 2003, Wentworth et al., 2010]. The infiltration 
of ATM adopting a M1 phenotype is thought to be the fundamental step in AT inflammation, 
which results in AT dysfunction and subsequent systemic insulin resistance (IR) [Osborn and 
Olefsky, 2012]. In addition to the phenotypic heterogeneity of ATM in both lean and obese 
states, ATM can also ‘switch’ their phenotypes [Morris et al., 2011]. Although ATM can adopt 
a range of phenotypes between M1 and M2, the simplified M1/M2 model of macrophage 
polarisation (Table 4.1) is most frequently used [Morris et al., 2011]. Thus, obesity is not only 
characterised by quantitative increase in ATM, but also with qualitative changes (‘phenotype 
switch‘) in ATM from the anti-inflammatory M2 phenotype to the pro-inflammatory M1 
phenotype. These cellular alterations in AT are associated with an increased production of 
pro-inflammatory mediators and reduced expression of anti-inflammatory mediators by ATM 
and hypertrophic adipocytes, resulting in a state of systemic chronic low-grade inflammation 
[Fain et al., 2004, Maury and Brichard, 2010]. This is in turn contributes to systemic IR and 
dyslipidemia [Lumeng et al., 2007A and 2007B] that are part of the metabolic syndrome 
(MetS), and contribute to an increased risk of cardiovascular disease (CVD) [Barbarroja et 
al., 2010, Hotamisligil, 2006, Van Gaal et al., 2006]. 
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Table 4.1. Phenotypic and functional characteristics of adipose tissue macrophages (ATM) 
according to the M1/M2 model of macrophage polarisation [Morris et al., 2011]. 
 M1 (pro-inflammatory) M2 (anti-inflammatory) 
Activators LPS, IFN-γ IL-4, IL-13 
Surface markers (human) CD11c
+
 CD206
-
 CD40
+
 CD86
+
  CD11c
-
 CD206
+
 CD150
+
  
Surface markers (mice) CD11c
+
 CD206
-
 MGL1
-
   CD11c
-
 CD206
+ 
MGL1
+
  
Change with obesity increased decreased 
Gene expression Tnfα 
Il1β 
Il6 
Nos2 
Il10 
Mgl1/2 
Arginase 1 
Mrc2 
Ym1/Chi3l3 
Production  TNF-α, IL-6, IL-12, ROS  IL-10, IL-1RA, arginase 
M1, classically activated pro-inflammatory macrophages; M2, alternatively activated anti-inflammatory  
macrophages; CD11c, integrin alpha X chain; CD206, mannose receptor; CD40, co-stimulatory protein 
CD40; CD86, co-stimulatory protein Cluster of Differentiation 86; IFN, inteferron; iNOS, inducible nitric 
oxide synthase IL, interleukin; IL-1RA, Interleukin-1 receptor antagonist; LPS, lipopolysaccharide; 
Mgl1/2, macrophage galactose N-acetyl-galactosamine-specific lectins 1 and 2; MGL, macrophage 
galactose type C-type Lectin; Mrc2, mannose receptor C type 2; ROS, reactive oxygen species; TNFα 
/ TNF-α, tumor necrosis factor alpha; Ym1/Chi3l3, Ym1/chitinase 3-like 3. 
 
APOE Epsilon genotype and adipose tissue inflammation and function  
In summary, the quantitative and qualitative properties of ATM determine AT inflammation, 
which together with the capacity of AT to ‘buffer‘ excess nutrients, are important 
determinants for maintaining adipocyte function and a metabolic healthy profile in obesity 
[Blüher, 2010, Lumeng et al., 2007A and 2007B, Ouchi et al., 2011]. The apolipoprotein 
Epsilon 4 (APOE4) allele is associated with a pro-inflammatory status in macrophages and 
human APOE TR mice [Jofre-Monseny et al., 2007A, Lynch et al., 2003, Maezawa et al., 
2006, Ophir et al., 2005, Tsoi et al., 2007]. In addition, our group has demonstrated that the 
APOE Epsilon genotype interacts with adiposity to determine plasma inflammatory marker 
concentrations [Kofler et al., 2012] suggesting that APOE Epsilon genotype may exert it 
effects on inflammation through AT. This is supported by two recent studies in human APOE 
Epsilon targeted replacement (TR) mice showing that the APOE4 allele is associated with an 
impaired expandability of the visceral (epididymal) fat depot and greater epididymal 
adipocyte size, an impaired insulin sensitivity, and an impaired ex vivo adipocyte 
differentiation and lipid-storage capacity [Arbones-Mainar et al., 2008 and 2010]. 
Furthermore, APOE4 TR mice were more susceptible to the metabolic complications of 
obesity, where APOE4 TR mice developed impaired glucose tolerance earlier (4 wks vs. 12 
wks) and had greater predisposition to developing a fatty liver than APOE3 TR mice upon 
high fat diet (HFD) feeding with rosiglitazone, a peroxisome proliferator-activated 
receptor(PPAR)-γ ligand. However, we found that APOE4 TR mice were protected from 
HFD-induced obesity and impaired glucose tolerance (Chapter 3). Also, we found no 
indication for an impaired liver function after 8 weeks of HFD feeding with eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA), two long chain (LC) n-3 polyunsaturated fatty 
acids (PUFA) that are ligands for PPAR-γ (Chapter 3). In conclusion, these findings show 
that the APOE4 allele is associated with a reduced AT expansion. The effects of the APOE4 
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allele on predisposition to the metabolic complications of obesity, that is IR and ectopic lipid 
deposition in the liver, are less clear. Moreover, the impact of APOE Epsilon genotype on AT 
inflammation and ATM phenotype is unknown, although a similar ATM infiltration in APOE3 
and APOE4 TR mice was reported in a single previous study [Arbones-Mainar et al., 2008]. 
Long chain n-3 PUFA and adipose tissue function 
LC n-3 PUFA exert various beneficial effects on AT function including increased 
mitochondrial biosynthesis and β-oxidation [Flachs et al., 2009]. In addition, LC n-3 PUFA 
have been shown to reduce AT mass upon HFD feeding, which is dependent on the genetic 
background in mice [Puglisi et al., 2011]. However, the beneficial effects of LC n-3 PUFA on 
systemic IR, dyslipidemia, hepatic steatosis, AT inflammation and AT IR are independent of 
the change in AT mass [Puglisi et al., 2011]. Finally, LC n-3 PUFA have been shown to 
reduce ATM infiltration and/or markers of AT inflammation in db/db mice [Todoric et al., 
2006], LDLR
-/-
 mice [Saraswathi et al., 2007], APOE*3-Leiden mice [Muurling et al., 2003] 
and wild type C57BL/6 mice [Oh et al., 2010]. LC n-3 PUFA exert anti-inflammatory effects 
in macrophages, they lower the pro-inflammatory cytokine and eicosanoids production and 
promote a phenotype switch towards the anti-inflammatory M2 phenotype [Calder, 2012, 
Oliver et al., 2010, Oliver et al., 2012, Oh et al., 2010, Weldon et al., 2007]. Therefore, LC n-
3 PUFA may provide a potential therapeutic molecule to reverse the unfavourable ATM and 
adipocyte phenotype. 
Research gaps  
Our understanding of how genetic determinants interact with the environment and lead to 
the development of metabolic disease is still poor [Osborn and Olefsky, 2012]. The 
macrophage-mediated AT inflammation leading to AT dysfunction has been recognised as 
the underlying pathology causing systemic IR and systemic inflammation in obesity. 
However, more knowledge is needed about the factors that direct the polarisation state of 
ATM to either the pro- or anti-inflammatory phenotype [Osborn and Olefsky, 2012]. 
Previous research from our group and other research groups has demonstrated that the 
APOE4 allele is associated with a pro-inflammatory macrophage phenotype in vitro [Jofre-
Monseny et al., 2008A] and an impaired AT expandability and greater predisposition to the 
metabolic complications of obesity in vivo [Arbones-Mainar et al., 2008 and 2010]. However, 
the impact of the APOE4 allele on AT inflammation and ATM phenotype is unknown. LC n-3 
PUFA have been shown to promote an anti-inflammatory M2 phenotype in macrophages, 
decrease AT inflammation and improve AT function [Oh et al., 2010, Puglisi et al., 2011], 
providing a potential strategy to reverse the adverse adipocyte and ATM phenotype 
associated with the APOE4 allele. However, the interactive impact of APOE Epsilon 
genotype and LC n-3 PUFA on AT inflammation and ATM phenotype has never been 
investigated. 
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Research question 
The aim of this study was to investigate the independent and interactive impact of APOE 
Epsilon genotype and fish oil on the ATM infiltration rate and phenotype in human APOE3 
and APOE4 TR mice using a HFD diet-induced obesity (DIO) model. 
Hypotheses 
Previous limited research has demonstrated that the APOE4 allele is associated with an 
impaired AT expansion and perhaps a differential predisposition to the metabolic 
complications of obesity (i.e. IR and ectopic lipid deposition in the liver). Though a similar 
ATM infiltration in APOE3 and APOE4 TR mice was reported in a single study, its effect on 
AT inflammation has never been thoroughly investigated. Therefore, I hypothesise that ATM 
infiltration in human APOE3 and APOE4 TR mice upon HFD feeding will be similar but the 
ATM phenotype will be different, with a more pro-inflammatory ATM phenotype in APOE4 
TR mice.  
The LC n-3 PUFA EPA and DHA have beneficial effects on adipocyte function in addition to 
their anti-inflammatory effects in macrophages. Therefore, I hypothesize that EPA and DHA 
will improve adipocyte function and lower ATM infiltration. In addition, I hypothesize that EPA 
and DHA exert anti-inflammatory effects in resident ATM stimulating polarisation towards the 
M2 phenotype. Altogether this will reduce AT inflammation. 
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Materials & Methods 
We used a mouse model humanised for human APOE3 and APOE4 gene to investigate the 
independent and interactive impact of APOE Epsilon genotype and fish oil on ATM 
infiltration rate and phenotype in diet-induced obesity. Studies in human APOE3 and APOE4 
TR mice allowed us to characterize the macrophages present in AT and investigate AT 
inflammation using an experimental design tailored specifically to answer our research 
question controlling for many confounding intrinsic and environmental factors difficult to 
control for in human studies, such as genetic background and diet. The ATM phenotype was 
investigated using flow cytometry, which quantifies the expression of one or more cell 
surface markers simultaneously in individual cells. Using cell type-specific markers, a 
specific cell type (e.g. macrophages) can be identified within a heterogeneous cell 
population (e.g. all cells from AT). Adding additional markers (e.g. M1 and M2 phenotypic 
markers) to the panel allows further characterisation of the phenotype of the cell type of 
interest, i.e macrophages. Although rare cell types can be identified within large 
heterogeneous cell populations using flow cytometry, it is recommended to have a high 
concentration of your cell type of interest. AT consist of mainly mature adipocytes and some 
other cells collectively called stromal-vascular fraction (SVF) that include monocytes and 
macrophages. Therefore, the SVF was isolated and separated from mature adipocytes using 
tissue digest procedures. The number of ATM was investigated using gene expression 
levels of ATM markers in AT. The ATM phenotype data obtained with flow cytometry was 
corroborated by performing a detailed analysis of gene expression levels of previously used 
additional M1 and M2 phenotype marker genes. AT fatty acid status was determined by gas-
liquid chromatography and established in order to examine the association between tissue 
fatty acid changes, in particular EPA and DHA enrichment in response to dietary fish oil, and 
AT inflammation. 
Animals & treatment 
For details regarding the animals, diets and tissue collection please see Chapter 3 Materials 
& Methods section (page 95 – 100).  
Isolation of stromal-vascular fraction 
The isolation and flow cytometry analysis of the SVF of white AT was based on the 
methodology described by Brake and Smith (2008). One epididymal fat pad was collected in 
DMEM (with 4500 mg/L glucose, L-glutamine, sodium pyruvate, and sodium bicarbonate) 
(Sigma Aldrich, Dorset, UK) and kept at 37 °C, 95 % O2 – 5 % CO2 until further analysis 
within 4 hours. Tissues were rinsed and minced in sterile (0.2 μm) Krebs-Ringer bicarbonate 
(KRB) buffer (0.77 M NaCl, 0.77 M KCl, 0.77 M KH2PO4, 0.77 M MgSO4, 0.77 M NAHCO3, 
0.275 M CaCl2, 4 % bovine serum albumin (BSA), 0.3 M D-glucose, gassed with 95 % O2 – 
5 % CO2) using 3 ml KRB buffer / 1 g tissue. The mature adipocytes and SVF were isolated 
by digesting the minced fresh tissue with 1 mg/ml Collagenase Type II (from Clostridium 
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histolyticum, Sigma Aldrich) in KRB buffer for 30 minutes at 37 °C in a shaking water bath. 
The SVF cells were obtained by filtering the digested tissue through a 40 μm cell strainer 
(Fisher Scientific, Loughborough, UK), washing twice with 2x initial volume KRB buffer, 
followed by centrifugation (500 x g, 4 °C, 5 min) to separate from floating mature adipocytes. 
Next, red blood cells (RBC) were removed by incubation with 1 ml RBC lysis buffer (Sigma 
Aldrich) for 1 min at room temperature. Finally, SVF cells were washed with 15 ml KRB 
buffer and centrifuged before being resuspended in 200 μl PBS (Oxoid, Fisher Scientific) 
with 10 mM D-glucose and 1 % BSA (Sigma Aldrich). The cell number was determined using 
Cellometer Auto T4 Cell Counter (Nexcelom Bioscience, Peqlab Ltd., Sarisbury Green, UK).  
Flow cytometry analysis 
SVF cells were resuspended in 100 μl at 1 x 10
6
 cells/ml in PBS with 10 mM D-glucose and 
1 % BSA. Next, the cells were incubated with antibodies at the recommended 
concentrations; CD11b-PE, 0.2 mg/ml (BD Biosciences, Oxford, UK); CD11c-Alexa700, 0.2 
mg/ml (eBiosciences, Hatfield, UK); CD206-FITC, 0.1 mg/ml (AbD Serotec, Kidlington, UK), 
for 30 min at 4 ºC in the dark. Cells were washed with PBS (10 mM glucose and 1 % BSA) 
and centrifuged (300 x g, 2 min) twice before being resuspended in 100 μl PBS (10 mM 
glucose and 1 % BSA). For each antibody used, a control sample was incubated with 
isotype control Rat igG2b, kappa, isotype-PE (BD Biosciences), Armenian Hamster IgG 
isotype-Alexa700 (eBiosciences) and Rat igG2a-FITC (AbD Serotec) at similar 
concentrations to determine non-specific binding. A single stain and fluorophore minus-one 
(FMO) controls were taken along to set gates and compensation. A representative sample 
was incubated with 7-AAD (BD Biosciences) for 20 min at 4 ºC, to assess cell viability. 
Samples were kept on ice and immediately analysed using BD Accuri™ C6 (BD 
Biosciences). For each sample, data of 30,000 events was collected using a gate excluding 
debris (Appendix 4-1, Figure A4-1.1) as follows; CD11b-PE, 488 nm laser with 585/40 BP 
filter; CD11c-Alexa700, 640 nm laser with 675/25 BP filter; CD206-FITC, 488 nm laser with 
533/30 BP filter; 7-AAD, 488 nm laser with 670/LP filter. The instrument settings for 
detecting CD11c-Alexa700 were suboptimal as the emission peak of Alexa700 fell outside of 
the 675/25 BP filter detection range and only a small proportion of the emission spectra of 
Alexa700 was detected using the 675/25 BP filter. The data was further analysed as 
described in the next paragraph. 
Flow cytometry data analysis 
The SVF of AT contains pre-adipocytes, mesenchymal stem cells, endothelial progenitor 
cells, dendritic cells, lymphocytes, neutrophils, monocytes, macrophages and mast cells 
[Ouchi et al., 2011]. Therefore, first a gate (gate E) including ATM but excluding debris, 
small cells (i.e. red blood cells) and cell clumps was applied to the original data of 30,000 
collected events (Figure A4-1.1 and A4-1.2, for more details see Appendix 4-1), which was 
based on the methodology described by Brake and Smith (2008). This gate E, containing the 
ATM cell population of interest, yielded on average 32.7 ± 6.0 (SD) % of the total collected 
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events for the APOE Epsilon genotype * diet groups (Appendix 4-1, Table A4-1.1). Next, the 
threshold to define the positive and negative cell populations (within gate E) for the markers 
CD11b-PE, CD11c-Alexa700 and CD206-FITC were set using FMO control samples 
(Appendix 4-1, Figure A4-1.3). A single stained sample was used to confirm that the positive 
cell population could be distinguished with this threshold. The threshold for the cell viability 
stain 7-AAD was set using an unstained sample. Next, single stains controls were used to 
determine spillover of CD206-FITC into 585/40 BP and 670/LP filter; and CD11b-PE into 
533/30 BP filter and 670/LP filter, to apply appropriate compensation as presented in the 
spillover table (Table 4.2). The compensation was setup using our cell population of interest 
(gate E), which contains besides ATM also autofluorescent eosinophils, neutrophils and 
granulocytes that posed a challenge to setting compensation (for more details see Appendix 
4-1). The results regarding the number of CD11b
+
 cells was expressed as % of cells in gate 
E, whereas the number of CD11b
+
CD11c
+
 and CD11b
+
CD206
+
 cells were expressed % of 
CD11b
+
 cells (gate A). A graphical representation of the results from a representative 
sample of the APOE Epsilon genotype * diet groups can be found in Appendix 4-2. The non-
specific binding was determined using the isotype controls which was for CD11b 17.6 %, for 
CD11c 5.8 % and for CD206 8.1 % cells in gate E (Appendix 4-1, Figure A4-1.8). The 
viability of the samples determined using representative samples stained with the cell 
viability stain 7-AAD was 83 ± 8.3 (SD) % (Appendix 4-1, Figure A4-1.9). 
 
Table 4.2. Spillover table.  
Spillover (%) 
CD206-
FITC 
533/30 
CD11b-
PE 
585/40 
7-AAD 
675/25 
CD11c-
Alexa700
670/LP 
CD206-FITC 533/30 
 
2.70 N/A 1.30 
CD11b-PE 585/40 1.90 
 
N/A 0.00 
7-AAD 675/25 N/A N/A 
 
N/A 
CD11c-Alexa700 670/LP 0.80 0.00 N/A 
 
 
mRNA expression analysis by real-time quantitative PCR  
For details of RNA isolation and mRNA expression analysis by real-time quantitative PCR 
(RT-QPCR) see Chapter 3 Materials & Methods section (page 102 – 103). The primers for 
integrin alpha X (Itgax), interleukin 6 (Il6), C-type lectin domain family 10, member A 
(Clec10a, also known as Mgl1) and macrophage galactose N-acetyl-galactosamine specific 
lectin 2 (Mgl2), arginase 1 (Arg1) and interleukin 10 (Il10) were designed using primer-
BLAST (www.blast.ncbi.nlm.nih.gov/Blast). The primers for EGF-like module containing 
mucin-like hormone receptor-like sequence 1 (Emr1), integrin alpha M (Itgam), mannose 
receptor, C type 1 (Mrc1), nitric oxide synthase 2, inducible (Nos2), and tumor necrosis 
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factor alpha (Tnfa) were designed by PrimerDesign (PrimerDesign Ltd., Southampton, UK). 
Primer sequences are shown in Table 4.3.  
 
Table 4.3. Primers used for mRNA expression analysis using RT-QPCR. 
Gene Primer Sequence Product size 
Arg1 
F: 5’- TGGCTTGCGAGACGTAGAC -3’  
R: 5’- GCTCAGGTGAATCGGCCTTTT -3’ 
160 
Cd11b (Itgam) 
F: 5’- ACAGAGCAGGGGTCATTCG -3’  
R: 5’- ATGGTATTCAGGGCTTCAAAGTT -3’ 
145 
Cd11c (Itgax) 
F: 5’- ACGTCAGTACAAGGAGATGTTGGA -3’  
R: 5’- ATCCTATTGCAGAATGCTTCTTTACC -3’ 
190 
Cd206 (Mrc1) 
F: 5’- TGGCTACTGGAGAACATCATAC -3’  
R: 5’- AAGGAATCCACGCAGTCTGT -3’ 
134 
F4/80 (Emr1) 
F: 5’- GAAGATGAAGATGAATGTGTGACTC -3’  
R: 5’- GCCCTCCTCCACTAGATTCAA -3’ 
118 
Il6 
F: 5’- CTTCCATCCAGTTGCCTTCTTG -3’  
R: 5’- AATTAAGCCTCCGACTTGTGAAG -3’ 
142 
Il10 
F: 5’- CTGGACAACATACTGCTAACCG -3’  
R: 5’- GGGCATCACTTCTACCAGGTAA -3’ 
108 
Mgl1/2 
F: 5’- GCATCCTCTCTTGGACCCAC -3’  
R: 5’- GGTGCCTAGGTCCCTCCTTA-3’ 
116 
Nos2  
F: 5’- CACCTACTTCCTGGACATTACG -3’  
R: 5’- TACTCTGAGGGCTGACACAA -3’ 
120 
Tnfα 
F: 5’- AGCCAGGAGGGAGAACAGA -3’  
R: 5’- CAGTGAGTGAAAGGGACAGAAC -3’ 
96 
Arg1, arginase 1; Cd11b, integrin alpha M (Itgam); Cd11c, integrin alpha X (Itgax); Cd206, mannose 
receptor, C type 1 (Mrc1); F4/80, EGF-like module containing, mucin-like, hormone receptor-like 
sequence 1 (Emr1); Glut4, solute carrier family 2 (facilitated glucose transporter), member 4 (Slc2a4); 
Il6, interleukin 6; Il10, interleukin 10; Mgl1/2, C-type lectin domain family 10, member A (Clec10a, also 
known as Mgl1) and macrophage galactose N-acetyl-galactosamine specific lectin 2 (Mgl2); Nos2, 
nitric oxide synthase 2, inducible; Tnfα, tumor necrosis factor alpha. 
 
Lipid extraction and fatty acid analysis 
High-performance liquid chromatography (HPLC) grade solvents for chromatography and 
solvents for extraction (pro analysis quality) (Fisher Scientific, Loughborough, UK) were 
used throughout the lipid extraction and fatty acid analysis. Total lipids were extracted from 
50 – 200 mg of epididymal AT with chloroform/methanol (2:1 v/v) containing 0.01 % 
butylated hydroxytoluene (BHT) (Sigma-Aldrich, Dorset, UK) as antioxidant [Folch et al., 
1957]. The organic solvent was evaporated under a stream of nitrogen and the lipid content 
was determined gravimetrically. Two mg of the total lipid fraction was subjected to acid-
catalyzed transmethylation for 16 h at 50 °C, using 1 ml of toluene and 2 ml of 1% sulphuric 
acid (v/v) in methanol. Prior to transmethylation, nonadecanoic acid (19:0) (Sigma-Aldrich, 
Dorset, UK) was added as internal standard (5 % of the total lipid analysed) to the lipid 
extracts. The resultant fatty acid methyl esters (FAME) were separated and purified from TG 
skeletons (i.e. glycerol), phospholipid skeletons, cholesterol and cholesterol wax on TLC (20 
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x 20 cm) plates, pre-coated with silica gel (without fluorescent indicator) (Macherey-Nagel, 
Düren, Germany) by thin layer chromatography (TLC) and visualised under spraying with 1 
% iodine in chloroform [Christie, 2003]. After elution, FAME were separated and quantified 
by gas-liquid chromatography (GC) using a Hewlett Packard 5890 GC and a SGE BPX70 
capillary GC column (30 m x 0.22 mm I.D.; SGE UK Ltd) with helium as carrier gas and 
using on-column injection. The temperature gradient started at 115°C for 3 min, then went to 
200°C at 2°C / min, 2 min at 200°C, and then to 240°C at 60°C / min. After 5 min at 240°C, it 
cooled down to 115°C and equilibrated for 3 min before the next injection. Individual methyl 
esters were identified by reference to authentic standards (BSA (fatty-acid free), α-linolenic 
acid, docosahexaenoic acid, eicosapentaenoic acid, tridecanoic acid, nonadecanoic acid, 
gallic acid, procatechuic acid, and syringic acid; Sigma-Aldrich, Dorset, UK) and to well-
characterised fish oil standard (PUFA-3 from menhaden oil, SUPELCO, Supelco Park, 
Bellefonte, USA). Data were collected and processed using GC Chemstation (version B04-
02). 
Statistical analysis 
The independent and interactive impact of APOE Epsilon genotype and diet was analysed 
using 2 x 2 factorial univariate Analysis of Variance (ANOVA) with APOE Epsilon genotype 
and diet as independent between-subject variables and considered statistically significant 
when p < 0.05. In the presence of a significant APOE Epsilon genotype * diet interaction 
effect, post-hoc analysis was performed using the two-tailed Student’s t-test with Bonferroni 
correction to analyse differences between the APOE Epsilon genotype * diet groups. 
Differences were considered significant at p < 0.008 (= 0.05 / 6). Statistical analysis of the 
mRNA expression levels in AT was done using log transformed values. Data with a non-
normal distribution and/or unequal variances was analysed using a non-parametric Kruskal-
Wallis test and untransformed data, and was considered statistically significant when p < 
0.05. Post-hoc Mann-Whitney U test with Bonferroni correction was employed to test for 
differences between the APOE Epsilon genotype * diet groups and was considered 
significant at p < 0.008 (= 0.05 / 6). Various outcome measures had not-normally distributed 
data and/or unequal variances which was not improved and often worsened by log (
10
log or 
e
log), square root (√x) or inverse (1/x) transformation, and as a consequence for several 
outcome measures non-parametric testing had to be employed. In the results section, the 
statistical test employed will be clearly indicated in the tables and figures. All statistical 
analysis was performed using SPSS 18.0.  
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Results 
Adipose tissue inflammation 
Flow cytometry analysis  
The ATM infiltration and phenotype in epididymal AT of APOE3 and APOE4 mice fed a HFD 
or a HFD containing 30 g EPA+DHA per kg of diet (HFD+FO) was first characterised by 
analysing the cell surface expression of CD11b (total ATM), CD11c (M1 marker) and CD206 
(M2 marker) in the SVF of disaggregated AT using flow cytometry. The flow cytometry data 
was analysed as depicted in Figure 4.1. Briefly, the cell population of interest (containing 
ATM) within the SVF was first selected using a specific gate (Figure 4.1A). Next, ATM in the 
cell population of interest were identified by the cell surface expression of CD11b (Figure 
4.1B). The M1 and M2 phenotype of the CD11b
+
 ATM was then determined by the cell 
surface expression of CD11c (M1) and CD206 (M2) (Figure 4.1C).  
We found that the abundance of ATM in the SVF of disaggregated epididymal AT was 
determined by APOE Epsilon genotype (F1,35 = 227.139, p < 0.05), but not diet (F1,35 = 
0.048, p = 0.86), and this effect was independent of diet (genotype * diet F1,35 = 0.033, p = 
0.86; Table 4.4). APOE4 mice had significantly higher percentage of CD11b
+
 ATM (% of 
total cell events in cell population of interest) in the epididymal SVF compared to APOE3 
mice (p < 0.05) (Figure 4.2A). Taking a closer look at the ATM cell population (CD11b
+
 cells) 
revealed that we failed to identify any pro-inflammatory M1 ATM (Table 4.4; Figure 4.2B). 
Diet had a borderline non-significant impact on the percentage of anti-inflammatory M2 ATM 
(F1,35 = 137.617, p = 0.05; Figure 4.2C), with higher percentage of M2 ATM in mice on HFD 
compared to HFD+FO. There was a trend for lower percentage of M2 ATM in APOE4 mice 
compared to APOE3 mice, but this did not reach significance (p = 0.09). Diet interacted with 
APOE Epsilon genotype to determine the percentage of double positive ATM expressing 
both M1 marker CD11c and M2 marker CD206 (F1,35 = 5.518, p < 0.05; Figure 4.2D). The 
percentage double positive ATM was significantly higher in mice on the HFD+FO compared 
to HFD (p < 0.05). The ATM cell surface expression ratio of CD11c (M1) to CD206 (M2) was 
not significantly different between the APOE Epsilon genotypes (F1,35 = 1.144, p = 0.48) or 
diet groups (F1,35 = 66.243, p = 0.08; Figure 4.2E). Though there was a trend for a higher 
ratio in mice on HFD+FO compared to those on control HFD (p = 0.08), which was attributed 
to the increase in double positive ATM (CD11b
+
CD11c
+
CD206
+
 cells) (Table 4.4; see also 
Appendix 4-2, Figure A4-2.3 and Table A4-2.1). 
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Figure 4.1. Analysis of the adipose tissue macrophage (ATM) content and phenotype using flow 
cytometry. [A] First, the cell population of interest (containing macrophages) within the stromal 
vascular fraction was selected (gate E, orange dots). [B] Next, the ATM in the cell population of 
interest were identified by the cell surface expression of CD11b. [C] Finally, M1 and M2 
phenotype of the CD11b
+
 ATM cell population was determined by the cell surface expression of 
CD11c (M1) and CD206 (M2), with CD11b+CD11c+CD206– (M1), CD11b+CD11c–CD206+ (M2) 
cells and CD11b+CD11c+CD206+ (double+) cells. Representative plots are given for APOE3 and 
APOE4 mice fed a high-fat diet (HFD) and HFD containing 30 g EPA+DHA / kg of diet (HFD+FO). 
APOE, apolipoprotein E; CD11b, integrin alpha M; CD11c, Integrin alpha X; CD206, mannose 
receptor C type 1.  
APOE3
APOE4
HFD HFD+FO
ATM
M1
M2
A B
C
Double+
 Slim (2015), Chapter 4. In vivo studies – inflammation 
137 
S
lim
 (2
0
1
5
), C
h
a
p
te
r 1
. L
ite
ra
tu
re
 re
v
ie
w
 
A      B 
  
C      D 
  
E  
  
C
D
1
1
b
+
 c
e
ll
s
 (
%
)
A P O E 3 A P O E 4
0
2 0
4 0
6 0
8 0
1 0 0
T o ta l A T M
*
A N O V A
p < 0 .0 5 ;  G
C
D
1
1
c
+
C
D
2
0
6
- 
c
e
ll
s
(%
 o
f 
C
D
1
1
b
+
)
A P O E 3 A P O E 4
0 .0 0
0 .0 2
0 .0 4
0 .0 6
0 .0 8
0 .1 0
M 1
A N O V A
n s .
A P O E 3 A P O E 4
0
4 0
4 0
6 0
8 0
1 0 0
C
D
1
1
c
-C
D
2
0
6
+
 c
e
ll
s
(%
 o
f 
C
D
1
1
b
+
)
M 2
A N O V A
n s .
C
D
1
1
c
+
C
D
2
0
6
+
 c
e
ll
s
(%
 o
f 
C
D
1
1
b
+
)
A P O E 3 A P O E 4
0
1 0
2 0
3 0
4 0
D o u b le +
*
A N O V A
p < 0 .0 5 ;  G * D
*
S
u
r
fa
c
e
 e
x
p
r
e
s
s
io
n
 o
f
C
D
1
1
c
 t
o
 C
D
2
0
6
A P O E 3 A P O E 4
0 .0
0 .5
1 .0
1 .5
C D 1 1 c :C D 2 0 6
A N O V A
n s .
 Slim (2015), Chapter 4. In vivo studies – inflammation 
138 
S
lim
 (2
0
1
5
), C
h
a
p
te
r 1
. L
ite
ra
tu
re
 re
v
ie
w
 
Figure 4.2. Characterisation of the adipose tissue macrophage (ATM) content and phenotype 
using flow cytometry. The percentage of ATM and their phenotype in the stromal vascular 
fraction (SVF) of disaggregated epididymal adipose tissue was determined for APOE3 and 
APOE4 mice fed a high-fat diet (HFD) (circles) and HFD with 30 g EPA+DHA / kg of diet 
(HFD+FO) (squares) by the cell surface expression of CD11b (total ATM), CD11c (M1 marker) 
and CD206 (M2 marker). [A] The total number of ATM (CD11b
+
 cells, % of total cell events in 
gate E confining the cell population of interest) in SVF was higher in APOE4 mice compared to 
APOE3 mice (p < 0.05), but similar between the diets. [B] No ATM with a pro-inflammatory M1 
phenotype (CD11b
+
CD11c
+
CD206
–
 cells) were identified. [C] The percentage of ATM with an 
anti-inflammatory M2 phenotype (CD11b
+
CD11c
–
CD206
+
 cells) was not significantly different 
between the APOE Epsilon genotypes or diets (p > 0.05), although there was a trend for a 
higher percentage M2 ATM in mice on HFD compared to HFD+FO (p = 0.05) and APOE3 mice 
compared to APOE4 mice (p = 0.09). [D] APOE Epsilon genotype interacted with diet to 
determine the percentage of double positive ATM (Double+; CD11b
+
CD11c
+
CD206
+
 cells; p < 
0.05), with higher percentage of double positive ATM in mice on HFD+FO compared to HFD (p < 
0.05). [E] The ratio of the CD11c to CD206 ATM cell surface expression was not significantly 
different between the APOE Epsilon genotypes or diets (p > 0.05), although there was a trend 
for a higher ratio in mice on HFD+FO compared to HFD (p = 0.08). Data is presented as mean ± 
SEM for n = 9 – 10 mice per group. Statistical analysis was done by ANOVA for APOE Epsilon 
genotype (G), diet (D) and G*D interaction effect and considered statistically significant when p 
< 0.05. Significant effects are displayed on top of each figure. Differences between the groups 
were tested using Student’s t-test with Bonferonni correction, *p < 0.008 (= 0.05 / 6). APOE, 
apolipoprotein E; CD11b, integrin alpha M; CD11c, Integrin alpha X; CD206, mannose receptor 
C type 1. 
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Table 4.4. Adipose tissue macrophage (ATM) content and phenotype in the stromal vascular fraction of disaggregated epididymal adipose 
tissue of human APOE3 and APOE4 TR mice fed a high-fat diet (HFD) or HFD containing 30 g EPA+DHA / kg of diet (HFD+FO).  
 APOE3-HFD APOE3-HFD+FO APOE4-HFD APOE4-HFD+FO  
CD11b
+
 cells (ATM) 
(% of total) 
35.2 ± 2.6
a 
34.8 ± 2.1
a 
41.3 ± 2.8
b 
41.8 ± 1.9
b ANOVA 
p<0.05; G 
CD11b
+
CD11c
+
CD206
– 
 cells (M1) 
(% of CD11b
+
 cells) 
0.0 ± 0.0
 
0.0 ± 0.0
 
0.0 ± 0.0
 
0.0 ± 0.0
 ANOVA 
ns. 
CD11b
+
CD11c
–
CD206
+
 cells (M2) 
(% of CD11b
+
 cells) 
79.3 ± 1.4 66.6 ± 1.2
 
72.3 ± 2.5
 
57.3 ± 1.9
 ANOVA 
ns. 
CD11b
+
CD11c
+
CD206
+
 cells (double 
positive) (% of CD11b
+
 cells) 
7.1 ± 1.3
a
 17.1 ± 0.9
b
 10.0 ± 0.7
a
 15.7 ± 0.6
b
 
ANOVA 
p<0.05; G*D 
CD11c:CD206 ratio 0.21 ± 0.03 0.42 ± 0.02 0.21 ± 0.01 0.47 ± 0.07 
ANOVA 
ns. 
Values are mean ± SEM for 9 – 10 animals per group. The CD11b
+
 cells (ATM) are presented as percentage of total cell events in gate E that 
confines the cell population of interest. The CD11b
+
CD11c
+
CD206
–
 (M1), CD11b
+
CD11c
–
CD206
+
 (M2) and CD11b
+
CD11c
+
CD206
+
 (double positive) 
cells are presented as percentage of CD11b
+
 cells, i.e. total ATM. The CD11c:CD206 ratio presents the ratio of the cell surface expression of CD11c 
to CD206. Statistical analysis was done by ANOVA for APOE Epsilon genotype (G), diet (D) and G*D interaction effect and considered statistically 
significant when p < 0.05. Significant effects are indicated in the last column of the table. Differences between the groups were tested using Student’s 
t-test with Bonferroni correction; different letters indicate differences between the APOE Epsilon genotype * diet groups, p < 0.008 (= 0.05 / 6). APOE, 
apolipoprotein E genotype; CD11b, integrin alpha M; CD11c, Integrin alpha X; CD206, mannose receptor C type 1; HFD, high-fat diet; HFD+FO, HFD 
containing 30 g EPA+DHA / kg of diet; n/a, not applicable. 
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In summary, APOE4 mice had relatively more ATM in disaggregated epididymal SVF 
compared to APOE3 mice, but the ATM phenotype distribution was similar. On the other 
hand, fish oil determined the ATM phenotype distribution by increasing the number of ATM 
that coexpress the M1 and M2 phenotypic marker CD11c and CD206, without affecting the 
relative number of ATM in the disaggregated epididymal SVF in both APOE3 and APOE4 
mice. The greater abundance of ATM in the epididymal SVF of APOE4 mice compared to 
APOE3 mice could reflect a higher ‘absolute’ number of ATM in epididymal AT; something 
which needs to be confirmed using a quantitative technique, such as mRNA expression 
analysis.  
mRNA expression analysis 
For a more quantitative analysis of the ATM number and phenotype in the epididymal AT of 
APOE3 and APOE4 mice fed a HFD or a HFD containing 30 g EPA+DHA / kg of diet 
(HFD+FO), the mRNA expression of F4/80 (total ATM), Cd11b (total ATM), Cd11c (M1 
marker), Cd206 (M2 marker) and additional M1 (Tnfa, Nos2, Il6) and M2 (Mgl1/2, Arg1, Il10) 
markers was investigated.  
Statistical analysis revealed a significant effect of diet (F1,35 = 358.861, p < 0.05), but not 
APOE Epsilon genotype (F1,35 = 15.523, p = 0.16), on the F4/80 mRNA expression, with 
dietary fish oil increasing the expression levels in epididymal AT although group comparison 
revealed no significant differences (Figure 4.3A). There was no significant effect of APOE 
Epsilon genotype or diet on the mRNA expression levels of the ATM markers analysed in 
the flow cytometry experiment Cd11b, Cd11c and Cd206 (p > 0.05) (Figure 4.3A, 4.3B). 
However, when correcting for body weight there was a borderline significant effect of APOE 
Epsilon genotype (F1,33 = 41.824, p = 0.05) and a significant effect of diet (F1,33 = 15.688, p < 
0.05) on the expression of Cd11b. Subsequent group comparisons revealed that APOE4 
mice on HFD+FO had significantly higher Cd11b expression than APOE3 mice on HFD and 
HFD+FO (p < 0.01). These results indicate there was a trend for a greater number of ATM in 
AT of APOE4 mice compared to APOE3 mice, which was supported by the flow cytometry 
results showing a greater abundance of ATM in the SVF of APOE4 mice compared to 
APOE3 mice, but not by the F4/80 mRNA expression levels. Furthermore, fish oil increased 
the number of ATM based on the F4/80 and Cd11b expression in AT, something that was 
not reflected in the flow cytometry results of the SVF. There was some inconsistency 
between the mRNA expression levels of F4/80 and Cd11b, especially for the APOE4 mice 
on HFD+FO group (Figure 4.3A). F4/80 is a specific marker for tissue resident 
macrophages, whereas Cd11b is also expressed by neutrophils, natural killer cells and 
subsets of T- and B-cells, therefore F4/80 provides a more reliable measure of the resident 
ATM in AT. Regarding the ATM phenotype, the whole-tissue mRNA expression levels of 
Cd11c and Cd206 did not entirely reflect the flow cytometry results from the SVF. Briefly, 
there were no differences in Cd11c and Cd206 mRNA expression levels between the APOE 
Epsilon genotypes and diets (Figure 4.3B), which was in line with the flow cytometry results. 
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However, the suggestive increase in the CD11c:CD206 ratio by fish oil observed in the flow 
cytometry experiment was not confirmed in the mRNA expression level (Figure 4.4).  
To corroborate the ATM phenotype data, mRNA expression levels of six additional M1 and 
M2 markers were investigated (Figure 4.5). There was no significant effect of APOE Epsilon 
genotype or diet on the expression of M1 markers Tnfa, Nos2 and Il6 (p > 0.05), although a 
trend was observed for higher expression levels in mice on HFD+FO (Figure 4.5A). In 
addition, there was no significant effect of APOE Epsilon genotype or diet on the expression 
of M2 markers Mgl1/2 and Arg1 (p > 0.05). However, APOE Epsilon genotype interacted 
with diet to determine IL-10 mRNA expression levels (F1,34 = 6.477, p < 0.05) (Figure 4.5B). 
APOE4 mice on HFD+FO had significantly higher IL-10 expression than APOE4 mice on 
HFD (p < 0.05). The mRNA expression results of the three M1 markers (Tnfa, Nos2 and Il6) 
are mostly in line with the gene expression and cell surface expression of Cd11c, namely 
there is no effect of APOE Epsilon genotype or diet. If we can speak of any trend, then fish 
oil tended to increase, rather than decrease, the number of M1 ATM. The mRNA expression 
results of the M2 markers (Mgl1/2, Arg1 and Il10) are also fairly consistent with the gene 
expression and cell surface expression of Cd206, namely there is either no significant effect 
of APOE Epsilon genotype or diet, or APOE Epsilon genotype interacts with diet to 
determine its effect. In more detail, the M2 marker expression was not significantly different 
between APOE3 and APOE4 mice on HFD, although flow cytometry data suggested 
different. Furthermore, there was no effect of fish oil on the expression of M2 markers in 
both APOE3 and APOE4 mice, with exception of IL-10. For this marker the most strikingly 
effect was observed, with fish oil increasing the mRNA expression of IL-10 in APOE4, but 
not APOE3, mice. 
In summary, APOE3 and APOE4 mice had a similar number of ATM in epididymal AT and 
fish oil increased the number of ATM. There was no effect of APOE Epsilon genotype or diet 
on the M1 ATM phenotype expression and if we can speak of any subtle trend, then fish oil 
tends to increase, rather than decrease, the number of M1 ATM. Likewise, there was no 
consistent effect of APOE Epsilon genotype or diet on the M2 ATM phenotype expression 
indicating the mice had a similar number of M2 ATM in epididymal AT. However, fish oil 
increased IL-10 mRNA expression and these effects were confined to APOE4 mice. 
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Figure 4.3. The relative mRNA expression of adipose tissue macrophage (ATM) markers F4/80 
(total ATM), Cd11b (total ATM), Cd11c (M1 marker) and Cd206 (M2 marker) in epididymal 
adipose tissue of human APOE3 and APOE4 targeted replacement mice fed a high-fat diet 
(HFD) (black bars) or a HFD containing 30 g EPA+DHA / kg of diet (HFD+FO) (white bars). 
Statistical analysis revealed a significant effect of diet on F4/80 expression (F1,35 = 358.861, p < 
0.05), but no differences between the APOE Epsilon genotypes [A]. There was no significant 
effect of APOE Epsilon genotype, diet or APOE Epsilon genotype * diet on the expression of 
Cd11b, Cd11c or Cd206 (p > 0.05) [A,B]. Data is presented as relative quantity normalised to the 
reference genes Actb, Atp5B and Gapdh, mean ± SEM for n = 8 – 10 mice per group. Statistical 
analysis was done by ANOVA for APOE Epsilon genotype (G), diet (D) and G*D interaction 
effect and considered statistically significant when p < 0.05. Differences between the groups 
were tested using Student’s t-test with Bonferroni correction and considered statistically 
significant when p < 0.008 (= 0.05 / 6). APOE, apolipoprotein E; Cd11b, integrin alpha M (Itgam); 
Cd11c, Integrin alpha X (Itgax); Cd206, mannose receptor C type 1 (Mrc1); F4/80, EGF-like 
module containing, mucin-like, hormone receptor-like sequence 1 (Emr1). 
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Figure 4.4. The ratio of the relative mRNA 
expression of the adipose tissue 
macrophage (ATM) marker Cd11c (pro-
inflammatory M1 phenotype) to Cd206 
(anti-inflammatory M2 phenotype) in 
epididymal adipose tissue of human 
APOE3 and APOE4 targeted replacement 
mice fed a high-fat diet (HFD) (black bars) 
or a HFD containing 30 g EPA+DHA / kg of 
diet (HFD+FO) (white bars). Statistical 
analysis revealed no significant effect of 
APOE Epsilon genotype, diet or APOE 
Epsilon genotype * diet on the ratio of 
Cd11c to Cd206 expression (p > 0.05). Data 
is presented as ratio of the relative quantity 
normalised to the reference genes Actb, 
Atp5B and Gapdh of Cd11c to Cd206, mean 
± SEM for n = 8 – 10 mice per group. 
Statistical analysis was done by ANOVA for 
APOE Epsilon genotype (G), diet (D) and 
G*D interaction effect and considered 
statistically significant when p < 0.05.  
APOE, apolipoprotein E; Cd11c, Integrin 
alpha X (Itgax); Cd206, mannose receptor C 
type 1 (Mrc1). 
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Figure 4.5. The relative mRNA expression of adipose tissue macrophage (ATM) phenotypic 
markers of the pro-inflammatory M1 phenotype [A] and anti-inflammatory M2 phenotype [B] in 
epididymal adipose tissue of human APOE3 and APOE4 targeted replacement mice fed a high-
fat diet (HFD) (black bar) or a HFD containing 30 g EPA+DHA / kg of diet (HFD+FO) (white bars). 
There was no significant effect of APOE Epsilon genotype or diet on the expression of M1 
markers Tnfa, Nos2 and Il6 (p > 0.05). Though, a trend for higher expression levels in mice fed 
HFD+FO compared to control HFD was observed [A]. APOE Epsilon genotype interacted with 
diet to determine mRNA expression levels of M2 marker IL-10 (F1,34 = 6.477, p < 0.05), but there 
was no significant effect of APOE Epsilon genotype or diet on the expression of the other two 
M2 markers Mgl1/2 and Arg1 (p > 0.05) [B]. Post-hoc analysis revealed that APOE4 mice on 
HFD+FO had significantly higher IL-10 mRNA expression than APOE4 mice on HFD (p < 0.05). 
Data is presented as relative quantity normalised to the reference genes Actb, Atp5B and 
Gapdh, mean ± SEM for n = 8 – 10 mice per group. Statistical analysis was done by ANOVA for 
APOE Epsilon genotype (G), diet (D) and G*D interaction effect or by Kruskal-Wallis test for G*D 
effect and considered statistically significant when p < 0.05. Significant effects are displayed on 
top of each figure. Differences between the groups were tested using Student’s t-test with 
Bonferroni correction, *p < 0.008 (= 0.05 / 6). APOE, apolipoprotein E; Il6, interleukin 6; Il10, 
interleukin 10; Mgl1/2, C-type lectin domain family 10, member A (Mgl1) and macrophage 
galactose N-acetyl-galactosamine specific lectin (Mgl2); Nos2, inducible nitric oxide synthase; 
Tnfa, Tumor necrosis factor alpha. 
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Adipose tissue fatty acid composition 
To determine if a differential LC n-3 PUFA enrichment of AT could underlie the differential 
response to fish oil supplementation in APOE3 and APOE4 mice fed a HFD or a HFD 
containing 30 g EPA+DHA / kg of diet (HFD+FO), the fatty acid composition of the 
epididymal AT was investigated.  
Statistical analysis revealed there were significant differences in the fatty acid composition in 
epididymal AT of APOE3 and APOE4 mice on HFD or HFD+FO (Table 5.5). As expected 
the largest differences were observed for EPA, DHA and total LC n-3 PUFA between the 
HFD and HFD+FO diet in APOE3 and APOE4 mice. The levels of EPA (20:5 n-3) in AT were 
significantly different between the APOE Epsilon genotype * diet groups (Kruskal-Wallis, p < 
0.001). EPA levels were negligible (0.00 and 0.01 %) in mice on HFD, but increased to 
about 1 % of the total fatty acids in mice on HFD+FO (p < 0.05). The levels of DHA in AT 
were determined by diet (F1,36 = 738.778, p < 0.05), but not APOE Epsilon genotype (F 1,36 = 
0.758 p = 0.54), and the effect of diet was not different according to APOE Epsilon genotype 
(F1,36 = 2.763 p = 0.11). DHA levels were 0.13 and 0.14 % of the total fatty acid of mice on 
HFD and increased to about 3 % in mice on HFD+FO (p < 0.05). The HFD did not contain 
EPA and DHA, thus the 0.13 and 0.14 % DHA in AT of mice on HFD likely reflect 
endogenous synthesis of DHA from α-linolenic acid (ALA). The EPA:DHA ratio in AT was 
0.33 whereas the EPA:DHA ratio of the diet was 0.67, indicating that DHA was more 
conserved within AT. The total LC n-3 PUFA content in AT was determined by diet (F1,36 = 
1114.135, p < 0.05), but not APOE Epsilon genotype (F 1,36 = 3.030, p = 0.33), and the effect 
of diet was independent of APOE Epsilon genotype (F1,36 = 1.590, p = 0.22). Briefly, total LC 
n-3 PUFA increased from 0.18 % in mice on HFD to 3.97 % of total fatty acids in mice on 
HFD+FO (p < 0.05). The levels of arachidonic acid (AA, 20:4 n-6), n-6 PUFA pre-cursor 
linoleic acid (LA, 18:2 n-6) and n-3 PUFA pre-cursor ALA (18:3 n-3) were not significantly 
different between the APOE Epsilon genotypes and diets (p > 0.05). For ALA (18:3 n-3), the 
effect of diet (F1,36 = 46.639, p = 0.09) and its interaction with APOE Epsilon genotype (F1,36 
= 2.783, p = 0.10) were borderline non-significant. There was a trend for lower LA (23 - 24 % 
vs. 21 %) and higher ALA (1.5 - 1.7 % vs. 1 %) levels in AT of mice on HFD+FO compared 
to those on HFD. In line with this, total n-3 PUFA was higher in AT at the cost of total n-6 
PUFA in APOE3 and APOE4 mice on HFD+FO compared to those on HFD (total n-3 PUFA, 
6 % vs. 1 %; total n-6 PUFA, 22 % vs. 24.5 %). Furthermore, the levels of the saturated fatty 
acids myristic acid (14:0) and palmitic acid (16:0) in AT were higher in APOE3 and APOE4 
mice on HFD+FO compared to mice on HFD (p < 0.05). Whereas, the APOE3 and APOE4 
mice on HFD had higher levels of the monounsaturated fatty acids vaccenic and oleic acid 
(18:1 n-7 and C18:1 n-9) compared to mice on HFD+FO (p < 0.05).  
Besides, the fatty acid composition in epididymal AT was not significantly different between 
the APOE Epsilon genotypes in mice fed a similar diet, either HFD or HFD+FO. Briefly, there 
were no significant differences in levels of EPA (20:5 n-3), DHA (22:6 n-3), ALA (18:3 n-3), 
LA (18:2 n-6) or AA (20:4 n-6) in AT between APOE3 and APOE4 mice on HFD+FO diet (p 
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> 0.05). The composition of the saturated fatty acids in AT showed minor differences 
between the APOE Epsilon genotypes. On the HFD+FO diet, APOE3 mice had slightly 
higher levels of lauric acid (12:0) and myristic acid (14:0) compared to APOE4 mice (0.21 vs. 
0.16 % and 3.23 vs. 2.82 %, p < 0.05). 
 
To explore if the LC n-3 PUFA, EPA and DHA enrichment of epididymal AT determined the 
response to fish oil supplementation in APOE3 and APOE4 mice, we investigated the 
correlation between LC n-3 PUFA, EPA and DHA levels and several outcome measures 
related to AT inflammation and IR using the Pearson’s correlation coefficient (Appendix 4-3).  
Regarding the measures of AT inflammation, we found that the level of LC n-3 PUFA, EPA 
and DHA in epididymal AT was negatively associated with the expression of M2 ATM 
(CD11b
+
CD11c
-
CD206c
+
 cells) (r = -0.661, r = -0.644 and r = -0.668, p < 0.001) and 
positively associated with the percentage of double positive ATM (CD11b
+
CD11c
+
CD206c
+
 
cells) (r = 0.809, r = 0.805 and r = 0.810, p < 0.001) and the ATM surface expression of 
CD11c to CD206 (r = 0.680, r = 0.685 and r = 0.677, p < 0.001) in SVF of disaggregated 
epididymal AT. There was no correlation between LC n-3 PUFA, EPA and DHA levels and 
the percentage of ATM (CD11b
+
 cells) and M1 ATM (CD11b
+
 CD11c
+
CD206
-
 cells) in SVF 
of disaggregated epididymal AT. The F4/80 mRNA expression levels correlated with EPA 
levels (r = 0.339, p < 0.05) and Cd11b mRNA expression levels correlated with LC n-3 
PUFA, EPA and DHA levels in AT (r = 0.344, r = 0.348 and r = 0.337, p < 0.05). There was 
no relationship between Cd11c, Cd206, Il10 mRNA expression and LC n-3 PUFA, EPA and 
DHA levels in AT. These findings support that there is a positive relation between LC n-3 
PUFA and the number of ATM in epididymal AT of APOE3 and APOE4 mice.  
Regarding the measures related to IR (see Chapter 3), the level of LC n-3 PUFA, EPA and 
DHA levels in AT were negatively associated with the homeostatic model assessment - 
insulin resistance (HOMA-IR) (r = -0.540, r = -0.534 and r = -0.541, p < 0.001), fasting 
plasma glucose (r = -0.416, r = -0.420 and r = -0.410, p < 0.01) and fasting plasma insulin (r 
= -0.520, r = -0.514 and r = -0.522, p < 0.01) and positively associated with Glut4 mRNA 
expression in epididymal AT (r = 0.401, r = 0.459 and r = 0.376, p < 0.05). These findings 
indicate there is a negative relationship between LC n-3 PUFA and measures related to IR in 
APOE3 and APOE4 mice. 
  
 Slim (2015), Chapter 4. In vivo studies – inflammation 
147 
S
lim
 (2
0
1
5
), C
h
a
p
te
r 1
. L
ite
ra
tu
re
 re
v
ie
w
 
Table 4.5. Fatty acid composition (% of total fatty acids) of the epididymal adipose tissue of 
human APOE3 and APOE4 TR mice fed a high-fat diet (HFD) or HFD containing 30 g EPA+DHA / 
kg of diet (HFD+FO). 
Saturated 
APOE3- 
HFD 
APOE3-
HFD+FO 
APOE4- 
HFD 
APOE4-
HFD+FO 
 
12:0 0.02 ± 0.01
a 
0.21 ± 0.01
b 
0.05 ± 0.03
a 
0.16 ± 0.01
c Kruskal-Wallis 
p<0.001; G*D 
14:0 0.87 ± 0.03
a 
3.23 ± 0.04
b 
0.98 ± 0.04
a 
2.82 ± 0.06
c ANOVA 
p<0.001; G*D 
16:0 19.36 ± 0.31
a 
22.64 ± 0.27
b 
20.07 ± 0.41
a 
23.40 ± 0.70
b Kruskal-Wallis 
p<0.001; G*D 
18:0 3.90 ± 0.14
 
4.20 ± 0.14
 
3.19 ± 0.20
 
3.70 ± 0.22
 ANOVA 
ns. 
20:0 0.00 ± 0.00 0.02 ± 0.01 0.01 ± 0.01 0.06 ± 0.05 
Kruskal-Wallis 
ns. 
Monounsaturated 
14:1 0.01 ± 0.01
a 
0.07 ± 0.01
b 
0.00 ± 0.00
a 
0.10 ± 0.02
b Kruskal-Wallis 
p<0.001; G*D 
16:1 n-7 4.25 ± 0.15
 
6.52 ± 0.20
 
5.48 ± 0.29 6.77 ± 0.39
 ANOVA 
ns. 
18:1 (n-7 
& n-9) 
44.66 ± 0.45
a 
33.18 ± 0.19
b 
44.33 ± 0.49
a 
33.86 ± 0.35
b ANOVA 
p<0.05; D 
20:1 n-9 0.60 ± 0.03
 
0.54 ± 0.01
 
0.59 ± 0.03
 
0.51 ± 0.02
 ANOVA 
ns. 
22:1 n-9 0.01 ± 0.01 0.01 ± 0.01 0.02 ± 0.01 0.09 ± 0.03 
Kruskal-Wallis 
ns. 
24:1 n-9 0.05 ± 0.01
a 
0.46 ± 0.02
b 
0.01 ± 0.01
a 
0.47 ± 0.02
b Kruskal-Wallis 
p<0.001; G*D 
Polyunsaturated 
18:2 n-6 
(LA) 
24.00 ± 0.21
 
21.25 ± 0.20
 
23.13 ± 0.47
 
21.33 ± 0.42
 ANOVA 
ns. 
18:3 n-6 
(GLA) 
0.07 ± 0.01 0.12 ± 0.02 0.06 ± 0.03 0.10 ± 0.01 
Kruskal-Wallis 
p<0.05; G*D 
18:3 n-3 
(ALA) 
1.03 ± 0.05
 
1.68 ± 0.03
 
1.00 ± 0.06
 
1.47 ± 0.06
 ANOVA 
ns. 
18:4 n-3 0.00 ± 0.00
a 
0.48 ± 0.05
b 
0.00 ± 0.00
a 
0.36 ± 0.03
b Kruskal-Wallis 
p<0.001; G*D 
20:2 n-6 0.44 ± 0.01
a 
0.28 ± 0.01
b 
0.41 ± 0.01
a 
0.27 ± 0.01
b Kruskal-Wallis 
p<0.001; G*D  
20:3 n-6 0.16 ± 0.01
a 
0.14 ± 0.00
b 
0.19 ± 0.01
a 
0.14 ± 0.00
b ANOVA 
ns. 
20:3 n-3 0.09 ± 0.04
a 
0.09 ± 0.01
ab 
0.01 ± 0.01
a 
0.07 ± 0.01
b ANOVA 
ns. 
20:4 n-6 
(AA) 
0.28 ± 0.02
 
0.35 ± 0.01
 
0.33 ± 0.01
 
0.34 ± 0.01
 ANOVA 
ns. 
20:4 n-3 0.00 ± 0.00
a 
0.33 ± 0.01
b 
0.00 ± 0.00
a 
0.27 ± 0.01
c Kruskal-Wallis 
p<0.001; G*D  
20:5 n-3 
(EPA) 
0.01 ± 0.01
a 
1.19 ± 0.05
b 
0.00 ± 0.00
a 
0.97 ± 0.07
b Kruskal-Wallis 
p<0.001; G*D 
22:5 n-3 
(DPA) 
0.05 ± 0.02 0.01 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 
Kruskal-Wallis 
ns. 
22:6 n-3 
(DHA) 
0.13 ± 0.01
a 
3.02 ± 0.11
b 
0.14 ± 0.02
a 
2.71 ± 0.13
b
 
ANOVA 
p<0.05; D 
LC n-3 
PUFA 
0.20 ± 0.03
a 
4.22 ± 0.15
b 
0.16 ± 0.02
a 
3.71 ± 0.19
b
 
ANOVA 
p<0.05; D  
Values are mean ± SEM for n = 10 animals per group. Statistical analysis was done by ANOVA for 
APOE Epsilon genotype (G), diet (D) and G*D interaction effect using untransformed or √(x+0.001) 
transformed data or by Kruskal-Wallis test for G*D effect using untransformed data and considered 
statistically significant when p < 0.05. Continues on the next page.. 
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…continued from previous page. The data was normally distributed for all outcome measure but many 
outcome measure had unequal variances Therefore, Student’s t-test assuming equal variances or 
Student’s t-test not assuming equal variances with Bonferroni correction was used to test for 
differences between APOE3 HFD and APOE3-HFD+FO, APOE4-HFD and APOE4-HFD+FO, APOE3-
HFD and APOE4-HFD, APOE3-HFD+FO and APOE4-HFD+FO group and considered statistically 
significant when p < 0.0125 (= 0.05 / 4), different letters indicate different means. 12:0, lauric acid; 
14:0, myristic acid; 14:1, myristoleic acid; 16:0, palmitic acid; 16:1 n-7, palmitoleic acid; 17:0, margaric 
acid; 18:0, stearic acid; 18:1 (n-7 & n-9), vaccenic acid and oleic acid; 18:2 n-6, linoleic acid (LA); 18:3 
n-6, gamma-linolenic acid (GLA); 18:3 n-3, alpha-linolenic acid (ALA); 18:4 n-3, stearidonic acid; 20:0, 
icosanoioc acid; 20:1 n-9, gondoic acid; 20:2 n-6, eicosadienoic acid; 20:3 n-6, dihomo-gamma-
linolenic acid; 20:3 n-3, eicosatrienoic acid; 20:4 n-6, arachidonic acid (AA); 20:5 n-3, 
eicosapentaenoic acid (EPA); 22:1 n-9, erucic acid; 22:5 n-3, docosapentaenoic acid; 22:6 n-3, 
docosahexaenoic acid (DHA); 24:1 n-9, nervonic acid; APOE, apolipoprotein E; HFD, high-fat diet; 
HFD+FO, high fat diet containing 30 g EPA+DHA / kg of diet; LA, linoleic acid; LC n-3 PUFA, long 
chain n-3 polyunsaturated fatty acids. 
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Discussion 
In summary, APOE3 and APOE4 TR mice had a similar number of ATM and a similar ATM 
phenotype distribution in epididymal AT. Fish oil increased the number of ATM, but their 
effect on the ATM phenotype was less clear. Flow cytometry data suggested that fish oil 
increased the number of double positive ATM expressing both M1 and M2 phenotypic 
marker, which was not confirmed by mRNA expression analysis. In addition, mRNA analysis 
revealed that fish oil increased IL-10 expression in AT of APOE4, but not APOE3, mice. The 
LC n-3 PUFA enrichment of the epididymal AT was not significantly different between 
APOE3 and APOE4 mice. Mice on HFD without LC n-3 PUFA had negligible levels and 
dietary fish oil significantly increased the LC n-3 PUFA levels in epididymal AT. There was a 
trend towards lower EPA and DHA levels in APOE4 mice compared to APOE3 mice on the 
HFD+FO. 
APOE Epsilon genotype and adipose tissue macrophages 
We are the first to thoroughly investigate the ATM number and phenotype in epididymal AT 
in APOE3 and APOE4 mice, and show that they had a similar ATM number and phenotype 
distribution upon HFD feeding. Surprisingly, APOE3 mice on HFD showed a greater weight 
gain but had a similar F4/80 and Cd11b expression level compared to APOE4 mice on HFD, 
implying a similar ATM infiltration. These findings are in line with Arbones-Mainar et al. 
(2008), who reported no differences in the mRNA expression levels of the ATM markers 
Cd68 and F4/80 in epididymal AT between APOE3 and APOE4 mice fed a Western-diet 
(21% w/w fat, 0.2% w/w cholesterol, 34% w/w sucrose) for 8 weeks, implying no differential 
ATM infiltration [Arbones-Mainar et al., 2008]. Similarly, Cash et al. observed no difference 
in the F4/80 mRNA expression in epididymal AT of APOE3 and APOE4 mice fed a similar 
Western-diet for 4 weeks [Cash et al., 2012]. Moreover, they reported a similar HFD-induced 
increase in F4/80 mRNA expression in APOE3 and APOE4 mice fed the Western-diet 
compared to chow [Cash et al., 2012]. These studies together with our findings indicate that 
on a HFD APOE3 and APOE4 mice have a similar ATM infiltration rate.  
Second, this is the first study thoroughly investigating the ATM phenotype distribution in 
epididymal AT of APOE3 and APOE4 mice. A study by Baitsch et al. has showed that apoE 
promoted macrophage polarisation toward M2 phenotype in vitro and in vivo, but the isoform 
differences remained to be elucidated [Baitsch et al., 2011]. We showed here that there 
were no differences in the M1:M2 ATM phenotype distribution in epididymal AT between the 
APOE3 and APOE4 mice fed a HFD or HFD containing fish oil. These results were 
supported by the mRNA expression level of six additional M1 (Tnfa, Nos2, Il6) and M2 
(Mgl1/2, Arg1, Il10) genes, for which all but IL-10, were similar between the genotypes and 
diets. These findings are also in line with Cash et al., who investigated the mRNA 
expression of two M1 ATM markers, Nos2 and Tnfa, in epididymal AT of APOE3 and 
APOE4 mice fed a Western-diet or control chow diet for 4 weeks and reported no 
differences between the genotypes [Cash et al., 2012]. Moreover, the APOE3 and APOE4 
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mice showed a similar HFD-induced increase in Nos2 and Tnfa compared to mice on chow 
diet. These results clearly indicate that APOE3 and APOE4 mice have a similar ATM 
phenotype distribution in epididymal AT upon HFD feeding.  
Fish oil increases adipose tissue macrophages 
We are the first to investigate the effect of dietary fish oil on ATM number and phenotype in 
the epididymal AT in APOE3 and APOE4 mice and show that fish oil increased the number 
of ATM, but did not affect the ATM phenotype. There was a significant effect of diet on the 
F4/80 expression levels with 40 – 80% higher expression levels in mice on HFD+FO 
compared HFD, indicating dietary fish oil increases the number of ATM in the epididymal AT 
on a HFD background. The Cd11b expression levels showed a similar picture to the F4/80 
expression levels except for the APOE4 mice on HFD+FO, who had a high Cd11b 
expression level that was not fully reflected by the F4/80 expression level. F4/80 is a specific 
marker for tissue resident macrophages, whereas CD11b is also expressed by neutrophils, 
natural killer cells and subsets of T- and B-cells that have all been identified within AT, 
therefore F4/80 provides a more reliable measure of the resident ATM in AT [Lee and Lee, 
2014]. The presence of neutrophils, natural killer cells and subsets of T- and B-cells in 
epididymal AT was not determined in this study, so we can only speculate that the Cd11b 
expression levels also reflects the expression from these cells. Thus, dietary fish oil 
augmented the ATM infiltration in APOE3 and APOE4 mice resulting in a greater ATM 
accumulation in these mice. These results are surprising in the context of previous studies in 
mice reporting beneficial effects of fish oil on AT inflammation [Muurling et al., 2003, 
Neuhofer et al., 2013, Saraswathi et al., 2007], ATM infiltration [Oh et al., 2010, Saraswathi 
et al., 2007, Todoric et al., 2006] and ATM phenotype [Neuhofer et al., 2013, Oh et al., 
2010]. For example, Oh et al. showed using flow cytometry and immunohistochemistry a 
lower ATM content, a decreased number of M1 macrophages and increased number of M2 
macrophages in AT of C57BL/6 wild type mice fed a HFD providing 150 mg EPA+DHA per 
day per mouse, compared to mice fed a control HFD [Oh et al., 2010]. In line with this, a 
recent randomised placebo controlled fish oil intervention trial reported a similar effect on 
ATM in humans [Spencer et al., 2013]. In more detail, fish oil supplementation (4 g/day) for 
12 weeks decreased the number of ATM in the abdominal AT with the greatest response in 
subjects with a high baseline ATM count, along with a decrease in plasma and AT monocyte 
chemoattractant protein (MCP)-1 levels in non-diabetic subjects with MetS and IR. These 
studies demonstrate that fish oil can have direct beneficial effects on ATM in both mice and 
humans. However, although using a similar dose to Oh et al. we observed a modest 
increase in ATM number and failed to observe an effect on ATM phenotype in APOE3 and 
APOE4 mice. The modest increase in ATM number is relative to the total cell population 
within the tissue as mRNA was extracted from all tissue cells, with mature adipocytes being 
the main cell type within AT. One could speculate that the increase in ATM number upon fish 
oil supplementation may reflect a relative increase in ATM resulting from a slight decrease in 
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the number of mature adipocytes with the number of ATM remaining stable. This is a 
reasonable explanation given that LC n-3 PUFA inhibit adipocyte proliferation and 
differentiation and reduce adipocyte hypertrophy and hyperplasia [Flachs et al., 2009]. 
Future studies using immunohistochemistry techniques allowing visual inspection of the 
relative abundance of ATM and appearance of mature adipocytes are needed to verify the 
effects of fish oil on ATM infiltration, their localisation and phenotype in APOE3 and APOE4 
mice. The importance of this future research is emphasized by a previous report of an 
increased adipocyte size and reduced number of adipocytes in epididymal AT of APOE4 
mice upon HFD feeding compared to APOE3 mice, although the effect of dietary fish oil was 
not investigated [Arbones-Mainar et al., 2008].  
The impact of dietary fish oil on the ATM phenotype distribution is less clear. If we can speak 
of any trend, the flow cytometry data suggests fish oil tended to increase ATM coexpressing 
M1 and M2 phenotypic marker, which was not entirely supported by the mRNA expression 
analysis. The different results found for the different approaches, i.e. flow cytometry and 
mRNA expression analysis, could relate to different methodology. The cell surface 
expression of ATM markers for individual cells was investigated in the flow cytometry 
analysis, whereas the gene expression level of ATM markers in whole adipose tissue was 
investigated in the mRNA expression analysis. The whole tissue ATM marker expression 
level is the pooled expression of tissue macrophages and non-macrophage cells, and may 
not fully reflect the individual cells ATM marker expression. Furthermore, mRNA expression 
levels may not fully reflect protein and cell surface expression levels. Protein levels are the 
balance between its synthesis and degradation, and in general mRNA expression correlate 
well with protein levels. However, for some proteins their levels are not determined by its 
gene expression levels but are controlled at the translation and/or protein degradation level. 
Therefore, mRNA expression levels always have to be verified with protein expression 
levels. This could explain the discrepancies between our flow cytometry and mRNA 
expression results. Of note, the CD11c flow cytometry data was collected using suboptimal 
instrument settings allowing the detection of only a small proportion of the CD11c-Alexa700 
signal. It reduced our power to detect a small difference in the cell surface expression of the 
M1 phenotypic marker CD11c and explains why we failed to identify any M1 ATM in the 
epididymal AT using flow cytometry. This is a limitation of the current study and asks for 
some caution when interpreting these results. Besides, our findings are in sharp contrast 
with the findings from Oh et al., who used a similar dose of EPA and DHA and reported a 
reduction in M1 macrophages and an increase in M2 macrophages using flow cytometry and 
immunohistochemistry, with a concomitant decrease in mRNA expression levels of M1 
markers (Il6, Mcp1, Il1β, Nos2, Cd11c) and increase in M2 markers (Arg1, Il10, Mgl1, Ym1, 
Mmr) in AT of C57BL/6 wild type mice upon fish oil supplementation [Oh et al., 2010]. 
Therefore, more studies in APOE3 and APOE4 mice are required to verify the effect of 
dietary fish oil on the ATM M1:M2 phenotype distribution in epididymal AT.  
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Fish oil increases IL-10 mRNA expression in APOE4 mice 
Our most striking finding was that the beneficial effect of fish oil on IL-10 mRNA expression 
in epididymal AT was confined to mice with the APOE4 genotype. Various in vitro studies 
have demonstrated that DHA specifically, and not EPA, is responsible for these beneficial 
effects on IL-10 expression levels in macrophages and adipocytes [Bradley et al., 2008, 
Oliver et al., 2012, Weldon et al., 2007]. However, we did not find any relation between AT 
LC n-3 PUFA, EPA or DHA content and IL-10 expression levels (Appendix 3-4). The effect 
of DHA on IL-10 expression in adipocytes can be either direct [Bradley et al., 2008] or 
mediated by ATM [Oliver et al., 2012]. The changes in IL-10 production have been 
associated with concomitant changes in insulin sensitivity in adipocytes [Lumeng et al., 
2007B, Oliver et al., 2012]. The important role for IL10 in maintaining insulin sensitivity in 
adipocytes was demonstrated by Lumeng et al., who showed first that the IL-10 receptor 
(IL10R) was expressed by adipocytes, but not by SVF cells in epididymal AT of mice, and 
secondly that IL-10 prevented the TNF-α-induced IR by preventing the TNF-α-induced 
suppression of GLUT4 and insulin receptor protein expression and insulin signalling in 3T3-
L1 adipocytes [Lumeng et al., 2007B]. Thus, IL-10 is an important insulin sensitising cytokine 
in adipocytes. A previous study showed increased adipocyte hypertrophy in epididymal AT 
of APOE4 mice fed a Western-diet that was associated with local and systemic IR [Arbones-
Mainar et al., 2008]. Therefore, the increased IL-10 mRNA expression in epididymal AT of 
APOE4 mice upon fish oil supplementation could be a defensive response to the increased 
adipocyte stress resulting from adipocyte hypertrophy in these mice, which is aimed at 
maintaining adipocyte insulin sensitivity in these mice.  
APOE Epsilon genotype and long chain n-3 PUFA status 
To determine if a differential DHA enrichment in AT could underlie the differential response 
to fish oil supplementation in APOE3 and APOE4 mice, the fatty acid composition of 
epididymal AT was investigated. There were no significant differences in the fatty acid 
composition, including EPA and DHA levels, between the APOE3 and APOE4 mice fed a 
similar diet. The changes in the fatty acid composition between the diet groups reflected in 
most cases the differential dietary fatty acid intake. Dietary fish oil increased total n-3 PUFA 
in epididymal AT from 1% to 6% with a concomitant 2% reduction in total n-6 PUFA content. 
EPA and DHA levels were negligible in mice on HFD diet deficient in EPA and DHA, but 
increased to approximately 1% and 3% upon feeding the HFD+FO containing 30 g 
EPA+DHA / kg of diet. The EPA and DHA enrichment in AT in our study was similar to 
previous reported EPA and DHA concentrations of approximately 1% and 3% of total lipids 
in white AT in C57BL/6 mice fed a HFD containing 30 g EPA+DHA / kg of diet for 9 weeks 
[Kopecky et al., 2009, Rossmeisl et al., 2012]. DHA was more conserved within AT than 
EPA, as the EPA:DHA ratio in epididymal AT of mice on HFD+FO was 0.33 compared to 
dietary EPA:DHA ratio of 0.67. This ratio is in line with previous reports [Kopecky et al., 
2009, Rossmeisl et al., 2012]. Besides, we observed a trend for almost 20 % lower EPA and 
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10 % lower DHA levels in APOE4 mice compared to APOE3 mice on HFD+FO. This finding 
is in line with previous reports of an increased β-oxidation and altered DHA metabolism and 
suboptimal n-3 PUFA availability in APOE4 carriers [Chouinard-Watkins et al., 2013, 
Conway et al., 2014, Plourde et al., 2009, Vandal et al., 2014]. Briefly, DHA concentrations 
in plasma triglycerides were increased by only 75 % in APOE4 carriers after a 6 week 
dietary supplementation with 3 g EPA+DHA / d compared to a 240 % increase in non-
carriers [Plourde et al., 2009]. Moreover, in a kinetics study using isotopically labelled DHA 
APOE4 carriers had 31 % lower DHA levels in plasma total lipids and a more rapid β-
oxidation of DHA 1 – 28 days post-dose (40 mg [
13
C]DHA) compared to non-carriers 
[Chouinard-Watkins et al., 2013]. In line with this, Vandal et al. showed that APOE4 mice 
had higher plasma DHA levels, lower cortex DHA levels and impaired transport of DHA 
across the blood-brain barrier (BBB) compared to APOE2 mice at age of 13 months after 9 
months of high n-6 / low n-3 PUFA diet feeding (n-3 PUFA, 0.36 g/kg of diet; no EPA or 
DHA) [Vandal et al., 2014]. The impaired DHA transport across the BBB in APOE4 mice 
manifested itself already at the age of 4 month prior to the high n-6 / low n-3 PUFA feeding 
intervention [Vandal et al., 2014]. Thus, the APOE4 genotype appears to be associated with 
an increased β-oxidation of DHA in humans and an impaired DHA transport across the BBB 
resulting in a suboptimal DHA bioavailability in brain of these mice. The LC n-3 PUFA 
availability in liver and AT of APOE2, APOE3 and APOE4 TR mice was investigated recently 
by Conway et al. (2014) [Conway et al., 2014]. They showed that total n-3 PUFA 
concentrations were 46 % lower in AT and 47 % lower in liver in APOE4 mice compared to 
APOE3 mice. In addition, the levels of DHA were 75 % lower in AT and 34 % lower in liver in 
APOE4 mice compared to APOE3 mice. However, plasma levels of total n-3 PUFA and DHA 
were not different between the APOE3 and APOE4 genotype. The lower total n-3 PUFA and 
DHA levels in APOE4 mice were associated with higher fatty acid binding protein (FABP) 
and carnitine palmitoyltransferase 1 (CPT1) levels in liver and higher fatty acid transport 
protein (FATP) levels in AT. CPT1 is the rate limiting enzyme in initiation of fatty acid 
oxidation, whereas FATPs and FABPs regulate transport, uptake and release of fatty acids 
by cells. We demonstrated that the n-3 PUFA enrichment of epididymal AT did not 
significantly differ between APOE3 and APOE4 mice, although levels tended to be lower in 
APOE4 mice. The lower n-3 PUFA levels could be the result of the previously described 
increased β-oxidation in APOE4 carriers [Chouinard-Watkins et al., 2013] resulting in an 
increased oxidation of EPA and DHA, although a reduced n-3 PUFA uptake [Vandal et al., 
2014] by AT cannot be ruled out as plasma n-3 PUFA status was not investigated in this 
study. Furthermore, the failure to show a significant APOE Epsilon genotype effect on the 
availability of n-3 PUFA in AT could be caused by the high dose of EPA and DHA added to 
the experimental diet in this study, with perhaps significant genotype-mediated differences 
emerging following consumption of a more modest dose of EPA and DHA. We fed mice a 
HFD without or with 30 g EPA+DHA / kg of diet that also contained approximately 4 g ALA / 
kg of diet, whereas Vandal et al. investigating the bioavailability of DHA in the brain used a 
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high n-6 / low n-3 PUFA diet containing only 0.36 g n-3 PUFA / kg of diet, of which mainly 
ALA and no EPA or DHA [Vandal et al., 2014]. Similarly, Conway et al. used a low fat (5.0 % 
w/w) and high n-6 / low n-3 PUFA diet containing 0.4 g ALA / kg of diet and no EPA or DHA 
[Conway et al., 2014]. Thus, by providing a dietary excess of EPA and DHA it is possible 
that we might have overcome the potential impact of APOE4 genotype on LC n-3 PUFA 
bioavailability in tissues, such as AT, something that remains to be elucidated. Besides, the 
EPA and DHA levels in epididymal AT were negligible in APOE3 and APOE4 mice on the 
HFD deficient in EPA and DHA and there was no APOE Epsilon genotype effect indicating 
that the bioavailability of EPA and DHA in AT is reflecting dietary fatty acid intake and do 
novo synthesis of EPA and DHA from its precursor ALA is unlikely to play an important role 
in epididymal AT. The 20 % and 10 % lower EPA and DHA levels in AT of APOE4 mice 
compared to APOE3 mice did not reach statistical significance but might be of clinical 
relevance. Overweight subjects and metabolically unhealthy obese (MUO), but not 
metabolically healthy obese (MHO), have lower plasma levels of EPA and DHA compared to 
lean healthy subjects [Fernandez-Real et al., 2003, Perrault et al., 2014]. This suggests a 
lower whole-body bioavailability of LC n-3 PUFA in overweight and MUO individuals that 
might also persist at tissue levels. 
In summary, we showed that epididymal AT fatty acid composition is reflecting dietary intake 
and APOE4 mice tend to have a lower bioavailability of EPA and DHA in epididymal AT. 
Future studies should confirm the impact of APOE Epsilon genotype on LC n-3 PUFA 
bioavailability in plasma, brain, AT and liver using different dietary LC n-3 PUFA dosages, 
e.g. deficient, low and high dose. Besides, studies using isotopically labelled fatty acids 
should be used to verify the impact of APOE Epsilon genotype on the uptake and 
metabolism of LC n-3 PUFA within these tissues. 
Anti-inflammatory effects of long chain n-3 PUFA  
The anti-inflammatory effects of LC n-3 PUFA on cell and tissue function were originally 
suggested to be mediated via four general mechanisms; 1) transcription factor function and 
cell signalling; 2) cell membrane and lipid raft fatty acid composition influencing membrane 
fluidity, protein composition and receptor function; 3) cell membrane fatty acid composition 
influencing production of fatty acid-derived bioactive mediators; 4) oxidative status [Calder, 
2012]. Recently, a fifth mechanism has been identified that involves signalling via lipid 
sensing G-protein coupled receptors (GPR), such as GPR120 and GPR40, that are 
activated by long chain fatty acids [Oh et al., 2010]. 
To start, the LC n-3 PUFA EPA and DHA are known to influence the peroxisome proliferator-
activated receptor (PPAR) and nuclear factor kappaB (NF-κB) signalling pathways. 
Specifically, LC n-3 PUFA serve as endogenous ligands for PPARα and PPARγ, which are 
important regulators of fatty acid metabolism, glucose homeostasis, cellular proliferation, 
differentiation and apoptosis and inflammation [Calder, 2012, Chinetti et al., 2000, Delerive 
et al., 2001]. PPARα is mainly expressed by hepatocytes and PPARγ is mainly expressed by 
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adipocytes, whereas macrophages express both [Chinetti et al., 2000, Delerive et al., 2001]. 
The activation of these PPARs by LC n-3 PUFA is in part responsible for their anti-
inflammatory and metabolic effects in adipocytes and macrophages, such as decreased 
inflammation and increased β-oxidation in macrophages and improved adipocyte 
differentiation, lipid storage and insulin sensitivity in adipocytes [Calder, 2012]. In addition, 
PPAR activation by LC n-3 PUFA inhibits the NF-κB signalling pathway which plays an 
important role in inflammation associated metabolic diseases, via direct binding of the 
PPAR-fatty acid complex to NF-κB thereby preventing the expression of NF-κB target genes 
[Baker et al., 2011]. Our group has shown that the basal NF-κB transcription factor activity 
was 80 % higher and the LPS-induced increase in NF-κB activity was 1.5 – 2 fold greater in 
APOE4 macrophages compared to APOE3 macrophages [Jofre-Monseny et al., 2007A]. 
Hence, the NF-κB signalling pathway provides a potential link between the APOE Epsilon 
genotype and their associated inflammatory and metabolic phenotype, which potentially can 
be reversed by LC n-3 PUFA. Although the interactive impact of APOE Epsilon genotype 
and fish oil on NF-κB signalling pathway remains to be investigated, Oliver et al. 
demonstrated that DHA decreased LPS-induced NF-κB activity in macrophages that in turn 
resulted in decreased adipocyte inflammation and maintained adipocyte insulin sensitivity 
[Oliver et al., 2012]. Noteworthy, the reduction in NF-κB activity was accompanied by a 
greater IL-10 production in both macrophages and adipocytes [Oliver et al., 2012], 
suggesting that suppression of the NF-κB pathway by LC n-3 PUFA is one mechanism via 
which LC n-3 PUFA exert their anti-inflammatory effects, such as increasing AT IL-10 
expression as we observed in the current study.  
The second important mechanism through which LC n-3 PUFA EPA and DHA exert anti-
inflammatory effects is through the formation of bioactive mediators, such as eicosanoids, 
resolvins and protectins, through a series of reactions involving cyclooxygenase (COX) and 
lipoxygenase (LOX) enzymes [Calder, 2009]. It is increasingly recognised that these 
mediators, in particular resolvins, play an important role in governing the inflammatory tone 
in obese AT [Claria et al., 2012, Titos and Clària, 2013]. For example, obese AT showed an 
increased production of the pro-inflammatory n-6 AA-derived leukotriene B4 (LTB4), with 
LTB4 triggering NF-kB activation and increasing production of MCP-1, TNF-α and IL-6 in AT 
explants [Horrillo et al., 2010]. Furthermore, the production of anti-inflammatory n-3 DHA-
derived mediators resolvin D1 (RvD1), resolvin D1 precursor (17-hydroxydocosahexaenoic 
acid, 17-HDHA) and protectin D1 (PD1) were decreased in obese AT, together with a 
marked decrease in markers of resolvin biosynthesis (18-HEPE, 17-HDHA) [Claria et al., 
2012, Neuhofer et al., 2013]. In other words, there appears to be a disturbed balance in the 
pro-inflammatory and anti-inflammatory bioactive mediator levels in obese AT. Using an 
elegant study design, Neuhofer et al. demonstrated that dietary EPA and DHA 
supplementation was able to restore the obesity-associated deficit in 17-HDHA and PD1 
levels together with mRNA levels of 12/15-LOX, an essential enzyme for 17-HDHA and PD1 
biosynthesis in mice, in epididymal AT [Neuhofer et al., 2013]. Moreover, Claria et al. 
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showed that RvD1 and RvD2 not only decreased inflammatory cytokine production and 
restored adiponectin levels in AT ex vivo, but also decreased the ex vivo MCP-1-induced 
monocyte adhesion to adipocytes and monocyte transmigration [Claria et al., 2012]. In line 
with this, Hellmann et al. showed that RvD1 treatment decreased the number of crown-like 
structures rich in pro-inflammatory M1 macrophages and the M1:M2 ratio in epididymal AT, 
and improved insulin sensitivity in db/db mice [Hellmann et al., 2011]. These findings clearly 
indicate an important role for eicosanoids and resolvins in AT inflammation in obesity, that 
provides a pivotal mechanism through which EPA and DHA exert their anti-inflammatory 
effects in AT. 
Finally, EPA and DHA can exert their anti-inflammatory effects through GPR such as GPR40 
and GPR120, which can be activated by long chain fatty acids [Hirasawa et al., 2005, Itoh et 
al., 2003]. GPR120 is the only receptor that is highly expressed in mature adipocytes and 
CD11c
+
 pro-inflammatory macrophages and has been shown to be essential in mediating 
the anti-inflammatory and insulin sensitising effects of EPA and DHA [Oh et al., 2010]. 
Briefly, Oh et al. demonstrated that fish oil supplementation reduced the HFD-induced 
accumulation of pro-inflammatory M1 (Cd11b
+
Cd11c
+
) ATM and improved insulin sensitivity 
in wild type C57BL/6 mice, but not in GPR120
-/-
 mice [Oh et al., 2010]. Also, fish oil induced 
the mRNA expression of M2 markers Arg1, Il10, Mgl1, Ym-1, MMR and decreased 
expression of M1 markers Il6, Mcp1, Il1β, Nos2, Cd11c in AT solely in wild type mice. These 
results illustrate the important role GPR120 plays in mediating the anti-inflammatory effects 
of fish oil. GPR120 activation has been shown to inhibit IKKβ / NF-κB (inhibitor of nuclear 
factor kappa-B kinase / nuclear factor kappa-B) and JNK / AP1 (c-Jun N-terminal kinase / 
activator protein-1) signalling pathways, providing a potential mechanism via which GPR120 
activation reduces inflammation [Oh et al., 2010].  
 
A strength of this study is that the human APOE TR mice express human APOE under 
control of the murine regulatory sequence and produce apoE at physiological levels. This 
gives us a complete in vivo model for direct comparison of APOE Epsilon isoform-specific 
effects. In addition, this mouse model allowed us to use an experimental design tailored 
specifically to answer our research question while controlling for many confounding intrinsic 
and environmental factors difficult to control for in human studies, such as genetic 
background and diet. This provided us significant power to evaluate the effects of APOE 
Epsilon genotype and fish oil on AT inflammation and LC n-3 PUFA status. Besides, in 
human studies it is difficult to study internal organs, such as the liver and visceral AT, 
because they are difficult if not impossible or unethical to collect. This mouse model 
provided free access to our tissue of interest (i.e. visceral AT) and enabled us to perform a 
thorough investigation into the role of apoE in AT biology, which is a strength of this study. 
 
In this study the number and phenotype of ATM were evaluated using flow cytometry and 
mRNA expression analysis. The first provided a qualitative measure of the cell surface 
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expression of phenotypic markers for every single cell, whereas the second provided a 
quantitative measure of the mRNA expression levels of these markers in whole tissue. 
Therefore, both methods complement each other. Immunohistochemistry is considered the 
gold standard providing quantitative data on the number, phenotype and localisation of 
macrophages in AT. This technique also allows the measurement of adipocyte size that 
provides insight into adipocyte hypertrophy, which is associated with macrophage infiltration. 
Future studies in human APOE TR mice should investigate adipocyte and macrophage 
phenotype using immunohistochemistry. 
As mentioned above, the CD11c flow cytometry data was collected using suboptimal 
instrument settings allowing the detection of only a small proportion of the CD11c-Alexa700 
signal and reduced our power to detect a small difference in the cell surface expression of 
the M1 phenotypic marker CD11c. It explains why we failed to identify any M1 ATM in the 
epididymal AT using flow cytometry and is a key limitation of the current study.  
Another limitation of this study is that we did not include a low-fat diet control group. The 
findings of this study suggest LC n-3 PUFA do not alter AT inflammation status and if we can 
speak of any trend, then LC n-3 PUFA selectively increase anti-inflammatory gene 
expression in AT in human APOE4 TR mice. Since this study did not include a low-fat diet 
control group, the HFD-induced inflammatory marker response in AT could not be 
determined. If the HFD-induced inflammatory response was only small or absent, it may 
explain the overall neutral effect of LC n-3 PUFA on AT inflammation in this study.  
We investigated the effects of LC n-3 PUFA on AT inflammation in a humanised mouse 
model which may not fully represent the response in humans, and is considered a limitation 
of this study. 
 
This study was most likely underpowered for flow cytometry analysis, mRNA expression 
analysis and analysis of the fatty acid composition in epididymal AT. Our study with n = 10 
mice per APOE Epsilon genotype * diet group was designed to detect a standardised mean 
difference (SMD) of 1.45 with power of 90 % at significance level of α = 0.05 (see Chapter 3 
Material & Methods). Using the variation data (i.e. standard deviation) obtained from this 
study for the outcomes ATM infiltration and phenotype and LC n-3 PUFA status in AT, we 
retrospectively determined the effect size (absolute mean difference) our study could detect 
with a power of 90 %. Our study only had the power to detect a 10 % absolute difference in 
percentage of percentage of M2 ATM in the SVF of the epididymal AT, whereas the 
difference between the APOE Epsilon genotypes was approximately 7 – 9%. Moreover, our 
study only had a power to detect a difference in Cd11c and Cd206 mRNA expression levels 
of 0.7 or larger, whereas the approximate difference between APOE Epsilon genotypes and 
diets was 0.5 or smaller. Thus overall our study was underpowered to detect an effect of 
APOE Epsilon genotype on ATM phenotype in flow cytometry and mRNA expression 
analysis. The absolute difference in EPA and DHA concentrations in the epididymal AT 
between APOE3 and APOE4 mice was approximately 0.2 and 0.3 %, whereas our study 
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only had the power to detect an absolute difference of 0.9 % and 2.0 % or larger for EPA 
and DHA concentrations. Hence our study was also underpowered to detect an effect of 
APOE Epsilon genotype on LC n-3 PUFA status in epididymal AT.  
 
In conclusion, our results indicate that APOE3 and APOE4 mice have a similar ATM 
infiltration rate that is increased by dietary fish oil. The ATM phenotype distribution in the 
epididymal AT was similar between the APOE Epsilon genotypes and was not influenced by 
dietary fish oil. However, the beneficial effect of dietary fish oil on IL-10 expression in 
epididymal AT was confined to mice with the APOE4 genotype. Although more research is 
needed to verify these results, it is tempting to speculate that the increased AT IL-10 
expression in APOE4 mice on HFD+FO represents an APOE Epsilon genotype-specific fish 
oil-induced response to control AT inflammation and maintain adipocyte insulin sensitivity. In 
contrary to previous reports, we observed no differential bioavailability of LC n-3 PUFA in 
epididymal AT of APOE3 and APOE4 mice. 
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Chapter 5. In vitro studies – macrophage polarisation: 
The impact of APOE Epsilon genotype on macrophage 
polarisation towards pro- (M1) and anti-inflammatory 
(M2) phenotype. 
Studies in primary murine bone marrow-derived APOE3 and APOE4 macrophages 
 
 
Introduction 
Macrophages govern adipose tissue inflammation 
The expansion of adipose tissue (AT) with obesity is associated with structural and 
functional changes and alterations in cellular composition and cell phenotype [Dalmas et al., 
2011, Ouchi et al., 2011]. Adipocytes increasingly store triglycerides becoming hypertrophic 
and start to secrete mediators that attract macrophages which infiltrate the expanding AT. 
The recruited macrophages (ATM) will predominantly acquire a pro-inflammatory (M1) 
phenotype and start to outnumber the resident ATM that have an anti-inflammatory (M2) 
phenotype [Weisberg et al., 2003, Wentworth et al., 2010]. The macrophage recruitment and 
phenotype switch towards the M1 phenotype are thought to be fundamental steps in AT 
inflammation resulting in AT dysfunction and subsequent systemic insulin resistance 
[Osborn and Olefsky, 2012]. A simplified M1/M2 phenotype model of macrophage 
polarisation has been introduced in Chapter 4 [Table 4.1, Morris et al., 2011]. Briefly, M1 
macrophages are classically activated pro-inflammatory macrophages that the express cell 
surface marker CD11c (integrin alpha X chain) and produce the pro-inflammatory cytokines 
tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-12 and reactive oxygen species (ROS). 
On the other hand, M2 macrophages are alternatively activated anti-inflammatory 
macrophages that express the cell surface marker CD206 (mannose receptor) and MGL1 
(macrophage galactose type C-type) and produce the anti-inflammatory cytokines IL-10, IL-1 
receptor antagonist (IL-1RA) and arginase (Arg). In summary, the ATM number and 
phenotype are important determinants of AT inflammation, AT function and metabolic health 
in obesity [Blüher, 2010, Lumeng et al., 2007B, Ouchi et al., 2011]. 
APOE Epsilon genotype and macrophage inflammatory state 
Besides its role in lipoprotein metabolism apolipoprotein E (apoE) has immunomodulatory 
properties [Jofre-Monseny et al., 2008A]. Previous research from our group has 
demonstrated that the APOE4 allele is associated with an exacerbated inflammatory 
response upon lipopolysaccharide (LPS) stimulation in murine RAW 264.7 macrophages 
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stably transfected with human APOE3 or APOE4 gene [Jofre-Monseny et al., 2007A]. In 
more detail, apoE4-expressing macrophages had increased IL-1β, TNF-α, and macrophage 
inflammatory protein (MIP)-α mRNA levels, increased TNF-α and decreased IL-10 protein 
levels, with no difference in IL-6 levels compared to apoE3-expressing macrophages. Only 
one study to date has specifically investigated the impact of apoE on macrophage 
polarisation towards M1 and M2 phenotypes. In this study, Baitsch et al. investigated the 
impact of exogenous apoE on macrophage phenotype in RAW 264.7 macrophages stably 
expressing the human apoE receptors, VLDL-receptor (VLDL-R) and apoE receptor-2 
(apoER2), and demonstrated that exogenous exposure to apoE (5 μg/mL for 24 hr) 
promoted a phenotypic switch from the pro-inflammatory M1 to the anti-inflammatory M2 
phenotype [Baitsch et al., 2011]. Although this study showed apoE exerts anti-inflammatory 
effects, it remains to be elucidated whether these effects are exerted in an isoform-
dependent manner. In conclusion, these findings support a potential impact of apoE on the 
macrophage inflammatory response and phenotype [Jofre-Monseny et al., 2007A, Baitsch et 
al., 2011], however future studies are needed to verify the impact of apoE Epsilon isoforms 
on macrophage polarisation. 
Research gaps 
Our understanding of how genetic determinants interact with the environment and lead to 
the development of metabolic disease is still limited [Osborn and Olefsky, 2012]. The 
macrophage-mediated AT inflammation leading to AT dysfunction has been recognised as a 
main pathological feature of systemic insulin resistance and systemic inflammation in 
obesity. However, knowledge of the regulation of AT inflammatory status is incomplete 
including the factors that direct the polarisation state of ATM to either a pro- or anti-
inflammatory phenotype [Osborn and Olefsky, 2012]. 
The described effect of apoE4 on the inflammatory response and the effect of apoE on 
macrophage polarisation were reported in the murine RAW 264.7 cell line, which naturally 
produces low levels of apoE [Jofre-Monseny et al., 2007A, Baitsch et al., 2011]. Jofre-
Monseny et al. transfected the cells with mammalian expression vectors to induce 
endogenous apoE3 or apoE4 expression, whereas Baitsch et al. coincubated cells with 
exogenous apoE. Since both studies have not used primary cells and cells that naturally 
express apoE3 and apoE4 at physiological levels, the acquired phenotype may not fully 
represent of what happens in the body. Furthermore many in vitro studies employ supra-
physiological concentrations of compounds therefore their findings may not reflect a 
physiological response but rather an adaptation to the stimulus (i.e. hormesis). Thus, the 
impact of APOE Epsilon genotype on inflammatory status in the more habitual basal state is 
still unknown.  
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Research question 
The aim of this study was to investigate the impact of APOE Epsilon genotype on the ‘basal’ 
pro- and anti-inflammatory phenotype in primary murine bone marrow-derived macrophages 
(BMM). 
Hypotheses 
This study will investigate the ‘basal’ pro- and anti-inflammatory phenotype in primary murine 
BMM obtained from human APOE targeted replacement (TR) mice that express apoE at 
physiological levels [Sullivan et al., 1997]. The mice will not be exposed to a dietary stressor 
(nutrient and fat surplus) like our previous in vivo studies or an inflammatory stimulus like 
previous in vitro studies. In Chapter 4 our flow cytometry data suggested that the APOE4 
allele is associated with a greater abundance of macrophages and a higher prevalence of 
the M2 phenotype in the stromal vascular fraction (SVF) of disaggregated epididymal AT, 
although mRNA expression analysis did not corroborate this. Thus we first want to 
understand as to whether there is a difference in macrophage polarisation according to 
APOE Epsilon genotype, i.e. is the APOE4 allele associated with higher expression of the 
anti-inflammatory M2 phenotype in macrophages compared to APOE3 allele?  
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Materials & Methods 
Primary BMM were obtained from the human APOE TR strain, which we have also used for 
our in vivo studies (see Chapter 3 and 4). Flow cytometry analysis allowed characterisation 
of the BMM phenotype using the cell surface expression of the macrophage phenotype 
markers; CD11b (macrophage marker), CD11c (M1 marker) and CD206 (M2 marker). 
Bone marrow-derived macrophages isolation and culture 
BMM were obtained from six 11 – 20 week old male human APOE3 and APOE4 TR mice (n 
= 3 per APOE Epsilon genotype). The APOE3 and APOE4 TR mice are homozygous for the 
human APOE3 or APOE4 gene by targeted replacement of the endogenous mouse apoe 
gene with human APOE3 or APOE4 gene, as previously described (Chapter 3). Male mice 
were used to match our previous in vivo studies (Chapter 3 and 4). Mice were fed a 
palletized maintenance diet (Rat and Mouse No.3 Breeding Expanded diet (RM3); SDS 
Diets, Essex, UK) (Table 5.1), housed in groups of two to five per cage, allowed free access 
to food and water and maintained under a 12 h light – 12 h dark cycle (7 am – 7 pm) in a 
temperature-controlled environment (21 °C, humidity 55 %) in pathogen-free facility at the 
University of East Anglia.  
 
Table 5.1. Composition of the maintenance diet. 
Macronutrients (kcal%)  
Protein 27 
Carbohydrate 61 
Fat 12 
Total 100 
Kcal/g 3.31 
Fatty acid composition (%)  
12:0 0.05 
14:0 0.17 
16:0 0.37 
18:0 0.11 
16:1 n-7 0.09 
18:1 n-9 1.01 
18:2 n-6 1.26 
18:3 n-3 0.17 
20:4 n-6 0.12 
 
Bone marrow-derived macrophage culture - materials 
Macrophage medium composed of Roswell Park Memorial Institute (RPMI) 1640 with L-
glutamine (2 mmol/L); 1 % sodium pyruvate; 1 % non-essential amino acids; 1 % penicillin-
streptomycin (10000 IU/ml); 24 µM β-mercaptoethanol; 10 % fetal calf serum; and 10 % L-
conditioned medium. L-conditioned medium was source of L-929 murine fibroblast cell 
culture, which produce colony stimulating factor-1, also known as macrophage colony-
stimulating factor (M-CSF), that controls the survival, proliferation and differentiation of 
monocytes, macrophages and its progenitor cells from bone marrow [Manzanero, 2012]. L-
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929 cells were cultured in Dulbecco's modiﬁed Eagle's medium (DMEM) (4500 mg/L 
glucose, 1 % L-glutamine, 1 % sodium pyruvate, 1 % PS (10000 IU/ml), 10 % FCS) in 75 
cm
2
 flasks until confluent at 5 % CO2, 37 °C, then lids of the flask were closed, and medium 
was left to condition with CSF-1 for 3 weeks. After three weeks, L-conditioned medium was 
aspirated and centrifuged, supernatants were pooled and sterile filtered (0.2 µm), 5 ml 
aliquots were stored at -20 °C until use. All culture medium ingredients were obtained from 
Life Technologies, Paisley, UK. 
Bone marrow-derived macrophage culture - protocol 
Bone marrow was removed from femurs by flushing with 20 ml of macrophage medium 
using a 25-G needle and syringe. Cells were counted on the Cellometer Auto T4 Cell 
Viability Counter (Nexcelom Bioscience, Lawrence, Massachusetts U.S.A), centrifuged for 5 
min at 1000 rcf and resuspended at 1 x 10
6
 cells/ml, and plated (11 ml, 1 x 10
6
 cells/ml) onto 
bacteriological petri dishes (Falcon©, BD Biosciences, Oxford, UK) and incubated at 5 % 
CO2, 37 °C. After three days, non-adherent stem cell population was removed and plated 
onto new bacteriological petri dishes (11 ml, 1 x 10
6
 cells/ml) and incubated (5 % CO2, 37 
°C). After seven days, the non-adherent population was discarded and adherent BMM were 
scraped into fresh medium and immediately used for flow cytometry experiments.  
Flow cytometry analysis 
Flow cytometry analysis was performed as described in Chapter 4. Briefly, BMM were 
resuspended in 100 μl PBS with 10 mM D-glucose and 1 % bovine serum albumin (BSA) (1 
x 10
6
 cells/ml); incubated with the antibodies at the recommended concentrations, CD11b-
PE, 0.2 mg/ml (BD Biosciences), CD11c-Alexa700, 0.2 mg/ml (eBiosciences), CD206-FITC, 
0.1 mg/ml (AbD Serotec); and immediately analysed using BD Accuri™ C6 (BD 
Biosciences). Isotype controls were used to determine non-specific binding; single stain and 
fluorophore minus-one (FMO) controls were used to set gates and compensation; and a 
representative sample incubated with 7-AAD (BD Biosciences) was used to assess cell 
viability. For each sample, data of 30,000 events were collected using the gate capturing our 
target cell population (CD11b
+
 cells) as follows; CD11b-PE, 488 nm laser with 585/40 BP 
filter; CD206-FITC, 488 nm laser with 533/30 BP filter; CD11c-Alexa700, 640 nm laser with 
670/LP; 7-AAD, 488 nm laser with 675/25 BP filter. Forward and backward-gating strategies 
were used to 1.) validate our gate capturing our target cell population (CD11b
+
 cells); 2.) 
verify our target cell population consisted of single cells; 3.) confirm that debri and cells 
excluded from analysis showed no expression of the markers of interest (data not shown). 
Compensation was set as described in Chapter 4 using target cell populations stained for 
only one of the markers of interest (single stain samples) so that the median of negative cell 
populations were similar (Table 5.2). No compensation was needed for CD11c-Alexa700-
670/LP into 533/30 or 585/40 BP filter.  
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Table 5.2. Spillover table.  
Spillover (%) 
CD206-
FITC 
533/30 
CD11b-
PE 
585/40 
7-AAD 
675/25 
CD11c-
Alexa700
670/LP 
CD206-FITC 533/30 
 
3.40 N/A 0.00 
CD11b-PE 585/40 1.90 
 
N/A 0.00 
7-AAD 675/25 N/A N/A 
 
N/A 
CD11c-Alexa700 670/LP 2.50 0.00 N/A 
 
 
In this study, on average 31 ± 7 (SD) % of all events were within our target cell population. 
Off the cells within our target cell population 99.5 ± 0.1 % were CD11b
+
. The cell viability 
was 89 ± 2 % (n = 2). 
Statistical analysis 
Two-tailed Student’s t-test was used to test for differences between the APOE Epsilon 
genotypes and considered statistically significant when p < 0.05. All statistical analysis was 
performed using SPSS 18.0.  
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Results 
In this study we investigated the cell surface expression of CD11b, CD11c, and CD206 in 
primary murine BMM obtained from human APOE3 and APOE4 TR mice to determine the 
impact of the APOE Epsilon genotype on the ‘basal’ pro- and anti-inflammatory macrophage 
phenotype.  
Here, we report that the APOE4 allele is associated with a higher percentage of BMM with 
an anti-inflammatory M2 phenotype and a non-significant trend towards a lower percentage 
of BMM with a pro-inflammatory M1 phenotype compared to APOE3 allele (Table 5.3). 
Briefly, APOE4 BMM showed a higher cell surface expression of the M2 marker CD206 
compared to APOE3 BMM (41.4 % vs. 30.5%, p < 0.05), with no significant difference in M1 
marker CD11c expression (1.7 % vs. 2.2 %, p = 0.76) or the M1 to M2 ratio (0.04 vs. 0.08 , p 
= 0.53) (Figure 5.1). BMM with the pro-inflammatory M1 phenotype (CD11b
+
CD11c
+
CD206
-
 
cells) were the smallest cell population identified, consisting of approximately 2.0 ± 0.8 
(SEM) %. In addition, we identified approximately 10.8 ± 3.9 % of the BMM as double 
positive cells (CD11b
+
CD11c
+
CD206
+
). There were no differences in the percentage of BMM 
(CD11b
+
 cells) obtained from the APOE3 and APOE4 BMM cultures, which yielded 99% 
CD11b
+
 cells.  
 
Table 5.3. Prevalence of the pro- (M1) and anti-inflammatory (M2) phenotype in primary murine 
bone marrow-derived macrophages according to APOE Epsilon genotype. 
 
APOE3 APOE4 
CD11b
+
 cells  
(% of total) 
98.8 ± 0.1
 
99.0 ± 0.2
 
CD11b
+
CD11c
+
CD206
-
 cells (M1) 
(% of CD11b
+
 cells) 
2.2 ± 1.4
 
1.7 ± 0.9
 
CD11b
+
CD11c
-
CD206
+
 cells (M2) 
(% of CD11b
+
 cells) 
30.5 ± 1.8
a 
41.4 ± 3.0
b 
CD11b
+
CD11c
+
CD206
+
 cells 
(% of CD11b
+
 cells) 
6.8 ± 3.9 14.8 ± 6.8 
M1:M2 ratio 0.08 ± 0.05  0.04 ± 0.03  
All values are mean ± SEM, n = 3 primary bone marrow-derived macrophage (BMM) cultures per 
APOE Epsilon genotype. CD11b
+
 cells are CD11b
+
 cells within our set target cell population; 
CD11b
+
CD11c
+
CD206
-
 (M1), CD11b
+
CD11c
-
CD206
+
 (M2) and CD11b
+
CD11c
+
CD206
+
 cells are 
percentage of CD11b
+
 cells; the M1:M2 ratio presents the ratio of CD11b
+
CD11c
+
 to CD11b
+
CD206
+
 
cells. Student’s t-test was used to determine differences between the APOE Epsilon genotypes, 
different letters indicate different means, p < 0.05.  
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A       B 
  
Figure 5.1. Pro- (M1) and anti-inflammatory (M2) phenotype marker expression in primary 
murine bone marrow-derived APOE3 (black bars) and APOE4 (white bars) macrophages. The 
cell surface expression of CD11b (macrophage marker), CD11c (M1 marker) and CD206 (M2 
marker) was analysed using flow cytometry. [A] Macrophages with pro-inflammatory M1 
phenotype were CD11b
+
CD11c
+
CD206
-
; macrophages with anti-inflammatory M2 phenotype 
were CD11b
+
CD11c
-
CD206
+
; Double positive (Double+) macrophages were 
CD11b
+
CD11c
+
CD206
+
; data presented as percentage of CD11b
+
 cells. [B] The M1:M2 ratio was 
ratio of CD11b
+
CD11c
+
CD206
-
 to CD11b
+
CD11c
-
CD206
+
 macrophages. Data is presented as 
mean ± SEM (n = 3). Student’s t-test was used to determine differences between the APOE 
Epsilon genotypes, *p < 0.05. APOE, apolipoprotein E; CD11b, integrin alpha M; CD11c, Integrin 
alpha X; CD206, mannose receptor C type 1. 
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Discussion 
In this study we investigated the cell surface expression of CD11b, CD11c, and CD206 in 
primary murine APOE3 and APOE4 BMM obtained from human APOE TR mice to 
determine the impact of the APOE Epsilon genotype on the ‘basal’ pro- and anti-
inflammatory macrophage phenotype. Here, we report that the APOE4 allele was associated 
with a higher cell surface expression of CD206, but not CD11c, in BMM compared to APOE3 
allele, indicating a higher prevalence of the anti-inflammatory M2 phenotype and no 
difference in the prevalence of the pro-inflammatory M1 phenotype. There was no difference 
in the M1 to M2 ratio between APOE3 and APOE4 BMM cultures indicating a similar M1:M2 
phenotype distribution. 
 
Baitsch et al. were the first to investigate the impact of apoE on macrophage polarisation in 
vitro using RAW 264.7 murine macrophages stably expressing human apoE receptors 
VLDL-R and apoeR2 and demonstrated that exogenous exposure to apoE promoted a 
phenotypic switch from M1 to M2 phenotype [Baitsch et al., 2011]. In more detail, 
macrophages exposed to apoE (5 μg/mL for 24 hr) showed increased expression of M2 
markers and cytokines (arginase 1 (Arg1), found in inflammatory zone/resistin-like molecules 
(Fizz/Relm), suppressor of cytokine signaling 3 (Socs3), IL-1RA, granulocyte colony-
stimulating factor (G-CSF), IL-13), and reduced expression of M1 cytokines (MIP-1α, IL-12). 
These changes were accompanied by functional characteristics of M2 macrophages, i.e. 
reduced migration, attenuated ROS production, and increased phagocytic activity. These 
findings clearly indicate a role for apoE in modulating macrophage polarisation, although a 
potential isoform-dependent effect was not investigated. We are the first to demonstrate that 
endogenous expression of apoE4 was associated with a higher prevalence of the M2 
phenotype compared to apoE3 using cell surface marker expression analysis and flow 
cytometry. Future experiments should corroborate these findings by looking at mRNA 
expression levels of M1 and M2 markers, especially since we have shown that CD11b, 
CD11c and CD206 mRNA expression levels may not reflect their cell surface expression 
levels (Chapter 4). Moreover, the functional characteristics of macrophages, such as 
migration, ROS production, and phagocytic activity, should be investigated to confirm a 
differential macrophage phenotype. Our findings contradict with the previously reported 
immunomodulatory properties of apoE indicating that apoE4 is pro-inflammatory [Jofre-
Monseny et al., 2008A]. An explanation for these conflicting results is that we investigated 
the impact of apoE4 in a basal unstimulated state, whereas most other studies have 
investigated the impact of apoE4 upon stimulation with a pro-inflammatory stimulus, such as 
LPS [Jofre-Monseny et al., 2008A]. This warrants further investigation into the impact of 
APOE4 allele on macrophage phenotype in both basal state and upon stimulation with an 
inflammatory stimulus.  
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We identified approximately 10 % of the BMM as double positive cells for CD11c and CD206 
(CD11b
+
CD11c
+
CD206
+
) suggesting these macrophages have an intermediate phenotype 
between M1 and M2 and macrophages can potentially ‘switch phenotypes’, which has been 
implicated before [Morris et al., 2012]. Morris et al. proposed a new nomenclature for ATM to 
capture their phenotypic heterogeneity in both mice and humans describing the four best 
characterized types identified in mice and humans. Their classification distinguished 
between CD11c
+
CD206
-
, CD11c
+
CD206
+
 and CD11c
-
CD206
+
 macrophages, with 
CD11c
+
CD206
-
 and CD11c
+
CD206
+
 macrophages (formerly both M1, here two different 
subtypes) showing distinct gene expression profiles and potentially different functions. Thus, 
macrophages can display an intermediate phenotype and ‘switch’ between M1 and M2 
phenotypes under the influence of their microenvironment [Morris et al., 2011]. This is 
relevant given that AT macrophages undergo changes in their activation state to promote AT 
inflammation during obesity [Lumeng et al., 2007B, Li et al., 2010] and CD11c
+
 ATM have 
been associated with glucose intolerance and metabolic syndrome in humans [Wentworth et 
al., 2010, Wu et al., 2009]. Thus, research into potential factors, including APOE Epsilon 
genotype, to determine macrophage phenotype switching will be important for our 
understanding of how macrophage phenotype switching may potentially determine AT 
inflammation and subsequent disease risk. 
 
Our APOE3 and APOE4 BMM cultures yielded approximately 99% CD11b
+
 cells. CD11b is 
a cell surface marker for monocytes and macrophages, although it can also expressed by 
natural killer cells, activated T-cells and B-cell subsets. We used conditioned medium 
containing macrophage colony-stimulating factor (M-CSF), a specific growth factor inducing 
macrophage differentiation of myeloid cells, to selectively culture macrophages from bone 
marrow stem cells [Manzanero, 2012]. Therefore, we are sure that we have studied 
macrophages derived from bone marrow stem cells.  
 
A strength of this study was the use of primary BMM cultures, which yield a homogeneous 
not-yet-activated macrophage population. An alternative method to obtain primary 
macrophages would be to isolate peritoneal cavity cells from mice. However, this method 
produces a heterogeneous cell population consisting of approximately 53 % B-cells, 40 % 
macrophages, and 6 % T-cells, with the potential risk of contamination with blood cells if the 
peritoneal lavage is not performed carefully. Thus a strength of our primary BMM model was 
that we were able to investigate the effect of the APOE Epsilon genotype on macrophage 
phenotype polarisation in a homogeneous macrophage cell population in a basal (not-
activated) state.  
The primary BMM were obtained from human APOE3 and APOE4 TR mice which are 
homozygous for the human APOE3 or APOE4 gene by targeted replacement of the 
endogenous mouse Apoe gene. In these mice, the expression of the human apoE3 or 
apoE4 isoform is under the control of the murine Apoe regulatory sequence and as a result 
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apoE3 and apoE4 are produced at physiological levels. Therefore, another strength of our 
study compared to the only previous study reporting an effect of apoE on macrophage 
phenotype polarization [Baitsch et al., 2011] is that we used primary cells endogenously 
expressing human APOE at physiological levels, whereas Baitsch et al. exposed a murine 
cell line to exogenous human apoE. 
We used methods and primary BMM from male mice similar to those used in our in vivo 
studies (Chapter 3 and 4), which allowed us to directly compare the findings from both 
studies. Compared to Chapter 4, we used in this study modified instrument settings for the 
detection of Cd11c-Alexa700 with 640 nm laser and 670/LP filter using flow cytometry, which 
provided more reliable information on CD11c cell surface expression of BMM.  
 
The main limitation of this study is that the data on the impact of apoE4 on the macrophage 
phenotype is limited to the basal unstimulated state only. Most studies have investigated the 
impact of apoE4 upon stimulation with a pro-inflammatory stimulus [Jofre-Monseny et al., 
2008A]. Therefore, conclusions can only be drawn after comparison with stressor-induced 
responses has been made.  
Another generic limitation of our study in that we evaluated the impact of APOE Epsilon 
genotype on macrophage phenotype in an in vitro primary murine cell model, which may not 
fully represent the macrophage cell behavior in vivo in humans. 
A potential limitation of our cell culture protocol was the use of M-CSF to selectively grow 
macrophages from bone marrow stem cells, as M-CSF is a growth factor known to induce a 
M2 phenotype in macrophages [Jaguin et al., 2013]. This might have directed the phenotype 
of the BMM towards the M2 phenotype in our study. If there was any effect of M-CSF on 
macrophage polarisation in this study, it would indicate that APOE4 BMM might be more 
responsive to M-CSF-induced M2 polarisation than APOE3 BMM. 
 
In conclusion, we demonstrated that the APOE4 allele is associated with a higher 
prevalence of the M2 phenotype in BMM in the basal state which may represent a natural 
protective response to counterbalance the previously reported pro-inflammatory properties 
of apoE4 compared to apoE3. Future studies investigating the impact of the APOE4 allele 
on the macrophage phenotype in both basal state and upon stimulation with inflammatory 
stimulus are needed to determine if this protective effects of the APOE4 allele on 
macrophage phenotype polarisation also persists in the presence of an inflammatory 
stimulus. 
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Chapter 6. General discussion: Obesity, adipose tissue 
inflammation, APOE genotype and long chain n-3 
polyunsaturated fatty acids 
Summary of results and general discussion 
 
 
Main findings 
In this PhD project, we investigated the relationships between apolipoprotein E (APOE) 
Epsilon genotype, adiposity, long chain (LC) n-3 polyunsaturated fatty acids (PUFA) status 
and inflammation. In line with the small amount of recent emerging literature, we observed 
that APOE3 is an energy-thrifty allele associated with the development of obesity and its 
associated metabolic complications, whereas APOE4 is an energy-dissipative allele that 
appears to protect against the development of obesity. In addition, we observed a trend that 
APOE4 allele is associated with altered LC n-3 PUFA metabolism and bioavailability. Novel 
observations have been made that show no effect of the APOE Epsilon genotype on high fat 
diet (HFD)-induced macrophage infiltration and macrophage phenotype distribution in 
visceral AT. Finally, we are the first to show that APOE Epsilon genotype interacted with a 
single nucleotide polymorphism (SNP) in the APOE promoter region to determine plasma 
inflammatory marker concentrations in humans, which may have implications for disease 
risk. This demonstrates the importance of considering common genotypes in combination 
with often subtle effects of individual SNPs in either the same gene region or in genes in 
related metabolic pathways that have additive or even synergistic effects, and result in a 
highly significant combined impact on the phenotype of interest. Altogether this PhD project 
contributes to our understanding of the potential mechanisms through which APOE Epsilon 
genotype modulates disease risk and is an important lead for future nutrigenetics research. 
General discussion 
Single SNPs and diet-gene interactions 
It has become clear that the effects of diet on health may be dependent on an individual’s 
genetic background. A full understanding of the interplay between diet and genes to 
determine human health will have important implications for public health. It will not only tell 
us what a person’s nutrient needs are based on their genetic predisposition, but also how 
this person will respond to dietary intervention and intake, which forms the basis of 
personalised nutrition.  
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SNPs in the coding and non-coding region of genes can influence the function and 
expression of a gene that in turn can predispose an individual to certain diseases or nutrient 
deficiencies. For example, a SNP may influence the uptake, metabolism and/or 
bioavailability of ingested nutrients or bioactive food compounds. This could influence the 
individual’s response to dietary intake. The association between SNPs (i.e. genetic variants) 
and disease phenotypes are studied using two different approaches. The first approach is a 
candidate gene or single SNP study that investigate the impact of a single SNP on a disease 
phenotype. Candidate gene studies focus on genes that are selected based on an a priori 
hypothesis about the role of that gene in the disease aetiology or underlying biological 
pathways. The second approach is a genome-wide association study (GWAS) which 
investigates the impact of many SNPs (over 10,000) on a disease phenotype. GWAS do not 
require a priori hypothesis but require thousands of subjects. GWAS are often useful for 
screening the genome for candidate genes for complex traits and diseases, but are typically 
unable to establish disease causality or differentiate between the effects of variants in 
linkage disequilibrium (LD). Initially most studies were candidate gene studies, but the 
advances in technology have allowed the analysis of many SNPs (up to 3,000,000) on a 
single chip opening the door to larger GWAS. A great advantage of GWAS compared to 
candidate gene studies is that it allows the investigation of the impact of single SNPs in the 
context of other SNPs (i.e. its genetic context). The effect of an individual SNP may be 
modest but collectively they may have a significant larger effect on specific traits. Also the 
incorporation of the knowledge about the relationship between individual SNPs can help to 
identify clusters of genes influencing underlying molecular mechanisms of complex traits. 
GWAS have been shown to be useful for nominating candidate genes for traits that have 
high heritability and low experimental variability, such as the APOE gene for Alzheimer’s 
Disease [Bertram et al., 2007]. However, the identification of genetic loci involved in more 
complex disease phenotypes, such as obesity [Hebebrand et al., 2010] and insulin 
resistance [Harrington and Phillips, 2014], have been proven to be more difficult. Although 
single genes, such as fat mass and obesity-associated (FTO) gene, have been identified for 
the risk of obesity and BMI, more than 95 % of the genetic variation in BMI remains 
unaccounted for [Hebebrand et al., 2010]. The failure to identify the genetic variants that 
determine complex traits such as BMI may be caused by the small effect size of SNPs or 
rare SNPs may play a more important role than initially anticipated [Frazier-Wood, 2015]. In 
addition, SNPs may interact with environmental factors, such as diet and exercise, to 
determine BMI. For example, the genetic variant -1131T/C (rs622799) in the apolipoprotein 
A-V (APOA5) gene has been shown to modulate the effect of dietary fat intake on BMI and 
obesity risk [Corella et al., 2007].  Thus the identification of SNPs with small effect size that 
potentially interact with diet have been proven to be difficult for complex traits. However, 
complex diseases are often highly heritable and human health results from complex 
interactions between genetic predisposition and the environment in which the genes 
manifest. Furthermore, genetic variants may account for the large inter-individual variation in 
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the response to dietary intervention. Therefore, large GWAS including tens of thousands 
individuals that take into account important environmental factors including diet are needed 
to unravel the genetic heritability of complex traits and indentify diet-gene interactions to 
determine complex disease phenotypes such as obesity.  
Candidate gene studies and GWAS look for an association between genetic variants and a 
disease phenotype, but tell us nothing about the cause-effect relationship. Therefore, 
subsequent animal and human studies are needed to elucidate the mechanistic link between 
a genetic variant and disease phenotype. 
Biomarkers of inflammation 
Many metabolic diseases including atherosclerosis, Type 2 Diabetes Mellitus (T2DM) and 
obesity have an inflammatory component [Calder et al., 2011A, Hansson, 2005]. Dietary 
intervention studies investigating the effect of genetic and/or dietary factors on inflammation 
should ideally investigate the inflammatory process in the tissue of interest, i.e. brain, liver or 
adipose tissue (AT). However, many internal organs and tissues are not easily if not 
impossible or unethical to collect in human volunteers. This asks for the identification of 
sensitive biomarkers of inflammation. The biomarkers must reflect the inflammatory process 
that is studied and be predictive of future health or disease status [Biomarkers Definition 
Working Group, 2001]. 
In human studies blood samples are in general readily available and inflammation is often 
determined using soluble or cellular markers in blood. Common soluble plasma markers of 
inflammation include cytokines, chemokines, lipids, acute-phase proteins and adhesion 
molecules, whereas common blood cellular markers of inflammation include various 
subclasses of leukocytes [Calder et al., 2013]. Plasma markers of inflammation are the sum 
of inflammatory mediators produced by blood cells and those leaking into the circulation 
from the inflammatory site (i.e. AT, brain, gastrointestinal tract, vascular wall and more) 
[Calder et al., 2013]. They provide a measure of systemic inflammatory status, but may not 
fully reflect tissue inflammatory status, which is a important limitation. Moreover, there is a 
wide inter-individual variation in plasma markers of inflammation which are affected by 
various factors including age, body fatness, physical (in)activity, gender, genetic variants, 
smoking, gut microbiota, diet, use of medications and other factors such as emotional stress, 
pollution, viral infection and sleep behaviour [Calder et al., 2013]. Single circulating 
biomarkers of inflammation have been shown to be often not informative but rather patterns 
and clusters may be important as robust biomarkers of inflammation [Calder et al., 2013]. 
Whole blood samples are also a source of human peripheral blood mononuclear cells 
(PBMC), which include monocytes and lymphocytes. PBMC circulate through the body and 
are exposed to metabolic tissues and may therefore reflect systemic health. The immune 
response capacity of PBMCs in vitro and the PBMC inflammatory gene expression in vivo 
have been used as biomarkers of inflammation in human dietary intervention trials [Afman et 
al., 2014]. The omics technologies have allowed the large scale analysis of genes 
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(genomics), mRNA (transcriptomics), proteins (proteomics) and metabolites (metabolomics). 
Whole genome transcriptomics of PBMC have provided a powerful tool to study the effect of 
dietary bioactive compounds on the expression of genes involved in metabolism and/or 
inflammatory processes [Afman et al., 2014, Bouwens et al., 2009]. Whole genome 
transcriptomics of PBMC have been proven to be a more sensitive tool than plasma 
biomarkers of inflammation for the detection of the effects of LC n-3 PUFA on inflammatory 
marker expression [Afman et al., 2014, Bakker et al., 2010, Myhrstad et al., 2011 B]. 
Furthermore, the PBMC transcriptome has been shown to reflect white AT inflammation but 
not lipid metabolism, and thus may partly reflect AT biology [O’Grada et al., 2014]. Finally 
whole genome transcriptomics of PBMC enables annotation and pathways analysis that will 
provide more insight into underlying molecular mechanisms and have the benefit of 
integrating diverse biological processes such as metabolism and inflammation. In summary, 
whole genome transcriptomics of PBMC are a more sensitive biomarker of inflammation 
than circulating markers, provide a sensitive tool to investigate the effects of LC n-3 PUFA 
on inflammatory processes, and could potentially explain why some individuals seem to 
respond to an intervention but others do not [Afman et al., 2014, Ulven et al, 2014]. 
It has been suggested that the dynamic response to a challenge (e.g. inflammatory) will 
provide a more relevant, sensitive and better interpretable indicator of health and the impact 
on inflammatory homeostasis and inflammatory resilience (i.e the control of an acute 
inflammatory response) [Calder et al., 2013, Huber et al., 2011, Van Ommen et al., 2009]. 
Finally, the integration of data from various omics technologies including those from the 
genome, epigenome, metabolome, proteome, microbiome with the use of the computational 
methods and predictive mathematical models may allow the identification of even more 
sensitive and early biomarkers for pre-disease states.  
In conclusion, PBMC are an accessible tissue and whole genome transcriptomics of PBMC 
provide at present a sensitive tool to investigate the effects of genetic variants and/or dietary 
factors on inflammatory and metabolic processes. Future studies integrating data from omics 
technologies may lead to the discovery of even more sensitive biomarkers of inflammation. 
Extrapolation of findings from animal models to humans 
The mouse (Mus musculus) is the most commonly used laboratory animal. Many inbred and 
outbred, knock-in and knock-out, and genetically modified strains are available, which 
provide useful models for human diseases, such as atherosclerosis, diabetes mellitus, and 
cancer. Although human and mouse anatomy, physiology and genetics show many 
similarities there are also considerable differences between the two species. For example, 
mice are smaller and thus have a higher metabolic rate and accelerated lifespan (one 
mouse year equals about 30 human years).  
There are some important differences between mice and humans when it comes to the 
development of obesity. Unlike humans, mice are generally resistant to obesity (with 
exception of several genetically modified strains) and require high fat diet (45 to 60 kcal% 
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from fat) feeding to develop obesity. The AT depots show great similarity between mice and 
humans. Most of white subcutaneous and visceral fat depots found in humans have an 
equivalent in mice. For example, the periovarian fat depot is found both in humans and mice. 
The epididymal fat depot that we studied in the mice in Chapter 3 and 4, however knows no 
human equivalent. The amount of brown fat differs between mice and humans. Mice have 
relatively more brown fat, because this tissue plays an important role in the regulation of 
body temperature in small rodents.  
Human and mouse metabolism show many similarities, but there are also some differences. 
As mentioned earlier mice have a much higher metabolic rate. In addition, the cholesterol 
metabolism is somewhat different between the species. Humans carry cholesterol in their 
blood mainly in low-density lipoprotein (LDL) and to lesser extent in high-density lipoprotein 
(HDL). Whereas mice carry cholesterol mainly in HDL and to lesser extent in LDL in their 
blood. In humans, LDL cholesterol levels are considered the ‘bad cholesterol’ because it 
increases the risk of cardiovascular disease, but this may not apply to mice.  
Mice are popular laboratory animals to create genetically modified strains. Mouse genes can 
be replaced with human genes to study gene function and to produce a more human-like 
model system in the mouse. A humanised mouse model provides a promising tool to study 
the effect of human genetic variants on gene and protein function. In Chapter 3 and 4, we 
used human APOE targeted replacement mice as a model system to study the function of 
the common human APOE Epsilon allelic variants. A strength of humanised mouse models 
is that one can control for many genetic and environmental factors such as diet which are 
difficult to control in human studies. However, the human gene is expressed in the genetic 
context of the mouse genome and although murine genes and proteins show high-degree of 
homology with human genes and proteins, slight differences between mouse and human 
proteins may influence the function of the human protein in the mouse model system. This 
potential limitation of a mouse model system has been illustrated in an in vitro study which 
showed that human apoE required the expression of human apoE receptors for its full effect 
in the murine RAW 264.7 cell line [Baitsch et al., 2012]. Therefore the findings of a human-
like model system in the mouse may not directly be extrapolated to humans.  
In summary, mouse models provide a promising tool to study the impact of human genetic 
variants and/or dietary bioactive food compounds on health outcomes and the underlying 
molecular mechanism. In doing so mouse models provide an important lead for future 
human studies, as findings from animal studies often cannot be directly extrapolated to 
humans. 
Fish consumption versus long chain n-3 PUFA supplementation 
An important point of discussion is whether dietary recommendations for LC n-3 PUFA 
should include recommendations for (oily) fish consumption and/or LC n-3 PUFA  
supplements. The bioavailability, efficacy and health benefits of eicosapentaenoic acid 
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(EPA) and docosahexaenoic acid (DHA) derived from supplements compared that of (oily) 
fish consumption are namely still under debate.  
The bioavailability of EPA and DHA may be affected by the food matrix and chemical form of 
EPA and DHA present in supplements and fish, as they appear to influence the digestion 
and absorption of EPA and DHA in humans. Furthermore, the dietary fat content of a meal is 
known to impact on the digestion and absorption of EPA and DHA [Schuchardt and Hahn, 
2013], which may be specially an important determinant of the bioavailability of EPA and 
DHA from supplements. Supplements are namely often taken in the morning with breakfast 
which is usually a low-fat meal. The chemical structure of EPA and DHA in supplements, 
which can be either as free fatty acids (FFA), ethylesters (EE), phospholipids (PL) or 
triglycerides (TG), affects the bioavailability of EPA and DHA in humans [Schuchardt and 
Hahn, 2013]. In fish, EPA and DHA are mainly present as TG and to a lesser extent present 
as FFA. The naturally-occuring TG in fish and chemically-modified TG in supplements 
appear to have the highest bioavailability in humans.  
Although an LC n-3 PUFA intake of > 1 g/d corresponding to consumption of > 4 portions of 
fish a week may be difficult to achieve by diet alone, an intake of about 0.5 g/d can in 
general easily be achieved through fish consumption (2 portions per week) or supplements. 
However, the overall health benefits of LC n-3 PUFA derived from fish consumption may 
differ from those derived from supplements. Fish is namely a source of other nutrients such 
as vitamin D, selenium, iodine and antioxidants (e.g. carotenoids), that are often missing in 
supplements. Also the protein present in fish may have specific beneficial effects 
[Rudkowska et al., 2010]. On the other hand, fish in particular oily fish and species high on 
the food chain (e.g. shark and swordfish) are a source of pollutants, such as heavy metals 
(mercury, cadmium, arsenic and lead), dioxins and polychlorinated biphenyls (PCBs). The 
effects of these pollutants fail to negate the beneficial effects of LC n-3 PUFA present in fish 
[Mozaffarian and Rimm, 2006]. For example, the modestly increased risk of myocardial 
infarction (MI) associated with mercury could not negate the risk reducing effect of LC n-3 
PUFA on MI [Wennberg et al., 2012]. Furthermore, the levels of dioxins and PCBs in fish are 
low and similar to those in several other foods [Mozaffarian and Rimm, 2006]. Likewise, 
dioxins and PCBs are often not entirely eliminated from fish oil products in particular those 
made from farmed fish and may thus also be present in fish oil supplements. Overall, the 
potential risk mercury, dioxins and PCBs in adults are greatly exceeded by the benefit of fish 
intake [Mozaffarian and Rimm, 2006]. However, mercury may pose a risk to pregnant 
women who are recommended to avoid species such as shark, marlin and swordfish [SACN, 
2004].  
LC n-3 PUFA intake from fish consumption or supplements will likely have differential effects 
on habitual diet. Dietary supplements are namely often taken on top of the normal diet and 
therefore people often do not account for the additional calories provided by LC n-3 PUFA in 
the supplement. On the other hand, a portion of fish is in most cases consumed with a meal 
where it often replaces a portion of meat, thereby accounting for the calories provided by 
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fish. In addition, the regular consumption of fish will likely influence the consumption of other 
meats such as pork and beef that are rich in saturated fat, thereby having additional 
beneficial effects on habitual diet.  
Finally, LC n-3 PUFA are very prone to oxidation because of their highly desaturated nature 
and therefore need to be protected from oxidation by for example antioxidants. Though it 
also applies to LC n-3 PUFA in fish, it is specially of concern for LC n-3 PUFA supplements 
that undergo more elaborate processing and are often stored longer. Oxidized LC n-3 PUFA 
may have potential unfavourable effects, for example if present in LDL lipoproteins they may 
increase oxidized LDL which is known risk factor for atherosclerosis [Maiolino et al., 2013]. 
However, in a low quantitiy they may exert beneficial effects by activating Nrf2 an important 
transcription factor activating the anti-oxidant response [De Roos and Duthie, 2015].  
In summary, the health benefits of LC n-3 PUFA derived from fish are likely superior to that 
of supplements. This is supported by the beneficial effects of fish consumption on T2DM 
disease risk in populations with high habitual fish intake compared to those with a low fish 
intake, which consistently fail to be reproduced in randomised controlled trials (RCTs) that 
often use fish oil supplements [Jafari et al., 2013]. Dietary recommendations should 
encourage the consumption of fish, but specifying both recommended (oily) fish 
consumption and LC n-3 PUFA intake. Vegans, individuals who are allergic, do not like fish 
or choose to not include it in their diet, or fail to meet the recommended EPA and DHA levels 
by diet alone, would namely depend on supplements to meet their recommended LC n-3 
PUFA intake.  
Short term strategies targeting structural changes in obesity 
In obesity several structural and cellular changes take place in AT. Adipocytes become 
hypertrophic by intracellular triglyceride (TG) accumulation and start to secrete mediators 
that attracts macrophages which increasingly infiltrate the AT. The recruited AT 
macrophages (ATM) will predominantly acquire a pro-inflammatory M1 phenotype and start 
to outnumber the resident ATM that have a more anti-inflammatory M2 phenotype. This is 
associates with increased pro-inflammatory mediator production resulting in local and 
systemic inflammation, which in turn increases the risk for insulin resistance (IR), metabolic 
disease and cardiovascular disease (CVD) [Osborn and Olefsky, 2012, Van Gaal et al., 
2006]. It is believed that ATM infiltration and the ATM phenotype switch towards the pro-
inflammatory M1 phenotype are the underlying cause of AT inflammation and dysfunction 
[Hotamisligil, 2006, Lumeng et al., 2007A, Osborn and Olefsky, 2012]. Therefore reducing 
ATM infiltration and switching the ATM phenotype from the M1 towards M2 phenotype may 
prove a strategy to reverse AT inflammation and dysfunction and disease risk in obesity.  
Non-pharmacological strategies will likely be most effective in reducing AT inflammation and 
dysfunction if they include a combination of a healthy diet, exercise and/or caloric restriction. 
Diet plays an important role in the development of obesity, its metabolic complications as 
well as disease risk. The amount and type of dietary fat influence AT function and whole 
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body metabolism. Saturated fatty acids have pro-inflammatory properties, whereas LC n-3 
PUFA, EPA and DHA, have anti-inflammatory properties. Likewise the intake of saturated fat 
is associated with an increased risk for CVD, whereas the intake of LC n-3 PUFA is 
associated with decreased risk of CVD [Willet, 2012]. Polyphenols are bioactive compounds 
found in plants, fruits and vegetables that have a range of valuable bioactivities including 
anti-oxidative, anti-obesity and anti-inflammatory properties [Bakker et al., 2010], and exert 
beneficial effects on AT inflammation and IR [Siriwardhana et al., 2013]. Therefore strategies 
should aim at a healthy diet rich in bioactive food compounds including LC n-3 PUFA and 
polyphenols. Physical activity stimulates energy expenditure and exerts beneficial effects on 
IR. Furthermore, physical activity improves AT blood flow which in turn reduces AT hypoxia 
and improves AT function. Caloric restriction is an important component of long and short 
term strategies, as it stimulates weight loss and is associated with a reduction in ATM 
infiltration and systemic low grade-inflammation [Cancello et al., 2005]. Furthermore, weight 
loss is associated with reduction in AT mass and adipocyte size (hyperthrophy). Thereby a 
healthy diet, caloric restriction and/or exercise can improve and may even reverse adipocyte 
hyperthrophy and AT inflammation, which in turn may improve metabolic derangements and 
lower disease risk in obesity. 
Statistical power analysis for the animal study 
As discussed in Chapter 4, our study was most likely underpowered for the outcomes 
described in that chapter. A power calculation was employed to calculate the number of n = 
10 mice per APOE Epsilon genotype * diet group that enabled us to detect a standardised 
mean difference (SMD) of 1.45 for a two sample comparison of means with power of 90 % at 
significance level of α = 0.05 (Chapter 3). Our study had the power to detect a 4.4 gram 
difference in body weight between the diets and 6.5 gram difference in body weight between 
the APOE Epsilon genotypes. The difference in body weight between the APOE Epsilon 
genotypes at the end of the dietary intervention was about 4.0 g for the HFD group, and 
hence our study was underpowered to detect a potential true effect of APOE Epsilon 
genotype on body weight in human APOE3 and APOE4 TR mice on HFD background. 
Furthermore, our study was underpowered to detect a potential true effect of APOE Epsilon 
genotype on ATM phenotype in flow cytometry and mRNA expression analysis, and LC n-3 
PUFA status in epididymal AT (see discussion Chapter 4). Thus, although we did not detect 
a significant difference between the APOE Epsilon genotypes for body weight, ATM 
infiltration and phenotype, and AT LC n-3 PUFA status, our study was most likely 
underpowered. Therefore there may have been a true difference between the APOE Epsilon 
genotypes for these outcomes, but our study was most just too small to detect it. In 
summary, there is insufficient data to conclude that there is no effect of APOE Epsilon 
genotype on ATM infiltration and phenotype, and LC n-3 PUFA status. Future studies in 
human APOE TR mice, in particular those investigating ATM infiltration and phenotype 
and/or LC n-3 PUFA status, are recommended to use a larger and adequate sample size. 
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Conclusion 
This PhD project showed in line with the small amount of recent emerging literature that 
APOE3 is an energy-thrifty allele, whereas APOE4 is an energy-dissipative allele that is 
associated with an altered LC n-3 PUFA metabolism and bioavailability. Novel observations 
have been made that show no effect of the APOE Epsilon genotype on HFD-induced 
macrophage infiltration and macrophage phenotype distribution in visceral AT. Besides, we 
are the first to show that APOE Epsilon genotype interacted with SNPs in the APOE 
promoter region to determine plasma inflammatory marker concentrations in humans, which 
may have implications for disease risk. This demonstrates the importance of considering 
common genotypes in combination with often subtle effects of individual SNPs in either the 
same gene region or in genes in related metabolic pathways that have additive or even 
synergistic effects, and result in a highly significant combined impact on the phenotype of 
interest. Altogether this PhD project contributes to the current understanding of the potential 
mechanisms through which APOE Epsilon genotype modulates disease risk and is an 
important lead for future nutrigenetics research.  
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Future directions 
With plenty of new data we would like to discuss questions resulting from this PhD project. 
There are still many gaps in the knowledge on the relationships between APOE Epsilon 
genotype, adiposity and inflammation to determine disease risk and still many scientific and 
social relevant questions have to be addressed. We will discuss some of these research 
gaps and questions with a suggested approach towards their answer. 
 
What is the impact of APOE Epsilon genotype on the basal macrophage phenotype? 
Most in vitro studies investigating the impact of APOE Epsilon genotype on the inflammatory 
response in macrophages reported a pro-inflammatory effect of APOE4 allele compared to 
APOE3 allele upon stimulation with a pro-inflammatory stimulus. We have used HFD feeding 
as a stressor to evaluate the effect of APOE Epsilon genotype on AT macrophage 
phenotype in human APOE TR mice. Second, we performed a pilot study using bone 
marrow-derived macrophages which suggested that the APOE4 allele is associated with 
higher expression of the M2 phenotype in macrophages in a basal un-stimulated state 
compared to APOE3 allele. Altogether, these findings suggest that APOE4 allele may be 
associated with more anti-inflammatory phenotype in the basal state, yet with a more pro-
inflammatory phenotype upon stimulation (i.e. activated state), compared to APOE3 allele. 
Future studies should elucidate the effect of APOE4 allele on the pro- and anti-inflammatory 
phenotype in macrophages in both basal and activated state. In vitro studies using primary 
macrophages from human APOE TR mice could provide insight into potential impact on 
tissue macrophages as well as underlying mechanism, whereas studies using primary 
human macrophages are warranted to verify these results to humans. Primary human 
macrophages can be obtained from whole blood human peripheral blood mononuclear cells 
(PBMC) which include macrophages, monocytes and lymphocytes, by isolating the 
monocyte fraction from the PBMC first using a magnetic selection step and then culture with 
M-CSF to differentiate the monocytes into macrophages. Flow cytometry could be used to 
determine the effect of APOE Epsilon genotype on the phenotype of murine and human 
primary macrophages in the basal and activated state and the macrophage phenotype 
response to LC n-3 PUFA supplementation using cell surface markers including CD11b, 
CD11c and CD206. The involvement of inflammatory signalling pathways such as nuclear 
factor kappa-B (NF-κB) and peroxisome proliferator activated receptor (PPAR)-γ in 
mediating the APOE Epsilon genotype effect on macrophage polarisation could be 
investigated using western-blot, which can be used to quantify the levels of key enzymes 
and proteins involved in the activation of these signalling pathways such as phospho-NF-
kappaB p65. 
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Do LC n-3 PUFA increase the number of macrophages in AT and what are the health 
consequences? 
We showed that LC n-3 PUFA increase the number of macrophages in AT without changing 
their phenotype distribution in human APOE TR mice. Also, we found insufficient evidence to 
indicate that this was associated with an increased AT inflammation, suggesting that the 
increase in ATM may not be detrimental. In fact, macrophages may exert beneficial effects 
in AT, such as limit adipocyte hypertrophy, regulating extra-cellular matrix remodelling and 
fibrosis, restore local lipid homeostasis with their phagocytic activity against lipids [Dalmas et 
al., 2011]. Future studies using immunohistochemistry techniques should investigate the 
impact of different doses of LC n-3 PUFA on the number, phenotype and localisation of 
macrophages in AT in mouse models and humans to give more insight into dose-dependent 
effect of LC n-3 PUFA on AT inflammation and function. Human RCTs could prospective 
recruit individual according to their baseline level of AT inflammation (i.e. low versus high) 
and use different dosages of LC n-3 PUFA (e.g. 0.5 g/d, 1 g/d and 3 g/d) to determine the 
optimal dosage of LC n-3 PUFA on AT inflammation response in humans according to 
baseline AT inflammation level.  
 
Could the altered LC n-3 PUFA metabolism and bioavailability in APOE4 carriers explain 
their higher CHD risk? 
The APOE4 allele is associated with 6 – 42% increased coronary heart disease (CHD) risk 
[Bennet et al., 2007, Song et al., 2004, Wilson et al., 1996] and an altered LC n-3 PUFA 
metabolism and bioavailability [Chouinard-Watkins et al., 2013, Conway et al., 2014, Vandal 
et al., 2014]. CHD patients have lower levels of LC n-3 PUFA compared to healthy controls 
[Shearer et al., 2009] and LC n-3 PUFA have been shown to reduce cardiac mortality in 
humans [Harris et al., 2008]. This raises the possibility that the lower LC n-3 PUFA 
bioavailability in APOE4 carriers could be involved in their increased CHD risk, something 
that remains to be investigated in future prospective studies and trials. One approach would 
be to retrospective genotype for APOE Epsilon genotype in an existing prospective cohort 
with data on LC n-3 PUFA intake, plasma or tissue fatty acid status, cardiovascular events 
and mortality, and a follow-up period that was sufficient to observe a significant number of 
cardiovascular events. The inclusion of tissue fatty acid status is recommended because this 
is where LC n-3 PUFA are bioactive. Circulating fatty acid status in different plasma lipid 
fractions (i.e. TG, PL, CE and total lipids) and red blood cells should be investigated as it is 
likely that the plasma lipid fraction, cell type or tissue studied will influence the impact of 
APOE Epsilon genotype on circulating fatty acid status in humans. If these studies provide 
supporting evidence for a relationship between APOE4 genotype, a low LC n-3 PUFA status 
and increased risk of cardiovascular events and mortality, RCT should be conducted to 
investigate first if LC n-3 PUFA supplementation and what dosage can restore plasma 
and/or tissue LC n-3 PUFA levels in APOE4 carriers. Kinetics studies using isotopically 
labelled [
13
C]EPA or [
13
C]DHA can provide insight into mechanisms underlying the lower LC 
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n-3 PUFA status in APOE4 carriers by investigating fatty acid absorption, incorporation in 
plasma lipid fractions and tissues (if biopsy sampling is possible), and fatty acid utilisation as 
fuel substrate. Next, RCT should investigate if restoring LC n-3 PUFA levels via LC n-3 
PUFA supplementation in APOE4 carriers can result in a risk reduction for CHD.  
 
What is the recommended intake of EPA and DHA for optimal health? And do we have to 
make recommendations according to APOE Epsilon genotype? 
Many organisations and expert committees have acknowledged the important role of LC n-3 
PUFA in human nutrition, but to date no dietary reference intakes (DRI) have been set for 
EPA and DHA [Flock et al., 2013]. The first challenge to making DRI recommendations is 
the selection of a health outcome of interest, such as prevention of obesity, CHD or 
mortality, on which DRI will be based. Flock et al. reviewed the extensive data on the effect 
of LC n-3 PUFA on CVD outcomes to make DRI recommendations for EPA and DHA and 
proposed an adequate intake (AI) of 566 mg/d for EPA and DHA which was associated with 
the greatest reduction (37 %) in risk for CHD mortality [Flock et al., 2013, Harris et al., 2008]. 
However, more dose-response data is needed to determine optimal intake of EPA and DHA 
in various populations, specially for the APOE Epsilon genotypes. Genetic variants 
influencing the synthesis, absorption and/or metabolism of LC n-3 PUFA will likely be an 
important determinant of the response to LC n-3 PUFA supplementation. First, prospective 
and cross-sectional cohort studies should investigate the impact of APOE Epsilon genotype 
on tissue LC n-3 PUFA status and it correlation with CHD disease risk in humans, thereby 
distinguishing between individuals consuming no LC n-3 PUFA and individuals with a high 
LC n-3 PUFA intake. This would provide us more insight into the impact of APOE Epsilon 
genotype on LC n-3 PUFA status and its relation with risk of CHD in humans and if dietary 
LC n-3 PUFA intake can potentially overcome the genotype effect. Next, RCT and dose-
response studies will have to verify the optimal intake of EPA and DHA for the different 
APOE Epsilon genotypes to obtain optimal LC n-3 PUFA status in humans and its potential 
implications for the risk of CHD. Thereby addressing the question if in the future a stratified 
approach to dietary recommendations for EPA and DHA should be taken, with higher 
intakes suggested for carriers of the APOE4 allele. The previously described 
recommendations for DRI for EPA and DHA were aimed at reducing the risk of CHD. More 
dose-response data is needed to determine optimal intake of EPA and DHA on other 
outcomes including inflammatory disease and body weight control.  
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Appendix 2-1. Baseline plasma long chain n-3 PUFA status  
There was no significant effect of APOE Epsilon genotype, -219G/T genotype, -219G/T * 
APOE Epsilon haplotype, gender, smoking, alcohol intake and habitual diet other than oily 
fish intake on the plasma long chain (LC) n-3 PUFA concentrations at baseline (Table A2-
1.1). The mean baseline plasma LC n-3 PUFA concentrations according to APOE Epsilon 
genotype are presented in Table A2-1.2. 
 
Table A2-1.1. Impact of subject characteristics and habitual diet on plasma long chain n-3 PUFA 
status. 
Variable Outcome measure Model 1  Model 2 Direction of effect  
APOE Epsilon 
genotype 
EPA p=0.29 p=0.50  
DPA p=0.53 p=0.35  
DHA p=0.27 p=0.42  
LC n-3 PUFA p=0.17 p=0.43  
EPA:AA ratio p=0.50 p=0.79  
SFA:PUFA ratio p<0.05 p<0.05 E3 > E2 and E4 
-219G/T genotype EPA p=0.32 p=0.22  
DPA p=0.20 p=0.10  
DHA p=0.10 p=0.20  
LC n-3 PUFA p=0.38 p=0.27  
EPA:AA ratio p=0.34 p=0.20  
SFA:PUFA ratio p=0.45 p=0.48  
-219G/T * APOE 
Epsilon haplotype 
EPA p=0.78 p=0.83  
DPA p=0.75 p=0.37  
DHA p=0.23 p=0.49  
LC n-3 PUFA p=0.63 p=0.81  
EPA:AA ratio p=0.80 p=0.80  
SFA:PUFA ratio p=0.13 p=0.18  
Age (years) EPA p<0.001 p<0.001 β = 0.01 
DPA p<0.001 p<0.001 β = 0.01 
DHA p<0.001 p<0.001 β = 0.02 
LC n-3 PUFA p<0.001 p<0.001 β = 0.04 
EPA:AA ratio p<0.001 p=0.001 β = 0.001 
SFA:PUFA ratio p=0.018 p=0.042 β = 0.001 
Gender EPA p=0.56 p=0.84  
DPA p<0.01 p<0.001 women < men 
DHA p=0.09 p=0.60  
LC n-3 PUFA p=0.18 p=0.93   
EPA:AA ratio p=0.57 p=0.77   
SFA:PUFA ratio p=0.51 p=0.77  
BMI (kg/m2) EPA p=0.78 p=0.12  
DPA p=0.28 p=0.27  
DHA p=0.11 p<0.001 β = -0.06 
LC n-3 PUFA p=0.24 p<0.01 β = -0.09 
EPA:AA ratio p=0.79 p=0.10  
SFA:PUFA ratio p=0.13 p=0.29  
Waist circumference 
(cm) 
EPA p=0.73 p<0.05 β = -0.15 
DPA p=0.22 p=0.93  
DHA p=0.18 p=0.78  
LC n-3 PUFA p=0.33 p=0.35  
EPA:AA ratio p=0.86 p=0.10  
SFA:PUFA ratio p=0.10 p=0.21  
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Table A2-1.1. continued. 
Variable Outcome measure Model 1  Model 2 Direction of effect  
Smoking  EPA p=0.18 p=0.52  
 DPA p=0.13 p=0.12  
 DHA p<0.05 p=0.09  
 LC n-3 PUFA p<0.01 p<0.05 smoker < non-
smoker 
 EPA:AA ratio p=0.17 p=0.76  
 SFA:PUFA ratio p=0.75 p=0.37  
Alcohol intake 
(units of alcohol / 
wk)* 
EPA p=0.16 p=0.52  
DPA p=0.97 p=0.69  
DHA p=0.40 p=0.90  
LC n-3 PUFA p=0.83 p=0.26  
EPA:AA ratio p=0.51 p=0.12  
SFA:PUFA ratio p=0.39 p=0.18  
Total energy from 
alcohol (%) 
EPA  p=0.73 p=0.45  
DPA p=0.80 p=0.59  
DHA p=0.29 p=0.80  
LC n-3 PUFA p=0.45 p=0.93  
EPA:AA ratio p=0.78 p=0.92  
SFA:PUFA ratio p=0.08 p=0.20  
Habitual oily fish 
intake (portions / 
week) 
EPA p<0.001 p<0.001 β = 0.16 
DPA p=0.19 p=0.54  
DHA p<0.001 p<0.001 β = 0.29 
LC n-3 PUFA p<0.001 p<0.001 β = 0.64 
EPA:AA ratio p<0.001 p<0.001 β = 0.03 
SFA:PUFA ratio p=0.83 p=0.71  
Fruit and vegetable 
intake (portions / 
day 
EPA  p<0.05 p=0.44  
DPA p=0.23 p=0.19  
DHA p=0.25 p=0.13  
LC n-3 PUFA p=0.005 p=0.90  
EPA:AA ratio p<0.05 p=0.76  
SFA:PUFA ratio p=0.58 p=0.31  
Total energy intake 
(MJ) 
EPA  p=0.44 p<0.05 β = 0.25 
DPA p=0.44 p=0.80  
DHA p=0.55 p<0.05 β = -0.06 
LC n-3 PUFA p=0.59 p<0.01 β = -0.09 
EPA:AA ratio p=0.37 p<0.01 β = -0.004 
SFA:PUFA ratio p=0.40 p=0.41  
Total energy from 
fat (%) 
EPA  p<0.01 p<0.01 β = -0.01 
DPA p=0.80 p=0.73  
DHA p=0.56 p=0.42  
LC n-3 PUFA p<0.05 p<0.05 β = -0.05 
EPA:AA ratio p<0.05 p<0.05 β = -0.002 
SFA:PUFA ratio p<0.05 p<0.05 β = -0.002 
SFA intake 
(proportion of total 
fat) 
EPA  p=0.12 p<0.05 β = -0.01 
DPA p=0.49 p=0.70  
DHA p=0.37 p=0.13  
LC n-3 PUFA p=0.09 p=0.006 β = -0.02 
EPA:AA ratio p=0.25 p=0.045 β = -0.001 
SFA:PUFA ratio p=0.72 p=0.68  
MUFA intake 
(proportion of total 
fat) 
EPA  p=0.15 p<0.05 β = -0.01 
DPA p=0.97 p=0.75  
DHA p=0.24 p<0.05 β = -0.01 
LC n-3 PUFA p=0.17 p<0.01 β = -0.03 
EPA:AA ratio p=0.24 p<0.05 β = -0.0002 
SFA:PUFA ratio p=0.50 p=0.55  
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Table A2-1.1. continued. 
Variable Outcome measure Model 1  Model 2 Direction of effect  
PUFA intake 
(proportion of total 
fat) 
EPA  p=0.16 p<0.01 β = -0.02 
DPA p=0.84 p=0.52  
DHA p=0.16 p<0.01 β = -0.03 
LC n-3 PUFA p=0.35 p<0.01 β = -0.05 
EPA:AA ratio p=0.20 p<0.01 β = -0.002 
SFA:PUFA ratio p=0.38 p=0.38  
Dietary P:S ratio EPA  p=0.56 p=0.90  
DPA p=0.33 p=0.26  
DHA p=0.56 p=0.10  
LC n-3 PUFA p=0.24 p=0.91  
EPA:AA ratio p=0.40 p=0.83  
SFA:PUFA ratio p=0.38 p=0.37  
Model 1, ANOVA main-effects model (unadjusted) including only the explanatory variable. Model 2, 
ANOVA main-effects model (adjusted) including covariates age, gender, BMI, centre, smoking, 
habitual oily fish intake. The direction of effect is the regression coefficient (β) for continues variables 
and the trend for categorical variables for variables with a significant main effect in Model 2. * 1 UK unit 
= 10 mL or 8 g pure alcohol. APOE, apolipoprotein E; DHA, docosahexaenoic acid; DPA, 
docosapentaenoic acid; EPA, eicosapentaenoic acid ; EPA:AA ratio, ratio of EPA to arachidonic acid; 
LC n-3 PUFA, long chain n-3 polyunsaturated fatty acid; SFA:PUFA ratio, ratio of saturated fatty acids 
to PUFA.   
 
Table A2-1.2. Baseline plasma long chain n-3 PUFA status according to APOE Epsilon 
genotype. 
 APOE2 APOE3 APOE4 
EPA 1.71 ± 0.10 1.54 ± 0.07 1.65 ± 0.07 
DPA 1.08 ± 0.03 1.12 ± 0.03 1.12 ± 0.03 
DHA 4.37 ± 0.14 4.10 ± 0.11 4.27 ± 0.10 
LC n-3 PUFA 7.29 ± 0.22 6.79 ± 0.18 7.15 ± 0.17 
EPA:AA ratio 0.18 ± 0.01 0.17 ± 0.01 0.18 ± 0.01 
SFA:PUFA ratio 1.02 ± 0.01 1.04 ± 0.01 1.02 ± 0.01 
All values are mean ± SEM. APOE Epsilon groups, APOE2 (E2/E2, E2/E3, n = 87), APOE3 (E3/E3, n 
= 111), APOE4 (E3/E4, E3/E4, n = 114). Student’s t-test using Bonferroni correction revealed no 
difference between the APOE Epsilon genotypes, p > 0.05. APOE, apolipoprotein E; DHA, 
docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid ; EPA:AA ratio, ratio 
of EPA to arachidonic acid; LC n-3 PUFA, long chain n-3 polyunsaturated fatty acid; SFA:PUFA ratio, 
ratio of saturated fatty acids to PUFA.  
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Appendix 2-2. Plasma oxLDL-C to apoB ratio 
There was no effect of BMI on the plasma oxidized LDL-C (oxLDL-C) to apolipoprotein B 
(apoB) ratio at baseline adjusting for age, gender, centre, smoking and habitual oily fish 
intake (p = 0.80) (Figure A2-2.1). 
 
 
Figure A2-2.1. Baseline plasma oxLDL-C to apoB ratio according to BMI. Data is presented as 
mean ± SEM for BMI groups < 25 kg/m2 (n = 155), 25 – 29.9 kg/m2 (n = 128) and ≥ 30 kg/m2 (n = 
29). One-way ANOVA including covariates age, gender, centre, smoking and habitual oily fish 
intake revealed no significant effect of BMI. apoB, apolipoprotein B; BMI, body mass index; 
oxLDL-C, oxidized low-density cholesterol. 
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Appendix 2-3. Age, gender, BMI and baseline plasma 
inflammatory marker concentrations 
There was a significant effect of gender (p < 0.05; Table A2-3.1), BMI (p < 0.05; Table A2-
3.2), but not of age (p ≥ 0.07; Table A2-3.3), on plasma inflammatory marker concentrations 
at baseline.  
 
Table A2-3.1. Baseline plasma inflammatory marker concentrations according to gender. 
 Men
 
Women
 
Model 1 Model 2 
CRP (mg/l) 1.36 ± 0.13
 
1.54 ± 0.13
 
p=0.31 p=0.07 
TNF-α (pg/ml) 1.69 ± 0.07
a
 1.42 ± 0.05
 b
 p<0.01 p<0.05 
IL-6 (pg/ml) 1.32 ± 0.10 1.25 ± 0.10 p=0.64 p=0.69 
IL-10 (pg/ml) 1.04 ± 0.08 1.02 ± 0.09 p=0.92 p=0.83 
ICAM-1 (ng/ml) 303 ± 10 301 ± 10 p=0.90 p=0.89 
VCAM-1(ng/ml) 1877 ± 70 1906 ± 74 p=0.77 p=0.74 
E-sel (ng/ml) 80.3 ± 3.1
a 
66.7 ± 2.6
b 
p<0.001 p<0.05 
P-sel (ng/ml) 63.8 ± 4.8 64.3 ± 4.9 p=0.95 p=0.98 
All values are mean ± SEM for men (n = 149) and women (n = 163). Model 1, ANOVA main-effects 
model (unadjusted) including only gender as the explanatory variable. Model 2, ANOVA main-effects 
model (adjusted) including covariates age, BMI, centre, smoking, habitual oily fish intake. CRP, C-
reactive protein; TNF-α, tumor necrosis factor α; IL-6, interleukin 6; IL-10, interleukin 10; ICAM, 
intercellular adhesion molecule; VCAM, vascular cellular adhesion molecule;  E-sel, E-selectin; P-sel, 
P-selectin.  
 
Table A2-3.2. Baseline plasma inflammatory marker concentrations according to BMI. 
 <25 kg/m
2
 25-29.9 kg/m
2
 ≥30 kg/m
2
 Model 1 Model 2 
CRP (mg/l) 1.28 ± 0.12
a
 1.50 ± 0.15
ab
 2.12 ± 0.31
b
 p<0.01 p<0.01 
TNF-α (pg/ml) 1.45 ± 0.06
a
 1.60 ± 0.07
b
 1.86 ± 0.20
b
 p<0.05 p=0.22 
IL-6 (pg/ml) 1.27 ± 0.11 1.29 ± 0.11 1.32 ± 0.17 p=0.73 p=0.74 
IL-10 (pg/ml) 1.02 ± 0.09 1.04 ± 0.09 1.06 ± 0.24 p=0.83 p=0.72 
ICAM-1 (ng/ml) 296 ± 10 315 ± 10 278 ± 29 p=0.78 p=0.85 
VCAM-1(ng/ml) 1967 ± 78 1840 ± 72 1729 ± 162 p<0.05 p<0.05 
E-sel (ng/ml) 65.3 ± 2.7
a
 80.4 ± 3.1
b
 83.2 ± 8.4
b
 p<0.001 p<0.01 
P-sel (ng/ml) 63.4 ± 5.0 62.6 ± 5.1 74.1 ± 12 p=0.56 p=0.88 
All values are mean ± SEM for BMI groups <25 kg/m2 (n=155), 25-29.9 kg/m2 (n=128) and ≥30 kg/m2 
(n=29). Model 1, ANOVA main-effects model (unadjusted) including only gender as the explanatory 
variable. Model 2, ANOVA main-effects model (adjusted) including covariates age, gender, centre, 
smoking, habitual oily fish intake. CRP, C-reactive protein; TNF-α, tumor necrosis factor α; IL-6, 
interleukin 6; IL-10, interleukin 10; ICAM, intercellular adhesion molecule; VCAM, vascular cellular 
adhesion molecule;  E-sel, E-selectin; P-sel, P-selectin.  
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Appendix 2-4. Habitual oily fish intake and baseline plasma 
inflammatory marker concentrations 
There was a significant effect of habitual oily fish intake (portions / week) on plasma IL-10 
concentrations adjusting for age, gender, BMI, centre and smoking (p < 0.01), but not on any 
of the other inflammatory markers (Table A2-4.1). 
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Appendix 2-5. Plasma long chain n-3 PUFA status and plasma 
IL-10 concentrations 
There was no association between the quintiles of plasma LC n-3 PUFA status and plasma 
IL-10 concentrations (p = 0.17; Table A2-5.1).  
 
Table A2-5.1. Plasma IL-10 concentrations across quintiles of plasma LC n-3 PUFA status. 
All values (pg/ml) are mean ± SEM for quintiles of plasma LC n-3 PUFA status; Q1, 3.6 – 5.5; Q2, 5.5 
– 6.3; 6.3 – 7.0; Q4, 7.0 – 8.6; Q5, 8.6 – 15.2 % of total fatty acids. Model 1, ANOVA main-effects 
model (unadjusted) including only plasma LC n-3 PUFA status as the explanatory variable. Model 2, 
ANOVA main-effects model (adjusted) including covariates age, gender, BMI, centre and smoking. IL-
10, interleukin 10; LC n-3 PUFA, long chain n-3 polyunsaturated fatty acid.  
 
 
Q1 Q2 Q3 Q4 Q5 Model 1 Model 2 
4.87 ± 0.07 5.96 ± 0.03 6.68 ± 0.03 7.71 ± 0.07 10.16 ± 0.18 p=0.24 p=0.17 
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Appendix 2-6. Multiple linear regression analysis 
To determine what factors, i.e. APOE Epsilon genotype, age, gender, BMI and habitual oily 
fish intake, were the strongest determinant of the baseline plasma LC n-3 PUFA 
concentrations, we performed multiple linear regression analysis (Table A2-6.1). 
 
Table A2-6.1. Multiple linear regression analysis plasma LC n-3 PUFA status. 
Multiple linear regression model containing APOE Epsilon genotype as explanatory variable including 
covariates age, gender, BMI, smoking and habitual oily fish intake. Predictor variables, APOE2, 
APOE2 genotype (APOE3 is reference); APOE4, APOE4 genotype (APOE3 is reference); AGE, age 
(continuous); FEM, female gender (male is reference); BMI, BMI (continuous); SMOKE, smoker (non-
smoker is reference); FISH, habitual oily fish intake (continuous); CON, constant. B, beta coefficient; 
SEM B, standard error B; t, t-test statistic; P, p-value; 95% CI, 95% confidence interval. * p < 0.05, ** p 
< 0.01, *** p < 0.001. APOE, apolipoprotein E; BMI, body mass index; DHA, docosahexaenoic acid; 
DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid ; EPA:AA ratio, ratio of EPA to arachidonic 
acid; LC n-3 PUFA, long chain n-3 polyunsaturated fatty acid; n/a, not applicable; SFA:PUFA ratio, 
ratio of saturated fatty acids to PUFA.  
 
  
EPA Overall model fit R^2 = 0.11 
Predictor 
variable 
B SEM B t P 95% CI 
APOE2  0.140 0.109 1.29 0.20 -0.074, 0.354 
APOE4 0.075 0.101 0.74 0.46 -0.125, 0.275 
AGE 0.011** 0.003 3.29 <0.01 0.005, 0.018 
FEM -0.029 0.090 -0.32 0.75 -0.207, 0.149 
BMI  -0.025 0.014 -1.77 0.08 -0.052, 0.003 
SMOKE -0.084 0.133 -0.64 0.53 -0.346, 0.177 
FISH 0.151*** 0.036 4.18 <0.001 0.080, 0.222 
CON 1.534*** 0.360 4.26 <0.001 0.825, 2.243 
DHA Overall model fit R^2 = 0.17 
Predictor 
variable 
B SEM B t P 95% CI 
APOE2  0.204 0.158 1.29 0.20 -0.107, 0.514 
APOE4 0.105 0.147 0.71 0.48 -0.185, 0.395 
AGE 0.019*** 0.005 3.68 <0.001 0.009, 0.029 
FEM 0.049 0.131 0.37 0.71 -0.210, 0.307 
BMI  -0.057** 0.020 -2.81 <0.01 -0.097, 0.088 
SMOKE -0.292 0.193 -1.51 0.13 -0.672, 0.088 
FISH 0.291*** 0.053 5.54 <0.001 0.188, 0.395 
CON 4.443*** 0.523 8.49 <0.001 3.412, 5.473 
LC n-3 PUFA  Overall model fit R^2 = 0.26 
Predictor 
variable 
B SEM B t P 95% CI 
APOE2  0.359 0.243 1.48 0.14 -0.119, 0.838 
APOE4 0.217 0.227 0.96 0.34 -0.229, 0.664 
AGE 0.035*** 0.008 4.43 <0.001 0.019, 0.049 
FEM -0.027 0.202 -0.13 0.89 -0.424, 0.371 
BMI  -0.093** 0.031 -2.98 <0.01 -0.154, -0.031 
SMOKE -0.570 0.297 -1.92 0.06 -1.154, 0.015 
FISH 0.632*** 0.081 7.81 <0.001 0.473, 0.791 
CON 7.108*** 0.805 8.82 <0.001 5.523, 8.693 
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To determine what factors, i.e. -219G/T genotype, APOE Epsilon genotype, age, gender, 
BMI and habitual oily fish intake, were the strongest determinant of the baseline plasma 
inflammatory marker concentrations, we performed similar multiple linear regression 
analysis (Table A2-6.2). 
 
Table A2-6.2. Multiple linear regression analysis plasma inflammatory marker concentrations. 
 
  
CRP (mg/l) Overall model fit R^2 = 0.06 
Predictor 
variable 
B SEM B t P 95% CI 
APOE2  0.010 0.245 0.04 0.97 -0.472, 0.492 
APOE4 -0.032 0.216 -0.15 0.88 -0.456, 0.392 
-219GT -0.340 0.240 -1.42 0.16 -0.813, 0.132 
-219TT -0.374 0.286 -1.31 0.19 -0.935, 0.188 
AGE -0.001 0.007 -0.15 0.88 -0.016, 0.013 
FEM 0.340 0.191 1.78 0.08 -0.035, 0.716 
BMI  0.090** 0.029 3.07 <0.01 0.032, 0.148 
SMOKE 0.531 0.298 1.79 0.08 -0.053, 1.116 
FISH -0.010 0.076 -0.14 0.89 -0.156, 0.138 
CON -0.716 0.798 -0.90 0.37 -2.286, 0.855 
TNF-α (pg/ml) Overall model fit R^2 = 0.06 
Predictor 
variable 
B SEM B t P 95% CI 
APOE2  0.042 0.119 0.36 0.72 -0.192, 0.276 
APOE4 0.112 0.106 1.05 0.29 -0.097, 0.321 
-219GT -0.157 0.115 -1.37 0.17 -0.384, 0.069 
-219TT -0.009 0.138 -0.06 0.95 -0.280, 0.263 
AGE 0.006 0.004 1.70 0.09 -0.001, 0.013 
FEM -0.257** 0.094 -2.72 <0.01 -0.442, -0.071 
BMI  0.013 0.014 0.89 0.38 -0.016, 0.041 
SMOKE -0.013 0.138 -0.09 0.93 -0.285, 0.259 
FISH -0.015 0.037 -0.40 0.69 -0.089, 0.059 
CON 1.129** 0.391 2.89 <0.01 0.359, 1.897 
IL-6 (pg/ml) Overall model fit R^2 = 0.03 
Predictor 
variable 
B SEM B t P 95% CI 
APOE2  0.107 0.199 0.54 0.59 -0.285, 0.499 
APOE4 0.077 0.178 0.43 0.67 -0.273, 0.427 
-219GT 0.029 0.193 0.15 0.88 -0.351, 0.409 
-219TT 0.198 0.231 0.86 0.39 -0.256, 0.652 
AGE 0.008 0.006 1.31 0.19 -0.004, 0.020 
FEM -0.051 0.158 -0.32 0.75 -0.362, 0.260 
BMI  -0.004 0.024 -0.14 0.89 -0.051, 0.044 
SMOKE 0.608* 0.234 2.60 <0.05 0.148, 1.0677 
FISH 0.001 0.063 0.01 0.99 -0.122, 0.124 
CON 0.848 0.658 1.29 0.20 -0.446, 2.142 
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Table A2-6.2. continued. 
IL-10 (pg/ml) Overall model fit R^2 = 0.05 
Predictor 
variable 
B SEM B t P 95% CI 
APOE2  -0.154 0.160 -0.97 0.33 -0.469, 0.160 
APOE4 -0.192 0.143 -1.35 0.18 -0.473, 0.089 
-219GT 0.187 0.155 1.21 0.23 -0.117, 0.491 
-219TT 0.105 0.185 0.57 0.57 -0.259. 0.469 
AGE -0.003 0.005 -0.69 0.49 -0.013, 0.006 
FEM -0.023 0.127 -0.18 0.86 -0.272, 0.226 
BMI  -0.003 0.019 -0.15 0.88 -0.041, 0.035 
SMOKE 0.146 0.187 0.78 0.44 -0.223, 0.514 
FISH 0.181*** 0.050 3.61 <0.001 0.082, 0.280 
CON 1.055 0.526 2.00 0.05 0.019, 2.090 
ICAM-1 (ng/ml) Overall model fit R^2 = 0.03 
Predictor 
variable 
B SEM B t P 95% CI 
APOE2  3.824 19.344 0.20 0.84 -34.243, 41.891 
APOE4 5.572 17.239 0.32 0.75 -28.353, 39.497 
-219GT -35.644 18.725 -1.90 0.06 -72.493, 1.206 
-219TT -3.209 22.388 -0.14 0.89 -47.266, 40.848 
AGE 0.749 0.587 1.28 0.20 -0.406, 1.904 
FEM -6.090 15.338 -0.40 0.69 -36.273, 24.093 
BMI  -1.372 2.362 -0.58 0.56 -6.020, 3.277 
SMOKE 34.510 22.496 1.53 0.13 -9.759, 78.779 
FISH 0.993 6.080 0.16 0.87 -10.973, 12.959 
CON 316.406*** 63.717 4.97 <0.001 1991.018, 441.793 
VCAM-1 (ng/ml) Overall model fit R^2 = 0.06 
Predictor 
variable 
B SEM B t P 95% CI 
APOE2  307.609* 134.765 2.28 <0.05 42.400, 572.818 
APOE4 334.072** 120.551 2.85 <0.01 106.837, 581.307 
-219GT -186.325 130.556 -1.43 0.16 -443.250, 70.601 
-219TT 52.842 156.824 0.34 0.74 -255.777, 361.461 
AGE -0.316 4.094 -0.08 0.94 -8.372, 7.740 
FEM -73.420 106.853 -0.69 0.49 -283.699, 136.860 
BMI  -35.826* 16.413 -2.18 <0.05 -68.126, 3.527 
SMOKE -68.962 156.983 -0.44 0.66 -377.892, 239.969 
FISH 44.839 42.740 1.06 0.29 -38.679, 128.357 
CON 2680.64*** 44.666 6.03 <0.001 1805.568, 3556.712 
E-sel (ng/ml) Overall model fit R^2 = 0.10 
Predictor 
variable 
B SEM B t P 95% CI 
APOE2  -9.609 5.280 -1.82 0.07 -20.000, 0.781 
APOE4 -12.030* 4.705 -2.56 <0.05 21.288, 2.771 
-219GT 5.411 5.116 1.06 0.29 -4.657, 15.478 
-219TT -1.977 6.127 -0.32 0.75 -14.034, 10.080 
AGE 0.219 0.160 1.37 0.17 -0.096, 0.534 
FEM -8.645* 4.180 -.207 <0.05 -16.871, -0.420 
BMI  1.851** 0.643 2.88 <0.01 0.586, 3.116 
SMOKE 4.820 6.152 0.78 0.43 -7.286, 16.927 
FISH -0.865 1.664 -0.52 0.60 -4.139, 2.410 
CON 26.463 17.401 1.52 0.13 -7.780, 60.705 
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Table A2-6.2. continued. 
Multiple linear regression model containing APOE Epsilon genotype and -219G/T genotype as 
explanatory variable including covariates age, gender, BMI, smoking and habitual oily fish intake. 
Predictor variables, APOE2, APOE2 genotype (APOE3 is reference); APOE4, APOE4 genotype 
(APOE3 is reference); -219GT, -219GT genotype (-219GG is reference); -219TT, -219TT genotype (-
219GG is reference); AGE, age (continuous); FEM, female gender (male is reference); BMI, BMI 
(continuous); SMOKE, smoker (non-smoker is reference); FISH, habitual oily fish intake (continuous); 
CON, constant. B, beta coefficient; SEM B, standard error B; t, t-test statistic; P, p-value; 95% CI, 95% 
confidence interval. * p < 0.05, ** p < 0.01, *** p < 0.001. APOE, apolipoprotein E; BMI, body mass 
index; CRP, C-reactive protein; TNF-α, tumor necrosis factor α; IL-6, interleukin 6; IL-10, interleukin 10; 
ICAM, intercellular adhesion molecule; VCAM, vascular cellular adhesion molecule;  E-sel, E-selectin; 
P-sel, P-selectin. 
 
P-sel (ng/ml) Overall model fit R^2 = 0.07 
Predictor 
variable 
B SEM B t P 95% CI 
APOE2  -36.536*** 9.059 -4.03 <0.001 -54.363, 18.709 
APOE4 -26.772 8.032 -3.33 <0.01 -42.579, 10.965 
-219GT -6.593 8.774 -0.75 0.453 -23.860, 10.673 
-219TT -16.169 10.477 -1.54 0.12 -36.787, 4.450 
AGE 0.461 0.274 1.68 0.09 -0.079, 1.001 
FEM 2.644 7.187 0.37 0.72 -11.500, 2.605 
BMI  0.410 1.115 0.37 0.71 -1.785, 2.605 
SMOKE 7.166 10.510 0.68 0.50 -13.518, 27.849 
FISH -0.419 2.849 -0.15 0.88 -6.024, 5.187 
CON 58.485 30.148 1.94 0.05 -0.844, 117.815 
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Appendix 3-1. Fatty acid composition of the diets  
Animals had free access to food and water, with fresh food being provided every 2
nd
/3
rd
 day. 
The stability of the fatty acids in the experimental diets over the course of three days was 
investigated to confirm that the fatty acid composition did not change over time. The results 
are displayed in Table A3-1.1 presenting the fatty acid composition of the experimental diets 
after 24, 48 and 72 hr at room temperature and exposed to air. Briefly, the results confirm 
that the fatty acid composition, in particular that of EPA and DHA, of the experimental diets 
did not significantly change after 3 days at room temperature.  
 
Table A3-1.1. Fatty acid composition of the experimental diets over the course of three days. 
  HFD HFD+FO 
% of total fatty acids day 1 day 2 day 3 day 1 day 2 day 3 
saturated       
14:0 Myristic acid 5.6 6.0 5.1 25.6 33.1 36.9 
15:0 Pentadecanoic acid ND ND ND 1.8 2.3 2.4 
16:0 Palmitic acid 107.7 116.3 97.3 99.6 130.4 137.2 
17:0 Margaric acid 1.9 2.1 1.7 5.5 7.0 8.0 
18:0 Stearic acid 58.9 63.3 52.5 42.6 55.7 57.6 
20:0 Arachidic acid 1.2 1.3 1.1 3.2 13.8 2.6 
22:0 Behenic acid ND ND ND 0.6 0.9 0.8 
24:0 Lignoceric acid ND ND ND 0.6 0.7 0.7 
monounsaturated       
14:1 Myristoleic acid ND ND ND ND ND ND 
16:1 n-7 Palmitoleic acid 7.5 8.2 6.8 30.8 38.2 43.1 
18:1 trans  1.4 1.5 1.0 0.9 1.8 1.4 
18:1 n-7 Vaccenic acid 10.8 11.7 9.8 12.4 15.4 17.0 
18:1 n-9 Oleic acid 177.0 193.6 161.9 125.2 155.7 172.7 
20:1 n-9 Gondoic acid 3.0 3.3 2.7 2.6 5.7 3.9 
24:1 n−9 Nervonic acid 0 0 0 4.0 5.1 5.7 
polyunsaturated       
18:2 n-6 Linoleic acid 124.6 133.6 112.5 88.6 107.9 122.5 
18:3 n-3 α-Linolenic acid 8.2 8.9 7.6 10.0 13.9 13.8 
18:4 n-3 Parinaric acid ND ND ND 4.7 6.0 6.7 
20:2 n-6 Eicosadienoic acid 3.6 3.8 3.2 2.3 2.6 3.2 
20:3 n-6 
Dihomo-gamma-
linolenic acid 
ND ND ND 0.8 1.0 1.1 
20:3 n-3 Eicosatrienoic acid 0.6 0.6 0.5 0.6 0.8 0.9 
20:4 n-3 Eicosatetraenoic acid ND ND ND 2.1 3.1 3.1 
20:4 n-6 Arachidonic acid 1.2 1.1 1.0 3.2 3.8 4.5 
20:5 n-3 Eicosapentaenoic acid ND ND ND 20.7 26.2 29.6 
22:5 n-3 Docosapentaenoic acid ND ND ND 0.6 0.7 0.9 
22:6 n-3 Docosahexaenoic acid ND ND ND 31.1 40.1 44.4 
HFD, high-fat diet; HFD+FO, HFD containing 30 g EPA+DHA / kg of diet. 
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Appendix 3-2. mRNA expression analysis by RT-QPCR 
Reference gene selection 
The six reference candidate genes 18S rRNA gene (18S), actin, beta, cytoplasmic (Actb), 
ATP synthase subunit (Atp5b), eukaryotic translation initiation factor 4A2 (Eif4a2), 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh), ribosomal protein L13a (Rpl13a), 
were screened for gene expression stability using 3 – 4 random samples from each APOE 
Epsilon genotype * diet group. The average expression stability of the six reference 
candidate genes, expressed as geNorm M-values, is presented in Figure A3-2.1. The 
analysis of the optimal number of reference genes, indicated by geNorm Vn/n+1 values, is 
depicted in Figure A3-2.2. 
 
 
Figure A3-2.1. GeNorm M graph presenting the average expression stability of the reference 
candidate genes. The geNorm M graph shows the ranking of the reference candidate genes 
according to their stability, expressed in geNorm M values, from most unstable genes at the left 
(high M value) to the best reference genes at the right (low M value). The threshold value for M 
is 0.5, with values ≤ 0.5 indicating a high expression stability. The six reference candidate 
genes screened all had M-values greater than 0.5, indicating a suboptimal to poor average 
expression stability. 18S rRNA gene (18S), actin, beta, cytoplasmic (Actb), ATP synthase 
subunit (Atp5b), eukaryotic translation initiation factor 4A2 (Eif4a2), glyceraldehyde-3-
phosphate dehydrogenase (Gapdh), ribosomal protein L13a (Rpl13a). 
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Figure A3-2.2. GeNorm V graph indicating the optimal number of reference genes. The GeNorm 
V graph presents the Vn/n+1 value for every comparison between two consecutive number (n 
and n+1) of candidate reference genes. The benefit of using an extra (n+1)th reference gene is 
limited as soon as the Vn/n+1 value drops below the 0.15 threshold (green horizontal line) 
[Hellemans et al., Genome Biology, 2007.]. The lowest Vn/n+1 value was obtained for V3/4 and 
V4/5, indicating that the optimal number of reference genes to use was 3 – 4 target reference 
genes with the lowest M value (i.e. highest expression stability). The Vn/n+1 value did not drop 
below the 0.15 threshold indicating that the variability between sequential normalization factors 
(based on the n and n+1 least variable reference target genes) was relatively high. 
 
In summary, the six reference candidate genes had a low expression stability (geNorm M > 
0.5). In addition, the variability between sequential normalization factors (based on the n and 
n+1 least variable reference genes) was relatively high (geNorm V > 0.15), which made it 
difficult to determine the optimal number of reference genes. Due to high variability in 
normalisation factors and the low reference gene stability, it was recommended to use 3 – 4 
reference genes with the lowest M value, as the use of multiple reference genes results in 
more accurate normalization compared to the use of a single non-validated reference gene. 
 
The reference candidate genes Act), Atp5b and Gapdh had the most stable gene expression 
levels between the mice and different treatment groups. Therefore, data was normalized 
against the reference genes actin, beta (Actb), ATP synthase, H+ transporting mitochondrial 
F1 complex, beta subunit (Atp5b) and glyceraldehyde-3-phosphate dehydrogenase (Gapdh). 
 
RT-QPCR data control, modification and exclusion 
Prior to the analysis of the relative expression levels, the RT-QPCR raw data was 
investigated to verify an exponential amplification efficiency and correct for the sensitivity 
limit of the assay. In more detail, the samples with a non-exponential amplification, indicating 
poor reaction efficiency, were omitted from analysis (missing values). Samples with cycle 
threshold (CT) values below the sensitivity limit of the assay but 5 or more CT’s greater than 
the NTC for that assay (indication of target-specific amplification), were assigned the CT 
value corresponding to the detection limit of that assay, in order to minimise the bias 
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resulting from the exclusion of these samples on the end results (Table A3-2.1). Sample 4 
from the APOE3-HFD group was excluded from all analysis due to too many missing values. 
 
Table A3-2.1. Overview of samples with CT-values below the detection limit or missing values. 
Gene Sample (APOE Epsilon genotype* 
diet group, sample no.) 
CT change (original -> 
assigned value) 
Apoe 
APOE3-HFD #4 
APOE3-HFD #1 
APOE4-HFD #8 
Missing values 
Missing values 
Missing values 
Arg1 
APOE3-HFD #4 
APOE3-HFD+FO #3, 4, 5, 6, 7 
APOE4-HFD #2, 3, 4, 9 
APOE4-HFD+FO #3, 4, 7, 8 
APOE4-HFD+FO #9, 10 
Missing values 
26.8, 26.8, 26.2, 28.0, 27.2 -> 26 
26.2, 27.8, 27.5, 28.3 -> 26 
26.4, 26.4, 27.3, 26.4 -> 26 
Missing values 
Cd11b (Itgam) 
APOE3-HFD #4 
APOE4-HFD #8 
Missing values 
Missing values 
Cd11c (Itgax) 
APOE3-HFD #4 
APOE3-HFD+FO #6 
APOE3-HFD+FO #10  
APOE4-HFD+FO #1 
Missing values 
32.4 -> 31 
Missing values 
Missing values 
Cd206 (Mrc1) 
APOE3-HFD #8 
APOE3-HFD+FO #10 
APOE4-HFD #8  
APOE4-HFD+FO #7 
Missing values 
Missing values 
Missing values 
Missing values 
Il6 
APOE4-HFD #3, 4, 6, 9 
APOE4-HFD+FO #9,10 
31.5, 32.5, 31.5, 31.7 -> 31 
Missing values 
Il10 
APOE3-HFD #4 
APOE4-HFD #6 
Missing values 
Missing values 
Mgl1/2 
APOE3-HFD #4 
APOE4-HFD #6 
37.0 -> 31 
Missing values 
Nos2  n/a n/a 
Tnfa n/a n/a 
Apoe, apolipoprotein E; Arg1, arginase 1; Cd11b, integrin alpha M (Itgam); Cd11c, integrin alpha X 
(Itgax); Cd206, mannose receptor, C type 1 (Mrc1); HFD, high-fat diet; HFD+FO, HFD containing 30 g 
EPA+DHA / kg of diet; Il6, interleukin 6; Il10, interleukin 10; Mgl1/2, C-type lectin domain family 10, 
member A (Clec10a, also known as Mgl1) and macrophage galactose N-acetyl-galactosamine specific 
lectin 2 (Mgl2); n/a, not applicable; Nos2, nitric oxide synthase 2, inducible; Tnfa, tumor necrosis factor 
alpha. 
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Appendix 3-3. Food intake results 
Average food intake per week 
The average food intake (gram / mouse / day) of the human APOE3 and APOE4 targeted 
replacement mice fed a high-fat diet (HFD) without or with 30 g EPA+DHA / kg of diet 
(HFD+FO) per week is presented in Figure A3-3.1. Briefly, APOE3 mice on the HFD had a 
consistent higher average food intake (g / mouse / day) compared to the APOE3 mice on 
HFD+FO and the APOE4 mice on either of the two diets, which was most pronounced in the 
first three weeks. 
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Food efficiency per week 
There were no major differences in the average weekly food efficiency of the human APOE3 
and APOE4 targeted replacement mice fed a high-fat diet (HFD) without or with 30 g 
EPA+DHA / kg of diet (HFD+FO) (Figure A3-3.2). Overall, mice gained on average 0.07 g of 
body weight for each gram of food consumed (Figure 3.6B). 
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Appendix 3-4. Adipose tissue long chain n-3 PUFA status and IL-
10 mRNA expression 
There was no relationship between between adipose tissue long chain (LC) n-3 PUFA, EPA 
or DHA content and IL-10 expression levels (Table A3-4.1). 
 
Table A3-4.1. Correlation LC n-3 PUFA status and measures related to insulin resistance. 
Dependent variable Independent variable Pearson r p-value 
IL-10 mRNA LC n-3 PUFA 0.287 p=0.08 
 EPA 0.276 p=0.09 
  DHA 0.282 p=0.09 
Pearson’s correlation efficient (r) was used to determine the correlation between the adipose tissue LC 
n-3 PUFA, EPA and DHA concentrations and adipose tissue IL-10 mRNA expression levels. DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid; IL-10, interleukin 10; LC n-3 PUFA, long chain n-
3 polyunsaturated fatty acid. 
 
 
 
Figure A3-4.1. continues on next page... 
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Figure A3-4.1. Correlation between adipose tissue IL-10 mRNA expression levels and adipose 
tissue LC n-3 PUFA (r = 0.287), EPA (r = 0.276) and DHA (r = 0.282) concentrations. Crosses, 
APOE3-HFD; squares, APOE3-HFD+FO; circles, APOE4-HFD; triangles, APOE4-HFD+FO. 
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Appendix 4-1. Flow cytometry analysis 
Flow cytometry data collection 
For each sample, data of 30,000 events was collected using a gate excluding debri (gate P1, 
Figure A4-1.1). 
 
Figure A4-1.1. The gate P1 that was used to collect 30,000 events for each sample. On the left 
the forward (FSC-A) and sideward (SSC-A) scatter plot with gate P1, and on the right the same 
graph but then zoomed in showing the target cell population is presented.  
 
Gate setup 
The setup of the gate E including the adipose tissue macrophages (ATM) and excluding 
debris, small cell (i.e. red blood cells) and cell clumps, which was applied to the original data 
of 30,000 collected events, is presented in Figure A4-1.2. The setup of gate E was based on 
the methodology described by Danett and Smith (Methods in Molecular Biology, Vol. 456: 
Adipose Tissue Protocols, Second Edition.). The setup of the thresholds to define the 
positive and negative cell populations for the cell surface markers CD11b, CD11c and 
CD206 using fluorophore minus-one control and single-stained samples is presented in 
Figure A4-1.3. 
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Figure A4-1.2. The setup of gate E to exclude cell clumps using the correlation between forward 
scatter height (FSC-H) and area (FSC-A). The left graph (A) presenting the forward scatter 
height (FSC-H) versus area (FCS-A) plot of all 30,000 events (ungated), shows the single cell 
population in gate F. Each cell, singlet or doublet, generates upon passing the laser a pulse 
that has a height (H), width (W) and area (A) underneath the peak. For single cells, there is a 
linear correlation between the height (FSC-H) and the area under the peak (FSC-A). However, 
this correlation will be violated by cell clumps, which have the same FSC-H but a greater FSC-
A, and would be to the right of the linear correlation between FSC-A and FSC-H (indicated as 
gate F). The two other graphs presenting the sideward scatter height (FSC-H) versus forward 
scatter area (FCS-A) plot of all 30,000 events (ungated) (B) and of events in gate F (C), show 
that doublets and cell clumps (grey dots) are mainly located outside on the top right of gate 
E.Most single cells (coloured dots, graph A) are located within the gate E (orange dots), 
whereas very small cells (i.e. red blood cells) and debris are located to the left of gate E (green 
dots). The data was obtained from an unstained stromal vascular fraction (SVF) sample of the 
epididymal adipose tissue from a male APOE4 mouse. 
  
 Slim (2015), Appendix 3-4 
225 
S
lim
 (2
0
1
5
), C
h
a
p
te
r 1
. L
ite
ra
tu
re
 re
v
ie
w
 
A      B 
  
C      D 
  
Figure A4-1.3. continues on next page. 
  
 Slim (2015), Appendix 3-4 
226 
S
lim
 (2
0
1
5
), C
h
a
p
te
r 1
. L
ite
ra
tu
re
 re
v
ie
w
 
E      F 
  
Figure A4-1.3. The setup of the thresholds to define positive and negative cell populations for 
the cell surface markers CD11b, CD11c and CD206 using fluorophore minus-one control and 
single-stained samples. The fluorophore minus-one control sample was used to define the 
negative cell population. The single stained sample was used to confirm that the positive cell 
population can be distinguished using this threshold. The threshold was set at the point to 
exclude the fluorescent signal (peak) of the negative cell populations (graphs A, C and E) and 
to include the fluorescent signal (peak) of the positive cell population (graphs B, D and F). The 
threshold for CD11b-PE-FL2-A with positive cell population in gate A, classified 4.52 % of cells 
from fluorophore minus-one sample (graph A) and 35.75 % of cells in the single stained sample 
(graph B) as cells expressing CD11b on their cell surface. The threshold for CD11c-Alexa700-
FL4-A with positive cell population in gate C, classified 3.96 % of cells from fluorophore minus-
one sample (graph C) and 70.00 % of cells in the single stained sample (graph D) as cells 
expressing CD11c on their cell surface. A limitation of the CD11b single stained sample was 
that it contained very few CD11b positive cells. The threshold for CD206-FITC-FL1-A with 
positive cell population in gate B, classified 4.85 % of cells from fluorophore minus-one sample 
(graph E) and 99.09 % of cells in the single stained sample (graph F) as cells expressing CD206 
on their cell surface. Data was obtained from stromal vascular fraction (SVF) cell samples from 
various epididymal adipose tissues from male APOE3, EFAD, APOE4 mice. The EFAD mouse 
strain expresses the human gene associated with the familial form of Alzheimer's disease 
(FAD) and the human APOE4 gene, a known risk factor for Alzheimer’s disease.  
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Cell yield 
The cell yield in gate E (% of the total collected events) was between 27.6 ± 1.48 (SEM) % 
and 41.1 ± 2.43 % for the APOE Epsilon genotype*diet groups and was significantly higher 
for the APOE4-HFD group compared to the APOE3-HFD+FO group (p < 0.05). 
 
Table A4-1.1. Cell yield in gate E (% of total events) for the APOE Epsilon genotype*diet groups. 
Group Mean (% of total)* SD n SEM  
APOE3-HFD 32.8 13.610 10 4.304 
APOE3-HFD+FO 27.6 4.433 9 1.478 
APOE4-HFD 41.1 7.685 10 2.430 
APOE4-HFD+FO 29.1 9.172 10 2.901 
*Kruskal-Wallis test revealed a significant difference between the APOE Epsilon genotype*diet groups 
(p<0.05), with a higher cell yield for APOE4-HFD group compared to APOE3-HFD+FO group (p<0.05). 
HFD, high-fat diet; HFD+FO, HFD containing 30 g EPA+DHA/kg of diet. 
Compensation set up 
Single stain control samples were used to determine spill over of CD206-FITC into 585/40 
BP and 670/LP filter; and CD11b-PE into 533/30 BP filter and 670/LP filter, to apply 
appropriate compensation (Table A4-1.2).  
 
Table A4-1.2. Compensation table - Spill over (%) matrix  
Spill over (%)  FL1 FL2 FL3 FL4 
FL1  2.70 N/A 1.30 
FL2 1.90  N/A 0.00 
FL3 N/A N/A  N/A 
FL4 0.80 0.00 N/A  
 
The compensation was setup using the target cell population (gate E), which was also used 
for final analysis of experimental samples. This target population contained besides our 
adipose tissue macrophages of interest also eosinophils, neutrophils and granulocytes. 
These last three cell types have a high autofluoresence resulting in a population with a tail in 
the CD11c-Alexa700-FL4 versus CD206-FITC-FL1 plot (Figure A4-1.4A and A4-1.4B). This 
posses some challenge to setting compensation, since the tail is fairly impossible to bring 
down and compensation aims to lower the fluorescence median of this population to a value 
similar to the negative cell population. Future experiments are recommended to include in 
the panel one or more markers for these cells, so that the cells positive for CD11b+, but 
negative for the eosinophil/neutrophil/granulocyte marker(s) can be selected (negative 
selection). 
 
 Slim (2015), Appendix 3-4 
228 
S
lim
 (2
0
1
5
), C
h
a
p
te
r 1
. L
ite
ra
tu
re
 re
v
ie
w
 
Using the single stain CD11b-PE sample spill over into CD206-FITC-FL1 and CD11c-
Alexa700-FL4 was determined; a compensation of 2.70 % was needed to correct for spill 
over of CD11b-PE into CD206-FITC-FL1 (Figure A4-1.5A), whereas there was no spill over 
into CD11c-Alexa700-FL4 (Figure A4-1.5B). Using the single stain CD11c-Alexa700 sample 
spill over into CD11b-PE-FL2 and CD206-FITC-FL1 was determined; a compensation of 
1.30 % was needed to correct for spill over of CD11c-Alexa700 into CD206-FITC-FL1 
(Figure A4-1.6B). However, no compensation could be set for spill over of CD11c-Alexa700 
into CD11b-PE-FL2 (Figure A4-1.6A) due to lack of CD11c positive cells in the sample. 
Using the single stain CD206-FITC sample spill over into CD11b-PE-FL2 and CD11c-
Alexa700-FL4 was determined; a compensation of 1.90 % and 0.80 % was needed to 
correct for spill over of CD206-FITC into CD11b-PE-FL2 (Figure A4-1.7A) and CD11c-
Alexa700-FL4 (Figure A4-1.7B).  
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Figure A4-1.4. Plots illustrating the presence of highly autofluorescent cells (eosinophils, neutrophils and granulocytes) in the stromal vascular fraction as 
indicated by the tail (upper right corner graph A and B). The percentage of autofluorescent eosinophils and granulocytes - the cells in the upper right corner (plot 
area H++, graph A; B++ graph B) in the CD11c-Alexa700-FL4 versus CD206-FITC-FL1 plot - is approximately 5.0 % (range 1.46 – 8.51 %) of total cells in gate E. 
Among the CD11b-positive cells the percentage of autofluorescent cells is 3.45 % (plot area B++ graph C). Data was obtained from stromal vascular fraction (SVF) 
cell samples from various epididymal adipose tissues from male APOE3, EFAD, APOE4 mice. The EFAD mouse strain expresses the human gene associated with 
the familial form of Alzheimer's disease (FAD) and the human APOE4 gene, a known risk factor for Alzheimer’s disease. 
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Figure A4-1.5. Plots demonstrating a compensation of 2.70 % was needed to correct for spill over of CD11b-PE into CD206-FITC-FL1 (graph A), whereas there was 
no spill over of CD11b-PE into CD11c-Alexa700-FL4 (graph B). The presence of autofluorescent cells indicated by the tail in the upper right corner (graph A) made 
it difficult to set compensation, although Y-Median was fairly similar after compensation (0.08 vs. 0.07 (C-+ vs. C--, graph A). Data was obtained from CD11b-PE 
single stained stromal vascular fraction (SVF) sample from epididymal adipose tissue from male EFAD mouse. The EFAD mouse strain expresses the human gene 
associated with the familial form of Alzheimer's disease (FAD) and the human APOE4 gene, a known risk factor for Alzheimer’s disease. 
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Figure A4-1.6. Plots demonstrating no compensation could be set for spill over of CD11c-Alexa700 into CD11b-PE-FL2 (graph A) and a compensation of 1.30 % 
was needed to correct for spill over of CD11c-Alexa700 into CD206-FITC-FL1 (graph B). The number of CD11c positive cells was so low that compensation was 
fairly impossible. Data was obtained from CD11c-Alexa700 single stained stromal vascular fraction (SVF) sample from epididymal adipose tissue from male EFAD 
mouse. The EFAD mouse strain expresses the human gene associated with the familial form of Alzheimer's disease (FAD) and the human APOE4 gene, a known 
risk factor for Alzheimer’s disease. 
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Figure A4-1.7. Plots demonstrating a compensation of 1.90 % and 0.80 % was needed to correct for spill over of CD206-FITC into CD11b-PE-FL2 (graph A) and 
CD11c-Alexa700-FL4 (graph B). The presence of autofluorescent cells indicated by the tail in the upper right corner, in combination with very few CD206 positive 
cells in the sample made it was difficult to set compensation, with the Y-Median still remaining slightly different after compensation, 0.08 vs. 0.03 (C+- vs. C--, 
graph A). Data was obtained from CD206-FITC single stained stromal vascular fraction (SVF) sample from epididymal adipose tissue from male APOE4 mouse. 
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Non-specific binding  
The non-specific binding determined using isotype controls was for CD11b 17.62 %, for 
CD11c 5.8 % and for CD206 8.1 % cells of gate E. Representative graphs presenting the 
percentage of events that are classified as positive cells expressing the cell surface markers 
CD11b, CD11c, and CD206 of stromal vascular fraction (SVF) sample stained with the 
appropriate isotype control, are presented below.   
A    B    C 
  
Figure A4-1.8. Plots presenting the non-specific binding for the antibodies used to stain for the 
surface markers CD11b (graph A), CD11c (graph B), and CD206 (graph C). The non-specific 
binding was for CD11b 17.62 % (events in gate A expressed as percentage of % cells gate E), 
for CD11c 5.8 % (events in gate C expressed as percentage of % cells gate E) and for CD206 8.1 
% (events in gate B expressed as percentage of % cells gate E). The data was obtained using a 
representative stromal vascular fraction (SVF) cell sample from epididymal adipose tissue from 
a male APOE3 mouse incubated with isotype control Rat igG2b, kappa, isotype-PE (0.2 mg/ml) 
for CD11b, Armenian Hamster IgG isotype-Alexa700 (0.2 mg/ml) for CD11c and Rat igG2aFITC 
(0.1 mg/ml) for CD206. 
 
Cell viability 
The cell viability of the stromal vascular fraction (SVF) cell samples was 83 ± 8.3 % (SD). 
 
 
Figure A4-1.9. Plot showing the cell 
viability of a representative stromal 
vascular fraction (SVF) sample of the 
epididymal adipose tissue from a male 
APOE3 mouse stained with cell viability 
stain 7-AAD presenting events within gate 
E. The viability of the cells within gate E 
was 75 % (“100 - gate D, %Gated”), 
whereas the cell viability of all 30,000 event 
was 95 % (“100 - gate D, %Total”). 
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Appendix 4-2. Flow cytometry results 
The forward (FSC-A) versus sideward scatter area (SSC-A) plot of a representative stromal 
vascular fraction (SVF) sample from each APOE Epsilon genotype*diet group is presented 
in Figure A4-2.1. The percentage of adipose tissue macrophages (ATM) (CD11b+ cells in 
target cell population [gate E]) and their M1 (CD11b+CD11c+ cells) and M2 
(CD11b+CD206+ cells) phenotype in the SVF for a representative sample from each APOE 
Epsilon genotype*diet group are presented in Figure A4-2.2. Finally, a graphical 
representation of the expression of CD11c versus CD206 in the CD11b+ cell population is 
presented in Figure A4-2.3. 
 
A      B 
  
C      D 
  
Figure A4-2.1. Forward (FSC-A) versus sideward scatter area (SSC-A) plot of a representative 
sample from the APOE Epsilon genotype*diet groups. The plot shows the different cell 
populations (CD11b+ (red), CD11b+CD11c+ (orange), CD11b+CD206+ (green)) within the 
investigated cell population (gate E) in a representative stromal vascular fraction (SVF) sample 
of the epididymal adipose tissue from a male mouse from the APOE3-HFD (A), APOE3-HFD+FO 
(B), APOE4-HFD (C) and APOE4-HFD+FO (D) group.   
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Figure A4-2.2. Plots presenting the CD11b+ (gate A, left graph) and CD11b+CD11c+ (gate C, 
middle graph) and CD11b+CD206+ (gate B, right graph) cell populations in representative 
samples from the APOE Epsilon genotype*diet groups. Data is shown for a representative 
stromal vascular fraction (SVF) sample of the epididymal adipose tissue from a male mouse 
from the APOE3-HFD (A), APOE3-HFD+FO (B), APOE4-HFD (C) and APOE4-HFD+FO (D) group. 
The CD11b+ cells are presented as percentage of cells within investigated cell population (gate 
E), and the CD11b+CD11c+ and CD11b+CD206+ cells are expressed as percentage of CD11b+ 
cells (gate A). APOE, apolipoprotein E; HFD, high-fat diet; HFD+FO, HFD containing 30 g EPA + 
DHA per kg of diet. 
 
A      B 
    
C      D 
   
Figure A4-2.3. The expression of the M1 (CD11c) and M2 (CD206) phenotypic markers in 
adipose tissue macrophages (ATM) in representative samples for the different APOE Epsilon 
genotype*diet groups. Data is presented as cell surface expression of CD11b and CD206 in the 
ATM cell population (CD11b+ cells in gate E) of the epididymal stromal vascular fraction from 
APOE3 [A, B] and APOE4 [C, D] mice fed a high-fat diet (HFD) [A,C] or a HFD containing 30 g 
EPA + DHA per kg of diet (HFD+FO) [B,D]. The plots show a clear change in the appearance of 
the CD11b+ ATM cell population based on their expression of CD11b and CD206 for the mice on 
HFD+FO [B, D] compared those on the HFD [A,C]. The plots from the mice on the HFD+FO diet 
shows a more-spread out cell population with an upward ‘tail’ compared to a dense almost-
single cell population (‘dot’) in the mice on HFD, that is associated with a greater number of 
CD11b+ cells that co-express CD11b and CD206. Furthermore, the plots from the mice on a HFD 
[A,D] reveals that the CD11b+ cell population from the APOE4 mice [C] has a slightly greater 
expression of CD11b and CD206, as indicated by a very-slight shift of the cell population 
respectively upwards and to the right across the axes, compared to the APOE3 mice [A] on a 
HFD. APOE, apolipoprotein E. 
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Table A4-2.1. Summary statistics for Figure A4-2.3. The mean expression of M1 (CD11c) and M2 
(CD206) phenotypic markers in adipose tissue macrophages (ATM, CD11b+ cells) for the 
different APOE Epsilon genotype*diet groups.  
 APOE3-
HFD 
APOE3-
HFD+FO 
APOE4-
HFD 
APOE4-
HFD+FO 
CD11b
+
CD11c
-
CD206
-
 cells (B--)  
(% of CD11b
+
 cells) 
13.5 ± 1.0
 
16.3 ± 1.3
 
17.6 ± 2.3
 
27.0 ± 1.9
 
CD11b
+
CD11c
+
CD206
-
 cells (B-+)  
(% of CD11b
+
 cells) 
0.0 ± 0.0
 
0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
CD11b
+
CD11c
-
CD206
+
 cells (B+-) 
(% of CD11b
+
 cells) 
79.3 ± 7.1
 
66.6 ± 1.2  72.3 ± 2.5 57.3 ± 1.9 
CD11b
+
CD11c
+
CD206
+
 cells (B++) 
(% of CD11b
+
 cells) 
7.1 ± 1.3 17.1± 0.9 10.0 ± 0.7 15.7 ± 0.6 
Values are mean ± SEM of 9 – 10 animals per group. Data is presented as percentage of 
CD11b+ cells in gate E that confines the cell population of interest. APOE, apolipoprotein E 
genotype; CD11b, integrin alpha M; CD11c, Integrin alpha X; CD206, mannose receptor C 
type 1; HFD, high-fat diet; HFD+FO, HFD containing 30 g EPA+DHA / kg of diet. 
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Appendix 4-3. Pearson’s correlation analysis 
To explore if the LC n-3 PUFA, EPA and DHA enrichment of epididymal adipose tissue (AT) 
determined the response to fish oil supplementation in APOE3 and APOE4 mice, we 
investigated the correlation between LC n-3 PUFA, EPA and DHA levels and several 
outcome measures related to AT inflammation (Table A4-3.1; Figure A4-3.1 to A4-3.4) and 
insulin resistance (Table A4-3.2; Figure A4-3.5 to A4-3.8) using the Pearson’s correlation 
coefficient. 
 
Table A4-3.2. Correlation LC n-3 PUFA status and measures related to insulin resistance. 
Dependent variable Independent variable Pearson r p-value 
ATM flow LC n-3 PUFA -0.002 0.99 
 EPA -0.040 0.81 
  DHA 0.006 0.97 
M1 flow LC n-3 PUFA -0.221 0.17 
 EPA -0.227 0.16 
 DHA -0.220 0.18 
M2 flow LC n-3 PUFA -0.661 p<0.001 
 EPA -0.644 p<0.001 
  DHA -0.668 p<0.001 
Double positive flow LC n-3 PUFA 0.809 p<0.001 
 EPA 0.805 p<0.001 
 DHA 0.810 p<0.001 
CD11c:CD206 flow LC n-3 PUFA 0.680 p<0.001 
 EPA 0.685 p<0.001 
  DHA 0.677 p<0.001 
F4/80 mRNA LC n-3 PUFA 0.298 0.07 
 EPA 0.339 p<0.05 
  DHA 0.282 0.08 
CD11b mRNA LC n-3 PUFA 0.344 p<0.05 
 EPA 0.348 p<0.05 
  DHA 0.337 p<0.05 
CD11c mRNA LC n-3 PUFA 0.147 0.38 
 EPA 0.107 0.53 
  DHA 0.162 0.33 
CD206 mRNA LC n-3 PUFA 0.045 0.79 
 EPA 0.094 0.59 
  DHA 0.028 0.87 
IL-10 mRNA LC n-3 PUFA 0.287 0.08 
 EPA 0.094 0.59 
  DHA 0.028 0.87 
Pearson’s correlation efficient (r) was used to determine the correlation between the adipose tissue LC 
n-3 PUFA, EPA and DHA concentrations and several outcome measures related to AT inflammation. 
ATM, adipose tissue macrophage; CD11b, integrin alpha X (Itgax); CD11b, integrin alpha M (Itgam); 
CD206, mannose receptor C type 1 (Mrc1); DHA, docosahexaenoic acid; Double positive, 
macrophages expressing both M1 marker CD11c and M2 marker CD206; EPA, eicosapentaenoic acid; 
F40/80, EGF-like module containing mucin-like hormone receptor-like sequence 1; IL-10, interleukin 
10; LC n-3 PUFA, long chain n-3 polyunsaturated fatty acid; M1, proinflammatory macrophage 
phenotype; M2, anti-inflammatory macrophage phenotype. 
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Figure A4-3.1. Correlation between percentage of M2 adipose tissue macrophages 
(CD11b+CD11c-CD206+ cells) in stromal vascular fraction and adipose tissue LC n-3 PUFA (r = -
0.661), EPA (r = -0.644) and DHA (r = -0.668) concentrations. Crosses, APOE3-HFD; squares, 
APOE3-HFD+FO; circles, APOE4-HFD; triangles, APOE4-HFD+FO. 
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Figure A4-3.2. Correlation between percentage of double positive adipose tissue macrophages 
(CD11b+CD11c+CD206+ cells) in stromal vascular fraction and adipose tissue LC n-3 PUFA (r = 
0.809), EPA (r = 0.805) and DHA (r = 0.677) concentrations. Crosses, APOE3-HFD; squares, 
APOE3-HFD+FO; circles, APOE4-HFD; triangles, APOE4-HFD+FO. 
  
 Slim (2015), Appendix 4-3 
241 
S
lim
 (2
0
1
5
), C
h
a
p
te
r 1
. L
ite
ra
tu
re
 re
v
ie
w
 
 
Figure A4-3.3. Correlation between adipose tissue F4/80 mRNA expression levels and adipose 
tissue EPA (r = 0.339) concentrations. Crosses, APOE3-HFD; squares, APOE3-HFD+FO; circles, 
APOE4-HFD; triangles, APOE4-HFD+FO. 
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Figure A4-3.4. Correlation between adipose tissue Cd11b mRNA expression levels and adipose 
tissue LC n-3 PUFA (r = 0.344), EPA (r = 0.348) and DHA (r = 0.337) concentrations. Crosses, 
APOE3-HFD; squares, APOE3-HFD+FO; circles, APOE4-HFD; triangles, APOE4-HFD+FO. 
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Table A4-3.2. Correlation LC n-3 PUFA status and measures related to insulin resistance. 
Dependent variable Independent variable Pearson r p-value 
Glut4 mRNA LC n-3 PUFA 0.401 p<0.05 
 EPA 0.459 p<0.01 
  DHA 0.376 p<0.05 
HOMA-IR LC n-3 PUFA -0.540 p<0.001 
 EPA -0.534 p<0.001 
  DHA -0.541 p<0.001 
plasma glucose LC n-3 PUFA -0.416 p<0.01 
 EPA -0.420 p<0.01 
  DHA -0.410 p<0.01 
plasma insulin LC n-3 PUFA -0.520 p<0.01 
 EPA -0.514 p<0.01 
  DHA -0.522 p<0.01 
Pearson’s correlation efficient (r) was used to determine the correlation between the adipose tissue LC 
n-3 PUFA, EPA and DHA concentrations and several outcome measures related to AT inflammation 
and insulin reistance (IR). DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; Glut4, solute 
carrier family 2 (facilitated glucose transporter) member 4 (Slc2a4); HOMA-IR, homeostatic model 
assessment - insulin resistance; LC n-3 PUFA, long chain n-3 polyunsaturated fatty acid. 
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Figure A4-3.5. Correlation between adipose tissue Glut 4 mRNA expression levels and adipose 
tissue LC n-3 PUFA (r = 0.401), EPA (r = 0.459) and DHA (r = 0.376) concentrations. Crosses, 
APOE3-HFD; squares, APOE3-HFD+FO; circles, APOE4-HFD; triangles, APOE4-HFD+FO. 
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Figure A4-3.6. Correlation between HOMA-IR and adipose tissue LC n-3 PUFA (r = -0.540), EPA 
(r = -0.534) and DHA (r = -0.541) concentrations. Crosses, APOE3-HFD; squares, APOE3-
HFD+FO; circles, APOE4-HFD; triangles, APOE4-HFD+FO. 
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Figure A4-3.7. Correlation between fasting plasma glucose and adipose tissue LC n-3 PUFA (r = 
-0.416), EPA (r = -0.420) and DHA (r = -0.410) concentrations. Crosses, APOE3-HFD; squares, 
APOE3-HFD+FO; circles, APOE4-HFD; triangles, APOE4-HFD+FO. 
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Figure A4-3.8. Correlation between fasting plasma insulin and adipose tissue LC n-3 PUFA (r = -
0.520), EPA (r = -0.514) and DHA (r = -0.522) concentrations. Crosses, APOE3-HFD; squares, 
APOE3-HFD+FO; circles, APOE4-HFD; triangles, APOE4-HFD+FO. 
 
